Sunday, April 19 - American Association for Cancer Research

Transcription

11_15AM_Sun_Layout 1 3/27/15 12:20 PM Page 189
SUNDAY, APRIL 19 AT-A-GLANCE
All sessions eligible for CME credit unless otherwise noted.
7:00 a.m.-8:00 a.m.
Meet-the-Expert Sessions
191-194
7:00 a.m.-8:00 a.m.
NCI/NIH-Sponsored Session
195
8:15 a.m.-9:30 a.m.
Opening Ceremony and Award Presentations
196-209
9:30 a.m.-12:00 a.m.
Opening Plenary Session
210-211
12:30 p.m.-2:30 p.m.
212
12:45 p.m.-2:55 p.m.
Clinical Trials Plenary Session
213
1:00 p.m.-2:00 p.m.
Meet the CCR Editor-in-Chief
214
1:00 p.m.-2:30 p.m.
Science Policy Session
215
1:00 p.m.-3:00 p.m.
Drug Development Track: Special Session
216
1:00 p.m.-3:00 p.m.
Major Symposia
217-220
1:00 p.m.-3:00 p.m.
Professional Advancement Session
221
1:00 p.m.-3:00 p.m.
Recent Advances in Diagnostics and
Therapeutics Research
222-223
1:00 p.m.-3:00 p.m.
Recent Advances in Epidemiology and
Prevention Research
224
1:00 p.m.-3:00 p.m.
Recent Advances in Organ Site Research
225
1:00 p.m.-3:00 p.m.
Regulatory Science and Policy Session
226
1:00 p.m.-5:00 p.m.
POSTER SESSIONS
227-260
1:00 p.m.-5:00 p.m.
Late-Breaking Poster Sessions
261
1:30 p.m.-3:00 p.m.
MICR Council Meet and Greet
262
1:30 p.m.-3:00 p.m.
MEG Special Session
263
2:00 p.m.-4:00 p.m.
WICR Council Meet and Greet
264
2:30 p.m.-3:30 p.m.
Meet the Research Icon: Dr. Joan S. Brugge
265
2:30 p.m.-4:00 p.m.
266
April 18-22, 2015 • Philadelphia, PA
189
SUNDAY, APRIL 19 AT-A-GLANCE
All sessions eligible for CME credit unless otherwise noted.
3:00 p.m.-5:00 p.m.
Regulatory Science and Policy Session
267
3:15 p.m.-4:15 p.m.
Meet the Research Icon: Anirban Maitra, MBBS
268
3:15 p.m.-4:30 p.m.
Jane Cooke Wright Memorial Lectureship
269
3:15 p.m.-5:15 p.m.
Late-Breaking Minisymposium
270
3:15 p.m.-5:15 p.m.
Clinical Trials Minisymposium
271
3:15 p.m.-5:15 p.m.
Clinical Trials Plenary Session
272
3:15 p.m.-5:15 p.m.
Drug Development Track: Special Session
273
3:15 p.m.-5:15 p.m.
Minisymposia
274-278
3:30 p.m.-4:30 p.m.
Meet the Mentor: Undergraduate Focus
279
4:00 p.m.-5:00 p.m.
Meet the CR Editor-in-Chief
280
4:00 p.m.-5:30 p.m.
European Research Council-Sponsored Session
281
4:30 p.m.-5:30 p.m.
Pezcoller-AACR Award Lecture
282
5:30 p.m.-6:30 p.m.
Presidential Address
283
6:00 p.m.-8:30 p.m.
CIMM Town Meeting
284
6:30 p.m.-8:00 p.m.
AACR Networking Hubs
285
6:30 p.m.-9:00 p.m.
PCWG Town Meeting
286
7:00 p.m.-8:15 p.m.
Special Session
287
8:30 p.m.-11:30 p.m.
Annual Reception
288
190
AACR ANNUAL MEETING 2015
MEET-THE-EXPERT SESSIONS
Sunday, 7:00 a.m.-8:00 a.m.
Room 120, Pennsylvania Convention Center
The Biologic Signature of Melanoma to
Guide Therapy
Meenhard Herlyn, The Wistar Institute, Philadelphia, PA
The genetic signature of melanomas has become an
integrated part in the decision process of patients’ therapy.
Establishing a biologic signature of melanoma is complex
and challenging but needed to achieve more long-term
therapy responses. Developmental pathways are activated
in melanoma including pathways related to Notch, Wnt,
Shh signaling that lead to a stem cell-like phenotype. Each
tumor also contains malignant cell subpopulations that are
relatively dormant and poorly amendable to any therapy
targeting actively dividing tumor cells. Activated
mitochondrial metabolism or normal stromal cells including
B cells, macrophages, and endothelial cells provide support
for the malignant cells when stressed by drugs. New
experimental models such patient-derived xenografts and
humanized immune systems in NSG mice, and acquired
resistance under continuous drug exposure, are all part of a
multifaceted effort to drastically improve strategies for
patients’ therapy.
Clinical Application of Next-Generation
Sequencing as a Guide to Treatment Selection
biomarkers of response for agents that show profound
responses in only a minority of patients. As an example, we
explored the molecular basis of an outlier phenotype, an
apparent disease cure of a 51-year-old woman with
recurrent metastatic small cell carcinoma. The patient was
treated on a phase 1 clinical trial that combined
topoisomerase I inhibition with an ATP-competitive
inhibitor of checkpoint kinase 1 (Chk1). Whole-genome
sequencing revealed a complex but highly clonal tumor
genome with a somatic, missense mutation in the Mre11
complex gene RAD50, which functions to initiate double
stranded break (DSB) repair by homologous recombination
or non-homologous end joining. Through modeling in
yeast, we confirmed that this heterozygous RAD50
mutation, which affects a highly conserved residue and
whose wild type copy was focally deleted, conferred
sensitivity to topoisomerase I inhibition. Drug sensitivity
was markedly enhanced upon genetic ablation of the DNA
damage checkpoint pathway, suggesting a synthetic lethal
interaction between checkpoint kinase inhibition and
clastogenic chemotherapy. These results and additional
examples to be presented demonstrate the feasibility of
using whole-genome sequencing in the clinical setting to
identify previously occult biomarkers of drug sensitivity
that can aid in the identification of patients most likely to
respond to targeted anticancer drugs. The use of novel
clinical trial designs to confirm genotype-phenotype
associations will also be discussed.
David B. Solit, Memorial Sloan Kettering Cancer Center,
New York, NY
Profound and durable responses are often observed in
early-stage clinical trials of novel cancer agents in only a
small minority of patients. It has long been postulated that
these responses have a definable genetic basis but until
now it was not feasible to perform a comprehensive
genomic analysis of such patients. Rather, at best a few
candidate genes were examined. Technical feasibility thus
ensured that oncology trials were designed to identify
agents that have a statistically significant benefit in a
genetically unselected population, a paradigm that has led
to the development of many agents that have modest or
no benefit in the vast majority of patients. Agents with
profound activity in only a small number of patients were
on the other had deemed inactive and abandoned. Our
preliminary experience shows that next-generation
sequencing methodology can now be feasibly applied in
the clinical setting to identify previously unrecognized
191
Sunday, 7:00 a.m.-8:00 a.m.
Combinatorial Mapping of Vascular
Addresses in Cancer: Towards Mechanistic
Insights and Targeted Delivery
Identifying Metabolic Dependencies of
Cancer Cells
Renata Pasqualini, University of New Mexico Cancer
Research and Treatment Center, Albuquerque, NM
Patterns of luminal vascular protein expression vary
according to tissue of origin, and these so-called vascular
zip codes play an important role in the maintenance of
normal physiological processes in multiorgan species.
These zip codes are also often modified in response to
pathology and play a critical role in the response to and
recovery from disease. These differentially expressed
proteins offer opportunities for organ- and disease-specific
ligand-targeted molecular delivery, offering clear
pharmacologic advantages to traditional systemic drug
delivery. However, this approach depends on the
availability of frequently elusive targets. Combinatorial
screening is a valuable tool for identifying optimal ligands
for targeted delivery to the vasculature, especially when
adapted for in vivo selection. Here we discuss molecular
heterogeneity of the vascular endothelium and the use of
phage display as a combinatorial screening method to
exploit this heterogeneity for tissue or disease-specific
vascular targeting. We also highlight applications of this
approach for both drug delivery and molecular imaging.
Matthew G. Vander Heiden, MIT Koch Institute for
Integrated Cancer Research, Cambridge, MA
Metabolic regulation influences tumorigenesis and tumor
progression. To sustain uncontrolled proliferation, cancer
cells must adapt metabolism to support anabolic processes
and allow the accumulation of biomass. Survival of cancer
cells in inappropriate tissue contexts also requires
metabolic adaptation, and understanding the how the
metabolic phenotypes of cancer cells support cancer cell
proliferation and survival is critical to target these
pathways for improved therapy. Approaches to study
cancer cell metabolism and identify dependencies that
might be exploited for treatment will be described. Studies
to understand how glucose and serine metabolism are
regulated in cancer cells will be highlighted, together with
a discussion of how these pathways modulate both
proliferation and survival pathways via effects on
nucleotide metabolism.
Terrace Ballroom IV (400 Level), Pennsylvania
Convention Center
New Strategies for Triple-Negative Breast
Cancer: Deciphering the Heterogeneity
Combining Molecularly Targeted Therapies
with Chemoradiation
Theodore S. Lawrence, University of Michigan, Ann Arbor, MI
Chemoradiation is the standard therapy for the majority of
locally advanced cancers. However, it is unlikely that
improvements in outcome can be achieved by increasing
the intensity of either chemotherapy or radiation therapy
due to toxicity. Molecularly targeted therapies offer the
potential to increase efficacy with little to modest increase
in toxicity. In this talk, I will review efforts to combine
chemoradiation with inhibitors of the epidermal growth
factor receptor as well as with agents that abrogate the G2
checkpoint and cause inhibition of homologous
recombination repair. I will also illustrate how preclinical
studies can motivate clinical trials through the example of
an ongoing trial in locally advanced pancreatic cancer.
192
Jennifer A. Pietenpol, Vanderbilt-Ingram Cancer Center,
Nashville, TN
Treatment of patients with triple-negative breast cancer
(TNBC) has been challenging due to the heterogeneity of
the disease and the absence of well-defined “drivers”
amenable to targeted therapies. Identification of molecular
targets and predictive biomarkers is critical to improve
outcomes for TNBC patients. Over the past several years,
analysis of integrated genomic and clinical data sets has
resulted in the classification of TNBC into subtypes. These
subtypes now provide insight to potential targets and new
strategies for this difficult-to-treat disease. The hope is that
the further identification and validation of subtypespecific, gain- and loss-of-function drivers will lead to new
strategies that align TNBC patients to effective targeted
therapy and generate insights for further discovery efforts.
Novel Therapeutic Targets in Myeloma
Kenneth C. Anderson, Dana-Farber Cancer Institute,
Boston, MA
This session will describe models of multiple myeloma
(MM) in the bone marrow (BM) which have allowed for
identification of novel targets and validation of targeted
agents, which in turn have rapidly translated to clinical
trials leading to nine FDA-approved treatments and a
threefold prolongation of patient median survival. Novel
immune therapies include: monoclonal antibodies;
immunotoxins; cellular or peptide vaccines; as well as TLR
agonists or checkpoint blockade. Next-generation
proteasome inhibitors and deubiquitylating (DUB) can
overcome resistance to first-generation bortezomib. Novel
epigenetic therapies include isoform selective histone
deacetylase inhibitors and bromodomain inhibitors. Finally,
genomic studies are delineating MM heterogeneity;
defining mechanisms of sensitivity or resistance to
targeted therapies; identifying novel targets; and allowing
for individualized treatments in MM.
Terrace Ballroom I (400 Level), Pennsylvania
Convention Center
PI3K in Cancer: Divergent Roles of
Isoforms, Modes of Activation, and
Therapeutic Targeting
Jean J. Zhao, Dana-Farber Cancer Institute and HMS,
Boston, MA
Phosphatidylinositol 3-kinases (PI3Ks) are critical
coordinators of intracellular signaling in response to
extracellular stimuli. Hyperactivation of PI3K signaling
cascades is one of the most common events in human
cancers. In this session, we discuss recent advances in our
knowledge of the roles of distinct PI3K isoforms in normal
and oncogenic signaling, the different ways in which PI3K
can be upregulated, and the current state and future
potential of targeting this pathway in cancer.
The Promise of Personalized Medicine
Patricia M. LoRusso, Yale Cancer Center, New Haven, CT
Opportunities for Immunotherapy in
Ovarian Cancer
George Coukos, University Hospital of Lausanne, Épalinges,
Switzerland
Clinical data indicate that the immune system naturally
recognizes epithelial ovarian cancers (EOC) and such
immune response affects the outcome of patients with
EOC; the presence of intraepithelial tumor-infiltrating
lymphocytes correlates with improved progression-free
and overall survival, as shown by studies conducted on
over 1,700 patients. Tumor-infiltrating lymphocytes (TILs)
isolated from ovarian cancers are oligoclonal and recognize
and can lyse autologous tumor. TILs from ovarian cancer
patients can recognize known tumor-associated antigens
(TAAs). Important questions remain on the underlying
biology that mediates the successful orchestration of
antitumor immune response or the lack of T cell infiltration,
as well as on the therapeutic opportunities to harness
endogenous immunity and boost it with current
immunotherapy approaches. We will attempt to elucidate
the biology of immunogenic and non-immunogenic
ovarian cancers, discuss data from emerging clinical
immunotherapy studies, and propose important
approaches to effectively mobilize antitumor immunity in
EOC in the future.
In the genome-enabled era, it is becoming obvious that a
more personalized approach to cancer will be necessary if
we are going to make an impact on the treatment of this
disease. However, the clinical complexities of incorporating
individualized molecular profiling into therapeutic
interventions are significant. The challenges are multiple:
defining the appropriate platform(s) for genomic
characterization; harvesting relevant tumor tissue; serial
sampling for determination of relevant molecular signature;
drug effect and mechanisms of resistance; having the right
drugs available; requiring agents from multiple different
sponsors; having “clean” agents that are not multitargeted
so as to maximize target inhibition and minimize nontarget
toxicities; inability to combine necessary targeted agents
due to overlap in toxicities, are but a few. Additionally,
many tumors have multiple pathways that need
simultaneous targeting, challenging such routine drug
development concepts as relevant drug doses and
schedules. Even if many of the above challenges are
overcome, there remain challenges regarding optimization
of trial design, especially for molecular subgroups of
patients that may be very small. In this session, we will
discuss these issues and how the clinical community is
attempting to advance forward into a more personalized
therapeutic approach to cancer treatment.
193
Sunday, 7:00 a.m.-8:00 a.m.
The PTEN Tumor Suppressor
Tumor Dormancy and Recurrence
Ramon E. Parsons, Icahn School of Medicine at Mount
Sinai, New York, NY
Lewis A. Chodosh, University of Pennsylvania,
Philadelphia, PA
PTEN, the phosphatase and tensin homolog on
chromosome 10, is inactivated in a wide array of human
cancers by a variety of different mechanisms that occur at
the genetic, epigenetic, transcript, and protein levels.
Understanding the mechanisms of inactivation of the gene
and different potential combinations of such mechanisms
in an individual tumor is important for gauging the extent
of PTEN’s contribution to tumor growth. Inactivation of
PTEN leads to increased levels of phosphatidylinositiol3,4,5-trisphostate inside the cell which activates multiple
parallel signaling pathways including RAC, AKT, mTOR,
BTK, and SGK3. Loss of PTEN function cooperates with
PI3K class I isoforms to activate cell surface receptor
signals, including insulin and EGF receptor family
members, to alter cell metabolism, increase proliferation,
and inhibit cell death. In addition, PTEN has tumor
suppressor functions that are outside of the PI3K pathway.
Reducing PI3K signals or restoring PTEN in tumors or the
tumor microenvironment has potential therapeutic benefit.
For many types of human cancer, residual tumor cells
remain following treatment that are not detected by
conventional clinical testing. These cells have the ability to
survive in a presumed dormant state within tissues for up
to 20 years, either as solitary cells or as micrometastases.
Ultimately, residual cells re-emerge from this latent state
and resume growth, leading to cancer recurrence. Despite
the unrivaled clinical importance of these aspects of breast
cancer progression, the mechanisms underlying them are
largely unknown. Since dormant residual tumor cells
constitute the reservoir from which recurrent cancers
invariably arise, the lack of therapeutic approaches
specifically targeted against these cells – as well as our
lack of understanding about their biology – constitute
major obstacles to the successful treatment of human
cancers. As such, the development of targeted therapies
designed to block pathways on which residual tumor cells
depend for survival and growth would represent an
attractive approach to preventing cancer recurrence.
Targeting Essential Growth Drivers in NonSmall Cell Lung Cancer: A Lesson from ALK
Unraveling Hormone Dependence in Cancer
Hiroyuki Mano, University of Tokyo Graduate School of
Medicine, Tokyo, Japan
Targeting essential growth drivers that cancer cells are
addicted to would be one of the most effective ways to
treat cancer. Such hypothesis is clearly approved in the
case for ALK fusions. Transgenic mice expressing EML4ALK in lung epithelial cells bear hundreds of lung tumors at
birth, and such cancer nodules disappear upon the
administration of an ALK inhibitor. Likewise, the first ALK
inhibitor, crizotinib, obtained a remarkable response rate of
~60% in patients, and was approved at only 4 years after
EML4-ALK discovery. Many “second-generation” ALK
inhibitors are under clinical investigation, and one of them,
alectinib, demonstrated a surprising response rate of
93.5%. Successful treatment by a single ALK inhibitor of
non-lung tumors with other ALK fusions further validates
an idea of “ALKoma,” a step toward a beyond-organ driver
gene-based cancer classification.
194
Myles A. Brown, Dana-Farber Cancer Institute, Boston, MA
Investigation of the steroid hormone dependence of breast
and prostate cancers has served as the paradigm for the
development of targeted therapies and has led to an
understanding of the importance of an epigenetically
defined cell of origin in determining response. It has also
highlighted the importance of considering both genetic
changes leading to clonal evolution and epigenetic changes
resulting in altered differentiation as mechanisms
underlying the development of acquired therapeutic
resistance. This session will discuss recent studies aimed at
elucidating the relative contributions of genetics and
epigenetics in determining sensitivity to therapies targeting
steroid receptor pathways and will provide potential new
therapeutic strategies to overcome resistance.
NCI/NIH-SPONSORED SESSION (not eligible for CME credit)
Sunday, 7:00 a.m.-8:00 a.m.
NIH Grants Session: Changes in Review, Funding, and Funding
Opportunities at the NCI
Chairperson: Suresh Mohla, National Cancer Institute, Rockville, MD
This session, held at every AACR annual meeting since the early 1990s, is primarily focused on
familiarizing new applicants with the NIH grants submission, review, and funding processes. The
session is predominantly focused on R01/R21 type grant applications since there are other NCI
sessions focusing primarily on training, mentoring, and career development grant applications.
Traditionally, this is a team effort between NCI and CSR. The one-hour session will include
presentations from an SRO and an NCI Program Director, after which there will be an opportunity for
questions. The session has been very popular with new, junior, and senior investigators because the
speakers present new policies, procedures, and funding opportunities that are available to applicants.
The major theme of this session is how to be proactive in preparing grant applications, and how to
interact with the CSR and NCI staff before and after the applications have been reviewed. A variety of
topics are discussed including how applicants can self-refer their applications, and issues related to
“grantsmanship,” such as the common mistakes made in research applications and how to avoid them.
It is a great opportunity for applicants to meet with NCI Program Staff, and with CSR and NCI
Scientific Review Officers. The NCI and CSR staff will be available to meet either immediately after the
session or in the NIH Resource Room for the duration of the meeting. Overall, this has been a
successful forum to provide an overview of NCI paylines, plans and programs, funding opportunities,
changes in grant submissions process, and other significant changes in review at CSR and NCI, and the
AACR has enthusiastically endorsed this session since the very early 1990s.
Speakers:
Angela Y. Ng, Center for Scientific Review, National Institutes of Health, Bethesda, MD
Ronald L. Johnson, National Cancer Institute, Rockville, MD
Suresh Mohla, National Cancer Institute, Rockville, MD
NCI Resource Room
The NCI Grants Resource Room, located in Room 102 of the Philadelphia Convention Center, provides
information and handouts related to new research initiatives and information on the grant application
process, including Program and Review staff contacts. Program and Review staff of the NCI as well as
Review staff from CSR will be available at the Resource Room for discussions and consultation
throughout the meeting. A list with details of specific NCI and CSR staff availability will be posted in the
room. Conferences can be scheduled to discuss individual grant/review questions. Interested members
of the scientific community are encouraged to meet with Program or Review staff to clarify specific
issues or other items of interest. New investigators are especially encouraged to meet with Program
staff handling grant portfolios in their area of scientific interest. The Resource Room will be open from
9:00 a.m. to 5:00 p.m. Sunday through Tuesday, and from 9:00 a.m. until noon on Wednesday,
195
OPENING CEREMONY (not eligible for CME credit)
Sunday, 8:15 a.m.-9:30 a.m.
Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly
tradition marking the start of four days filled with outstanding and
innovative science.
AACR CEO Margaret Foti, PhD, MD (hc), will address attendees and discuss
the immense progress the AACR has made over the past year.
AACR President Carlos L. Arteaga, MD, FAACR, will highlight the dramatic
advances in cancer research and today’s challenges to the cancer field.
The Opening Ceremony will also feature the presentation of some of the
AACR’s most prestigious awards, including:
• The Ninth Annual AACR Team Science Award
• The Twelfth Annual AACR Award for Lifetime Achievement in
Cancer Research
• Recognition of the newly inducted Fellows of the
AACR Academy
• The Ninth Annual AACR Margaret Foti Award for Leadership
and Extraordinary Achievements in Cancer Research
• The 2015 AACR Distinguished Public Service Awards
Don’t miss this exciting event,
which leads directly into the
opening plenary session!
AACR Team Science Award
Designing AR
Inhibitors Team
196
Charles L. Sawyers, MD, FAACR
Michael E. Jung, PhD
Howard I. Scher, MD
Lifetime Achievement Award
Mario R. Capecchi, PhD, FAACR
Distinguished Public Service Award
Siddhartha Mukherjee, MD, DPhil
AACR Margaret Foti Award
Donald S. Coffey, PhD, FAACR
Photo by Viva Sarah Press/ISRAEL21c
Senator Robert Casey
Distinguished Public
Service Award
Miri Ziv
Richard Pazdur, MD
197
Sunday, 8:15 a.m.-9:30 a.m.
Hall A (200 Level), Pennsylvania Convention Center
Ninth Annual
AACR Team Science Award
Designing AR Inhibitors Team
Charles L. Sawyers, MD, FAACR
Memorial Sloan Kettering Cancer Center, New York, NY
Michael E. Jung, PhD
University of California, Los Angeles, CA
Howard I. Scher, MD
Memorial Sloan Kettering Cancer Center, New York, NY
198
The AACR Team Science Award has been established by the American Association for
Cancer Research and Eli Lilly and Company to acknowledge and catalyze the growing
importance of interdisciplinary teams to the understanding of cancer and/or the
translation of research discoveries into clinical cancer applications.
The AACR Team Science Award recognizes an outstanding interdisciplinary research
team for its innovative and meritorious science that has advanced or likely will advance
our fundamental knowledge of cancer or a team that has applied existing knowledge to
advance the detection, diagnosis, prevention, or treatment of cancer.
The AACR recognizes the Designing AR Inhibitors Team for their collective efforts in
discovering and developing the novel antiandrogen drugs enzalutamide and ARN-509
for the treatment of castration-resistant prostate cancer. This multidisciplinary group,
comprised of cancer biologists, chemists, and clinical scientists, exemplifies the power of
team work and its ability to make a difference to change the way we treat major
diseases. The team used a combination of laboratory models and clinical samples to
discover that restoration of signaling through overexpression of the androgen receptor
(AR) is responsible for acquired resistance to androgen treatment. They then used this
information to discover and optimize novel small-molecule inhibitors of the androgen
receptor that retain activity in AR-overexpressing models of androgen-resistant prostate
cancer. The team also showed that these compounds work by impairing nuclear
translocation of the AR and disrupting its binding to promoter and enhancer regions of
AR target genes. The team then went on to carry out the first human trial of the drug
emerging from their preclinical work, initially known as MD3100 and then as
enzalutamide, which showed substantial clinical activity.
Subsequent clinical trials resulted in FDA approval in 2012. The team has also discovered
and progressed to clinical trial a further more potent antiandrogen (ARN-509). In
addition, they have provided important evidence supporting dual blockade of AR and
PI3 kinase to overcome reciprocal negative feedback signaling in castration-resistant
prostate cancer and again progressed this to the clinic. The outstanding scientific,
translational, and clinical accomplishments of the team and their commitment to a
multidisciplinary team approach is clearly evidenced by their innovative and meritorious
work that has resulted in major clinical impact and perfectly embodies the spirit of the
AACR Team Science Award.
199
Sunday, 8:15 a.m.-9:30 a.m.
Twelfth Annual
AACR Award for Lifetime Achievement in Cancer Research
Mario R. Capecchi, PhD, FAACR
University of Utah, Salt Lake City, UT
The American Association for Cancer Research Award for Lifetime Achievement in
Cancer Research was first established in 2004 to honor individuals who have made
significant fundamental contributions to cancer research, either through a single
scientific discovery or a collective body of work. These contributions, whether they have
been in research, leadership, or mentorship, must have had a lasting impact
on the cancer field and must have demonstrated a lifetime commitment to progress
against cancer.
The AACR honors Dr. Mario R. Capecchi for his tremendous scientific contributions,
which have had a profound impact on the understanding of cancer. Dr. Capecchi’s
groundbreaking work in the development of gene targeting technology in the mouse
has led to a revolution in our ability to study the function of cancer genes, as well
as the mechanisms of cancer development. He clearly embodies the tradition of
outstanding scientific accomplishments that are represented by this Award and its
previous recipients.
After initial training in physics and chemistry, Dr. Capecchi was seduced by the emerging
discipline of molecular biology. As a graduate student with Jim Watson at Harvard
University, he synthesized bacteriophage proteins in cell-free extracts and worked out
some of the basic mechanisms controlling protein synthesis. Dr. Capecchi then joined
the faculty of Harvard Medical School, but after four years he decided to move to the
University of Utah to pursue new long-term avenues of research in mammalian
molecular biology that ultimately revolutionized our approach to understanding
gene function.
The challenge Dr. Capecchi chose to pursue was how to manipulate the mammalian
genome to understand gene function. His first proposal, to inject DNA into nuclei, was
turned down by the NIH as “not worthy of pursuit.” Undaunted by rejection, he persisted
and four years later a second proposal was accepted with the belated apology from the
study section: “We are glad you did not follow our advice.” Introducing DNA into the
mammalian genome was just the first step in a series of discoveries leading to the
development of procedures to target, disable, and study individual mammalian genes
using homologous recombination. Key to the success of the approach was Dr.
Capecchi’s remarkable persistence and continued refinement of technology to the point
where targeted mutation of mammalian genes became routine. The demonstration that
this approach allows introduction of mutations into chromosomal DNA of embryoderived mouse stem (ES) cells, and transmission of the mutations through the germline
200
to progeny, was recognized by the award of the Nobel Prize in Medicine to Dr. Capecchi
together with Drs. Oliver Smithies and Martin Evans. It is hard to overstate the impact of
this advance in biology and medicine. Many tens of thousands of knockout mice and
their variants have been created leading to numerous advances in understanding and
modeling of many human diseases.
In cancer research, targeted mutation of oncogenes, tumor suppressor genes, and
modifier genes fundamentally changed the direction of the field, permitting direct
analysis of the molecular events leading to tumor initiation and progression. New
models that better reflect the biology of human cancer have been generated and used
to develop novel therapies. In his most recent work, Dr. Capecchi focused on
chromosomal translocations that cause sarcomas by usurping normal developmental
processes involved in muscle formation. Cancer researchers throughout the world
rapidly adopted Dr. Capecchi’s technology. It is now possible to identify the cell of origin
of many cancers and to investigate the actual mechanisms that generate cancer
mutations – in some cases a pathophysiological version of the mechanisms Dr. Capecchi
exploited to achieve gene targeting. Investigators can now approach the diversity of
cancer in mouse models and the heterogeneity of tumor cells that makes them so
difficult to eradicate.
Through a lifetime dedicated to scientific discovery, Dr. Capecchi has left an indelible
mark on cancer research and he has improved the lives of countless cancer patients. He
has also served as an inspiring mentor to his students, fellows, and colleagues and as a
role model for all young investigators who dare to think differently.
201
Sunday, 8:15 a.m.-9:30 a.m.
2015 AACR Distinguished Public Service Award
Siddhartha Mukherjee, MD, PhD
Pulitzer Prize-winning author of “The Emperor of all Maladies: A Biography of Cancer”
and assistant professor in the Department of Medicine at Columbia University
The AACR is honoring Dr. Siddhartha Mukherjee with the 2015 Distinguished Public Service Award in
recognition of his outstanding work educating the public about cancer and cancer research through
his Pulitzer Prize-winning book, The Emperor of All Maladies: A Biography of Cancer.
Dr. Mukherjee wrote the book, which was published in 2010, because he felt that his experiences as an
oncology fellow at the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston
during the mid-2000s were part of a much larger battle against cancer. Through his writing, he set out
to paint a picture of the history of cancer and to answer the tough questions from his patients that he
had been unable to answer about the origins of cancer, how treatment has evolved, and how we can
develop new and more effective treatments.
The Emperor of All Maladies: A Biography of Cancer provides deep insight into the amazing progress
that has been made against cancer over the years thanks to research, and accomplishes Dr.
Mukherjee’s goal of better educating the public about cancer and cancer research. By focusing on the
pioneering physicians and researchers who developed surgical procedures and conducted
experiments with chemotherapy, as well as the trailblazing scientists who revealed the mechanisms of
cancer initiation and progression, Dr. Mukherjee covers the first documented appearances of cancer
four thousand years ago through to the emergence of precision medicine. Intertwined with the stories
of research and medical advances are those of activists who raised public awareness of cancer and of
patients who experienced the highs and lows of treatment. These stories bring a level of humanity to
the book that resonates deeply with the public.
In 2011, The Emperor of All Maladies: A Biography of Cancer won the Pulitzer Prize for general nonfiction.
A six-hour documentary based on the book, Cancer: The Emperor of All Maladies, aired on Public
Broadcasting Service member stations across the United States, on March 30, 31, and April 1. The
American Association for Cancer Research and Stand Up To Cancer are proud supporters of the
documentary, executive produced by Ken Burns and directed by Barak Goodman, which has created a
national dialogue about cancer and the vital importance of cancer research. The documentary series is a
collaboration between Florentine Films, Laura Ziskin Pictures, and WETA, in association with Ark Media.
Dr. Mukherjee is an assistant professor in the Department of Medicine at Columbia University in New
York, where he studies the pathogenesis of acute myeloid leukemia and myelodysplastic syndromes.
He received his doctorate in immunology from the University of Oxford, United Kingdom and his
medical degree from Harvard Medical School.
He lives in New York with his wife and daughters.
202
Photo by Viva Sarah Press/ISRAEL21c
2015 AACR Award for Distinguished Public Service and Global
Impact in Cancer Advocacy
Miri Ziv
Director General, Israel Cancer Association, Givatayim, Israel
Miri Ziv, Director General of the Israel Cancer Association, is
being honored with the 2015 AACR Award for
Distinguished Public Service and Global Impact in Cancer
Advocacy for her sustained spectacular contributions to
the cancer field and her lifelong passionate commitment to
the global conquest of cancer.
Through her remarkable work as the Director General of
the Israel Cancer Association, the leading not-for-profit
cancer organization in Israel, she has served the cancer
field with distinction. Her advocacy in the area of breast
cancer has been especially significant. In addition, for
more than 20 years, her leadership and significant
achievements in the field, not only in Israel but also all over
the world, have spanned the full spectrum of cancer
research, early detection, prevention, and survivorship, and
have saved countless lives globally. She has initiated many
programs to raise awareness about cancer and has been a
tireless advocate for the cause of cancer control, providing
guidance in Israel and to numerous international
organizations on issues relevant to public awareness about
cancer, cancer prevention, and services to cancer survivors.
She has been the driving force as an advocate behind
initiatives such as the National Mammography Screening
Program in Israel, Skin Cancer Awareness Month, and many
other important public education programs.
Ms. Ziv is truly a global cancer ambassador and a precious
asset to the cancer field. Because of all of her past stellar
accomplishments and the global impact of her current
contributions to cancer advocacy, cancer control, and
cancer research, she is highly deserving of this recognition
by the AACR.
Ms. Ziv earned a master’s degree in medical sociology, with
honors, at Tel Aviv University, and completed the study
requirements for the PhD program there. She taught medical
sociology at Tel Aviv University for about a decade prior to
assuming her position at the Israel Cancer Association.
In Israel, Ms. Ziv has served for more than 20 years as a
member of The Israel National Health Committee
(appointed by the Minister of Health) and as Coordinator
of the Israel National Council of Oncology. She is a member
of the National Council for Women’s Health, the National
Council of Health Promotion (both of which are by
appointment of the Director General of the Ministry of
Health), and the Executive Board of the Israel Health
Consumers Coalition.
Internationally, Ms. Ziv has served since 1995 as Israel’s
representative to the European Breast Cancer Coalition Europa Donna, and on its Executive Board from 1995 to
2000. She is a member of the Executive Board of the
Senologic International Society (the World Society of
Breast Diseases) and is a Senior Research Fellow of the
International Prevention Research Institute. She has also
served on the Executive Board of the European Cancer
Leagues and on the Executive Board of the Union for
International Cancer Control. She was elected as a Global
Cancer Ambassador by the American Cancer Society, and
she was a member of the Israeli delegation to the U.N.
General Assembly Meeting on Non-communicable Diseases
in September 2011. In 2015, she was appointed as an ESMO
Faculty Member for Cancer Prevention in recognition of her
enormous expertise in this area.
In addition, Ms. Ziv has participated in and lectured at
conferences in Israel and around the world, such as the
Global Summit Consensus Conference on International
Breast Health in Washington, DC; a meeting of the
Senologic International Society in Paris; the Eighth
International Congress of Diagnosis and Treatment of Breast
Cancer in Warsaw; the Middle East Cancer Control
Leadership Forum in Ankara, Turkey; and the Second Breast
Cancer in Young Women Conference in Dublin, Ireland.
Ms. Ziv has received numerous awards including the “Best
CEO in Israel,” the Nurit Kadatzaki-Roz Award for her
achievements against cancer, and the Israeli Society for
Clinical Oncology & Radiation Therapy Gold Medal for her
contributions to its work, among other honors.
Her commitment to the cause of fighting cancer began
many years ago. It was deepened in 1992 when her own
son, Oren, died of melanoma at the age of 21, and it was
strengthened further when her brother also lost his life to
cancer 14 years ago.
Ms. Ziv and her husband, Joseph, a retired Israeli Defense
Forces helicopter pilot who works in environmental
services, live in the town of Yavne, south of Tel Aviv.
203
Sunday, 8:15 a.m.-9:30 a.m.
Fellows of the AACR Academy
Class of 2015
The AACR Academy serves to recognize and honor distinguished scientists whose
major scientific contributions have propelled significant innovation and progress
against cancer. These Fellows have been nominated and elected through a rigorous
peer-review process conducted by existing Fellows of the AACR Academy and ratified
by the AACR Executive Committee. This process includes an assessment of each
candidate on the basis of his or her scientific achievements in cancer research and
cancer-related biomedical science.
The AACR Academy is proud to have inducted its third class of illustrious Fellows at
the Annual Meeting 2015.
204
Kenneth C. Anderson, MD, FAACR
Carlos L. Arteaga, MD, FAACR
Anton J.M. Berns, PhD, FAACR
Bruce A. Chabner, MD, FAACR
Ronald A. DePInho, MD, FAACR
Susan D. Desmond Hellmann, MD, MPH, FAACR
Robert N. Eisenman, PhD, FAACR
Douglas R. Lowy, MD, FAACR
Carol L. Prives, PhD, FAACR
Steven A. Rosenberg, MD, PhD, FAACR
Craig B. Thompson, MD, FAACR
205
Sunday, 8:15 a.m.-9:30 a.m.
Ninth Annual
AACR Margaret Foti Award for Leadership and Extraordinary
Achievements in Cancer Research
Donald S. Coffey, PhD, FAACR
Catherine Iola and J. Smith Michael Distinguished Professor of Urology
Department of Urology, Johns Hopkins School of Medicine
Baltimore, MD
The American Association for Cancer Research established this Award in 2007 in honor
of Margaret Foti, PhD, MD (hc) for her exemplary leadership of the AACR as its Chief
Executive Officer; for her sustained, outstanding work in fostering research, scholarly
communications, education and training, science policy, and public education; and for
her extraordinary dedication and contributions to the conquest of cancer.
The Award recognizes a true champion of cancer research, an individual who embodies
the sustained commitment of Margaret Foti to the prevention and cure of cancer. The
Award is given to an individual whose leadership and extraordinary achievements in
cancer research or in support of cancer research have made a major impact on the field.
Such achievements may include scientific contributions to the acceleration of progress
against cancer, significant accomplishments in the national or international awareness of
the importance of cancer research, or other ways demonstrating a sustained
extraordinary commitment to cancer research.
The AACR honors Donald S. Coffey, PhD, for his tremendous leadership and profound
contributions to cancer research. Dr. Coffey’s distinct reputation as a natural advocate
and leader is clearly evidenced by his extraordinary tenure as AACR president, which
resulted in a number of new exciting initiatives for our organization. Dr. Coffey’s
pioneering work on the structure of the cell nuclei and the pathogenesis of prostate
cancer, coupled with his dedication to mentoring young cancer researchers and
promoting cancer research nationally, epitomizes the spirit of this award.
Dr. Coffey has also made many important discoveries about abnormal and normal cell
behavior and has launched major new research avenues in cell biology; he is widely
known for his discovery of the nuclear matrix and the fact that DNA synthesis occurs on
this matrix. He characterized the first Dunning animal models, which are used to isolate
tumor metastasis genes and design chemotherapy regimens in prostate cancer. In
addition, Dr. Coffey was the first to establish methods to identify androgen-insensitive
prostate tumors and to elucidate the mechanisms of clonal selection in this insensitivity.
He has also done groundbreaking work on telomerase in prostate cancer and
contributed to the first prostate cancer gene therapy trial ever conducted.
206
While working toward his bachelor’s degree in chemistry from East Tennessee State
University, which he received in 1957, Dr. Coffey was a chemist at the North American
Rayon Corporation. Upon graduating, he spent two years as a chemical engineer at the
Westinghouse Corporation in Baltimore. He began his tenure at Johns Hopkins in 1959,
where he has served since, joining the Johns Hopkins Hospital as acting director of the
Brady Urological Research Laboratory. He also received his doctorate from the
university’s medical school in 1964. Additionally, he is currently an adjunct professor of
medicine at Howard University in Washington, D.C.
Dr. Coffey has been recognized with numerous other honors, including the St. Paul’s
Medal from the British Association of Urological Surgeons, the Achievement Award from
the American Urological Association, the First Yamanouchi Award from the Society of
International Urology, the Eugene Fuller Prostate Award from the American Urological
Society, and the Falk Award from the National Institute of Environmental Science.
Dr. Coffey is a fellow of the AACR Academy and is the Catherine Iola and J. Smith
Michael distinguished professor of urology at Johns Hopkins School of Medicine in
Baltimore, MD.
207
Sunday, 8:15 a.m.-9:30 a.m.
The Honorable Robert P. Casey, Jr.
United States Senator from Pennsylvania
Senator Bob Casey has represented the Commonwealth of Pennsylvania in the United
States Senate since January 2007. In his eight years in the Senate, Bob Casey has been a
steadfast leader in support of funding for the National Institutes of Health (NIH). He has
consistently demonstrated, through his work as a member of the Senate Health,
Education, Labor and Pensions Committee, an unwavering commitment to advancing
science, protecting children, and improving public health. Perhaps most notably, Senator
Casey reaches across the political aisle and works with his Republican colleague,
Senator Richard Burr, to lead a Dear Colleague letter to Senate leadership in support of
NIH funding each year. This letter is critical to raising awareness among his colleagues
that NIH funding should be a national priority. Last year the letter garnered the support
of almost 60 senators.
In addition to his leadership on NIH funding, Senator Casey was the lead Senate sponsor
of the Creating Hope Act, which became law in 2012 and established the Priority Review
Voucher program at the U.S. Food and Drug Administration (FDA) to include treatments
for pediatric rare diseases, such as childhood cancers. He also has demonstrated
support for AACR-led initiatives such as National Cancer Research Month by serving as
an original cosponsor of a special resolution in Congress honoring the event.
Senator Casey and his wife of 30 years, Terese, live in Scranton, PA, and have four
daughters. Senator Casey is the eldest son of the late Governor Robert P. Casey.
Throughout his career in public service, which has spanned almost 20 years, Senator
Bob Casey has been guided by the legacy of his father and the principle that “All public
service is a trust, given in faith and accepted in honor.”
208
Richard Pazdur, MD
Director of the Office of Hematology and Oncology Products
U.S. Food and Drug Administration, Silver Spring, MD
The AACR is honoring Dr. Richard Pazdur with a Public Service Award in recognition of his
steadfast leadership as Director of the U.S. Food and Drug Administration’s (FDA) Office of
Hematology and Oncology Products and of his extraordinary dedication to improving
cancer treatment through the approval of safe and effective drugs for cancer patients.
Throughout his stellar career, Dr. Pazdur has made outstanding contributions to the fight
against cancer, initially through his highly regarded work as a physician and researcher and
now through his extraordinary dedication to improving cancer treatment via the approval
of safe and effective drugs for cancer patients at the FDA. Dr. Pazdur, who is sometimes
referred to as the “Cancer Drug Czar” by the media, has led the FDA Office of Hematology
and Oncology Products (OHOP) since 2005. During this time, he has worked tirelessly to
speed the availability of therapies for cancer patients, especially when the drugs are the
first available treatment or have advantages over existing therapies. On an annual basis,
approximately 30 percent of all new drugs approved by the FDA are oncology products,
and under his leadership, the Office has approved many novel, innovative treatments for
patients, such as the recent approvals of immune-checkpoint inhibitors, immune
modulators, and many of the targeted therapies that have not only extended patient lives,
but have also greatly improved the quality of their lives. For these reasons, Dr. Pazdur was
recently named one of “The World’s 50 Greatest Leaders” by Fortune magazine.
Dr. Pazdur has worked for years to build collaborative partnerships with academia,
industry, fellow government agencies, scientific societies, and patient advocacy
organizations to improve both the pace and the quality of new cancer drugs reaching
patients. He has embraced regulatory science to inform and improve the way in which
new cancer medicines can be evaluated for their safety and efficacy. He is also a thought
leader and has effectively employed a variety of regulatory tools such as master clinical
trial protocols, expedited approval pathways, including the agency’s new breakthrough
therapy designation and clinical trial enrichment strategies for approving targeted
therapies in oncology. A native of the Chicago area, he obtained his Doctor of Medicine
(MD) from Loyola Stritch School of Medicine. He served as an oncologist, researcher, and
teacher at Wayne State University before becoming a Professor of Medicine and Assistant
Vice President for Academic Affairs at the M.D. Anderson Cancer Center at the University
of Texas. He joined the FDA as the Director of the Division of Oncology Drug Products in
1999 and was named Director of the Office of Hematology and Oncology Drug Products in
April 2005.
He resides in Bethesda, MD, with his wife, Mary, and is a fitness enthusiast.
209
OPENING PLENARY SESSION
Sunday, 9:30 a.m.-12:00 p.m.
The Genome and Beyond
Chairperson: Lewis C. Cantley, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, New York, NY
9:30 a.m.
Insights from cancer genomes
into the mutational processes
underlying cancer development
Michael R. Stratton
Wellcome Trust Sanger Institute
Cambridge, United Kingdom
9:55 a.m.
Engineering the cancer genome
Tyler Jacks
David H. Koch Institute for Integrative
Cancer Research at MIT
Cambridge, MA
10:20 a.m. Above the genome: The
epigenome and its biology
and translational potential
Stephen B. Baylin
Johns Hopkins University
School of Medicine
Baltimore, MD
210
10:45 a.m. Using genomics to personalize
cancer immunotherapy
Robert D. Schreiber
Washington University
School of Medicine
St. Louis, MO
11:10 a.m.
Phase III study of pembrolizumab
(MK-3475) versus ipilimumab in
patients with ipilimumab-naive
advanced melanoma
Antoni Ribas
UCLA Medical Center
Los Angeles, CA
11:30 a.m.
Discussant
Jedd D. Wolchok
Memorial Sloan Kettering
Cancer Center
New York, NY
11:40 a.m.
Dual targeting of BCR-ABL with
ABL001, a novel potent allosteric
ABL kinase inhibitor in combination
with nilotinib suppresses the
emergence of disease resistance
in models of CML
William R. Sellers
Novartis Institutes for BioMedical
Research, Cambridge, MA
211
Sunday, 12:30 p.m.-2:30 p.m.
Fellowships, Career Development Awards, and Transitioning to
Independence Awards
Chairperson: Ming Lei, National Cancer Institute-CCT, Rockville, MD
The National Cancer Institute provides numerous opportunities for the training of the next generation
of cancer researchers. The NCI funds training at extramural institutions across the nation, utilizing
funding mechanisms such as institutional training and education grants, career development awards,
and fellowships. The NCI also offers fellowships in the intramural research programs at the Bethesda
campus studying all aspects of cancer including AIDS, behavioral research, epidemiology, clinical
sciences, basic cancer biology, and translational research. This session will provide a broad overview of
this wide range of opportunities. Presentations will describe the extramural funding mechanisms
managed by the Cancer Training Branch, as well as training opportunities in NCI’s three intramural
research programs.
Speakers:
Jonathan S. Wiest, National Cancer Institute-CCT, Bethesda, MD
Michael K. Schmidt, National Cancer Institute, Rockville, MD
Mark Damico, National Cancer Institute, Bethesda, MD
Susan N. Perkins, National Cancer Institute, Rockville, MD
212
CLINICAL TRIALS PLENARY SESSION
Sunday, 12:45 p.m.-2:55 p.m.
Terrace Ballroom I (400 Level), Pennsylvania Convention Center
Promising Trials in Immunotherapy
Chairperson: Michele Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
Additional chairperson to be announced
12:45 p.m.
CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with
malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
Evan W. Alley, University of Pennsylvania, Philadelphia, PA
1:05 p.m.
CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression
in patients with non-small cell lung cancer: Findings from KEYNOTE-001
Edward B. Garon, David Geffen School of Medicine at UCLA, Los Angeles, CA
1:25 p.m.
Discussant to be announced
1:35 p.m.
CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed
against mesothelin in patients with mesothelin expressing cancers
Janos L. Tanyi, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
1:55 p.m.
Discussant
Michele Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
2:05 p.m.
CT106: A phase I/IIa study of IMCgp100: Partial and complete durable responses with
a novel first-in-class immunotherapy for advanced melanoma
Mark R. Middleton, University of Oxford, Oxford, United Kingdom
2:25 p.m.
CT107: Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for treatment of
rituximab-refractory EBV-associated lymphoproliferative disorder
Susan E. Prockop, Memorial Sloan Kettering Cancer Center, New York, NY
2:45 p.m.
Discussant
Antoni Ribas, UCLA Medical Center, Los Angeles, CA
Please refer to the online Itinerary Planner or Annual Meeting App for program updates.
213
MEET AND GREET (not eligible for CME credit)
Sunday, 1:00 p.m.-2:00 p.m.
Booth #1827 (Publications Booth), Halls B-E
Meet the Editor-in-Chief of Clinical Cancer Research
Kenneth C. Anderson, MD, FAACR
Kraft Family Professor of Medicine, Harvard Medical School
Director, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute
Join us at Booth #1827 at AACR Annual Meeting 2015 to meet the editors of the AACR Publications.
The Editors-in-Chief will explain the mission and scope of their journal, recent submission trends, and
other topics of interest for researchers looking to publish their work in the highly esteemed AACR
journals. Learn what Editors look for in manuscripts and participate in a unique Q&A session.
Clinical Cancer Research’s focus is to publish innovative clinical and translational cancer research
studies that bridge the laboratory and the clinic. Clinical Cancer Research is especially interested in
clinical trials evaluating new treatments, accompanied by research on pharmacology and molecular
alterations or biomarkers that predict response or resistance to treatment. The journal also prioritizes
laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead
to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant
phenotype, and metastatic disease.
214
SCIENCE POLICY SESSION (not eligible for CME credit)
Sunday, 1:00 p.m.-2:30 p.m.
The Intersection of Science Policy and Cancer Research: A Town Hall
Meeting with the AACR Office of Science Policy and Government Affairs
Chairperson: William S. Dalton, M2Gen, Tampa, FL
We are making unprecedented progress in cancer research that is changing the way we prevent,
diagnose, and treat cancers in this country, thanks in no small part to federal investments in cancer
research at the National Cancer Institute (NCI) and the National Institutes of Health (NIH). But despite
the tremendous promise of cancer research, our nation’s premier sources of funding—the NIH and NCI—
are amidst a serious funding crisis as a result of cuts in domestic spending, including sequestration, and
years of budgets that have not kept pace with inflation. Through the actions of our Science Policy and
Government Affairs Committee, the AACR is raising awareness for how investments in cancer and
medical research will save lives, improve public health, and grow the economy in this country. The
AACR also works closely with other organizations across all areas of medical science to advocate for
increased research funding and support. By educating Congress about the importance of federal
investments in biomedical research and how those investments provide a significant health and
economic benefit to the country, the AACR is working tirelessly to ensure that our nation’s policymakers
prioritize the growth of the NIH and NCI budgets at a predictable, robust pace. The AACR also engages
with federal agencies to promote the development and implementation of sound, evidence-based
policies to support, cancer survivors, scientists, and the broader medical research ecosystem.
This special session will give you an overview of the AACR’s activities in Washington, D.C., to support
NIH funding and lead on other policy issues, such as tobacco and regulatory science. It also will arm
cancer researchers with the knowledge and tools needed to be effective advocates, especially in the
current, complex political and fiscal environments that exist in Washington, D.C. The session will
conclude with a roundtable “Ask Me Anything” discussion with leaders of the AACR Science Policy
and Government Affairs Committee.
Speakers:
William S. Dalton, M2Gen, Tampa, FL
Jon G. Retzlaff, American Association for Cancer Research, Washington, DC
Mary Lee Watts, American Association for Cancer Research, Washington, DC
Carrie Wollinetz, National Institutes of Health, Bethesda, MD
Jack Whelan, Jack-Whelan.com, Andover, MA
215
DRUG DEVELOPMENT TRACK: SPECIAL SESSION
Sunday, 1:00 p.m.-3:00 p.m.
New Drugs on the Horizon 1
Co-Chairpersons: Lori S. Friedman, Genentech, Inc., South San Francisco, CA; Indrawan J. Mcalpine,
Pfizer Global R&D, San Diego, CA
Advances in the understanding of the molecular basis of cancer have led to the identification of key
pathways involved in tumor initiation and progression, and translating this innovative science into the
next generation of therapeutic agents remains one of the major hurdles to meaningful improvements
in cancer treatment. While clinical successes remain extremely challenging to achieve, increasing
numbers of targeted agents are emerging through clinical trials and making differences in the lives of
patients. This symposium will provide the first disclosure of several new clinical agents that continue
the drive for successful targeted therapies.
1:00 p.m.
PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell
carcinoma [DDT01-01]*
Eli M. Wallace, Peloton Therapeutics, Inc., Dallas, TX
1:25 p.m.
Discussion
1:30 p.m.
Unleashing antitumor immunity through anti-OX40 monotherapy and in combination
with anti-PD-L1 [DDT01-02]*
(not eligible for CME credit)
Jeong M. Kim, Genentech, Inc., South San Francisco, CA
1:55 p.m.
Discussion
2:00 p.m.
Discovery and preclinical pharmacology of AZD9496: An oral, selective estrogen
receptor down-regulator (SERD) [DDT01-03]*
Hazel Weir, AstraZeneca, Macclesfield, United Kingdom
2:25 p.m.
Discussion
2:30 p.m.
Identification of LGH447: A potent and selective proviral insertion of moloney
murine leukemia (PIM) 1,2 and 3 kinase inhibitor in clinical trials for
hematological malignancies
Matthew Burger, Novartis Institutes for BioMedical Research, Emeryville, CA
2:55 p.m.
Discussion
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
216
MAJOR SYMPOSIA
Sunday, 1:00 p.m.-3:00 p.m.
Autophagy and Cancer
Cancer, Type 2 Diabetes, and Cardiovascular
Disease: Comparison of Risk Factors
Chairperson: Kay F. Macleod, University of Chicago Ben
May Institute for Cancer Research, Chicago, IL
Determining the role of the self-degradative cellular process
known as macro-autophagy in cancer has been complicated
by the realization that autophagy can be both tumorpromoting and tumor-suppressive depending on tissue
type, driving oncogene, and stage of progression. This
session addresses some of the key questions and
controversies pertaining to the role of autophagy in cancer
etiology and treatment including the function of autophagy
in the tumor microenvironment, the relative importance of
mitophagy relative to the process of autophagy as a whole,
the significance of key oncogenic signaling pathways in
modulating autophagy, and importantly the utility of
chloroquine and other lysosomotropic drugs in cancer
therapy. This session brings four experts in the field
together to present new data from their laboratories on
these topics and to discuss the ramifications of their work
for unanswered questions in the field.
1:00 p.m.
Introduction
1:10 p.m.
Contrasting consequences of autophagy
deficiency and mitophagy deficiency in
cancer [SY01-01]*
Kay F. Macleod, University of Chicago Ben
May Institute for Cancer Research, Chicago, IL
Chairperson: Tim E. Byers, University of Colorado Cancer
Center, Aurora, CO
The major chronic diseases (cancer, type 2 diabetes, and
cardiovascular disease) share many behavioral risk factors,
including tobacco, diet, obesity, and physical inactivity. In
addition, many mediating biological processes seem to
have similar effects on disease risk across these conditions,
including various hormonal factors and chronic
inflammation. In some instances, the mechanisms for how
behavioral factors affect risk are known, but in many
instances those mechanisms are unknown. The purpose of
this session is to systematically examine the similarities and
differences in how behavioral factors are related to risk of
cancer, type 2 diabetes, and cardiovascular disease within
the same cohorts in order to better define the limits of our
current understanding of common mechanisms that might
affect risk of multiple chronic diseases.
1:00 p.m.
Introduction
1:10 p.m.
Cancer, type 2 diabetes, and cardiovascular
diseases: Different stops on the same line?
Tim E. Byers, University of Colorado Cancer
Center, Aurora, CO
1:30 p.m.
Discussion
1:35 p.m.
Shared risk factors for diabetes,
cardiovascular disease, and cancer in a lowincome population [SY02-02]*
William J. Blot, International Epidemiology
Institute, Rockville, MD
1:30 p.m.
Discussion
1:35 p.m.
Autophagy and metabolic reprogramming
in the tumor stroma [SY01-02]*
Jorge Moscat, Sanford-Burnham Medical
Research Institute, La Jolla, CA
1:55 p.m.
Discussion
1:55 p.m.
Discussion
2:00 p.m.
2:00 p.m.
Oncogenic signaling and autophagy
regulation
Beth C. Levine, UT Southwestern Medical
Center, Dallas, TX
2:20 p.m.
Discussion
Mediators of the effect of overweight and
obesity on cardiovascular disease and
cancer: Evidence from pooling of
prospective studies
Goodarz Danaei, Harvard School of Public
Health, Boston, MA
2:25 p.m.
Chloroquine derivatives as anticancer
agents [SY01-04]*
Ravi K. Amaravadi, University of
Pennsylvania, Philadelphia, PA
2:20 p.m.
Discussion
2:25 p.m.
Risk factors associated with cancer, type 2
diabetes, and cardiovascular disease in the
multiethnic cohort: Comparisons across
ethnic groups [SY02-04]*
Lynne Wilkens, University of Hawaii Cancer
Center, Honolulu, HI
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:45 p.m.
Other
2:50 p.m.
General Discussion
217
MAJOR SYMPOSIA
Sunday, 1:00 p.m.-3:00 p.m.
Diverse Strategies for Targeting
Ras-Driven Cancers
Gene Expression Programs Underlying the
Stem Cell State
Chairperson: Karen Cichowski, Brigham and Women’s
Hospital, Boston, MA
Chairperson: Rudolf Jaenisch, Whitehead Institute for
Biomedical Research, Cambridge, MA
The Ras pathway is deregulated in the majority of human
cancers. However, there are currently no effective therapies
for Ras-driven tumors. This session will focus on how basic
mechanistic and preclinical studies in a variety of model
systems have been used to develop new small molecule
inhibitors, identify new targets and novel drug combinations,
and can guide mechanism-based clinical trials.
Key issues for using the full potential of the iPS cell
technology for disease research are creating molecular and
biological criteria that allow characterization of different
cell states. This symposium will discuss recent approaches
aimed at establishing molecular criteria that define the
pluripotent and differentiated state of human cells as well
as establishing stringent criteria that can be used for
quality control of iPS cells. In addition, efficient gene
editing approaches in human pluripotent cells that are
needed for creating disease-relevant phenotypes in the
culture dish will be discussed.
1:00 p.m.
Introduction
1:10 p.m.
Small molecule targeting K-Ras G12C
Kevan M. Shokat, University of California,
San Francisco, CA
1:30 p.m.
Discussion
1:35 p.m.
Developing novel combination therapies for
Ras-driven tumors
Karen Cichowski, Brigham and Women’s
1:55 p.m.
Discussion
2:00 p.m.
Targeting feedback mechanisms to
overcome addiction to oncogenic RAS
Jeffrey E. Settleman, Genentech, Inc.,
South San Francisco, CA
2:20 p.m.
Discussion
2:25 p.m.
Targeting Ras-driven tumors through cellextrinsic and -intrinsic mechanisms
Dafna Bar-Sagi, New York University
Langone Medical Center, New York, NY
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
1:00 p.m.
Introduction
1:10 p.m.
iPS cell technology, gene targeting, and
disease research
Rudolf Jaenisch, Whitehead Institute for
Biomedical Research, Cambridge, MA
1:30 p.m.
Discussion
1:35 p.m.
Mechanisms by which cells change
transcriptional programs
Kenneth S. Zaret, University of Pennsylvania,
Philadelphia, PA
1:55 p.m.
Discussion
2:00 p.m.
Molecular networks defining cell
identity [SY04-03]*
George Q. Daley, Children’s Hospital Boston,
Boston, MA
2:20 p.m.
Discussion
2:25 p.m.
Global analysis of long-range regulation of
gene expression in embryonic stem cells
Bing Ren, Ludwig Institute for Cancer
Research, La Jolla, CA
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
218
Terrace Ballroom IV (400 Level), Pennsylvania
Convention Center
Terrace Ballroom II-III (400 Level), Pennsylvania
Convention Center
Imaging of Immunotherapy in Action
Pan-Cancer Analysis of Whole Genomes
Chairperson: Sanjiv Sam Gambhir, Stanford University,
Stanford, CA
Chairperson: Peter J. Campbell, Wellcome Trust Sanger
Institute, Cambridge, United Kingdom
As immune therapies for cancer continue to advance with
promising results, molecular imaging strategies to monitor
immune cell subsets are also evolving. In order to truly
maximize benefit of a given individual’s immunotherapy, one
has to be able to answer many important questions. These
include: 1) Visualization of the location(s), numbers, and
viability of specific immune cell subsets, 2) Visualization of
the interaction of the immune cell with tumor cells, 3)
Visualization of specific immune cell and tumor cell targets
(e.g., checkpoint inhibitors), and 4)Visualization of the
efficacy of tumor volume reduction. Multiple new molecular
imaging probes for various imaging modalities (e.g., positron
emission tomography) are being translated for clinical use
and may help to fully optimize existing and evolving
immunotherapies. Investigators developing novel
immunotherapies working closely with the molecular
imaging community should lead to improved cancer
management through advances in both immunotherapy and
molecular imaging probe development.
The Pan-Cancer analysis of Whole Genomes (PCAWG)
project of the International Cancer Genome Consortium
(ICGC) and The Cancer Genome Atlas (TCGA) is
coordinating analysis of more than 2,000 whole cancer
genomes. Each genome is characterized through a suite of
centralized algorithms, including alignment to the
reference genome, standardized quality assessment, and
calling of all classes of somatic mutation. Scientists
participating in the research projects of PCAWG are
addressing a series of fundamental questions about cancer
biology and evolution based on these data, a sample of
which will be presented at this session. Key areas of study
include: 1) Discovery of driver mutations outside of the
protein-coding regions of the genome; 2) Integrating
mutational signatures across tumor types and mutation
categories; 3) Characterizing subclonal structures and
patterns of genome evolution across cancers; 4)
Investigating relationships between germline and somatic
mutations; 5) Investigating biological pathways targeted
by driver mutations.
1:00 p.m.
Introduction
1:10 p.m.
Non-immunogenic PET reporter imaging of
HSC transplants and T cell immunotherapies
[SY05-01]*
Owen N. Witte, University of California,
Los Angeles, CA
1:00 p.m.
Introduction
1:10 p.m.
Cancer genome analysis in the cloud:
Technical, ethical, and legal challenges
Lincoln Stein, Ontario Institute for Cancer
Research, Toronto, ON, Canada
1:30 p.m.
Discussion
1:30 p.m.
Discussion
1:35 p.m.
Fluorine-19 MRI cell tracking for immune
cell detection and quantification in vivo
Eric T. Ahrens, University of California-San
Diego, La Jolla, CA
1:35 p.m.
Investigation of germline genetic variation
in 2,500 whole cancer genomes
Jan Korbel, European Molecular Biology
Laboratory, Heidelberg, Germany
1:55 p.m.
Discussion
1:55 p.m.
Discussion
2:00 p.m.
Visualizing immune responses in cancer
patients
Jolanda de Vries, Nijmegen Centre for
Molecular Life Sciences, Nijmegen, The
Netherlands
2:00 p.m.
Pathways and drivers in 2,000 cancer
genomes
Joshua M. Stuart, University of California,
Santa Cruz, CA
2:20 p.m.
Discussion
2:20 p.m.
Discussion
2:25 p.m.
2:25 p.m.
Imaging of T cells in humans
Sanjiv Sam Gambhir, Stanford University,
Stanford, CA
Structural variation in 2,000 cancer
genomes
Peter J. Campbell, Wellcome Trust Sanger
Institute, Cambridge, United Kingdom
2:45 p.m.
Discussion
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:50 p.m.
General Discussion
219
MAJOR SYMPOSIUM
Sunday, 1:00 p.m.-3:00 p.m.
Grand Ballroom (300 Level), Pennsylvania Convention Center
Tumor Heterogeneity: Targets and
Mechanisms
Chairperson: Charles Swanton, Cancer Research UK
London Research Institute, London, United Kingdom
Cancer heterogeneity is a driving force for tumor
adaptation and therapeutic failure. Understanding
mechanisms that precipitate intratumor heterogeneity and
generating approaches that exploit cancer diversity are
likely to contribute to future advances in hematological
and solid tumor oncology. This session will review
emerging data from functional genomics and cell biological
studies that shed light on drivers of numerical and
structural chromosomal instability and the impact of
genome doubling events upon cancer evolution. Evidence
will be presented for the activity of specific mutational
processes during cancer progression and their impact upon
the origin of driver events during tumor evolution. This
session will review emerging therapeutic approaches that
exploit cancer diversity through vaccine development and
immune surveillance.
1:00 p.m.
Introduction
1:10 p.m.
New targets in combination cancer
immunotherapies [SY07-01]*
Mark J. Smyth, QIMR Berghofer Medical
Research Institute, Herston, Australia
1:30 p.m.
Discussion
1:35 p.m.
Identifying drivers of cancer diversity
Charles Swanton, Cancer Research UK
London Research Institute, London,
United Kingdom
1:55 p.m.
Discussion
2:00 p.m.
Mechanisms of numerical and structural
chromosomal instability: A driving force for
cancer heterogeneity
René H. Medema, Netherlands Cancer
Institute, Amsterdam, The Netherlands
2:20 p.m.
Discussion
2:25 p.m.
The evolutionary landscape of CLL:
Therapeutic implications [SY07-04]*
Catherine J. Wu, Dana-Farber Cancer
Institute, Boston, MA
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
220
PROFESSIONAL ADVANCEMENT SESSION (not eligible for CME credit)
Sunday, 1:00 p.m.-3:00 p.m.
Regency Ballroom A-B (Second Floor), Loews Philadelphia Hotel
Careers in the Pharmaceutical and Biotechnology Industries
Organized by the Associate Member Council (AMC)
Attendees will learn from senior leaders of major biotechnology and pharmaceutical companies about
the mission of and career opportunities in industry. Early-career scientists will also hear from a panel
of biomedical PhDs and MDs in the field who will provide diverse perspectives on the research
environment, career trajectories, and hiring process for transitioning into a career in industry.
Following the lectures and panel discussion, the session will conclude with a 30-minute networking
activity with invited industry scientists and representatives.
The Associate Member Council organizes several Professional Advancement Sessions aimed
specifically toward the professional needs of graduate students, medical students and residents, and
clinical and postdoctoral fellows. Each year the topics change to cover a broad range of interests
relevant to early-career scientists. For AACR members, all 2015 Professional Advancement Sessions
are free with your Annual Meeting registration (except for $45 for the Grant Writing Workshop) and
are an added benefit of your membership. For nonmembers, there is an additional fee of $50 ($95 for
the Grant Writing Workshop) for attendance at each session. If you are not an AACR member, we
strongly encourage you to join and take advantage of the many benefits of membership, which
include attendance at these sessions. Participation is on a first-come, first-served basis, and space is
limited. Nonmembers are required to pay on site. #AACRcareer
Why you should consider a career in industry
Ira Mellman, Genentech, Inc., South San Francisco, CA
How to start your career in industry
Victoria M. Richon, Sanofi Oncology, Wellesley Hills, MA
Panelists:
Steven D. Averbuch, Bristol-Myers Squibb Co., Princeton, NJ
Roy D. Baynes, Merck Research Laboratories, Rahway, NJ
Valeria R. Fantin, Pfizer, Inc., San Diego, CA
Susan M. Galbraith, AstraZeneca, Macclesfield, United Kingdom
Axel Hoos, GlaxoSmithKline Pharmaceuticals and The Sabin Vaccine Institute, Collegeville, PA
221
RECENT ADVANCES IN DIAGNOSTICS AND THERAPEUTICS RESEARCH
Sunday, 1:00 p.m.-3:00 p.m.
Biomarkers of Antiangiogenic Therapy: Are
We Lost in Translation?
Genomic Investigations in Childhood Cancers
Chairperson: Diether Lambrechts, Catholic University of
Leuven, Leuven, Belgium
Antiangiogenic therapies have been proven to slow
metastatic disease progression in patients with cancer.
Although they have changed clinical practice, some
patients do not respond or gradually develop resistance,
resulting in rather modest gains in terms of overall survival.
A major challenge is to develop robust biomarkers that can
guide selection of those patients for whom antiangiogenic
therapy is most beneficial. In this session, we will discuss
recent progress in identifying such markers, including
potential circulating plasma markers, as well as novel
(epi)genetic and imaging biomarkers. Finally, we will also
focus on novel insights underlying resistance to
antiangiogenesis, and how these may offer new strategies
and opportunities to overcome resistance to
antiangiogenic therapy.
1:00 p.m.
Personalized antiangiogenic therapy:
Insights, strategies, and opportunities
Lee M. Ellis, The University of Texas MD
Anderson Cancer Center, Houston, TX
1:20 p.m.
Discussion
1:25 p.m.
The quest for predictive markers of
antiangiogenic therapy in the age of
molecular classification of disease
Priti S. Hegde, Genentech, Inc., South San
Francisco, CA
1:45 p.m.
Discussion
1:50 p.m.
Genetic and epigenetic markers predictive
of antiangiogenic treatment outcome
Diether Lambrechts, Catholic University of
Leuven, Leuven, Belgium
2:10 p.m.
Discussion
2:15 p.m.
Insights from imaging biomarkers of
antiangiogenic therapy
Rakesh K. Jain, Massachusetts General
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
222
Chairperson: Olivier Delattre, Institut Curie, Paris, France
Genomic investigations have radically transformed the field
of pediatric oncology. They provide new clues to decipher
the molecular mechanisms of tumor development and new
biomarkers that can be tested in a clinical setting. The long
thought inter- and intratumor heterogeneity of
neuroblastoma, brain tumors, and sarcoma can now be
documented on precise genetic bases. The contributions of
divergent subclones in the dynamics and plasticity of the
tumor ecosystem can be addressed. Germline genetic
analyses have also considerably increased our knowledge
of the individual susceptibility to develop these cancers.
The challenge ahead is now to use this new information to
improve the management of patients and to propose and
implement new strategies for diagnosis, follow up,
and treatment.
1:00 p.m.
Translating genomic landscapes into better
treatments: Opportunities and challenges in
neuroblastoma
John M. Maris, Children’s Hospital of
Philadelphia, Philadelphia, PA
1:20 p.m.
Discussion
1:25 p.m.
Implication of omics data for the treatment
of childhood tumors
Peter Lichter, German Cancer Research
Center, Heidelberg, Germany
1:45 p.m.
Discussion
1:50 p.m.
Harnessing genomics for diagnosis,
prognosis, and treatment selection in the
pediatric oncology unit
Katherine A. Janeway, Dana-Farber Cancer
Institute, Boston, MA
2:10 p.m.
Discussion
2:15 p.m.
“Liaisons dangereuses” between germline
and somatic variations in Ewing sarcoma
Olivier Delattre, Institut Curie, Paris, France
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Phenotypic Screening for Optimizing
Cancer Therapy
Chairperson: Mark E. Burkard, University of WisconsinMadison, Madison, WI
Phenotypic screens simultaneously discover novel drug
leads and targets that elicit a desired biological effect.
These screens can yield seminal advances without
requiring prior detailed mechanistic knowledge. However,
phenotypic screens also pose the challenge of identifying
molecular targets and unraveling mechanism. This session
will provide an overview of how screening for phenotypes
can advance knowledge of cancer biology, discover drug
targets, and improve treatment of cancer.
1:00 p.m.
The impact of phenotypic screens in
cancer therapy
Mark E. Burkard, University of WisconsinMadison, Madison, WI
1:20 p.m.
Discussion
1:25 p.m.
Multidimensional profiling of small
molecules in cancer drug discovery
Brent R. Stockwell, Columbia University,
New York, NY
1:45 p.m.
Discussion
1:50 p.m.
Zebrafish screens and novel strategies for
drug target identification
Alejandro Gutierrez, Boston Children’s
2:10 p.m.
Discussion
2:15 p.m.
Systematic mapping of signaling pathways
controlling anticancer drug responses
Kris C. Wood, Duke University, Durham, NC
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
223
RECENT ADVANCES IN EPIDEMIOLOGY AND PREVENTION RESEARCH
Sunday, 1:00 p.m.-3:00 p.m.
Cancer Immunoprevention
Chairperson: Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA
Most immune-based approaches to dealing with the cancer epidemic, including vaccines, have
focused on people who have already developed cancer. Vaccines against cancer causing viruses
have had great successes in preventing cancer by targeting viral antigens. Non-viral cancers also
express antigens that trigger immune responses and testing vaccines against these antigens to
prevent cancer occurrence or progression has become possible. This session will review ongoing
efforts to prevent both viral and non-viral cancers by vaccinating individuals at risk. A combination
of animal and human studies will be presented with special emphases on targeting antigens present
on premalignant lesions.
1:00 p.m.
Vaccines targeting antigens expressed in preinvasive lesions
Mary L. Disis, University of Washington, Seattle, WA
1:20 p.m.
Discussion
1:25 p.m.
New strategies to use a clinically effective cancer vaccine in a prophylactic setting
Sjoerd H. Van Der Burg, Leiden University Medical Center, Leiden, The Netherlands
1:45 p.m.
Discussion
1:50 p.m.
Breast cancer vaccines: Opportunities for prevention
Elizabeth A. Mittendorf, The University of Texas MD Anderson Cancer Center,
Houston, TX
2:10 p.m.
Discussion
2:15 p.m.
Prophylactic cancer vaccines targeting human tumor associated antigens
Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
224
RECENT ADVANCES IN ORGAN SITE RESEARCH
Sunday, 1:00 p.m.-3:00 p.m.
New Insights in Estrogen Receptor Biology
and Implications for Treatment
New Insights into the Role of Ultraviolet
Radiation in Melanoma
Chairperson: John A. Katzenellenbogen, University of
Illinois at Urbana-Champaign, Urbana, IL
Chairperson: Adele C. Green, Queensland Institute of
Medical Research, Brisbane, Australia
Cancer is characterized by marked changes in the patterns
of gene expression arising from alterations in signaling
pathways and changes in transcription factor binding and
activity. This symposium will cover various approaches
taken to understand in what ways estrogen receptor (ER)
activity and ER itself are altered in breast cancers. It will
also explore how a better understanding of these changes
might lead to improved endocrine therapy agents
targeting ER or other components of its signaling pathway.
The presentations will cover how the genomic activity of
ER is altered in breast cancers, how ER mutations in
recurrent disease can defeat current endocrine therapies,
how the transcriptional activity of ER might be regulated
by targeting coregulators, and how positron emission
tomographic imaging of ER levels and ER function might
improve the selection of patients most likely to benefit
from endocrine therapies.
This session pulls together a diversity of recent evidence
about UV radiation as the main causal agent for melanoma.
Starting with an overview of the evidence from human
populations, we then consider the specific mechanisms
involved in melanoma’s pathogenesis. We show how mouse
models and next-generation sequencing are being used to
investigate UV-driven melanomagenesis. We next look at how
UV affects the balance between antitumor immunity and
protumorigenic inflammatory responses in the skin
microenvironment, focusing on the neutrophil’s ability to
promote melanoma-endothelial cell interactions. Finally we
discuss the interrelationships between the skin, melanin
synthetic pathways, and UV radiation that underlie melanoma
risk, with insights from genetically defined models and
measures ranging from the molecular to the behavioral.
1:00 p.m.
Understanding the genomic properties of
estrogen receptor activity in breast cancer
Jason Carroll, Cancer Research UK
Cambridge Research Institute, Cambridge,
United Kingdom
1:20 p.m.
Discussion
1:25 p.m.
Biologic and clinical significance of
estrogen receptor mutations in cancer
Sarat Chandarlapaty, Memorial Sloan
Kettering Cancer Center, New York, NY
1:45 p.m.
Discussion
1:50 p.m.
Mechanisms and therapy potential for
transcriptional coactivators
David M. Lonard, Baylor College of Medicine,
Houston, TX
2:10 p.m.
Discussion
2:15 p.m.
PET imaging of breast cancers to predict
patient benefit from endocrine therapies
John A. Katzenellenbogen, University of
Illinois at Urbana-Champaign, Urbana, IL
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
1:00 p.m.
Epidemiologic evidence of the causal
association between UV radiation and
melanoma
Adele C. Green, Queensland Institute of
Medical Research, Brisbane, Australia
1:20 p.m.
Discussion
1:25 p.m.
How ultraviolet radiation drives
melanomagenesis
Richard M. Marais, Cancer Research
UK Manchester Institute, Manchester,
United Kingdom
1:45 p.m.
Discussion
1:50 p.m.
UV irradiation, immunity, and inflammation
in melanoma pathogenesis
Thomas Tüting, University of Bonn, Bonn,
Germany
2:10 p.m.
Discussion
2:15 p.m.
Cutaneous UV and pigmentation pathways
and their effects on melanoma risk
David E. Fisher, Massachusetts General
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
225
REGULATORY SCIENCE AND POLICY SESSION
Sunday, 1:00 p.m.-3:00 p.m.
The Role of Neoadjuvant Treatment in Drug Development for Solid Tumors
Co-Chairpersons: Marc Theoret, U.S. Food and Drug Administration, Silver Spring, MD; Tatiana M.
Prowell, U.S. Food and Drug Administration, Silver Spring, MD, and Johns Hopkins Kimmel Cancer
Center, Baltimore, MD
Clinical evidence supports the use of neoadjuvant treatment in high-risk early-stage breast cancer. The
U.S. Food and Drug Administration (FDA) recently finalized guidance on "Pathological Complete
Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to
Support Accelerated Approval," and further has granted accelerated approval to pertuzumab for
neoadjuvant treatment of early-stage breast cancer.
This session will explore the potential for drug development and approval in the neoadjuvant setting
in other solid tumors, namely melanoma and bladder cancer. Speakers will discuss the scientific,
clinical, and regulatory considerations for use of the neoadjuvant pathway in drug development, as
well as lessons that can be learned from the neoadjuvant breast cancer setting that may be applicable
to other solid tumors.
A panel discussion moderated by Tatiana Prowell, U.S. Food and Drug Administration, and Marc
Theoret, Food and Drug Administration, and audience Q and A will follow the presentations.
Speakers:
Marc Theoret, U.S. Food and Drug Administration, Silver Spring, MD
Tatiana M. Prowell, U.S. Food and Drug Administration, Silver Spring, MD, and Johns Hopkins Kimmel
Cancer Center, Baltimore, MD
Renzo Canetta, Bristol-Myers Squibb Co., Wallingford, CT
Paul B. Chapman, Memorial Sloan Kettering Cancer Center, New York, NY
Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA
Caitlin Riley, Cancer Survivor and Patient Advocate, Washington, DC
226
POSTER SESSION
Poster Section 1 • Sunday, 1:00 PM-5:00 PM
Molecular and Cellular Biology
Cell Death Mechanisms
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
1 Noxa and ceramide: Crosstalk between Bcl-2 family
members and ceramide in mediating intrinsic apoptosis in
Molt-4 human T-cell leukemia. Hadile Kobeissy, Rouba
Hage-Sleiman, Ghassan Dbaibo.
2.
2 Phosphorylation of BNIP3 is a switch between life
and death in cancer cells. William Frazier, Katherine Liu,
Julie Dimitry, Benjamin Capoccia, Pamela Manning, Robert
Karr.
3.
3 Mechanistic rationale for MCL1 inhibition during
androgen deprivation therapy. Frédéric R. Santer, Holger H.
Erb, Su Jung Oh, Florian Handle, Gertrud E. Feiersinger, Birgit
Luef, Huajie Bu, Georg Schäfer, Christian Ploner, Martina
Egger, Jayant K. Rane, Norman J. Maitland, Helmut Klocker,
Iris E. Eder, Zoran Culig.
4.
4 ABT-263 is effective in a subset of non-small cell lung
cancer cell lines. Aoi Kuroda, Keiko Ohgino, Hiroyuki Yasuda,
Junko Hamamoto, Daisuke Arai, Kota Ishioka, Tetsuo Tani,
Shigenari Nukaga, Ichiro Kawada, Katsuhiko Naoki, Kenzo
Soejima, Tomoko Betsuyaku.
5.
6.
5 Mcl-1-mediated resistance to ABT-263 is combated
by mTOR inhibition in luminal breast cancers. Michelle M.
Williams, Linus Lee, Violeta Sanchez, Meghan M. Morrison,
Donna Hicks, Rebecca S. Cook.
6 Quantitative assessment of BCL-2:BIM complexes as
a pharmacodynamic marker for venetoclax (ABT-199). Sha
Jin, Paul Tapang, Donald J. Osterling, Wenqing Gao, Daniel H.
Albert, Andrew J. Souers, Joel D. Leverson, Darren C. Phillips,
Jun Chen.
Poster
Board
Abstract
Number
17.
17 Xiap over-expression is a poor prognostic marker in
breast cancer and can be targeted to induce efficient
apoptosis. Azhar R. Hussain, Maqbool Ahmed, Rong Bu,
Shaham Beg, Alanood M. Alrashed, Roxanne Melosantos,
Dahish S. Ajarim, Shahab Uddin, Khawla S. AlKuraya.
18.
18 Prohibitin 1 regulates apoptosis via its interaction
with XIAP. Yingjie Xu, Wen Yang, Virginia Guarani, Jinjun Shi,
J. Wade Harper, Bruce R. Zetter.
19.
19 Antitumor activity of selective inhibitors of XPO1/
CRM1-mediated nuclear export in diffuse malignant
peritoneal mesothelioma: the role of survivin. Nadia
Zaffaroni, Michelandrea De Cesare, Denis Cominetti,
Valentina Doldi, Alessia Lopergolo, Marcello Deraco, Paolo
Gandellini, Yosef Landesman, Sharon Friedlander, Michael G.
Kauffman, Sharon Shacham, Marzia Pennati.
20.
20 Honokiol radiosensitizes squamous cells carcinoma of
head and neck by down-regulation of survivin. Xu Wang,
Jonathan J. Beitler, Wen Huang, Guoqing Qian, Kelly Magliocca, Jun
Zhang, Sreenivas Nannapaneni, Sungjin Kim, Zhengjia Chen, Saba F.
Nabil, Zhuo G. Chen, Jack L. Arbiser, Dong M. Shin.
21.
21 TWIST1 is required for suppression of apoptosis in
oncogene driven non-small cell lung carcinoma. Zachary A.
Yochum, Jessica A. Cades, Lucia Mazacurati, Sarah Chatley,
Phuoc T. Tran, Timothy F. Burns.
22.
22 Genetic re-programming of the acute myeloid
leukemia cell line HL-60: Regulation of cell proliferation,
differentiation, and programmed cell death. Michael
Roberts, Cassandra Holbert, Mansoor Ghoto, Juliana
Schneider, Abigail Marriott, Jeffrey Forrester.
7.
7 PARP and Bcl-2 co-inhibition in small cell lung cancer
(SCLC). Janaya Shelly, Robert J. Cardnell, Fatemeh
Masrorpour, Lixia Diao, Jing Wang, Lauren Byers.
23.
8.
8 Differential roles of OCT3/4, SOX2 and NANOG for
constitutive high NOXA expression levels in embryonal
carcinoma (EC) cells. Christine Bayha, Matthias Gutekunst,
Walter E. Aulitzky, Heiko van der Kuip.
23 Nuclear receptor PPAR␣ activation triggers hepatic
cell death in Ikk␤-deficient mice. Jung-Hwan Kim,
Taehyeong Kim, Aijuan Qu, Frank J. Gonzalez.
24.
11 Molecular mechanisms of inverse association
between cancer and Alzheimer’s disease. Yoosoo Yang,
EunJung Lee, In-San Kim.
24 The phosphorylation of p53 at serine 46 is essential
to induce cell death through palmdelphin in response to
DNA damage. Nurmaa K. Dashzeveg, Kiyotsugu Yoshida.
25.
12.
12 Bclxl is a key regulator of mitochondria-induced
apoptosis in ovarian cancer stem cells. Ayesha B. Alvero,
Mary Pitruzello, Michele Montagna, Eydis Lima, Gil Mor.
25 Loss of interferon-induced transmembrane protein
1 enhances estrogen-induced cell death in AI-resistant
breast cancer cells. Hye Joung Choi, Joan Lewis-Wambi.
26.
13.
13 Biophysical evidence for the existence of a
functional interaction between the small GTPase Rac-1 and
the anti-apoptotic protein Bcl-2. Jia Kang, Shani Ajumal,
Kunchithapadam Swaminathan, Shazib Pervaiz.
26 Suppression of E-cadherin mediates gallotannin-induced
apoptosis in Hep G2 hepatocelluar carcinoma cells. Hee Young
Kwon, Ji Hoon Jung, Hyun Joo Lee, Myoung Seok Jeong, DeokBeom Jung, Bonglee Kim, Hyemin Lee, Sung-Hoon Kim.
27.
14.
14 Nucleolin phosphorylation by CK2 is important for
its role in regulating apoptosis. Esther Akinwunmi, Shu
Xiao, Yuqi Guo, Xin Li, Anjana D. Saxena.
27 The role of the mTORC2-dependent regulation of
FOXO3a in UVB-induced apoptosis. Robert P. Feehan, Lisa
M. Shantz.
28.
15.
15 gp78 is a negative regulator of TRAIL-induced
apoptosis in breast cancer cells. Jennifer L. Dine, Sireesha V.
Garimella, Kristie Gehlhaus, Magda Grandin, Daniel Letwin,
Natasha Caplen, Stanley Lipkowitz.
28 Deregulation of NAC complex inhibits muscle
differentiation and blocks apoptosis in
rhabdomyosarcoma cells. Meiling Zhang, Judith Davie.
29.
29 Potent curcumin analog FLLL12 induces apoptosis in
lung cancer cells through death receptor-5-dependent
pathway. Abedul Haque, Mohammad A. Rahman, James R.
Fuchs, Zhuo G. Chen, Fadlo R. Khuri, Dong M. Shin, A. R. M. R.
Amin.
11.
16.
16 Combination simvastatin and metformin induces G1phase cell cycle arrest and Ripk1- and Ripk3-dependent
necroptosis in C4-2B osseous metastatic castration-resistant
prostate cancer cells. Melissa A. Babcook, R. Michael
Sramkoski, Hisashi Fujioka, Firouz Daneshgari, Alexandru
Almasan, Sanjeev Shukla, Sanjay Gupta.
April 18 –22, 2015 • Philadelphia, PA
1
1
227
POSTER SESSION
Poster
:LJ[PVU
2
2
Cell Signaling in Cancer 1
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
228
Abstract
Number
30 Medi3622, a monoclonal antibody to ADAM17,
inhibits tumor growth by inhibiting EGFR- and non-EGFRmediated pathways. Darrin Sabol, Jonathan RiosDoria, Jon
Chesebrough, David Stewart, Kevin Schifferli, Raymond
Rothstein, Ching Ching Leow, Jenny Heidbrink-Thompson, Li
Cheng, Qun Du, Linda Xu, Xiaofang Jin, Ravinder Tammali,
Chanshou Gao, Jay Friedman, Brandy Wilkinson, Melissa
Damschroder, Andrew Pierce, MunMun Patnaik, Rong Zeng,
Yuling Wu, Susan Spitz, Gabriel Robbie, Lorin Roskos, Robert
Hollingsworth, David Tice, Emil Michelotti.
31 WEE1 kinase inhibition enhances PI3K inhibitor
response in p53 deficient gliomas. Shaofang Wu, Siyuan
Zheng, Shuzhen Wang, W. K. Alfred Yung, Dimpy Koul.
32 The role of Lrig1 signaling in mammary gland
development and tumorigenesis. Catalina Simion, Qian
J. Chen, Charles L. Wilkerson, Hanine Rafidi, Alexander D.
Borowsky, Colleen Sweeney.
33 Mammary gland-specific deletion of Sirt1 delays
mammary tumor growth and progression. Sabarish
Ramachandran, Rajneesh Pathania, Selvakumar Elangovan,
Ganapathy Vadivel, Muthusamy Thangaraju.
34 AMH and AMHR2 regulate survival signaling,
epithelial-mesenchymal transition (EMT) and resistance to
HSP90 inhibition in non-small cell lung cancer (NSCLC).
Tim Beck, Emmanuelle Nicolas, Yan Zhou, Ilya Serebriiskii,
Erica Golemis.
35 Diacylglycerol kinase zeta-mediated regulation of
mTOR and SREBP-1 offers new opportunities for cancer
management. PEDRO Torres-Ayuso, David Jones, Maria
Tello-Lafoz, Antonia Avila-Flores, Isabel Merida.
36 Cross-talk of the cytokine pathways in cancer
progression. Andrei V. Bakin, Michelle Limoge, Amy Beattie.
37 Role and regulation of CYP24A1 in endometrial
cancer. Amber A. Bokhari, Laura R. Lee, Raboteau Dewayne,
Chad A. Hamilton, George L. Maxwell, Gustavo C. Rodriguez,
Viqar Syed.
38 ERK5 inhibitor XMD8-92 for malignant
mesothelioma treatment: A preclinical study. Arti Shukla,
Joyce Thompson, Anurag Shukla, Alan Leggett, Maximilian
MacPherson, Stacie Beuschel.
39 Fibroblast growth factor induces neoplastic cell
transformation through a non-canonical signaling
pathway. Sun-Mi Yoo, Cheol-Jung Lee, Mee-Hyun Lee, YongYeon Cho.
40 HB-EGFmediated CITED4 signaling in lung cancer.
Cheng-Han Hsieh, Yu-Ting Chou, Cheng-Wen Wu.
41 The Wnt3a targetome in triple-negative breast
cancer cell lines. Sylvie Maubant, Bruno Tesson, Virginie
Maire, Mengliang Ye, Guillem Rigaill, David Gentien, Francisco
Cruzalegui, Gordon C. Tucker, Sergio Roman-Roman, Thierry
Dubois.
42 The NF-␬B/MDM2 pathway is engaged in activin/
PI3 kinase induced degradation of p21 in colon cancer
cells. Arundhati Jana, Seung Hyua Baik, Timothy Carroll,
Ozkan Ozden, Nancy L. Krett, Barbara Jung.
43 The role of discoidin domain receptor 2 (DDR2) and
its relationship with procollagen alpha 1 type 1(Col1A1) in
malignant glioma. Shumei Chen, Chunjing Wu, Ying Ying Li,
Medhi Wangpaichitr, Lynn G. Feun, Ronald Benveniste, Vy
Dinh, Niramol Savaraj.
44 EGFR and Dock180 activate MLK3 to drive invasion
of glioblastoma cells. Sean A. Misek, Jian Chen, Kathleen A.
Gallo.
45 TRAF2 phosphorylation regulates CD40 signaling
and B cell lymphoma progression. Hasem Habelhah, Lauren
Workman, Laiqun Zhang.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
46 XPC inhibits NSCLC cell proliferation and migration
by enhancing E-cadherin expression. Tiantian Cui, Amit K.
Srivastava, Chunhua Han, Ran Zhao, Linlin Yang, Ning Zou,
Meihua Qu, Wenrui Duan, Xiaoli Zhang, Weiqiang Zhao, Qi-En
Wang.
47 KRAS-mutation dependent effect of zoledronic acid
in human NSCLC preclinical models. István Kenessey,
Krisztina Kói, Mihály Cserepes, Judit Dobos, Balázs Hegedűs,
József Tóvári, József Tímár.
48 Identification of a novel binding protein playing a
critical role in HER2 activation in lung cancer cells. Tomoaki
Ohtsuka, Masakiyo Sakaguchi, Katsuyoshi Takata, Shinsuke
Hashida, Mototsugu Watanabe, Ken Suzawa, Yuho Maki,
Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Kazunori
Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka.
49 Interaction of the protein kinase C-related kinases
with the TP␣ and TP␤ isoforms of the T prostanoid
receptor: role in thromboxane-induced neoplastic
responses. Eamon P. Mulvaney, Aine G. O’Sullivan, B T.
Kinsella.
50 Elucidation of B cell receptor signaling in Burkitt’s
lymphoma reveals novel signaling nodes with potential
therapeutic relevance. Carmen Doebele, Jasmin Corso,
Anjali Cremer, Silvia Muench, Julia Beck, Christof Lenz,
Hanibal Bohnenberger, Astrid Wachter, Tim Beissbarth,
Ekkehard Schütz, Hubert Serve, Henning Urlaub, Thomas
Oellerich.
51 The codon 72 polymorphism in p53 is a gain-offunction alteration leading to activation of map kinase
signaling and epithelial-to-mesenchymal transition in
colon cancer. Venkat Katkoori, Lashmishankar Chaturvedi,
Marc D. Basson, Upender Manne, Harvey L. Bumpers.
52 Glycogen synthase kinase inhibition associated with
Notch-1 reduction in cholangiocarcinoma. Kevin M.
Sokolowski, Selvi Kunnimalaiyaan, T Clark Gamblin,
Muthusamy Kunnimalaiyaan.
53 Interplay among E3 ubiquitin ligases regulate timely
degradation of the circadian factor Period 2. Carla V.
Finkielstein, jingjing liu.
54 Ezrin enhances signaling and nuclear translocation
of the epidermal growth factor receptor in non-small cell
lung cancer cells. Yasemin Saygideger Kont, Haydar Celik,
Hayriye V. Erkizan, Tsion Minas, Jenny Han, Jeffrey Toretsky,
Aykut Uren.
55 Over-expression of FoxM1 in breast cancer can be
therapeutically targeted using thiostrepton. Maqbool
Ahmed, Azhar Hussain, Rafiya Begum, Saravanan Thangavel,
Dahish S. Ajarim, Shaham Beg, Shahab Uddin, Khawla S. AlKuraya.
56 Receptor-Interacting protein kinase 1 functions as
an oncogenic regulator in human melanoma. Lei Jin, Xiao
Ying Liu, Fritz Lai, Xu Guang Yan, Chen Chen Jiang, Su Tang
Guo, Chun Yan Wang, Amanda Croft, Hsin-Yi Tseng, James S.
Wilmott, Richard A. Scolyer, Xu Dong Zhang.
57 Substrates of protein kinase C drive cell rac1dependent motility. Susan A. Rotenberg, Xin Zhao,
Shatarupa De.
58 5-HT promotes hepatocellular carcinoma by
influencing ␤-catenin. Sarwat Fatima, Shi Xiaoki, Lin Zesie,
Chen Guo, John W. Ho, Nikki P. Lee, Xiang Bian Zhao.
59 Rhodiola Crenulata differentially regulates ER
activity over time in MCF7 breast cancer cell lines by
regulating ␤-catenin activity. Lotfi M. Bassa, Sallie S.
Schneider.
POSTER SESSION
Computational Tools / Genomic Profiling of Tumors
Poster
Board
Abstract
Number
1.
60 Genotranscriptomic meta-analysis of centromere
protein A (CENPA): An essential role in human cancer
progression. Xia Sun, Sifeng Qu.
2.
61 Sequence and structure-guided approach to
identify functional mutations in G-protein coupled
receptors. Sohini Sengupta, Kai Ye, Adam D. Scott, Beifang
Niu, Matthew H. Bailey, Michael D. McLellan, Michael C.
Wendl, Matthew A. Wyczalkowski, Li Ding.
3.
62 COSMIC: Combining the world’s knowledge of
somatic mutation in human cancer. Simon A. Forbes, Dave
Beare, Prasad Gunasekaran, Kenric Leung, Charambulos
Boutselakis, Minjie Ding, Mingming Jia, Tisham De, Nidhi
Bindal, Chai Yin Kok, Sally Bamford, Sari Ward, Charlotte
Cole, Jon Teague, Michael R. Stratton, Peter J. Campbell.
4.
63 Alview (ALignment VIEWer): A software tool to
visualize next generation sequencing (NGS) data. Daoud
Meerzaman, Richard Finney, Qing-Rong Chen, Cu Nguyen,
Chih Hao Hsu, Barbra Dunn.
5.
64 Targeting immune checkpoints: using a big data
approach for their identification, prioritization and
application. Sheetal Kaw, Sanatan Upmanyu, Himani
Sharma, Krishnan Nandabalan.
6.
65 An integrated bioinformatics approach for
identifying patient-specific gene networks and novel
therapeutic targets in glioblastoma. Vasileios Stathias,
Chiara Pastori, Ricardo Komotar, Ming Zhang, Stephan
Schürer, Jennifer Clarke, Nagi G. Ayad.
7.
66 CD99 functional analysis in glioblastoma by
RNAseq. Sueli M. Oba-Shinjo, Lais C. Cardoso, Roseli D. Silva,
Antonio M. Lerario, Miyuki Uno, Suely S. Marie.
8.
67 Genomic and mutational profiling of human colon
adenomas reveals early driver mutations and a TGF-␤CEA regulated profile. Vipin K. Menon, Raju S.
Gottumukkala, Jian Chen, Xiaoping Su, Nipun Mistry, Avijit
Majumdar, Ji-Hyun Shin, Shulin Li, Kirti Shetty, Xifeng Wu,
Brian Weston, Ethan Miller, John R. Stroehlein, Marta L.
Davila, Mehnaz A. Shafi, Asif Rashid, Bhaskar V. Kallakury,
Selvi Thirumurthi, John S. McMurray, Sue-Hwa Lin, Wilma
Jogunoori, Lopa Mishra.
9.
10.
68 Exomic landscape of uterine leiomyosarcomas.
Netta Mäkinen, Tuomas Heikkinen, Mervi Aavikko, Ralf
Bützow, Pia Vahteristo.
Poster
Board
Abstract
Number
11.
70 Targeted sequencing analyses of uterine and
ovarian carcinosarcoma. Seiichi Mori, Osamu Gotoh, Sayuri
Amino, Megumi Nakai, Yutaka Takazawa, Yuko Sugiyama,
Tetsuo Noda.
12.
71 Epigenetic control of signature gene expression in
the inducible differentiation of acute promyelocytic
leukemia cells. Chunhua Song, Xiaokang Pan, Zhanjun Li,
Yali Ding, Sunil Mudhusami, Chandrika Gowda, Zheng Ge,
Sadie Steffens, Bi-hua Tan, Sinisa Dovat.
13.
72 Comprehensive dissection of genomic signature of
acute myeloid leukemia: crosstalk between germline
variants and somatic mutations. Daeyoon Kim, Chansu Lee,
Kwang-Sung Ahn, Youngil Koh, Sung-Soo Yoon.
14.
73 Targeting KDR mutations in lung adenocarcinoma.
Susan M. Mockus, Christopher S. Potter, Grace A. Stafford,
Guruprasad Ananda, Douglas Hinerfeld, Gregory J. Tsongalis.
15.
74 Establishment and characterization of the new
sacral chordoma cell line Chor-IN-1. Paola Magnaghi,
Roberta Bosotti, Nadia Amboldi, Liviana Cozzi, Alessio
Somaschini, Silvia Stacchiotti, Fabio Bozzi, Elena Tamborini,
Elena Conca, Silvana Pilotti, Marco A. Pierotti, Sebastiano Di
Bella, Carlo Cusi, Dario Ballinari, Arturo Galvani, Barbara
Salom, Antonella Isacchi.
16.
75 Patient-specific genomic profiling for advanced
cancers in young adults. Soojin Cha, Jeongeun Lee, JongYeon Shin, Ji-Yeon Kim, Jong-Il Kim, Se-Hoon Lee.
17.
76 Molecular profiling of AML patient derived
xenograft models with deep sequencing using a 109 AML
associated gene panel and a 409 gene comprehensive
cancer panel. Stephen Huang, Paul Lira, Kai Wang, Cathy
Zhang, Amy Jackson-Fisher, Keith Ching, Paul Rejto.
18.
77 Genomic characterization of aggressive subtype of
neuroblastoma without MYCN amplification. Miki Ohira,
Kenji Tatsuno, Shuichi Tsutsumi, Shogo Yamamoto, Yohko
Nakamura, Takehiko Kamijo, Hiroyuki Aburatani, Akira
Nakagawara.
19.
78 Targeted next-generation resequencing in pediatric
osteosarcoma patients. Shintaro Iwata, Yasutoshi Tatsumi,
Tsukasa Yonemoto, Hiroki Nagase, Hiroto Kamoda, Takeshi
Ishii, Miki Ohira.
Poster
:LJ[PVU
3
3
69 Identification of rare and novel alleles in FFPE tumor
samples using laser capture microdissection (LCM) and
Ampliseq™ sequencing technologies. Stephen Jackson, Paul
Choppa, Kulvinda Kulvar, Kristin Schmidt.
229
POSTER SESSION
Poster
:LJ[PVU
4
4
Deregulation of Gene Expression in Prostate Cancer and Sarcoma
Poster
Board
1.
79 An androgen response element-based reporter
assay for the detection of androgen receptor activity in
prostate cells. Waqas Azeem, Margrete R. Hellem, Jan R.
Olsen, Yaping Hua, Kristo Marvyin, Lisha Li, Yi Qu, Biaoyang
Lin, Xisong Ke, Anne M. Oyan, Karl-Henning Kalland.
2.
80 Analysis of the regulation of angiogenesis pathway
by inhibiting MDM2 function in LNCaP-MST prostate cancer
cells using PCR array. Ali Alaseem, Thiagarajan Venkatesan,
Khalid Alhazzani, Appu Rathinavelu.
3.
81 Effect of HSP90 inhibition on the gene expression
profile of MDM2 transfected LNCaP-MST prostate cancer
cells. Thiagarajan Venkatesan, Ali Alaseem, Khalid Alhazzani,
Appu Rathinavelu.
4.
5.
230
Abstract
Number
82 Analysis of the role of MDM2 in regulation of cell
cycle arrest through p21 pathways in LNCaP-MST cells
using PCR array. Khalid Alhazzani, Ali Alaseem, Thiagarajan
Venkatesan, Appu Rathinavelu.
83 Comparison of surface-directed and classic
androgen receptor antagonists. Ji Ho Suh, Arundhati
Chattopadhyay, Douglas H. Sieglaff, Cheryl L. Storer, Marc B.
Cox, Paul Webb.
6.
84 Oncogenic activity of miRNA 650 in prostate cancer
is mediated by suppression of CSR1 expression. Ze-Hua
Zuo, Yan P. Yu, Jian-Hua Luo.
7.
85 CCAAT/enhancer binding protein beta facilitates
castrate-resistant prostate cancer cell growth and
sensitivity to mTOR inhibitors. David J. Barakat, Jing Zhang,
Alan D. Friedman, Samuel R. Denmeade, Ido Paz-Priel.
Poster
Board
Abstract
Number
8.
86 Live-cell profiling of inhibitors targeting the N/C
interaction within the androgen receptor. Larisa Yurlova,
Andrea Buchfellner, Jacqueline Gregor, Tina Romer, Ian
Hickson.
9.
87 Targeting androgen receptor acetylation as a
treatment for castrate-resistant prostate cancer. Erin
Heine, Diane E. Merry, Scott Dehm, Karen E. Knudsen,
Heather L. Montie.
10.
88 The Nkx3.1 homeobox gene maintains prostatic
identity while its loss leads to prostate cancer initiation.
Clémentine Le Magnen, Aditya Dutta, Cory Abate-Shen.
11.
89 Pin1 suppresses androgen receptor activity. Travis
Van der Steen, Haojie Huang, Donald Tindall.
12.
90 K63-linked JARID1B ubiquitination by TRAF6
contributes to aberrant elevation of JARID1B in prostate
cancer. Wenfu Lu, Shenji Liu, Bo Li, Yingqiu Xie, Christine
Adhiambo, Qing Yang, Billy R. Ballard, Keiichi I. Nakayama,
Robert J. Matusik, Zhenbang Chen.
13.
91 NF-␬B as a prognostic marker and therapeutic
target in prostate cancer. Eugene Vykhovanets, Eswar
Shankar, Sanjeev Shukla, Olena Vykhovanets, Gregory T.
MacLennan, Sanjay Gupta.
POSTER SESSION
Histone Methylation and Acetylation
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
92 Epigenetic inhibitors targeting colon cancer stem
cells. Yufeng Chen.
2.
3.
5.
6.
7.
Poster
Board
Abstract
Number
14.
93 Universal homogenous bioluminescent assay that
monitor the activity various classes of methyltransferases
in vitro. Kevin Hsiao, Said Goueli.
105 A rational approach for the discovery of inhibitors
of NSD2 for the treatment of cancer. Claudia Fromond,
Xavier Espanel, Anne Soudé, Laurent Chene, Philippe Masson,
Benaïssa Boubia, Christian Montalbetti, Pierre Broqua.
15.
94 Melatonin inhibits stemness of glioblastoma cancer
stem-like cells via regulation of histone methylation.
Hyemin Lee, Ji Hoon Jung, Hyun Joo Lee, Myoung Seok
Jeong, Deok-Beom Jung, Hee Young Kwon, Sung-Hoon Kim.
106 Characterization of polycomb repressive complex 2
(PRC2) subunits retinoblastoma-binding protein 4 and 7
(RbBP4/7) in triple-negative breast cancer. Rebecca A.
Reed, Miao-Chia Lo, Duxin Sun.
16.
96 Effect of LSD-1 inhibition on docetaxel resistance in
prostate cancer cells. Sumati Gupta, Alexis Weston, Jared
Bearrs, Raffaella Soldi, Sunil Sharma.
107 Critical role of lysine 134 methylation on histone
H2AX for ␥-H2AX production and DNA repair. Ryuji
Hamamoto, Kenbun Sone, Yusuka Nakamura.
17.
108 Inhibition of demethylase, JMJD3 sensitizes diffuse
large B-cell lymphoma (DLBCL) to chemotherapy. Rohit
Mathur, Lalit Sehgal, Zuzana Berkova, Sattva S. Neelapu,
Felipe Samaniego.
18.
109 Y chromosome genes contribute to higher male
bladder cancer incidence. Iawen Hsu, Reema Railkar,
Quentin Li, Piyush Agarwal.
19.
110 The role of the p53 target Wig-1 in senescence and
cancer. Fredrik Jerhammar, Cinzia Bersani, Dijana
Djureinovic, Patrick Micke, Klas G. Wiman.
20.
111 Adaptation to histone deacetylase inhibitors
induces switching of histone H3 lysine 27 modifications,
reprograming of cancer cell gene expression, and
attenuation of the malignant phenotype. Hsin-Ching Lin,
Diana Vengsarkar, Elke Markert, Arnold B. Rabson.
21.
112 FTY720-P is a potent inhibitor of class I histone
deacetylases that enhances histone acetylation,
reactivates ER␣ expression, and increases hormonal
therapeutic sensitivity of breast cancer. Nitai C. Hait, Dorit
Avni, Akimitsu Yamada, Sheldon Milstien, Kazuaki Takabe,
Sarah Spiegel.
97 CARM1 preferentially methylates H3R17 over H3R26
through a random kinetic mechanism. Suzanne L. Jacques,
Katrina P. Aquino, Jodi Gureasko, P A. Boriack-Sjodin, Robert
A. Copeland, Thomas V. Riera.
98 Genetic alterations of KDM4 subfamily and
therapeutic effect of novel demethylase inhibitor in breast
cancer. Andreana N. Holowatyj, Qin Ye, Jack Wu, Hui Liu,
Lihong Zhang, Takayoshi Suzuki, Zeng-Quan Yang.
8.
99 Identification of G9a inhibitors by AlphaLisa™
technology and hit confirmation using MT-Glo™. Claudia
Fromond, Xavier Espanel, Laurent Chene, Philippe Masson,
Benaïssa Boubia, Christian Montalbetti, Pierre Broqua.
9.
100 PTEN regulates polycomb repressive EZH2
expression and its deficiency correlates with active
transcription mark H3K4Me3. Abid Hamid, Mohammad
Imran Khan, Vaqar M. Adhami, Hasan Mukhtar.
10.
101 WHSC1L1 as a therapeutic target in squamous cell
carcinoma of the head and neck. Vassiliki Saloura, Theodore
Vougiouklakis, Mark Lingen, Tanguy Seiwert, Everett Vokes,
Yusuke Nakamura, Ryuji Hamamoto.
22.
11.
102 KDM5B plays a central role in esophageal cancer
progression. Naohiro Nishida, Yoshihiro Kano, Jun Koseki,
Masamitsu Konno, Koichi Kawamoto, Yuichiro Doki, Masaki
Mori, Hideshi Ishii.
113 Defining the metabolic regulation of epigenetics
using chemical proteomics. Jordan L. Meier, David C.
Montgomery, Alexander W. Sorum, Rhushikesh A. Kulkarni.
23.
103 Abundant expression of enhancer of zeste
homolog 2 in small cell lung cancer. Yasutaka Watanabe,
Nobuyuki Koyama, Yuki Iwai, Chihiro Miwa, Shinichiro
Koyama.
114 Mass balance study of 14C- belinostat in patients
with recurrent or progressive malignancy. Emiliano Calvo,
Valentian Boni, Lina Garcia Canamaque, Guru Reddy, Jette
Tjornelund, Tao Song, Mi Rim Choi, Lee F. Allen.
24.
115 SMYD2-mediated methylation regulates PTEN
activity. Makoto Nakakido, Yusuke Nakamura, Ryuji
Hamamoto.
25.
116 Targeting EZH2 catalytic independent functions in
breast cancer. Keng Gat Lim.
26.
117 DOT1L is a human chromosome stability gene.
Brent Guppy, Kirk McManus.
12.
13.
104 ATF7IP does not alter the substrate specificity of
the lysine methyltransferase SETDB1. Aravind
Basavapathruni, Jodi Gureasko, Margaret Porter Scott, P. Ann
Boriack-Sjodin, Timothy J. Wigle, Thomas V. Riera, Robert A.
Copeland.
5
5
231
POSTER SESSION
Poster
:LJ[PVU
6
6
Kinases and Inhibitors
Poster
Board
1.
118 EGFL6, a potential novel ligand of EGFR, play roles
in Nasopharyngeal cacinoma metastasis through
establishing invasive and long-distant metastatic niche by
paracrine and autocrine. Jinna Chen, Chen Jiang, Jing Yang,
Ya-hui Yu, Lei Li, Yang-qun Xiang, Xinyuan Guan.
2.
119 Heteroactivation amongst TAM receptor tyrosine
kinases and via EGFR in human glioma cells. Mikaella Vouri,
Qian An, Geoffrey J. Pilkington, Sassan Hafizi.
3.
120 CRNDE, an EGFR-regulated long non-coding RNA,
plays oncogenic role in glioma. Xiaoqin Zhang, Yan Yan
Chan, Gilberto Ka-Kit Leung.
4.
121 The EGFR gatekeeper mutation T790M is present in
selected patients with early breast cancer. Vahid
Bemanian, Torill Sauer, Joel Touma, Bjørn A. Lindstedt, Ying
Chen, Hilde P. Ødegård, Ida R. Bukholm, Jürgen Geisler.
5.
122 PARK2 is a negative regulator of Wnt and EGFR
pathways in glioma. Liang Xu, De-Chen Lin, Ye Chen, Haiyan
Yan, Masaharu Hazawa, Ngan Doan, Jonathan W. Said, LingWen Ding, Li-Zhen Liu, Henry Yang, Shi-zhu Yu, Michael
Kahn, Dong Yin, Phillip Koeffler.
6.
7.
8.
9.
123 Mechanism of oncogenic signal activation by the
novel fusion kinase FGFR3-BAIAP2L1. Yoshito Nakanishi,
Nukinori Akiyama, Toshiyuki Tsukaguchi, Toshihiko Fujii,
Yasuko Satoh, Hideaki Mizuno, Nobuya Ishii, Masahiro Aoki.
124 P21-activated protein kinase 1 high expression is a
positive prognostic factor in human primary and
metastatic pancreatic cancer. Shuqiang Yuan, Feng Wang,
Han Juan, Hengying Pu, Zhiwei Zhou, Rui-hua Xu.
125 Protein kinase C loss-of-function mutations in
cancer reveal role as tumor suppressor. Corina E. Antal,
Andrew M. Hudson, Emily Kang, Ciro Zanca, Christopher
Wirth, Natalie L. Stephenson, Eleanor W. Trotter, Lisa L.
Gallegos, Crispin Miller, Frank Furnari, Tony Hunter, John
Brognard, Alexandra C. Newton.
Poster
Board
127 Overexpression of neurotrophic tyrosine receptor
kinases (NTRKs) as a potential therapeutic target for
cancer. Ge (Gina) Wei, Nicholas Cam, Roopal Patel, Robert
Shoemaker, Robert Wild, Gang Li.
11.
128 Tyrosine 823 in the activation loop of c-Kit
regulates the transforming capacity of the oncogenic
mutant D816V and its sensitivity to kinase inhibitors.
Shruti Agarwal, Julhash U. Kazi, Sofie Mohlin, Sven Påhlman,
Lars Rönnstrand.
129 RAD17 loss of function is synthetically lethal with
the checkpoint kinase inhibitors AZD7762 or MK-1775.
John P. Shen, Rohith Srivas, Ana Bojorquez-Gomez,
Katherine Licon, Vignesh Sivaganesh, Jia L. Xu, Huwate
Yeerna, Andrew Gross, Jian Feng Li, Robert Sobol, Trey
Ideker.
Abstract
Number
13.
130 PF-06463922, a novel next generation ALK/ROS1
inhibitor, overcomes resistance to 1st and 2nd generation
ALK inhibitors in pre-clinical models. Luc Friboulet, Helen
Zou, David P. Kodack, Lars D. Engstrom, Qiuhua Li, Melissa
West, Ruth W. Tang, Hui Wang, Konstantinos Tsaparikos,
Jinwei Wang, Sergei Timofeevski, Dac M. Dinh, Hieu Lam,
Justine L. Lam, Shinji Yamazaki, Wenyue Hu, Bhushankumar
Patel, Divya Bezwada, Sidra Mahmood, Eugene Lifshits,
Timothy Affolter, Patrick B. Lappin, Hovhannes Gukasyan,
Nathan Lee, Shibing Deng, Rakesh K. Jain, Ted W. Johnson,
Alice T. Shaw, Valeria R. Fantin, Tod Smeal.
14.
131 ALK oncogene regulates epithelial-mesenchymal
transition (EMT) in ALK-rearranged non-small cell lung
carcinoma through repression of the epithelial splicing
regulatory proteins 1 and 2 (ESRP1 and ESRP2). Claudia
Voena, Lydia Varesio, Liye Zhang, Matteo Menotti, Teresa
Poggio, Filomena Di Giacomo, Elena Panizza, Cristina Mastini,
Mara Compagno, Stefano Monti, Roberto Chiarle.
15.
132 HER2 activating mutations are potential targets for
colorectal cancer treatment. Shyam M. Kavuri, Naveen Jain,
Francesco Galimi, Francesca Cottino, Adam C. Searleman,
Wei Shen, Livio Trusolino, Samuel A. Jacobs, Andrea Bertotti,
Ron Bose.
16.
133 Identification of a key region in the HER2
subdomain III required for transformation capability.
Barbara Schroeder, Ghiara Lugo, Javier Menendez, Ingrid
Espinoza, Ruth Lupu.
17.
134 CCN5 down regulates HER2/ neu expression in
HER2 positive breast cancer cells. Sandipto Sarkar, Gargi
Maity, Amlan Das, Monami Majumder, Snigdha Banerjee,
Sushanta Banerjee.
18.
135 Associations between VEGF polymorphisms and
clinical outcome in breast cancer. Jessica Furriol, Hanne E.
Puntervoll, Gøril Knutsvik, Monica Mannelqvist, Sura Aziz,
Elisabeth Wik, Lars A. Akslen.
19.
136 Evaluation of reversible BTK inhibitors in cell lines
with clinically relevant Ibrutinib resistance mutations.
Regina Wai-Yan Choy, Luciana Burton, Wendy Young, James
J. Crawford, Elicia Penuel, Lisa D. Belmont.
20.
137 PAK1 modulates a PPAR␥/NF-␬B cascade in
intestinal inflammation. Kyle Dammann, Vineeta Khare,
Michaela Lang, Thierry Claudel, Felix Harpain, Nicolas
Granofszky, Rayko Evstatiev, Jonathan M. Williams, D. Mark
Pritchard, Alastair Watson, Christoph Gasche.
21.
138 Novel PAK4 allosteric modulators (PAMs) provide
potential therapeutic options in human gastric cancer.
Wenwen Chien, Jinfen Xiao, Ling-Wen Ding, Muhammad
Ikhsan B. Muzakar, Qiao-Yang Sun, Sigal Gery, William
Senapedis, Sharon Shacham, Erkan Baloglu, H. P. Koeffler.
22.
139 Activating ERBB4 mutations in non-small cell lung
cancer. Kari J. Kurppa, Konstantin Denessiouk, Mark S.
Johnson, Klaus Elenius.
23.
140 Oncogenic signaling by MET and other
cabozantinib targets in cells derived from urothelial
carcinoma of the bladder. Young H. Lee, Tiffany K. Wong,
Andrea B. Apolo, Piyush K. Agarwal, Donald P. Bottaro.
24.
141 MUC16/CA125 and Epithelial Growth Factor
Receptor functionality in ovarian cancer. Amy Wang,
Dharmarao Thapi, Nestor Rosales, Xiu J. Yan, David R.
Spriggs.
126 PI3 kinase plays important role in c-Kit/V560D
mediated oncogenic signaling. Jianmin Sun.
10.
12.
232
Abstract
Number
POSTER SESSION
Long Non-Coding RNAs
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Abstract
Number
142 SiRNA therapy against novel lncRNA NRCP: shutting
down the fuel for cancer cells. Rajesha Rupaimole, Rebecca
Previs, Jaehyuk Lee, Sunila Pradeep, Sherry Y. Wu, Cristina Ivan,
Manuela Ferracin, Jennifer Dennison, Cristian Rodriguez-Aguayo,
George A. Calin, Gordon Mills, Wei Zhang, Gabriel Lopez-Berestein,
Pratip Bhattacharya, Anil K. Sood.
143 A long non-coding RNA activated by TGF-␤ can predict
the prognosis of gastric cancer patients. Tomoko Saito, Junji
Kurashige, Sho Nambara, Hisateru Komatsu, Hidenari Hirata,
Masami Ueda, Shotaro Sakimura, Ryutaro Uchi, Yuki Takano,
Yoshiaki Shinden, Tomohiro Iguchi, Hidetoshi Eguchi, Keishi
Sugimachi, Kazunari Murakami, Koshi Mimori.
144 CASC15 is a tumor suppressor lncRNA at the 6p22
neuroblastoma susceptibility locus. Mike R. Russell, Annalise
Penikis, Derek Oldridge, Juan R. Alvarez-Dominguez, Lee
McDaniel, Maura Diamond, Olivia Padovan, Pichai Raman, Yimei Li,
Jun Wei, Shile Zhang, Janahan Gnanachandran, Robert Seeger,
Shahab Asgharzadeh, Javed Khan, Sharon Diskin, John Maris,
Kristina Cole.
145 HOTTIP, an oncogenic long non-coding RNA, is
frequently up-regulated in hepatocellular carcinoma and is
negatively regulated by tumor suppressive microRNA miR125b. Felice H. Tsang, Sandy L. Au, Lai Wei, Dorothy N. Fan, Joyce
M. Lee, Carmen C. Wong, Irene O. Ng, Chun-Ming Wong.
146 The long noncoding RNA MALAT1 promotes hypoxiadriven angiogenesis by upregulating pro-angiogenic gene
expression in neuroblastoma cells. Andrew E. Tee, Peiyan Liu,
Jesper Maag, Renhua Song, Jinyan Li, Belamy B. Cheung, Michelle
Haber, Murray D. Norris, Glenn M. Marshall, Marcel Dinger, Tao Liu.
147 Epigenetic networks and promoter-associated long
noncoding RNAs (paRNAs) in prostate cancer. Sara Napoli, Sarah
Mapelli, Giuseppina Pisignano, Abhishek Mitra, Ramon GarciaEscudero, Giuseppina M. Carbone, Carlo V. Catapano.
148 Transcriptome sequencing reveals PCAT5 - new ERGregulated non-coding transcript in prostate cancer. Antti Ylipää,
Kati Kivinummi, Matti Annala, Annika Kohvakka, Leena Latonen,
Mauro Scaravilli, Kimmo Kartasalo, Simo-Pekka Leppänen, Serdar
Karakurt, Janne Seppälä, Olli Yli-Harja, Teuvo L. Tammela, Wei
Zhang, Tapio Visakorpi, Matti Nykter.
149 Overexpression of the long non-coding RNA PVT1 and
its role in cervical carcinogenesis. Marissa Iden, Samantha Fye,
Ramani Ramchandran, Janet S. Rader.
150 Long non-coding RNA are differentially expressed in
breast cancer clinical subtypes. Surendra Kumar, Michael Seiler,
Sunniva Bjørklund, Anne-Lise Børresen-Dale, Vessela Kristensen,
Gyan Bhanot, Shridar Ganesan.
151 Transcriptome-wide expression profiling of long
noncoding and small nucleolar RNAs in head and neck
squamous cell carcinomas identifies novel transcripts
associated with survival. Thomas K. Honda, Angela Zou, Vicky Yu,
Hao Zheng, Selena Kuo, Maarouf Saad, Yinan Xuan, Pranav Singh,
Jessica Wang-Rodriguez, Weg M. Ongkeko.
152 The long non-coding RNA HOTAIR affects exosomemediated bladder cancer progression. Claudia Berrondo,
Jonathan Flax, Edward M. Messing, Carla Beckham.
153 Long non-coding RNAs deregulated in Multiple
Myeloma impact therapeutic response to proteasome inhibitors.
Ehsan Malek, Rebekah Karns, Anil G. Jegga, Sajjeev Jagannathan,
Nikhil Vad, Mohamed A. Abdel Malek, James J. Driscoll.
154 Identification of TGF␤-regulated long noncoding RNAs
in mammary epithelia: lncRNA-HIT mediated TGF␤-induced
EMT and breast cancer metastasis. Edward Richards, Gu Zhang,
Jennifer Permuth-Wey, Zhu-Peng Li, Sridevi Challa, William Kong,
Dan Su, Domenico Coppola, Wei-min Mao, Thomas Sellers, Jin Q.
Cheng.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
155 LncRNA AK023948 promotes breast tumorigenesis by
enhancing AKT phosphorylation. Pratirodh Koirala, Yin Yuan MO.
156 LncRNA BC200 is induced by estradiol and regulates
apoptosis in MCF-7 breast cancer cells. Ramesh Singh, Yin-yuan
Mo.
157 LncRNA ANRIL indicates a potential prognostic
biomarker in gastric cancer and promotes tumor growth by
silencing of miR-99a/miR-449a. Zhi Xu, Jinfei Chen, John M. Luk,
Wei De.
158 The p16/ARF intron 2 imbedded long non-coding RNA
CAI2 is highly expressed in tumor cells and modulates
chromatin structure. Olga Cohen, Alice Yu, Mitchell B. Diccianni.
159 LncRNA RoR enhances the c-Myc mRNA stability in
colon cancer. Jianguo Huang.
160 ZFAS1, long non-coding RNA with significance in
colorectal cancer. Nithyananda Thorenoor, Petra Vychytilova,
Jitka Mlcochova, Sonja Hombach, Markus Kretz, Jiri Sana, Ondrej
Slaby.
161 Long noncoding RNA subtype classification of human
prostate adenocarcinomas. Gabriel G. Malouf, Jianping Zhang,
Jean-Philippe Spano, Eva Compérat, Nizar M. Tannir, Erika K.
Thompson, John N. Weinstein, Debasish Tripathy, David Khayat,
Xiaoping Su.
162 Overexpression of long noncoding RNA FTX was
associated with colorectal cancer progression. Takeshi Iwaya,
Kei Sato, Kohei Kume, Satoshi Nishizuka, Go Wakabayashi, Koshi
Mimori.
163 Investigation of molecular mechanisms by which PCA3
modulates prostate cancer cell survival. Ana E. Goulart, Luciana
B. Ferreira, Paula P. de Freitas, Nadia Batoreu, MARTIN H.
BONAMINO, Etel R. Gimba.
164 Long noncoding RNAs in the breast of healthy women
are detected in different subtypes of breast cancer. Maria
Barton, Julia Santucci-Pereira, Theresa D. Nguyen, Jose Russo.
165 Common long noncoding RNAs (lncRNA) with altered
expression levels in colorectal adenoma and carcinoma.
Alexandra Kalmar, Zsofia B. Nagy, Orsolya Galamb, Barnabas
Wichmann, Barbara K. Bartak, Zsolt Tulassay, Bela Molnar.
166 Identification of a novel long noncoding RNA as a
mediator for CRTC1-MAML2 fusion oncogenic function and a
biomarker for CRTC1-MAML2 fusion-positive tumors. Zirong
Chen, Jian-Liang Li, Shuibin Lin, Chunxia Cao, Frederic Kaye, Lizi
Wu.
167 Targeting non-coding RNAs with the CRISPR/Cas9
system in human cell lines. Tsui-Ting Ho, Nanjiang Zhou, Jianguo
Huang, Pratirodh Koirala, Min Xu, Roland Fung, Fangting Wu, YinYuan Mo.
168 MALAT1 is crucial for epithelial-mesenchymal transition
of breast cancer cells in acidic microenvironment. Subash C.
Gupta, Yin-Yuan Mo.
169 Metastatic colorectal cancer associated long noncoding RNAs identified by transcriptome sequencing of
matched primary and metastatic patient tissues. Jessica M. SilvaFisher, Ha Dang, Julie Grossman, Nicole White, Christopher
Cabanski, Simon Goedegebuure, Timothy Fleming, Elizabeth
Pittman, Robert Fulton, Matthew Strand, Albert C. Lockhart,
Timothy Ley, Richard Wilson, Ryan Fields, Christopher Maher.
170 Survival prediction model with long non-coding RNA
profile in lung adenocarcinoma cancer. Wei-An Wang, LiangChuan Lai, Mong-Hsun Tsai, Tzu-Pin Liu, Eric Y. Chuang.
171 Deciphering the role of long noncoding RNAs in the
progression of hepatocellular carcinoma using next-generation
sequencing. Davide Degli Esposti, Catherine Voegele, Vincent
Cahais, Nathalie Forey, Florence Le Calvez Kelm, James McKay,
Hector Hernandez-Vargas, Zdenko Herceg.
7
7
233
POSTER SESSION
Poster
:LJ[PVU
8
8
MicroRNA Regulation of Cancer Biology
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
234
Abstract
Number
172 Pathophysiological role of microRNA-29 in
pancreatic cancer stroma. Jason J. Kwon, Sarah C. Nabinger,
Ravi K. Alluri, Zachary Vega, Smiti S. Sahu, Zahi Abdul Sater,
Zhangsheng Yu, A Jesse Gore, Grzegorz Nalepa, Romil
Saxena, Murray Korc, Janaiah Kota.
173 SOX4 interacts with EZH2 and HDAC3 to suppress
microRNA-31 in invasive esophageal cancer cells. Rainelli
B. Koumangoye, Thomas Andl, Kenneth J. Taubenslag,
Steven T. Zilberman, Chase Taylor, Claudia D. Andl.
174 Identification of activin A mediated microRNAs in a
human prostate cancer cell line (LNCaP). Edward Ottley,
Elspeth Gold.
175 miR-1207-3p-induced downregulation of
fibronectin is a novel regulatory pathway in prostate
cancer. Dibash K. Das, Adeodat Ilboudo, Joseph R. Osborne,
Olorunseun O. Ogunwobi.
176 MicroRNA-122 is a potential regulator of DNA
methylation partly by affecting the global level profile of
5hmC. Ann-Ping Tsou, Kuan-Hua Wang, Hsi-Yuan Huang,
Li-Jung Chen, Tze-Tze Liu.
177 Role and mechanisms of miR-223 in the invasion
and metastasis of head and neck squamous cell carcinoma.
Yun Wang, Zhi Wang, Bin Cheng.
178 Targeting of multiple oncogenic miRNAs on NUMB
gene to mediate head and neck carcinogenesis. ChungShan Chou, Kuo-Wei Chang, Shu-Chun Lin.
179 Regulation of stromal miR-125b on normal colonic
epithelial cell renewal and its putative role in
tumorigenesis. Helen H. N. Yan, Jackie K. Y. Lau, Annie S. Y.
Chan, Wai Yin Tsui, Tsun Leung Chan, Suet Yi Leung.
180 Expanding the definition of core binding factor
leukemia. John A. Fischer, Stefano Rossetti, Arani Datta,
Alessandro Beghini, Nicoletta Sacchi.
181 miR-134 targets programmed cell death 7 (PDCD7)
gene to modulate the pathogenesis of head and neck
carcinoma. Shih-Yuan Peng, Kuo-Wei Chang, Shu-Chun Lin,
Hsi-Feng Tu.
182 Smoking Carcinogen (BaP) enhances tumorigenic
phenotypes of cervical cancer cells by modulation of HPV
oncogenes and microRNA profiles. Mohd S. Zaman, Neeraj
Chauhan, Rishi K. Gara, Diane Maher, Sonam Kumari,
Mohammed Sikander, Sheema Khan, Murali M. Yallapu,
Meena Jaggi, Subhash C. Chauhan.
183 Oncogenic miRNA miR-130a-induced inhibition of
the growth regulator protein ZAR2 in TNBC cells. Smita
Misra, Ashutosh Snghal, Gautam Chaudhuri.
184 miR-379/411 cluster regulates IL-18 and
contributes to drug resistance in malignant pleural
mesothelioma. Akihiko Miyanaga, Masahiro Seike, Kazuo
Yamamoto, Susumu Takeuchi, Rintaro Noro, Yuji Minegishi,
Kaoru Kubota, Akihiko Gemma.
185 MicroRNA-375 suppresses extracellular matrix
degradation and invadopodial activity in head and neck
squamous cell carcinoma. Lizandra Jimenez, Ved P. Sharma,
John S. Condeelis, Thomas M. Harris, Thomas J. Ow, Michael
B. Prystowsky, Geoffrey J. Childs, Jeffrey E. Segall.
186 microRNA-146a inhibits epithelial mesenchymal
transition in non small cell lung cancer by targeting insulin
receptor substrate 2. Ji Woong Son, Soo Young Lee, Moon
Jun Na, Sun Jung Kwan, Hyo Sung Jeon.
Poster
Board
16.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
187 miR-1205/FRYL as a novel regulatory mechanism
in androgen-independent prostate cancer. Victoria
Durojaiye, Adeodat Ilboudo, Fayola Levine, Joseph Osborne,
Jong Y. Park, Olorunseun O. Ogunwobi.
189 KRAS-induced microRNA-29b attenuates
apoptosis in non-small cell lung cancer. Stephanie Langsch,
Stefan Haemmig, Ulrich Baumgartner, Mario P. Tschan, Erik
Vassella.
190 Modulation of MiR-21 signaling by MPS1 in human
glioblastoma. Uday Bhanu Maachani, Anita Tandle, Uma
Shankavaram, Tamalee Kramp, Kevin A. Camphausen.
191 The role of microRNAs in the epigenetic silencing
of CHD5, a tumor suppressor in neuroblastoma. Koumudi
Naraparaju, Venkatadri Kolla, Tiangang Zhuang, Mayumi
Higashi, Gerd A. Blobel, Garrett M. Brodeur.
192 Exportin-5 downregulation induces miRNA
dysregulation and HDAC6 overexpression in
cholangiocarcinoma. Maria J. Lorenzo Pisarello, Brynn N.
Howard, Christy E. Trussoni, Sergio Gradilone.
193 Epigenetic regulation of Notch1 signaling-driven
melanoma progression. Ling Yin, Qinghua Huang, Alan S.
Livingstone, Omaida C. Velazquez, Zhao-Jun Liu.
194 Deregulation of miR-222-ABCG2 regulatory
module in tongue squamous cell carcinoma contributes to
chemoresistance and enhanced metastatic potential.
Anxun Wang, Luodan Zhao, Qianting He, Tingting Zhao, Wei
Wang, Xiaofeng Zhou.
195 Insight into microRNA regulation of autophagy
genes expression in crizotinib-treated Anaplastic Large
Cell Lymphoma. Julie Frentzel, Geraldine Mitou, Pierre
Brousset, Sylvie Giuriato.
196 A SNP in the 3=-untranslated region of FZD4 linked
to lung cancer survival modulates a miRNA-mediated
FZD4 transcript binding, cleavage, expression, and Wntsignaling in NSCLC cells. Jing Lin, Roza Zandi, Jian Gu,
Yuanqin Ye, Alexander Pertsemlidis, Xifeng Wu, Jack A. Roth,
Lin Ji.
197 miR-130b targets Arhgap1 increasing Cdc42
activity and metastic potential in Ewing sarcoma cells.
Laura Satterfield, Lyazat Kurenbekova, Ryan Shuck,
Lawrence Donehower, Jason Yustein.
198 Helicobacter pylori infection via miR-328
suppression and CD44 expression in gastric mucosa causes
gastric cancer initiation and progression. Keisuke Miyake,
Takatsugu Ishimoto, Hidetaka Sugihara, Kojiro Eto, Daisuke
Izumi, Junji Kurashige, Yukiharu Hiyoshi, Shiro Iwagami,
Yoshifumi Baba, Yuji Miyamoto, Naoya Yoshida, Hideo Baba.
199 Functional mechanism of hypoxia-inducible factor
1 alpha-mediated Dicer down-regulation. Hui-Huang Lai,
Yu-Jhen Lyu, Jie-Ning Li, Jen-Liang Su, Pai-Sheng Chen.
200 Effects of H. pylori infection in regulation of
miRNAs-associated with DNA mismatch repair. Juliana C.
Santos, Mitsue Brianti, Victor de Almeida, Ander Matheu,
Marcelo L. Ribeiro.
201 Expression of miR-124 suppresses spermine
oxidase-associated H2O2 generation in human gastric
adenocarcinoma cells: Implications for infection/
inflammation-induced carcinogenesis. Tracy MurrayStewart, Johanna C. Sierra, Rupesh Chaturvedi, Keith T.
Wilson, Robert A. Casero.
POSTER SESSION
New Insights from Imaging and Cell Isolation
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
202 Four dimensional quantitative label-free holographic imaging
of the cell cycle in tumor cell lines. Ed Luther, Jeffrey Agar, Mansoor
Amiji.
203 Visualization of drug delivery by using high resolution
microscopic mass spectrometry. Masahiro Yasunaga, Masaru Furuta,
Koretsugu Ogata, Yoshikatsu Koga, Yasuhiro Matsumura.
204 Single-molecule localization microscopy analysis of a
cancer metastasis-specific miRNA on the nanoscale. Mohammed
Abba, Olga Oleksiuk, Kerem Tezcan, Wladimir Schaufler, Felix
Bestvater, Peter Altevogt, Mathias Hafner, Christoph Cremer, Heike
Allgayer.
205 ELTD1 and Plexin-B2 as novel antibody therapies against
glioma biomarkers. Jadith Ziegler, Richard Pody, Landon Rodriguez,
Nataliya Smith, Debra Saunders, Patricia Coutinho de Souza, Jonathan
Wren, Rheal Towner.
206 Development of a molecular imaging system based on the
transcriptional activity of the DD3/PCA3 non-coding RNA for imaging
specifically the prostate cancer cells. Pallavi Jain, Bertrand Neveu, Yves
Fradet, Frederic Pouliot.
207 Caveolin-1 drives oncogenic TGF〉 effects in prostate cancer:
in vitro mechanistic insights integrated with systems pathology
visualization in primary tumor samples. Teijo Pellinen, Sami Blom, Sara
Sanches, Katja Välimäki, John-Patrick Mpindi, Antti Rannikko, Raffaele
Strippoli, Maria Montoya, Hind Azegrouz, Tuomas Mirtti, Miguel del Pozo,
Olli Kallioniemi.
208 Novel intracellular Doppler imaging predicts therapeutic
efficacy for personalized medicine. John J. Turek, Dan Merrill, Michelle
Custead, Michael Childress, David D. Nolte, Bakhtiyor Yakubov, Ran An,
Daniela Matei.
209 A quantitative analysis of paclitaxel-induced mitotic
catastrophe of MDA-MB-231 cells by high frequency ultrasound.
Maurice M. Pasternak, Gregory J. Czarnota.
210 In vivo metabolic imaging to differentiate aggressive versus
indolent prostate cancer. Niki Zacharias Millward, Christopher
McCullough, Youngbok Lee, Jingzhe Hu, Prasanta Dutta, David PiwnicaWorms, Pratip Bhattacharya.
211 A novel FRET assay for the intracellular activation of ADC
linkers. Byoung-Chul Lee, Cecile Chalouni, Sam Nalle, Sophia Doll, Martine
Darwish, Ira Mellman, Richard Vandlen.
212 Infrared spectral diagnosis for predictive cancer medicine:
application to the early diagnosis and prognosis of preinvasive
bronchial intraepithelial lesions. Vincent D. Gaydou, Myriame Polette,
Cyril Gobinet, Claire Kileztky, Michel Manfait, Philippe Birembaut, Olivier
Piot.
213 Evaluating high risk BI-RADS 4 mammographic lesions: a pilot
trial of textural analysis (TA) as a supplement to digital mammography
(DM). Melissa R. Gordon, Erkut Borazanci, Daniel D. Maki, Ron L. Korn.
214 Characterization of the near-infrared fluorescent protein iRFP
for plate-based assays and animal imaging. Haibiao Gong, Joy L. Kovar,
Teresa Urlacher.
215 Tracking transplanted cells with paramagnetic fluorinated
nanoemulsions. Alexander A. Kislukhin, Hongyan Xu, Stephen R. Adams,
Kazim Narsinh, Roger Y. Tsien, Eric T. Ahrens.
216 Pancreatic cancer fluorescence-guided surgery with a
fluorophore-conjugated antibody to carcinoembryonic antigen
(CEA) improves surgical resection and increases disease-free and
overall survival in orthotopic mouse models. Cristina A. Metildi,
Sharmeela Kaushal, George A. Luiken, Robert M. Hoffman, Michael
Bouvet.
217 5-ALA-induced fluorescence imaging of breast cancer
margins using a handheld imaging device. Emilie Chamma, Kristina M.
Blackmore, Danielle Starr, Liis Teene, Philip J. Medeiros, Stephanie DeLuca,
Alexandra Easson, Susan J. Done, Wey-Liang Leong, Ralph S. DaCosta.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
29.
Abstract
Number
218 The new and rapid technique of detecting breast cancer cells
using new fluorescent probe ‘gGlu-HMRG’ and its clinical application.
Yoshiaki Shinden, Hiroki Ueo, Taro Tobo, Ayako Ganachi, Hisateru
Komatsu, Sho Nambara, Tomoko Saito, Masami Ueda, Hidenari Hirata,
Shotaro Sakimura, Yuki Takano, Ryutaro Uchi, Tomohiro Iguchi, Hidetoshi
Eguchi, Keishi Sugimachi, Yoko Kubota, Yuichiro Kai, Yuko Kijima, Shoji
Natsugoe, Hiraki Ueo, Yasuteru Urano, Koshi Mimori.
219 Fluorescence-guided surgery with an anti-CA 19-9conjugated fluorophore in combination with neoadjuvant
chemotherapy inhibits metastatic recurrence in a pancreatic cancer
patient derived orthotopic xenograft (PDOX) nude mouse model .
Yukihiko Hiroshima, Ali Maawy, Yong Zhang, Takashi Murakami, Masashi
Momiyama, Ryutaro Mori, Ryusei Matsuyama, Matthew H. Katz, Jason B.
Fleming, Takashi Chishima, Kuniya Tanaka, Yasushi ichikawa, Itaru Endo,
Robert M. Hoffman, Michael Bouvet.
220 New computerized image analyzing technique for analysis of
bone marrow microvessel density in multiple myeloma. Kong SunYoung, Nuri Lee, Young Jae Kim, Ji Yeon Sohn, Hyewon Lee, Hyeon-Seok
Eom, Kwang Gi Kim.
221 Ex vivo cultures of freshly explanted tumors: a potent
translational approach for screening novel targeted agents. Annemilai
Tijeras-Raballand, Maria Serova, Cindy Neuzillet, Miguel Albuquerque,
Nathalie Colnot, Pierre Bourgoin, Safi Dokmak, Mohamed Bouattour,
Jacques Belghiti, Valérie Paradis, Eric Raymond, Sandrine Faivre, Armand
de Gramont.
222 PathLink: Leveraging clinical informatics to empower
translational pathology by connecting biospecimens to outcomes.
Jennifer M. Giltnane, Jana Shirey-Rice, Jodell Linder, Erica Bowton, James
Cowan, Xiaoming Wang, Jon Scherdin, Melissa Basford, Kimberly
Dahlman, Joseph Roland, Kerry Wiles, Cynthia Vnencak-Jones, Kay
Washington, Jill Pulley.
223 Generation of single cell-derived normal, benign and cancer
mini-prostates from primary patient-derived tissues. Monica Bartucci,
Michele Patrizii, Eric Huselid, Shamila Yussuf, Nitu Bansal, Kathleen
Flaherty, Denis Tolkunov, Hua Zhong, Mark N. Stein, Joseph Bertino,
Robert DiPaola, Isaac Kim, Hatem E. Sabaawy.
224 Enrichment and isolation of uncontaminated breast cancer
cells from human blood samples. Sandra V. Fernandez, Christopher
Wagner, Zahida Parveen, Lucy Aburto, Carmela Paolillo, George Hvichia,
Zhaomei Mu, Laura Austin, Massimo Cristofanilli.
225 Assessing and enriching human tumor cell content in patientderived cancer xenografts and co-cultures. Yu-An Zhang, Victor Stastny,
Mahboubeh Papari-Zareei, Heather Davidson, Boning Gao, Brenda
Timmons, Jingsheng Yan, C. Patrick Reynolds, John D. Minna, Adi F.
Gazdar.
226 Parallel microfiltration (PMF): A novel method to screen cell
mechanotype. Wolf-Ruprecht Wiedemeyer, Dongping Qi, Navjot Kaur
Gill, Chintda Santiskulvong, Oliver Dorigo, JianYu Rao, Barbie TaylorHarding, Amy C. Rowat.
227 Characterization of single cells from dissociated solid tumors.
Aaron J. Middlebrook, Shahryar Niknam, Joyce Ruitenberg, Albert J. Mach,
Maria Suni, Warren Porter, Friedrich Hahn, Eileen Snowden, Rainer
Blaesius, Smita Ghanekar.
228 A novel device to perform rapid high-throughput in vivo drug
sensitivity testing and identify optimal drug therapy for personalized
cancer treatment. Oliver Jonas.
230 Do-It-Yourself expression microdissection (DIY xMD): A lowcost, high-throughput cell and organelle isolation system. Michael A.
Tangrea, Avi Z. Rosenberg, Patricia A. Fetsch, Michael D. Armani,
Liqiang Xi, Mark Raffeld, Tina T. Pham, Yun Chen, Neil O’Flaherty,
Rebecca Stussman, Adele R. Blackler, Qiang Du, Jeffrey C. Hanson,
Mark J. Roth, Armando C. Filie, Michael H. Roh, Jason D. Hipp, Michael
R. Emmert-Buck.
9
9
235
POSTER SESSION
Poster
:LJ[PVU
10
10
Non-Coding RNAs in Cancer Biology 1
Poster
Board
1.
231 MicroRNA isoforms come of age: Going beyond the
one-locus-one-microRNA paradigm in cancer biology. Eric
R. Londin, Phillipe Loher, Aristeidis Telonis, Isidore Rigoutsos.
2.
232 Characterization of the human miRNA-ome reveals
numerous novel, tissue-specific miRNAs that are
implicated in cancer biology. Eric R. Londin, Phillipe D.
Loher, Isidore Rigoutsos.
3.
233 Mining cancer gene expression databases for
latent information on intronic microRNAs. Simona
Monterisi, Giovanni D’Ario, Elisa Dama, Nicole Rotmensz,
Stefano Confalonieri, Chiara Tordonato, Flavia Troglio,
Giovanni Bertalot, Patrick Maisonneuve, Giuseppe Viale,
Francesco Nicassio, Pier Paolo Di Fiore, Fabrizio Bianchi.
Poster
Board
Abstract
Number
7.
237 Piwi genes and tissue/serum piR-651 are related to
clinicopathologic features of renal cell carcinoma. Robert
Iliev, Petra Vychytilova-Faltejskova, Jaroslav Juracek, Hana
Mlcochova, Michal Stanik, Jan Dolezel, Michal Fedorko,
Dalibor Pacik, Marek Svoboda, Ondrej Slaby.
8.
238 Citrullination of miRNA regulators by PADs: A
potential mechanism for the promotion of colitis and
colitis-associated colorectal cancer. Erin E. Witalison,
Xiangli Cui, Corey P. Causey, Paul R. Thompson, Lorne J.
Hofseth.
10.
234 Computational characterization of microRNAmediated association between obesity and cancer. Jiang
Shu, Kevin Chiang, Juan Cui.
240 The ketogenic diet alters the expression of
microRNAs that play key roles in tumor development. Julia
Pazmandi, Kevin S. O’Neill, Adrienne C. Scheck, Peter W.
Szlosarek, Eric C. Woolf, Kenneth S. Brooks, Nelofer Syed.
11.
5.
235 SNORD76, a box C/D snoRNA, acts as a tumor
suppressor in glioblastoma. Luyue chen, Lei Han, kailiang
zhang, jianwei wei, peiyu pu, jianning zhang, chunsheng
kang.
241 A novel tumor suppressor miRNA co-regulating
EMT and p53-independent cell survival in breast cancer.
Umar Raza, Stefan Uhlmann, Emre Yurdusev, Stefan
Wiemann, Ozgur Sahin.
12.
6.
236 Autocrine regulation of stress-induced cytotoxic
Alu RNA expression in TNBC cells. Ashutosh Singhal, Smita
Mishra, Gautum Chaudhuri.
242 Evaluation of apoptosis-related microRNAs in
salivary gland tumors. Bianca T. Flores, Silvia V. Lourenço,
Maria A. Nagai, Luiz Paulo Kowalski, Fernando A. Soares,
Cláudia Coutinho-Camillo.
4.
236
Abstract
Number
POSTER SESSION
Immunology
Immune Checkpoints
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
7.
8.
9.
10.
11.
12.
13.
14.
Abstract
Number
243 Expression of T-cell checkpoint ligands on circulating
tumor cells is modulated following treatment of patients with an
anti-tumor DNA vaccine. Brian T. Rekoske, Brian M. Olson, Douglas
G. McNeel.
244 Abscopal responses in patients with refractory metastatic
NSCLC treated with concurrent radiotherapy and CTLA-4 immune
checkpoint blockade: evidence for the in situ vaccination
hypothesis of radiotherapy . Encouse B. Golden, Abraham
Chachoua, Maria Fenton-Kerimian, Sandra Demaria, Silvia C.
Formenti.
245 Identification of novel immune checkpoints as potential
therapeutic targets in pancreatic ductal adenocarcinoma (PDAC)
using RNAi screening. Antonio Sorrentino, Tillmann Michels, Ayse N.
Menevse, Nisit Khandelwal, Marco Breinig, Isabel Poschke, Rienk
Offringa, Michael Boutros, Philipp Beckhove.
246 Phase 1 study: Ipilimumab (anti CTLA-4) in combination
with Lenalidomide in patients with advanced cancers. Divya
Sakamuri, Sonia L. Betancourt Cuellar, Isabella C. Glitza, Siqing Fu,
Jennifer J. Wheler, Gerald S. Falchook, Apostolia M. Tsimberidou,
David S. Hong, Vivek Subbiah, Michelle A. Fanale, Maria E. Cabanillas,
Funda Meric-Bernstam, Filip Janku.
247 Comparing radiation therapy and ipilimumab to
ipilimumab alone in metastatic melanoma patients. Kirtesh R.
Patel, Daniel E. Oliver, Derick Okwan-Dadu, Yuan Liu, Ragini R.
Kudchadkar, David H. Lawson, Mohammad K. Khan.
249 Assessment of PD-L1 expression and tumor-associated
lymphocytes in pediatric cancer tissues. Robbie G. Majzner, Jason S.
Simon, Joseph F. Grosso, Daniel Martinez, Bruce Pawel, Mariarita
Santi-Vincini, Melinda S. Merchant, Poul Sorensen, Crystal L. Mackall,
John M. Maris.
250 Differential efficacy of immune checkpoint inhibitors on
bone metastasis and its associated immune dysfunction. Chie
Kudo-Saito, Takafumi Fuwa, Kouichi Murakami.
251 Combining Ibrutinib with immune checkpoint blockade to
induce therapeutic antitumor immune response in solid tumors.
Idit Sagiv-Barfi, Holbrook Kohrt, Debra Czerwinski, Patrick Ng, Betty
Chang, Ronald Levy.
252 Antibody-mediated phosphatidylserine blockade
significantly enhances the efficacy of immune checkpoint
blockades in K1735 and B16 mouse melanoma models. Bruce
Freimark, Jian Gong, Dan Ye, Rolf Brekken, Shen Yin, Jeff Hutchins,
Van Nguyen, Chris Hughes, Xianming Huang.
253 Synergistic antitumor activity of PD-1 signaling blockade
and CD27 costimulation correlates with enhanced ratio of effector
to regulatory T cells at the tumor site. Lawrence J. Thomas, Li-Zhen
He, Anna Wasiuk, Lauren E. Gergel, James M. Boyer, Sarah M. Round,
Henry C. Marsh, Tibor Keler.
254 TiMi1 is a novel immune-checkpoint in solid tumors
identified via a tumor-infiltrating lymphocyte (TIL)-based RNAi
screening. Tillmann Michels, Christina A. Hartl, Nisit Khandelwal,
Marco Breinig, Antonio Sorrentino, Christina Mäder, Ludmila
Umansky, Isabel Poschke, Rienk Offringa, Michael Boutros, Galit
Eisenberg, Michal Lotem, Philipp Beckhove.
255 Dual targeting of Delta-like ligand 4 (DLL4) and
programmed death 1(PD1) inhibits tumor growth and generates
enhanced long-term immunological memory. Angie Inkyung Park,
Christopher L. Murriel, Julie Roda, Minu Srivastava, Hyun-Bae Jie,
Fumiko Axelrod, Ming-Hong Xie, Erin Mayes, Rui Yun, Trevor Bentley,
Belinda Cancilla, Raymond Tam, Tracy Tang, Ann Kapoun, John
Lewicki, Austin Gurney, Tim Hoey.
256 Identification of additional cancers likely to respond to antiPD-1 therapy (pembrolizumab): Evaluation of PD-L1 expression in a
large molecular tumor profiling gene expression database. Mark D.
Ayers, Michael Nebozhyn, Razvan Cristescu, Terrill K. McClanahan,
Heather A. Hirsch, Jonathan D. Cheng, Andrey Loboda.
Poster
Board
15.
16.
17.
18.
19.
20.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
257 Class I HDAC inhibition upregulates PD-1 ligands in
melanoma and increases the efficacy of PD-1 blockade. David M.
Woods, Andressa L. Sodre, Amod Sarnaik, Eduardo M. Sotomayor,
Jeffrey Weber.
258 Talilmogene laherparepvec increases the anti-tumor
efficacy of the anti-PD-1 immune checkpoint blockade. Julia
Piasecki, Tiep le, Rafael Ponce, Courtney Beers.
259 Ibrutinib enhances the anti-tumor efficacy of CTLA-4
blockade in lymphoma and colon cancer models. Patrick Ng, Daniel
Lu, Betty Chang.
260 In vivo efficacy of intraperitoneal anti-PD-L1 therapy in
ovarian cancer. Shannon Grabosch, Jyothi T. Mony, Lixin Zhang,
Tianzhou Ma, Tejas Tirodkar, Joan Brozick, George Tseng, Esther
Elishaev, Robert P. Edwards, Xin Huang, Anda M. Vlad.
261 Nivolumab and urelumab enhance antitumor activity of
human T lymphocytes engrafted in Rag2-/-IL2R␥null
immunodeficient mice. Miguel F. Sanmamed, Inmaculada Rodriguez,
Carmen Oñate, Arantza Azpilikueta, Maria E. Rodriguez-Ruiz, Aizea
Morales-Kastresana, Sara Labiano, Jose L. Perez-Gracia, Salvador
Martín-Algarra, Carlos Alfaro, Kurt A. Schalper, Guillermo Mazzolini,
Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure-Kunkel,
Ignacio Melero.
262 Inhibition of the novel immune checkpoint CEACAM1
enhances antitumor immunological activity. Gal Markel, Ilana Mandel,
Yair Sapir, Motti Hakim, Sharon Hashmueli, Tehila Ben-Moshe.
265 Robust anti-tumor effects of combined anti-CD4
depleting antibody and anti-PD-1/PD-L1 immune checkpoint
antibody treatment in mice. Satoru Ito, Kouji Matsushima, Satoshi
Ueha, Shoji Yokochi, Yoshiro Ishiwata, Kosuke Hachiga, Haru
Ogiwara, Krishant Chand, Takumi Nakajima.
266 Antitumor activity of REGN2810, a fully human anti-PD-1
monoclonal antibody, against MC38.Ova tumors grown in
immune-competent humanized PD-1 mice. Elena Burova, Omaira
Allbritton, William Poueymirou, Venus Lai, Janelle White, Dimitris
Skokos, Nicholas Papadopoulos, Drew Murphy, Israel Lowy, Ella Ioffe,
Gavin Thurston.
267 Combining androgen deprivation with immune
checkpoint blockade delays the development of castration
resistance in a murine model of prostate cancer. Ying-Chun Shen,
Christina Kochel, Brian J. Francica, Angela Alme, Christopher Nirschl,
Thomas Nirschl, Zoila Areli Lopez Bujanda, Maria A. Carrera H, Mark
Selby, Alan Korman, Charles G. Drake.
268 Cytotopically modified antibodies to checkpoint proteins
can actively reconstitute immune checkpoint blockade and inhibit
tumor growth in a prostate cancer mouse model. Dorota Smolarek,
Christina A. Sakellariou, Prokar Dasgupta, Richard A. Smith, Christine
Galustian.
269 Evaluation of the antitumor activity of anti-PD-1
immunotherapy as a single agent and in combination with
approved agents in preclinical tumor models. Elaine M. Pinheiro,
Ruban Mangadu, Uyen T. Phan, Mingmei Cai, Yanhong Ma, Heather A.
Hirsch, Terrill K. McClanahan, Raymond J. Moniz, Ali-Samer AlAssaad, Samik Basu, Yaolin Wang, Venkataraman Sriram, Joseph H.
Phillips, Brian J. Long.
270 Preclinical assessment of combination therapy with
selumetinib and CTLA-4 for cancer. Stefanie R. Mullins, Edmund
Poon, Amanda Watkins, Paul D. Smith, Andrew Leishman, Ross
Stewart, Robert Wilkinson.
271 Targeting PD-1, TIM-3 and LAG-3 in combination for
improved immunotherapy combinations. Marilyn Kehry, Robert
Horlick, Peter Bowers, Toni Jun, Jean da Silva Correia, Jonathan
Graves, Yan Wang, Haley Laken, David J. King.
272 Checkpoint inhibitor combinations in a human mixed
leukocyte reaction. Erin Sult, Carl Hay, Qihui Huang, Stacy
Fuhrmann, Robert Hollingsworth, Kris F. Sachsenmeier.
12
12
237
POSTER SESSION
Immunology
Poster
:LJ[PVU
13
13
Tumor Microenvironment/Innate Immune Activators
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
13.
14.
15.
238
Abstract
Number
273 TLR8 agonist VTX-2337 (motolimod) decreases
monocytic myeloid-derived suppressor cells by inducing
differentiation to mature antigen-presenting cells. Zina J. Rutnam,
Yushe Dang, Gregory Diestch, Hailing Lu, Yi Yang, Robert Hershberg,
Mary L. Disis.
274 Bavituximab modulates tumor microenvironment and
activates CD8+ tumor infiltrating lymphocytes in a patient-derived
3D ex vivo system of lung cancer. Soner Altiok, Melanie MediavillaValera, Jenny Kreahling, David Noyes, Tiffany N. Razabdouski,
Nikoletta L. Kallinteris, Joseph Shan, Scott Antonia.
275 ER-886046, an antagonist of PGE2 receptor type-4,
induces an effective antitumor immune response in mice by
attenuating intratumoral MDSCs and TAMs. Diana I. Albu, Zichun
Wang, Jiayi Wu, Kuan-chun Huang, Wei Li, Diana Liu, Galina
Kuznetsov, Qian Chen, Xingfeng Bao, Mary Woodall-Jappe.
276 Recruitment of effector T cells into the tumor rim and
center with neoadjuvant systemic GM-CSF in patients with
localized prostate cancer. Xiao X. Wei, Stephen Chan, Jera Lewis,
Serena Kwek, Vinh Dao, Lawrence Fong.
277 Radioprotection of lung tissue involves modulation of
radiation-induced macrophage activation by soy isoflavones. Lisa
M. Abernathy, Matthew D. Fountain, John M. David, Christopher K.
Yunker, Michael C. Joiner, Gilda G. Hillman.
278 Antibody blockade of semaphorin 4D promotes
infiltration of activated tumor infiltrating leukocytes and reverses
tumor growth. Elizabeth E. Evans, Holm Bussler, Sebold Torno,
Crystal Mallow, Laurie A. Winters, Christine Reilly, Katya Klimatcheva,
Janaki Veeraraghavan, Alan S. Jonason, Maria Scrivens, Renee Kirk,
Sue Giralico, Alan Howell, John E. Leonard, Mark Paris, Terrence L.
Fisher, Ernest S. Smith, Maurice Zauderer.
279 Bexarotene increases tumor CD8+ T cells and improves
response to conventional breast chemotherapy in the transgenic
mouse mammary tumor model TgMMTV-neu. Sasha E. Stanton,
Ekram Gadd, Edmond Marzbani, Lauren Rastetter, Mary L. Disis.
280 Delta-24-RGDOX: making cancer more “visible” to the
immune system. Hong Jiang, Xuejun Fan, Karen Clise-Dwyer, Laura
Bover, Joy Gumin, Kathryn E. Ruisaard, Farah J. Mukheef, Frederick F.
Lang, Candelaria Gomez-Manzano, Juan Fueyo.
281 Virotherapy with a Semliki Forest virus-based vector
encoding IL-12 synergizes with PD-1/PD-L1 blockade. José I.
Quetglas, Sara Labiano, M. Á. Aznar, Elixabet Bolaños, Arantza
Azpilicueta, Inmaculada Rodríguez, Erkuden Casales, Alfonso
Rodríguez, Cristian Smerdou, Ignacio Melero.
282 Novel delivery system to bring immune checkpoint
antibodies to tumor microenvironment. Koichiro Shioya, Koichi
Koseki, Tomio Matsumura, Hitomi Shimizu, Yuko Shimatani,
Shun’ichiro Taniguchi.
283 Smac mimetic and radiotherapy synergize to enhance
antitumor immunity in lung cancer by targeting
immunosuppressive cells. Zhen Tao, Carey Myers, Norbert
Wiedemann, Gregoire Vuagniaux, Larry Harshyne, Adam Dicker, D. C.
Hooper, Bo Lu.
285 MEDI9447: enhancing anti-tumor immunity by targeting
CD73 In the tumor microenvironment. Carl Hay, Erin Sult, Qihui
Huang, Scott Hammond, Kathy Mulgrew, Kelly McGlinchey, Stacy
Fuhrmann, Raymond Rothstein, Edmund Poon, Ross Stewart, Robert
Hollingsworth, Kris Sachsenmeier.
286 Coordinated activation of TLR8 and NLRP3 by VTX-2337
(motolimod) ignites tumoricidal NK cell activity. Greg Dietsch,
Haling Lu, Yi Yang, Chihiro Morishima, Laura Q. Chow, Mary L. Disis,
Robert Hershberg.
287 Specific delivery of immunostimulatory RNA via
nanoparticles blocks growth of primary and disseminated ovarian
tumors. Thomas Primiano, Bey-ih Chang.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
288 TG3003, an immunomodulatory anti-CD115 mAb
targeting M2-macrophage polarization in the tumor
microenvironment. Hélène Haegel, Christelle Ziller-Remy, Luc
Barraud, Jean-Yves Bonnefoy, Sandrine Cochin, Vanessa Duong,
Michel Geist, Benoit Grellier, Rémy Hallet, Jean-Baptiste Marchand,
Thierry Menguy, Ronald Rooke, Christine Thioudellet, Carine
Reymann, Xavier Préville.
289 The combination of CD40 agonism and PD-L1 blockade
enhances anti-tumor immunity in a mouse syngeneic orthotopic
pancreatic tumor model. Nadia Luheshi, Jane Coates-Ulrichsen,
James Harper, Gareth Davies, James Legg, Robert Wilkinson.
290 In situ delivery and production of anti-HER2 scFv. Takeshi
Kikuchi, Hitomi Shimizu, Yasuto Akiyama, Shun’ichiro Taniguchi.
291 Targeting the stroma to hit the tumor: MMP11 as a novel
target for cancer immunotherapy. Laura Luberto, Rita Mancini,
Arianna Di Napoli, Daniela Peruzzi, Federica Mori, Giuseppe Roscilli,
Emanuele Marra, Manuela Cappelletti, Gennaro Ciliberto, Luigi
Aurisicchio.
292 Interleukin-12 gene therapy combined with local ablative
technique electrochemotherapy for treatment of canine
mastocytoma. Maja Cemazar, Jerneja Ambrozic Avgustin, Gregor
Sersa, Darja Pavlin, Ana Krhac Levacic, Natasa Tesic, Mitja Rak, Ursa
Lampreht, Natasa Tozon.
293 Therapeutic effects of the bromodomain inhibitors JQ1
and I-BET 762 on pancreatic cancer. Ana S. Leal, Charlotte R.
Williams, Michael B. Sporn, Karen T. Liby.
294 A novel cancer therapeutic strategy: inducing cytotoxic
functions in tumor-associated macrophages. Whitney Barham,
Oleg Tikhomirov, Ryan Ortega, Jeannette Saskowski, Courtney S.
Thompson, Andrew Wilson, Timothy Blackwell, Zahra Mirafzali, Dineo
Khabele, Todd Giorgio, Fiona E. Yull.
295 Delivery of checkpoint inhibitor antibodies and other
therapeutics directly to tumors by encoding them within the
oncolytic adenovirus enadenotucirev. Brian R. Champion, Prithvi
Kodialbail, Sam Illingworth, Nalini Rasiah, Daniel Cochrane, John
Beadle, Kerry Fisher, Alice Brown.
296 Synergistic actions of oncolytic vaccinia virus and
sunitinib on pancreatic neuroendocrine tumors in RIP-Tag2 mice.
Corry E. McDonald, Barbara Sennino, Brian J. Schriver, John C. Bell,
David H. Kirn, Caroline J. Breitbach, Donald M. McDonald.
297 Immunotherapy with a CD40L/4-1BBL double-armed
oncolytic adenovirus drives Th1 immunity and control tumor
progression in a pancreas cancer model. Emma Svensson, Ioanna
Milenova, Rafael Moreno, Ramon Alemany, Angelica Loskog.
298 Overcoming TGF-␤-related immunosuppression for
cancer immunotherapy by oncolytic adenovirus co-expressing
Interleukin-12 and decorin. Eonju Oh, Il-Kyu Choi, June Kyu Hwang,
Chae-Ok Yun.
299 In vitro compound screening identifies enhancers of
adenoviral oncolysis with Delta24-RGD in patient-derived
glioblastoma stem cells. Lotte M. Berghauser Pont, Rutger Balvers,
Jenneke Kloezeman, Michal O. Nowicki, Andreas Kremer, E. Antonio
Chiocca, Sieger Leenstra, Clemens M. Dirven, Sean Lawler, Martine L.
Lamfers.
300 increasing radiation dose enhances immunotherapy
efficacy and together prolongs tumor dormancy in a subgroup of
mice treated for advanced intracerebral melanoma. Henry M.
Smilowitz, Peggy Micca, Daniel Sasso, Qian Wu, Nathanial Dyment,
Lynn Kuo.
301 RealTVac, a novel strategy to treat advanced, late-stage
tumors with real-time tumor vaccination. Piotr Jachimczak,
Andreas Mitsch, Achim Aigner.
301A A novel epithelial ovarian cancer protein, SUSD2,
inhibits platelet activation and binding to tumor cells.
Tyson Lager, Megan Thacker, Charissa Etrheim, Kristi A.
Egland, Mark K. Larson, Jennifer A. Gubbels.
POSTER SESSION
Tumor Biology
3D Cultures and Tissue/Organoid Models
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
302 High throughput drug screening with engineered
tumor spheroids. Stephanie Lemmo, Ehsan Aefi, Gary Luker,
Hossein Tavana.
303 Effect of scaffold on drug sensitivity of
multicellular spheroids: Which method is close to in vivo
and suitable for HTS. Norio Masuda, Atsushi Mizuno,
M. Mamunur Rahman, Kazuya Arai, Manabu Itoh.
304 Formation of uniform and reproducible 3D cancer
spheroids in a high throughput plate format. Cindy Neeley,
Chetana M. Revankar.
305 An innovative 3D porous scaffold-based perfusion
bioreactor system for the in vitro maintenance and
expansion of primary breast cancer tissue. Manuele G.
Muraro, Simone Muenst, Giulio C. Spagnoli, Daniel Oertli,
Walter P. Weber, Savas D. Soysal.
306 Role of tumor beta-1 integrin in the tumor cell
extravasation cascade. Michelle B. Chen, John M. Lamar,
Roger D. Kamm, Richard O. Hynes.
307 Determination of cell surface receptors CD44 and
ErbB2 in NovaMatrix-3D - a 3D cell culture system. John M.
Dornish, Therese Andersen.
308 The role of PTEN PDZ-binding domain in mammary
gland tumorigenesis. Mingfei Yan, Penelope Or, Andrew
Chan.
309 Longitudinal monitoring of cell proliferation and
cytotoxicity in a biomimetic 3D culture model for lung
cancer using native extracellular matrix scaffolds. Luis F.
Tapias, Michael Lanuti, Xi Ren, Sarah E. Gilpin, Lan Wei, Bryan
C. Fuchs, Kenneth K. Tanabe, Harald C. Ott.
310 Breast cancer cell invasion in a highly organized
three dimensional (3D) microengineered tumor model.
Nitish Peela, Feba S. Sam, Wayne Christenson, Adam W.
Watson, Robert Ros, Ghassan Mouneimne, Mehdi Nikkhah.
311 High-throughput spheroid formation in a 384-well
format using magnetic 3D bioprinting. Hubert Tseng, Jacob
A. Gage, William L. Haisler, Glauco R. Souza.
312 Profiling drug sensitivity and kinomic pathways
utilizing a novel human tumor derived MicroTumor assay.
Christopher D. Willey, Ashley N. Gilbert, Rachael Shevin,
Catherine P. Langford, Raj Singh, Joshua C. Anderson, G.
Yancey Gillespie.
313 Examining the role of ABCA1 cholesterol
transporter in ovarian cancer spheroids. Rebekka Williams,
Amanda Russell, Angelika Bongers, Sharon Sagnella,
Christopher Fife, Wendy Jessup, Anna DeFazio, Georgia
Chenevix-Trench, Michelle Haber, Murray Norris, Michelle
Henderson.
314 A rapid 3D tumor spheroid analysis method using
the Celigo imaging cytometry. Leo L. Chan, Scott Cribbes,
Maria Vinci, Sarah Kessel, Lisa Patterson, Sue Eccles.
315 Modeling tumors with tridimensional biomimetic
scaffolds: effect of the microenvironment on cell behavior,
hypoxia response, and drug resistance. Chiara Liverani,
Alessandro De Vita, Silvia Minardi, Federico La Manna, Laura
Mercatali, Alessandro Parodi, Dino Amadori, Alberto
Bongiovanni, Toni Ibrahim, Ennio Tasciotti.
316 Development of a novel 3D cancer model by
cultivation of malignant effusions in a 3D cell culture
system. Arno Amann, Marit Zwierzina, Julia M. Huber,
Gabriele Gamerith, Stefan Koeck, Mario Bitsche, Edith Lorenz,
Heinz Zwierzina.
317 3D high-content screening for the identification of
compounds that target cells in dormant tumor spheroid
regions. Carsten Wenzel, Sven Christian, Carolyn Algire,
Wolfgang Schwede, Roland Neuhaus, Judith Guenther,
Ningshu Liu, Sebastian Raese, Karsten Parczyk, Stefan
Prechtl, Patrick Steigemann.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
30.
Abstract
Number
318 Enhancing drug discovery and development
throughput without sacrificing predictivity: ex vivo 3D
drug response profiling (DRP) using patient-derived
xenografts (PDX). Tessa M. DesRochers, Christina Mattingly,
Stephen Shuford, Matthew Gevaert, David Orr, Carol Bult,
Susie Airhart, Mingshan Cheng, Minan Wang, James Keck,
Howland Crosswell.
319 Comparison of 2D- and 3D-culture models as drugtesting platforms in breast cancer. Yoshinori Imamura, Toru
Mukohara, Yohei Shimono, Yohei Funakoshi, Naoko
Chayahara, Masanori Toyoda, Naomi Kiyota, Shintaro Takao,
Seishi Kono, Tetsuya Nakatsura, Hironobu Minami.
320 Perfused 3D tri-culture breast cancer microtumors
for accurate prediction of drug response. Tessa M.
DesRochers, Stephen Shuford, Christina Mattingly, Terri
Bruce, Zhiyi Liu, Kyle Quinn, Irene Georgakoudi, David L.
Kaplan, David Orr, Howland E. Crosswell.
321 In vitro recapitulation of 3D tumor
microenvironment with defined oxygen and pH levels
through a novel scalable bioreactor-based strategy. Vitor
E. Santo, Marta Estrada, Sofia Rebelo, Elizabeth Anderson,
Paula M. Alves, Catarina Brito.
322 Establishment and genomic characterization of
enteroid cultures from human colonic adenomas and
adenocarcinomas. Michael K. Dame, Shannon D. McClintock,
Durga Attili, Becky Simon, Kelly Copley, Stacy Finkbeiner,
Christopher Altheim, Jason Spence, Henry Appelman, D. K.
Turgeon, Linda C. Samuelson, Dean E. Brenner, James Varani.
323 Spheroid-based high throughput screening for
identification of molecules targeting different tumor
microenvironment characteristics. Wojciech Senkowski,
Xiaonan Zhang, Peter Nygren, Maria Hägg Olofsson, Mats
Gustafsson, Stig Linder, Rolf Larsson, Mårten Fryknäs.
324 High throughput triculture: A breast cancer
spheroid model for drug screening. Gabriel J. Benton,
Gerald DeGray, Irina Arnaoutova, Hynda K. Kleinman, Jay
George.
325 Multiple myeloma in a physiologically relevant
Me-HA -3D Hydrogel: Discovering new phenotypes of drug
resistance. Bhagavathi A. Narayanan, Bin Duan, Narayanan
K. Narayanan, Jonathan Butcher Butcher, Amitabha
Mazumder.
326 Differences in RNA expression and
chemosensitivity in 2D versus 3D non-small-cell lung
cancer cultures. Gabriele Gamerith, Johannes Rainer, Arno
Amann, Stefan Koeck, Edith Lorenz, Heinz Zwierzina, Julia M.
Huber.
327 3D dynamics of the response to cell cycle
checkpoint targeting drugs in multicellular tumour
spheroids. Valérie LOBJOIS, Odile MONDESERT, Céline
FRONGIA, Annaick DESMAISON, Aurélie GOMES, Martine
CAZALES, Bernard Ducommun.
328 Original microenvironment of different cancer
types is maintained upon culture of primary tissues in
perfused bioreactors. Christian Hirt, Manuele G. Muraro,
Valentina Mele, Francesca Amicarella, Celeste Manfredonia,
Savas D. Soysal, Simone Muenst, Luigi Mariani, Christoph
Kettelhack, Michael Heberer, Giulio C. Spagnoli, Ivan Martin,
Giandomenica Iezzi, Adam Papadimitropoulos.
329 Establishment of three-dimensional primary tumor
cell culture method and novel drug sensitivity test. Hiroshi
Goji, Manami Shimomura, Yasushi Uemura, Tetsuya
Nakatsura, M. Mamunur Rahman, Manabu Itoh.
331 A novel perfusion bioreactor system maintains
long-term viability of a three dimensional in vitro breast
carcinoma surrogate. Kayla F. Goliwas, Lauren E. Marshall,
Kun Yuan, Joel L. Berry, Andra R. Frost.
14
14
239
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
15
15
Cell Adhesion and Extracellular Matrix
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
240
Abstract
Number
332 Extracellular matrix stiffness regulates metabolic
state in metastatic, but not quiescent, breast carcinoma
cells. Brett A. Morris, Brian Burkel, Suzanne Ponik, Kevin
Eliceiri, Julio Aguirre-Ghiso, John Condeelis, James
Castracane, Patricia J. Keely.
333 Evaluation of the mixed solution of sodium
hyaluronate and hydroxyethylstarch on gynecologic
cancer cell line. Ha-Young Lee, Hyun-Jung Cho, Shin-Wha
Lee, Sang-Eun Lee, Dae-Yeon Kim, Jong-Hyeok Kim, YongMan Kim, Young-Tak Kim, Joo-Hyun Nam.
334 Glucose regulates chemoresistance and stemness
via Wnt/␤-catenin signaling in ovarian cancer cells.
HyeRan Gwak, Soochi Kim, UnTek Jo, Yong Sang Song.
335 Dynamic biochemical tissue analysis of novel
P-selectin ligands expressed by colon cancer. Eric Martin,
Ramiro Malgor, Douglas Goetz, Monica Burdick.
336 CD73 induces actin polymerization to protect
epithelial cell-cell adhesions: Loss of this physiological
reflex in endometrial carcinoma. Jessica L. Bowser, Michael
R. Blackburn, Kenneth Dunner, Russell R. Broaddus.
337 Mechanism of TKI resistance and role of epithelial
mesenchymal transition in NSCLC. Ichwaku Rastogi,
Gregory M. Botting, Andrew Webb, Brian L. Webb, Marie C.
Nlend, Neelu Puri.
338 Immunohistochemical expression of CD44/ERM
complex proteins in penile carcinoma. Juliana B.
de Andrade, Fernando A. Soares.
339 Different receptor tyrosine kinases mediate EMT
and erlotinib-resistance in NSCLC cell lines through bypass
signalling. Kristine Raaby Jakobsen, Christina Demuth, Anne
T. Madsen, Birgit Westh Mortensen, Peter Meldgaard, Anders
Lade Nielsen, Boe Sandahl Soerensen.
340 Identification of p62/IMP2 novel targets in breast
cancer metastasis. Yang Li, Bo Peng, Ningjing Lei, Wei Qian,
Giulio Francia, Jianying Zhang.
341 Breast cancer cell adhesion and degradome
interact to drive metastasize. Asif Rizwan, Menglin Cheng,
Zaver M. Bhujwalla, Balaji Krishnamachary, Lu Jiang, Kristine
Glunde.
342 Breast cancer adhesion cascade is influenced by
Galectin-1 and E-selectin receptor-ligand interactions.
Nathan M. Reynolds, Claire R. Hall, Sean E. Thomas, Monica M.
Burdick.
343 The homeobox gene DLX4 promotes inflammatory
signaling and peritoneal metastasis of ovarian cancer.
Dhwani Haria, Bon Q. Trinh, Song Yi Ko, Nicolas Barengo,
Honami Naora.
344 Downregulation of osteoblastic N-cadherin
decreases primary multiple myeloma cell - osteoblast
interactions. Wenting Zhang, Yexin Gu, Qiaoling Sun, David
S. Siegel, Peter Tolias, Zheng Yang, Woo Lee, Jenny
Zilberberg.
345 Mechanically tuned 3 dimensional gelatin
hydrogels support mammary fibroblast viability and
growth. Kathryn Woods, Catlyn Thigpen, Kyung Min Park,
Abby Hielscher.
346 The effects of targeting AMPK on microtubule
stability and microtentacles in breast cancer cells. Kristi R.
Chakrabarti, Rebecca A. Whipple, Lekhana Bhandary, Michele
Vitolo, Amanda Boggs, Keyata Thompson, Stuart S. Martin.
347 Mechanism of c-Met TKI resistance and role of
epithelial mesenchymal transition in melanoma. Supriya
Rajanna, Ichwaku Rastogi, Sunil Palani, Neelu Puri.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
348 Amino acid-based prodrugs of gemcitabine - a
therapeutic option to overcome chemoresistance in
pancreatic cancer. Yangzom D. Bhutia, Ellappan Babu,
Pankaj K. Singh, Vadivel Ganapathy.
349 Autophagy, cancer stem cells, and trastuzumab
resistance in three dimensional cultures of HER2+ breast
cancer cells. Cristina E. Rodríguez, Sara Reidel, Maria Adela
Jasnis, Elisa Bal de Kier joffe, Gabriel L. Fiszman.
350 HER3 mediates acquired resistance to HER2targeted therapy in esophageal adenocarcinoma. Eva A.
Ebbing, Jan Paul Medema, Sybren L. Meijer, Kausilia K.
Krishnadath, Mark I. van Berge Henegouwen, Maarten F.
Bijlsma, Hanneke W. van Laarhoven.
351 HO-1 modulates the actin stress fiber architecture
in prostate cancer cells: Towards a less aggressive
phenotype. Alejandra V. Paez, Carla Pallavicini, Jimena
Giudice, Noelia Carabelos, Nicolas Anselmino, Emiliano G.
Ortiz, Federico Schuster, Estefania Labanca, Marcelo Marti,
Maria Binaghi, Pia Valacco, Javier H. Cotignola, Luciana
Bruno, Valeria Levi, Nora Navone, Elba S. Vazquez, Geraldine
Gueron.
352 Up-regulation of CD44 in the development of
metastasis, recurrence and drug resistance of ovarian
cancer. Yan Gao, Rosemary Foster, Francis J. Hornicek,
Mansoor M. Amiji, Zhenfeng Duan.
353 Vorinostat enhances anti-tumor effects of cisplatin
in head and neck cancer cells by targeting cancer stem
cells. Bhavna Kumar, Arti Yadav, Theodoros N. Teknos,
Pawan Kumar.
354 Resistance to TGF-beta-induced apoptosis is not
associated with the de-differentiation in hepatocellular
carcinoma. Tomomi Kogiso, Etsuko Hashimoto, Kazuhisa
Kodama, Yuichi Ikarashi, Nobuyuki Torii, Makiko Taniai,
Katsutoshi Tokushige, Keiko Shiratori.
355 A monoclonal antibody against laminin alpha 4
inhibits both MCAM and integrin-a6b1 binding, blocks
tumor cell adhesion in vitro and slows melanoma tumor
growth in vivo. Stephen J. Tam, Lauri E. Li, Carlos Lorenzana,
Yue Liu, Ken Flanagan, Philip J. Dolan, Lana Alexander, Josh
Salmans, Robin M. Barbour, Jeffrey N. Higaki, Tarlochan
Nijjar, Wagner Zago, Ted A. Yednock, Gene Kinney.
356 Mutaome-based magnolin sensitivity in ovarian
cancer cells. Ji-Hong Song, Woo-Young Kim, Yong-Yeon
Cho.
357 Exosome-mediated transfer of alphaV integrins
promotes prostate cancer cell-cell communication. Amrita
Singh, Carmine Fedele, Renato V. Iozzo, Lucia R. Languino.
358 The role of GDF-15 on docetaxel resistance in lung
cancer. Mototsugu Watanabe, Yasutaka Masada, Shinsuke
Hashida, Tomoaki Ohtsuka, Ken Suzawa, Yuho Maki,
Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Kazunori
Tsukuda, Shinichi Toyooka, Shinichiro Miyoshi.
359 STAT3-axis activated snail expression and
promoted drug resistance in pediatric brain tumor. Tsai
Chi-Chang.
360 Senescent hepatocytes secrete CCL2 to accelerate
liver cancer growth via accumulation of
immunosuppressive myeloid cells. Tobias Eggert, Juling Ji,
Lars Zender, Xin W. Wang, Tim F. Greten.
361 Opposite regulation of stromelysin expression in
prostate tumor and its microenvironment. Shian-Ying
Sung, Chia-Ling Hsieh.
POSTER SESSION
Tumor Biology
Circulating Tumor Cells and Disseminated Tumor Cells
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Abstract
Number
362 Molecular characterization of circulating tumor cells
allows stratifying for prognosis in breast cancer patients
undergoing neoadjuvant therapy. Lisa König, Oliver Hoffmann,
Rainer Kimmig, Sabine Kasimir-Bauer.
363 Dissecting CTC phenotypes: insights into mechanisms of
breast cancer dormancy. Sirisha Peddibhotla, Monika Vishnoi, Wei
Yin, Yizhen Chen, Antonio Scamardo, David Hong, Dario Marchetti.
364 The molecular profiles of disseminated tumor cells in a
Patient Derived Xenograft model recapitulate those found in
patient bone marrow. Sreeraj G. Pillai, Shunqiang Li, Chidananda M.
Siddappa, Mark A. Watson, Timothy P. Fleming, Matthew J. Ellis,
Rebecca L. Aft.
365 Mobilizing prostate cancer cells from the endosteal niche
by targeting the SDF-1/CXCR4 axis. Kenneth C. Valkenburg,
Kenneth J. Pienta.
366 A novel transcript variant of androgen receptor identified
in circulating tumor cells from castration-resistant prostate cancer
patients as a potentially prognostic biomarker. Zhigang Kang,
Avani Shah, Yunkai Yu, Yuelin Zhu, Ali A. Bhagat, Kyra Zhao, Andrew
Wu, James Gao, Ravi Madan, James Gulley, William Dahut, Paul
Meltzer, Liang Cao.
367 Microfluidic devices for the interrogation of single
circulating tumor cells. Yoonsun Yang, Hoon Suk Rho, Joost F.
Swennenhuis, Michiel Stevens, Arjan G. Tibbe, Séverine
Le Gac, Han Gardeniers, Leon W. Terstappen.
368 Phage display derived antibodies for the detection of
mesenchymal CTCs in TNBC. Stephen Kalscheuer, Jayanth Panyam.
369 Association between tumor infiltrating immune cells,
circulating tumor cells in blood and disseminated tumor cells in
the bone marrow in patients with primary ovarian cancer. Issam
Chebouti, Agnes Bankfalvi, Christoph Friedrich, Rainer Kimmig,
Sabine Kasimir-Bauer.
370 Expansion of CTCs from early stage lung cancer patients
using a microfluidic co-culture model. Zhuo Zhang, Hiroe
Shiratsuchi, Jules Lin, Guoan Chen, Rishindra M. Reddy, Ebrahim
Azizi, Shamileh Fouladdel, Andrew C. Chang, Lin Lin, Hui Jiang,
Meghna Waghray, Diane M. Simeone, Max S. Wicha, David G. Beer,
Gary Luker, Nithya Ramnath, Sunitha Nagrath.
371 Longitudinal genetic characterization of circulating tumor
cells in metastatic breast cancer patients. Valeria Sero, Francesca
De Luca, Anna Doffini, Francesca Galardi, Marta Pestrin, Zbignew T.
Czyz, Genny Buson, Giulia Bregola, Chiara Bolognesi, Francesca
Fontana, Gianni Medoro, Bernhard Polzer, Angelo Di Leo, Christoph A.
Klein, Nicolo Manaresi.
372 Expression profiling of circulating tumor cells: A
prognostic and predictive biomarker in metastatic breast cancer.
Maren Bredemeier, Mikael Kubista, Robert Sjöback, Marie
Jendrichova, Eva Rohlova, Vednula Novosadova, Katarina Kolostova,
Siegfried Hauch, Bahriye Aktas, Mitra Tewes, Rainer Kimmig, Sabine
Kasimir-Bauer.
373 Analytical and clinical validation of an
EpCAM-independent assay for CTC detection in peripheral blood
of early breast cancer patients based on Cytokeratin-19 (CK-19)
RT-qPCR. Areti Strati, Athina Markou, Aliki Stathopoulou, Stella
Apostolaki, Dimitris Mavroudis, Vasilis Georgoulias, Evi S. Lianidou.
374 Expression of the autophagosomal marker LC3 on
circulating tumor cells (CTCs) of patients with early and metastatic
breast cancer (BC). Maria Spiliotaki, Chrysa Koukorava, Alexios
Matikas, Vassilis Georgoulias, Dimitrios Mavroudis, Sofia Agelaki.
375 Phenotypic and molecular characterization of circulating
tumor cells (CTCs) in patients with castration resistant prostate
cancer (CRPC) undergoing treatment with abiraterone acetate or
enzalutamide. Jaymala Patel, Vipul Bhargava, Miaoling He, Brad
Foulk, Denis A. Smirnov, Przemyslaw Twardowski, Marcin
Kortylewski, Sumanta Kumar Pal, Jeremy O. Jones.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
30.
Abstract
Number
376 Capture and release of circulating tumor cells by
temperature-sensitive graphene oxide-polymer composite. Hyeun
Joong Yoon, Apoorv Shanker, Yang Wang, Molly Kozminsky,
Shamileh Fouladdel, Monika L. Burness, Ebrahim Azizi, Max S. Wicha,
Jinsang Kim, Sunitha Nagrath.
377 EpCAM+ and EpCAM- circulating tumor cells in metastatic
lung cancer. Sanne de Wit, Guus van Dalum, Aufried T. Lenferink,
Arjan G. Tibbe, Jeroen T. Hiltermann, Harry J. Groen, Cees van Rijn,
Leon W. Terstappen.
378 Predictive and pharmacodynamic biomarkers of the
androgen receptor in circulating tumor cells. Jamie M. Sperger,
Lindsay Strotman, Benjamin P. Casavant, Chorom Pak, Sacha Horn,
Erika Heninger, Scott M. Berry, David J. Beebe, Joshua M. Lang.
379 Circulating tumor cells (CTCs) in clinically localized
prostate cancer (PCa): searching a prognostic tool. Elisabetta
Rossi, Antonella Facchinetti, Vittorio Aneloni, Emanuel Zilio, Massimo
Dal Bianco, Alice Zoccoli, Daniele Santini, Diletta Garrou, Francesco
Porpiglia, Rita Zamarchi.
380 Capture of EpCAM-negative circulating tumor cells (CTCs)
with a “Universal CTC-Chip”. Kazue Yoneda, Yasuhiro Chikaishi, Eri
Kawashima, Tomoko So, Hidetaka Uramoto, Takashi Ohnaga,
Fumihiro Tanaka.
381 Circulating tumor cells (CTC) but not circulating
endothelial cells (CEC) are independent prognostic factors in
neoadjuvant chemotherapy combined with bevacizumab in HER2
negative inflammatory breast cancer (IBC) in multicentre phase II
trial BEVERLY1. Jean-Yves Pierga, Francois-Clement Bidard, Aurelie
Autret, Fabrice Andre, Thierry Petit, Florence Dalenc, Christel Levy,
William Jacot, Jacques Bonneterre, Jean-Marc Ferrero, Pierre Kerbrat,
Jerome Lemonnier, Francois Bertucci, Patrice Viens.
382 Identification and characterization of circulating tumor
cells with multiplexed Quantum Dot conjugated antibodies. Lanlan
Zhou, Elizabeth M. Matthew, David T. Dicker, Wafik S. El-Deiry.
383 The AdnaCellector, a new fully automated selection for
circulating tumor cells in blood of primary and metastatic breast
cancer patients. Maren Bredemeier, Natalie Fenjuk, Siegfried Hauch,
Bahriye Aktas, Mitra Tewes, Rainer Kimmig, Sabine Kasimir-Bauer.
384 Detection of circulating melanoma cells in paired arterial
and venous specimens from uveal melanoma patients with hepatic
metastatic. Mizue Terai, Zhaomei Mu, David Eschelman, Carin
Gonsalves, Ken Kageyama, Michael J. Mastrangelo, Marlana Orloff,
Ryan Weight, Massimo Cristofanilli, Takami Sato.
385 Predictive factors of c-kit-positive cancer stem cells,
epithelial-mesenchymal transition and circulating tumor cells in
distant metastasis formation in non-small cell lung cancer. Shiyang
Wu, Jianyu Sun, Weihua Qiu, Suyan Liu, Yujie Ma, Jiaming Che, Beili
Gao, Jiasen Xu, David K. Ann.
386 Rapid in situ RNA analysis of circulating tumor cells using
magnetic micropore-based sorting and Turbo FISH. Jin A Ko, Neha
Bhagwat, Stephanie S. Yee, Erica Carpenter, Ben Stanger, David
Issadore.
387 Non small cell lung cancer and circulating tumor cell: A
different expression of EpCam and cytokeratins. Elisabetta Rossi,
Mariangela Manicone, Antonella Facchinetti, Michele Aieta, Stefania
De Faveri, Maria Chiara Scaini, Luciana Possidente, Leon W.
Terstappen, Rita Zamarchi.
388 EGR1 is a mediator of TWEAK-Fn14 pathway induced
prostate cancer bone metastasis. Amir H. Ameri, JuanJuan I. Yin,
Keith Jansen, Simeng Wang, Jessica Snyder, Paul Hynes, Kathleen
Kelly.
389 The identity of all nucleated cells enriched by CellSearch.
Guus van Dalum, Simone van Lin, Ana M. Barradas, Jeroen T.
Hiltermann, Harry J. Groen, Leon W. Terstappen.
391 Utility of circulating tumor cell (CTC) in advanced gastric
cancer. Won Suk Lee, Jeong Min Kim, Woo Sun Kwon, So Jung Lim,
Tae Soo Kim, Ga Yun Kim, Sung Ho Choi, Byung Hee Jeon, Min Kyu
Jung, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha.
Poster
:LJ[PVU
16
16
241
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
17
17
Crosstalk of the Microenvironment and the Tumor Clone
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
242
Abstract
Number
392 Synergistic anti-tumor effects of dabigatran etexilate and
cyclophosphamide co-treatment are associated with decreased
circulating tissue factor positive microparticles. Eric T. Alexander,
Allyson R. Minton, Candace S. Hayes, Ashley Goss, Joanne Van Ryn,
Susan K. Gilmour.
393 Nicotinamide phosphoribosyl transferase (NAMPT)
inhibitors: novel modulators of antitumor immunity. Cristina
Travelli, Sara Morlacchi, Ubaldina Galli, Gian Cesare Tron, Armando A
Genazzani, Antonio Sica.
394 A novel anti-a proliferation-inducing ligand hAPRIL.01A
monoclonal antibody targets multiple myeloma cells in the bone
marrow microenvironment. Yu-Tzu Tai, Chirag Acharya, Gang An,
Mike Y. Zhong, Xiaoyan Feng, Hua Jiang, Hans van Eenennaam,
Andrea van Elsas, Nikhil C. Munshi, Kenneth C. Anderson.
395 Effect of pantoprazole to enhance activity of docetaxel
against human tumor xenografts by inhibiting autophagy. Qian
Tan, Anthony M. Joshua, Jasdeep K. Saggar, Man Yu, Marina Wang,
Bradly Wouters, Ian F. Tannock.
396 Ibrutinib exerts potent antifibrotic activity in a mouse
model of pancreatic adenocarcinoma. Daniel Massó-Vallés, Toni
Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara,
Jonathan R. Whitfield, Marie-Eve Beaulieu, Gerard I. Evan, Laurence
Elias, Joaquín Arribas, Laura Soucek.
397 Rebastinib potently inhibits function of perivascular TIE2
expressing macrophages in vitro and in vivo. Allison Harney,
Jeanine Pignatelli, Edison Leung, Maja Oktay, Yarong Wang, Bryan D.
Smith, Daniel L. Flynn, John S. Condeelis.
398 Specific skeletal targeting of MMP-2 inhibitors for the
treatment of bone metastatic breast cancer. Marilena Tauro,
Antonio Laghezza, Paolo Tortorella, Conor C. Lynch.
399 Nanoparticle silencing of ␤1 and ␤3 integrins augments
Dasatinib sensitivity. Jenny G. Parvani, Vinson Chu, Sarah Roelle,
Zheng-Rong Lu, William Schiemann.
400 MEK inhibition enhances immune checkpoint blockade
treatment of murine models of neuroblastoma. Sakunthala
Muthugounder, Long Hung, Randall Chan, Jin Kim, Soheila Shirinbak,
Hiroyuki Shimada, Shahab Asgharzadeh.
401 A novel photoimmunotherapy targeting cancerassociated fibroblasts (CAFs) overcomes therapeutic resistance in
human esophageal cancer. Ryoichi Katsube, Kazuhiro Noma,
Shinichiro Watanabe, Shinichi Urano, Takayuki Ninomiya, Toshiaki
Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Hisataka Kobayashi,
Toshiyoshi Fujiwara.
402 Pasireotide reduces chemoresistance in pancreatic tumor
cells by inhibiting the synthesis and secretion of growth factors
from tumor associated fibroblasts. Camille Duluc, Siham Moatassim,
Mounira Chalabi, Aurélie Perraud, Yvan Martineau, Florence Breibach,
Marie-Bernadette Delisle, Muriel Mathonnet, Herbert A. Schmid,
Stéphane Pyronnet, Corinne Bousquet.
403 Acquired resistance to pegylated liposomal doxorubicin.
Megumi Kai, Tomonori Tanei, Yan Ting Liu, Yuki Saito, Mauro Ferrari,
Kenji Yokoi.
404 MK2461 suppress progression of pancreatic cancer
disrupting interaction between pancreatic cancer cells and stellate
cells. Koetsu Inoue, Hideo Ohtsuka, Fuyuhiko Motoi, Daisuke Douchi,
Shuhei Kawasaki, Kei Kawaguchi, Kunihiro Masuda, Koji Fukase,
Shinobu Ohnuma, Takeshi Naitoh, Yu Katayose, Shinichi Egawa,
Michiaki Unno.
405 Kindlin-2 regulates integrin function and sensitivity to
docetaxel in prostate cancer cells. Edward F. Plow, Mitali Das,
Jamila Hirbawi, Khalid Sossey-Alaoui.
406 Effects of an RGD peptide in osteoclast maturation and
behavior as a therapeutic option for metastatic bone disease.
Gerald Prager, Daniela Bianconi, Anastasia Chillà, Alexandra Dorda,
Nisha Geetha, Matthias Unseld, Despoina Sykoutri, Marina Poettler,
Kurt Redlich, Christoph Zielinski.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
407 FTY720 suppressed CT26 murine colon cancer peritoneal
carcinomatosis progression by decreasing tumor associated
macrophages and TNF-alpha. Tomoyoshi Aoyagi, Dorit Avini,
Masayuki Nagahashi, Akimitsu Yamada, Krista P. Terracina, WeiChing Huang, Kazunori Aoki, Yasunori Matsumoto, Sarah Spiegel,
Hisahiro Matsubara, Kazuaki Takabe.
408 ACP-196, an orally bioavailable covalent selective
inhibitor of Btk, modulates the innate tumor microenvironment,
exhibits antitumor efficacy and enhances gemcitabine activity in
pancreatic cancer. Brian J. Lannutti, Michael Gulrajani, Fanny Krantz,
Elena Bibikova, Todd Covey, Katti Jessen, Wayne Rothbaum, David
M. Johnson, Roger Ulrich.
409 Docetaxel induced-JNK2/PHD1 signaling pathway
increases cell death in cancer cells under hypoxia through the
degradation of HIF-1␣. Eun-Taex Oh, Min-Jeong Song, Hyemi Lee,
Yun-Jeong Choi, Heon Joo Park.
410 SPARC expression enhances cellular aggregation and
resistance to gemcitabine in pancreatic cancer cells. Edgardo
Salvatierra, Elvia Rivas, Leandro Guttlein, Emily Robitschek, Andrea
Llera, Osvaldo Podhajcer.
411 1,25(OH)2D3 deficiency accelerates colon cancer
progression via microenvironmental regulation. Xiaoqin Yuan, Yun
Liu, Lulu Chen, Dengshun Miao.
412 Phytochemical pterostilbene suppresses lung cancer stem
cell generation via modulating tumor-associated macrophages.
Wen-Chien Huang.
413 Targeting IL-6 as a preventive and therapeutic strategy
for K-ras mutant lung cancer. Mauricio S. Caetano, Amber M.
Cumpian, Lei Gong, Seon H. Chang, Huiyuan Zhang, Humam N.
Kadara, Cinthya Sternberg, Carlos G. Ferreira, Stephanie S. Watowich,
Seyed J. Moghaddam.
414 Prospective profiling of systemic and loco-regional
alterations during intraperitoneal chemotherapy for ovarian
cancer, results from GOG 271. Shannon Grabosch, Anda M. Vlad,
Tianzhou Ma, Jyothi T. Mony, Mary Strange, Joan Brozick, Julia
Thaller, George Tseng, Xin Huang, Kathleen Moore, Kunle Odunsi,
Robert P. Edwards.
415 Differential expression of therapeutic targets across
tumor micro-environments and at infiltrative margins in
glioblastoma. Myles R. McCrary, David Gutman, William Dunn, Milota
Kaluzova, Alexandros Bouros, Merete Williams, Xialong Zhang, Lee A.
Cooper, Constantinos G. Hadjipanayis, Daniel J. Brat.
416 Carbon monoxide targets Notch1 and MAPK-ERK1/2
signaling pathways to block growth of lung carcinoma. Zsuzsanna
Nemeth, Eva Csizmadia, Lisa Vikstrom, Mailin Li, Kavita Bisht, Alborz
Feizi, David Gallo, Leo Otterbein, Janos Fillinger, Balazs Dome, Daniel
B. Costa, Barbara Wegiel.
417 Integrative drug sensitivity analysis of PI3K/mTOR
pathway inhibitors in Head and Neck Squamous Cell Carcinoma
(HNSCC). Vaishnavi Sambandam, Li Shen, Ming Zhang, Rishi Saigal,
Lauren A. Byers, Curtis Pickering, Jeffrey N. Myers, Jing Wang, Faye
M. Johnson.
418 A novel animal study software application emulates
clinical trials by enabling the conduct of multi-center,
asynchronous pre-clinical trials. Eric M. Ibsen, Jeffrey L. Kumer.
419 Cooperative interactions between p53 and NF␬B enhance
cell plasticity. Federica Alessandrini, Vasundhara Sharma,
Alessandra Bisio, Sara Zaccara, Alberto Inga, Yari Ciribilli.
420 The role of tumor microenvironment in therapy resistance
and melanoma progression. Rajasekharan Somasundaram, Gao
Zhang, Stephan N. Wagner, Mizuho Fukunaga-Kalabis1, Meenhard
Herlyn.
421 The role of the tumor microenvironment of pancreatic
cancer to predict treatment outcome. Anne Steins, Remy Klaassen,
Oliver Gurney-Champion, Maarten Bijlsma, Jan Paul Medema, Hessel
Wijkstra, Geertjan van Tienhoven, Olivier Busch, Cornelis Punt, Marc
Besselink, Hanneke Wilmink, Marc van de Vijver, Jaap Stoker, Aart
Nederveen, Hanneke van Laarhoven.
POSTER SESSION
Tumor Biology
Cytokines and Chemokines and the Microenvironment
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Abstract
Number
422 The role of CCL2 in the breast cancer tumor
microenvironment and metastasis. Nicole Lavender, Jiqing
Sai, Jinming Yang, Sergey V. Novitskiy, Ann Richmond.
423 CXCL12/CXCR4 activation by cancer-associated
fibroblasts promotes integrin ␤1 clustering and invasive
ability in gastric cancer. Daisuke Izumi, Takatsugu Ishimoto,
Hidetaka Sugihara, Eto Kojiro, Hiroshi Sawayama, Keisuke
Miyake, Yuki Kiyozumi, Keisuke Kosumi, Ryuma Tokunaga,
Kazuto Harada, Junji Kurashige, Masaaki Iwatsuki, Shiro
Iwagami, Yoshifumi Baba, Yasuo Sakamoto, Yuji Miyamoto,
Naoya Yoshida, Masayuki Watanabe, Hideo Baba.
424 Chemokine CXCL14 is a multistep tumor
suppressor. Ryu-Ichiro Hata, Kazuhito Izukuri, Yasumasa
Kato, Soichiro Sasaki, Chihiro Miyamoto, Tetsu Akasaka,
Xiaoyan Yang, Yojiro Maehata, Yoji Nagashima, Kazuyoshi
Takeda, Tohru Kiyono, Naofumi Mukaida, Masaru Taniguchi.
425 A small molecule glycomimetic antagonist of
E-selectin and CXCR4 (GMI-1359) prevents pancreatic
tumor metastasis and improves chemotherapy. Maria M.
Steele, William E. Fogler, John L. Magnani, Michael A.
Hollingsworth.
426 Targeting CXCR4 reduced T regulatory cells
(Tregs) -mediated cell proliferation suppression in renal
cell carcinoma (RCC) patients. Sara Santagata, Maria
Napolitano, Crescenzo D’Alterio, Sabrina Cecere, Renato De
Domenico, Carmela Cacciapuoti, Salvatore Dimaro, Luciana
Marinelli, Nicola Longo, Sandro Pignata, Sisto Perdonà,
Stefania Scala.
427 Host and tumoral CXCR2 signaling contributes to
tumor growth. Danielle Carroll, James Harper, Karen McDaid,
Ruth Franks, Catherine Eberline, Jane Kendrew, Richard
Sainson, Judith Anderton, Chris Rossant, Karen Coffman,
Ching Ching Leow, Ivan Inigo, Mitchell Reville, Jacintha
Shenton, Lesley Young, Simon Barry.
428 Dual E-selectin and CXCR4 inhibition reduces
tumor growth and increases the sensitivity to docetaxel in
experimental bone metastases of prostate cancer.
Giovanni L. Gravina, Andrea Mancini, Alessandro Colapietro,
Simona D. Monache, Adriano Angelucci, Alessia Calgani,
William E. Fogler, John L. Magnani, Claudio Festuccia.
429 Novel role of CXCL12/CXCR4 signaling axis in
obesity-induced prostate cancer progression in HiMyc
mice. Achinto Saha, Jorge Blando, John DiGiovanni.
430 MCP-1/CCL2 and IL-8 regulate proteolytic activity
of triple negative inflammatory breast cancer via
cathepsin B, ERK1/2, JAK1 and Src signaling pathways.
Sherif A. Ibrahim, Eslam A. Elghonaimy, Mohamed
El-Shinawi, Medhat El-Halawany, Mohamed A. Nouh, Tahani
El-Mamlouk, Bonnie F. Sloane, Mona M. Mohamed.
431 Active secretion of CXCL10 and CCL5 from
colorectal cancer microenvironments associates with
GranzymeB+ CD8+ T-cell infiltration. Timothy J. Zumwalt,
C. Richard Boland, Ajay Goel.
432 Macrophage promotes EMT in gastric cancer
through activating CXCR2 signaling. Chang-Hua Zhang,
Guangkai Xia.
433 Role of IL-8/CXCR2 network in the tumor
microenvironment of esophageal squamous cell
carcinoma. Masazumi Inoue, Hiroya Takeuchi, Sachiko
Matsuda, Tomohiko Nishi, Kazumasa Fukuda, Rieko
Nakamura, Tsunehiro Takahashi, Norihito Wada, Hirofumi
Kawakubo, Yoshiro Saikawa, Yuko Kitagawa.
Poster
Board
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
Abstract
Number
434 Prostate cancer cell-derived cathelicidin-related
antimicrobial peptide regulates MCP-1 and CXCL1/2
through autocrine signaling. Ha-Ram Cha, Jonathan Hensel,
Selvarangan Ponnazhagan.
435 Adipocyte-derived monocyte chemotactic protein-1
(MCP-1) promotes prostate cancer progression through
matrix metalloproteinase (MMP-2) mediated extracellular
matrix degradation. Yusuke Ito, Hitoshi Ishiguro, Naohito
Kobayashi, Hisashi Hasumi, Masatoshi Watanabe, Masahiro
Yao, Hiroji Uemura.
436 SDF1␣/CXCR4 axis might be associated with
growth-interaction between cancer-associated fibroblasts
and gastric cancer cells in hypoxic tumor
microenvironment. Haruhito Kinoshita, Masakazu Yashiro,
Hiroaki Kasashima, Go Masuda, Tamami Morisaki, Tatsunari
Fukuoka, Katsunobu Sakurai, Takahiro Toyokawa, Kenjiro
Kimura, Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma,
Masaichi Ohira, Kosei Hirakawa.
437 Mena at the nexus of chemotaxis and haptotaxis
during tumor progression. Madeleine J. Oudin, Oliver Jonas,
Tatiana Kosciuk, Liliane C. Broye, Jeff Wyckoff, Miles A. Miller,
Alisha Lussiez, Sreeja Asokan, Robert Langer, Douglas
Lauffenburger, James E. Bear, Frank B. Gertler.
438 Granulocyte-colony stimulating factor (G-CSF)
facilitates metastasis of uterine cervical cancer by
recruiting myeloid-derived suppressor cells (MDSCs) via
CXCL12-CXCR4 axis. Tomoyuki Sasano, Seiji Mabuchi, Ryoko
Takahashi, Hiromasa Kuroda, Kenjiro Sawada, Tadashi
Kimura.
439 Interleukin-6 induces SPINK1 in colorectal cancer.
Kati A. Räsänen, Laura Hautala, Ulf-Håkan Stenman, Hannu
Koistinen.
440 Nicotinamide phosphoribosyltransferase (NAMPT):
a new cytokine in tumor progression. Ambra Grolla, Simone
Torretta, Angela Amoruso, Giuseppe Orsomando, Armando
Genazzani.
441 IL-17 and IL-17-producing cells associated with
advanced stage or poor prognosis in oral cancers, through
enhancing tumor progression. Meng Hua Lee.
442 Decreased tumor progression by the knockdown of
interleukin 17 receoptor A in the B16F10 melanoma model.
Ya-Shan Chen, Chao-Lin Liu, Hui-Shan Chen, Su-Ting Wu,
Chia-Rui Shen.
443 Mechanisms of IL-1 production and release in
pancreatic cancer cells. Emanuela Brunetto, Lucia De Monte,
Silvia Heltai, Maria Pia Protti.
444 Slit2 stimulation induces a chemorepellent effect
on the migration of human GBM brain tumor initiating
cells. Hugo Guerrero-Cazares, Emily Lavell, Gabrielle
Drummond, Sural Ranamukhaarachchi, Vivian CapillaGonzalez, Paula Schiapparelli, Alfredo Quinones-Hinojosa.
445 Tumor microenvironment influences survival of
mantle cell lymphoma-initiating cells through FGF/FGFR1
signaling. Lalit Sehgal, Rohit Mathur, Zuzana Berkova, Tamer
Khashab, Xin Wang, Jorge E. Romaguera, Alma E. Rodriguez,
Sattva Neelapu, Felipe Samaniego.
446 Reciprocal paracrine signaling between epithelial
and stromal cells alters the pancreatic tumor
microenvironment. Matthew C. Stout, Danielle R. Cole, Paul
M. Campbell.
Poster
:LJ[PVU
18
18
243
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
19
19
Immune Regulation in the Microenvironment
Poster
Board
1.
2.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
244
Abstract
Number
447 Tumor microenvironment in pancreatic cancer
(PDAC): interplay between tumor cells, stromal cells and
immune cells. Eva Karamitopoulou, Martin Wartenberg, José
A. Galván, Inti Zlobec, Alessandro Lugli, Aurel Perren.
448 The role of the Nanog transcription factor in tumor
immune escape. Emily Robitschek, Chih-Ping Mao, Shiwen
Peng, Chien-Fu Hung, TC Wu.
450 Suppression of innate and adaptive immune
responses in the human lung tumor microenvironment via
microRNA-183. Melba Marie Tejera, Melba Marie Tejera,
Sarah S. Donatelli, Jun-Min Zhou, Danielle L. Gilvary,
Xianghong Chen, Erika A.
451 The vigorous immune microenvironment of
microsatellite instable colon cancer is balanced by
multiple counter-inhibitory checkpoints. Nicolas J. Llosa,
Michael Cruise, Ada Tam, Elizabeth Wick, Elizabeth
Hechenbleikner, Janis Taube, Lee Blosser, Hongni Fan, Hao
Wang, Ming Zhang, Brandon Luber, Nickolas Papadopoulos,
Kenneth Kinzler, Bert Vogelstein, Cynthia Sears, Robert
Anders, Drew Pardoll, Franck Housseau.
452 Monocytic Gr-1+/CD11b+ myeloid cells are
necessary for natural killer cells to eradicate glioma and
are inhibited by tumor-derived galectin-1. Gregory J.
Baker, Peter Chockley, Daniel Zamler, Viveka N. Yadav, Maria
G. Castro, Pedro R. Lowenstein.
453 Engineering the tumor microenvironment: Hemin
conditioning in vivo impairs tumor growth and reprograms
the immune-modulatory response in prostate cancer.
Felipe M. Jaworski, Geraldine G. Gueron, Lucas D. Gentilini,
Daiana B. Leonardi, Ignacio González Pérez, Geraldine
Contrufo, Gabriel A. Rabinovich, Daniel G. Compagno, Diego
J. Laderach, Elba S. Vazquez.
454 Evaluating the progression of cutaneous
melanoma by the molecular immune response of the
sentinel lymph node. Richard Essner, Alexandra Gangi,
David Kaufman, Ke Wei Gong, Myung Sim, Dennis Slamon.
455 B cells actively participate to the anti-cancer
immune response in high grade serous ovarian cancer
metastases. Anne Montfort, Steffen Boehm, Thomas Dowe,
Joanne Topping, Michelle Lockley, Melania Capasso, Frances
Balkwill.
456 Defined co-mutation subgroups of KRAS-mutated
NSCLC display distinct immune profiles. Warren L. Denning,
Lixia Diao, Ferdinandos Skoulidis, Yanyan Lou, Lauren Byers,
Jing Wang, John Weinstein, Don Gibbons, John Heymach.
457 Depletion of glioma infiltrating myeloid derived
suppressor cells promotes anti-tumor T cell responses.
Neha Kamran, Youping Li, Mariela Moreno-Ayala, Hikmat
Assi, Marianela Candolfi, Marta Dzaman, Pedro Lowenstein,
Maria Castro.
458 Immune-inhibitory HLA-G is expressed in the
tumor microenvironment of Ewing Sarcomas. Christian
Spurny, Bianca Altvater, Sareetha Kailayangiri, Silke
Landmeier, Martina Ahlmann, Uta Dirksen, Andreas Ranft,
Heinz Wiendl, Wolfgang Hartmann, Eva Wardelmann,
Claudia Rossig.
459 Targeting TIGIT and PD-1 to increase the
expansion and function of tumor antigen-specific CD8+ T
cells in melanoma patients. Joe-Marc Chauvin, Ornella
Pagliano, Julien Fourcade, Zhaojun Sun, Cindy Sanders, John
M. Kirkwood, Tseng-hui T. Chen, Mark Maurer, Alan Korman,
Hassane Zarour.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
26.
27.
28.
Abstract
Number
460 Novel compound elicits anti-tumor macrophages
associated with tumor regression in breast cancer. Holly E.
Ponichtera, Jennifer L. Guerriero, Alaba O. Sotayo, Anthony
Letai.
461 Therapeutic effect of sorafenib is attenuated by
tumor-infiltrating Ly6G+ myeloid-derived suppressor cells
(MDSCs) and is restored by anti-interleukin-6 (IL-6)
antibody treatment in an orthotopic mouse liver cancer
model. Chun-Jung Chang, Yao-Hsu Yang, Chiao-Juno Chiu,
Bor-Luen Chiang, Xiao-yi Lee, Chih-Hung Hsu, Ann-Lii Cheng.
462 Cytotoxic CD8+ T cells and immunosuppressive T
regulatory cells are associated with aggressive breast
cancer subtypes. Galina F. Khramtsova, Rita Nanda,
Ekaterina A. Khramtsova, Lise Sveen, Sope Olugbile,
Olufunmilayo I. Olopade.
463 Successful generation of tumor infiltrating
lymphocytes from human non-small cell lung cancer
specimens. Kyoung-Hee Kim, Julia Kargl, Sylvia Lee, McGarry
Houghton.
464 Hypoxia-induced miR-210 potentiates MDSC
function through regulation of Arg1, Il-16 and Cxcl12, and
promotes tumor growth. Muhammad Zaeem Noman, Salem
Chouaib.
465 Progestin-driven regulatory T cells directly
promote an aggressive and metastatic phenotype in
triple-negative breast cancer. Tomas Dalotto Moreno, Juan
P. Cerliani, Diego O. Croci, Santiago P. Mendez-Huergo,
Florencia Moses, Gabriel A. Rabinovich, Mariana Salatino.
466 Systemic early immune priming via tumor-secreted
cytokines facilitates breast cancer metastasis in syngeneic mouse
model. Hasan Korkaya, Eunmi Lee, Maria Ouzounova,
Abdeljabar El Andaloussi, Ena Novakovic, Raziye Piranlioglu,
Mehmet F. Demirci, Shawn G. Clouthier, Max S. Wicha.
467 Oxidized lipids contribute to the suppression
function of myeloid derived suppressor cells in cancer.
Filippo Veglia, Vladimir Tyurin, Valerian Kagan, Dmitry
Gabrilovich.
468 Delayed tumor growth in breast cancer is
associated with reduced activity of the a2 isoform of
vacuolar ATPase. Gajendra K. Katara, Arpita Kulshrestha,
Alice Gilman-Sachs, Kenneth D. Beaman.
469 mPGES1 deletion and the mechanisms of tumor
growth suppression. Nune Markosyan, Andrew Rech, Robert
H. Vonderheide, Garret A. FitzGerald, Emer M. Smyth.
470 Nicotine reduces survival via augmentation of
paracrine HGF-MET signaling in the pancreatic cancer
microenvironment. Daniel Delitto, Dongyu Zhang, Song Han,
Brian S. Black, Andrea E. Knowlton, Adrian C. Vlada, George
A. Sarosi, Kevin E. Behrns, Ryan M. Thomas, Xiaomin Lu, Chen
Liu, Thomas J. George, Steven J. Hughes, Shannon M. Wallet,
Jose G. Trevino.
472 Galectin-3 modulates glioblastomas (GBM) tumor
microenvironment, and is linked to glioblastoma invasion.
Umadevi V. Wesley, Esat Resad, Paul Clark, Carolina Larrain,
John Kuo, Robert J. Dempsey.
473 Functional polarization of macrophage triggered
by tumor-conditioned medium. Weina Zhang.
474 Regulation of epithelial plasticity of cancer cells by
tumor-associated macrophages. CHIH-CHAN LEE, Muh-Hwa
Yang.
POSTER SESSION
Tumor Biology
Pediatric Cancer: Basic Science 1
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
7.
8.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
475 Identification of SHANK2 as a tumor suppressor disrupted by
recurrent somatic structural variation (SV) in neuroblastoma. Karina
Conkrite, Nicole Ferraro, Lee McDaniel, Derek A. Oldridge, Edward
Attiyeh, Shahab Asgharzadeh, Maura Diamond, Jaime Guidry Auvil,
Tanja Davidsen, Malcom Smith, Wendy B. London, Robert Seeger,
Javed Khan, Daniela S. Gerhard, John M. Maris, Sharon J. Diskin.
476 Loss of chd5-mediated tumor suppression accelerates
MYCN-driven neuroblastoma tumorigenesis in zebrafish. Mark W.
Zimmerman, Shuning He, Jimann Shin, Shizhen Zhu, Marc Mansour,
Keith Joung, Jinhua Quan, Timur Yusufzai, A. T. Look.
477 Inhibition of MEK confers hypersensitivity to X-radiation
in the context of BRAF mutation in a model of childhood
astrocytoma. Adam W. Studebaker, Kathryn Bondra, Star Seum,
Justin Leasure, Christopher Chronowski, Changxian Shen, Doris
Phelps, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Peter J.
Houghton.
478 EWS/FLI1 transcription is modulated by the PI3K pathway
via SP1 in Ewing sarcoma. Chiara Giorgi, Alexander Boro, Laura A.
Lopez-Garcia, Beat W. Schaefer, Felix K. Niggli.
479 Inhibition of the splicing of the EWS-FLI1 fusion transcript
reverses EWS-FLI1 driven oncogenic expression in Ewing sarcoma.
Patrick J. Grohar, Suntae Kim, Sara Haddock, Guillermo Rangel
Rivera, Matt Harlow, Nichole K. Maloney, Konrad Huppi, Kristen
Gehlhaus, Magdalena Grandin, Carleen Klumpp-Thomas, Eugen
Buehler, Lee J. Helman, Scott E. Martin, Natasha J. Caplen.
481 Rationale for targeting the protein chaperone network in
rhabdomyosarcoma. Amit J. Sabnis, Christopher J. Guerriero, Jeffrey
L. Brodsky, Trever Bivona.
482 Integrated genetic and epigenetic analysis defines novel
molecular clusters in rhabdomyosarcoma. Masafumi Seki, Riki
Nishimura, Kenichi Yoshida, Teppei Shimamura, Yuichi Shiraishi,
Yusuke Sato, Motohiro Kato, Kenichi Chiba, HIroko Tanaka, Genta
Nagae, Yusuke Okuno, Hajime Hosoi, Yukichi Tanaka, Hajime Ohkita,
Mitsuru Miyashi, Tomoaki Taguchi, Katsuyoshi Koh, Ryoji Hanada,
Akira Oka, Satoru Miyano, Hiroyuki Aburatani, Yasuhide Hayashi,
Seishi Ogawa, Junko Takita.
484 Fidelity of subclonal representation in human
neuroblastoma-derived cell line and patient-derived xenograft
models: A report from the NCI-TARGET project. Maya Schonbach,
Arnavaz Danesh, Jeff Bruce, Tito Woodburn, Tanja Davidsen, Leandro
Hermida, Patee Gesuwan, Jaime Guidry Auvil, Oliver Hampton, David
Wheeler, Julie Gastier-Foster, Malcolm Smith, Daniela Gerhard, John
M. Maris, Patrick Reynolds, Trevor J. Pugh.
485 EWS-FLI1 targeted small molecule YK-4-279 synergizes
with vinca alkaloids through double hit to mitotic machinery.
Stefan K. Zöllner, Ryan Commins, Sung H. Hong, Hayriye V. Erkizan,
Jeffrey A. Toretsky.
486 BET protein inhibition by JQ1 blocks EWS-FLI1 activity in Ewing
sarcoma. Krista L. Bledsoe, Aaron Stonestrom, Stephan Kadauke,
Laura Quick, Robert Young, Gerd A. Blobel, Margaret M. Chou.
487 Whole genome screen to identify genes targeting MYCNdriven embryonal tumors. Carol J. Thiele, Zhihui Liu, Veronica
Veschi, Eugene Buehler, Scott Martin.
488 High DKC1 expression supports neuroblastoma tumor cell
proliferation and is strongly associated with poor patient
outcomes. Rosemary O’Brien, Michelle F. Maritz, Cheng F. Kong,
Stefania Purgato, Bing Liu, Chen Yang, Amanda Russell, Jayne
Murray, Claudia Flemming, Michelle Haber, Giovanni Perini, Murray D.
Norris, Jamie I. Fletcher, Karen L. Mackenzie.
489 Loss of NOXA expression by INI1/SNF5 loss impaired
sensitivity to chemotherapeutic agents in malignant rhabdoid
tumor in vitro and iv vivo. Kazutaka Ouchi, Yasumichi Kuwahara,
Tomoko Iehara, Eiichi Konishi, Hajime Hosoi.
490 The Trithorax proteins menin and MLL promote Ewing
sarcoma tumorigenicity. Laurie K. Svoboda, Cassondra Cramer,
Ashley Harris, Natashay Bailey, Tomek Cierpicki, Jolanta Grembecka,
Elizabeth Lawlor.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
491 Tumor response to cabozantinib in the TH-MYCN GEM
model of neuroblastoma. Gilberto S. Almeida, Philippa King, Yann
Jamin, Albert Hallsworth, Hannah Webber, Sergey Popov, Andrew D.
Pearson, Louis Chesler, Simon P. Robinson.
492 Epigenetic suppression of miRNA-203 promotes Ewing
sarcoma malignancy. Tim Hensel, Esther Heid, Stephanie Plehm,
Stefan Burdach, Günther H. Richter.
493 Drug response profiling to inform individualized
treatment approaches in high risk leukemia. Viktoras Frismantas,
Anna Rinaldi, Maria Pamela Dobay, Salome Higi, Sabrina Eugster,
Blerim Marovca, Peter Horvath, Mauzro Delorenzi, Joachim Kunz,
Obul R. Bandapalli, Gunnar Cario, Martin Stanulla, Andreas E. Kulozik,
Martina Muckenthaler, Cornelia Eckert, Thomas Radimerski, JeanPierre Bourquin, Beat C. Bornhauser.
494 MYC, dominant negative p53 and AKT transform human
neural stem cells into primitive neuro-ectodermal tumors sensitive
to glutaminase inhibitors. Isabella Taylor, Sama Ahsan, Antoinette
Price, Charles Eberhart, Eric H. Raabe.
495 Amplification of chromosomal regions 12q13-14 and 12q15
defines a distinct subgroup of high-risk neuroblastoma patients and is
associated with atypical clinical features. Susanne M. Fransson, Hanna
Kryh, Niloufar Javanmardi, Inge Ambros, Ana Berbegall, Ingrid Ora,
Rosa Noguera, Jurate Asmundsson, Bengt Sandstedt, Ruth
Ladenstein, Peter F. Ambros, Per Kogner, Tommy Martinsson.
496 Checkpoint kinase 1 inhibition suppresses cell growth and
enhances cisplatin sensitivity in medulloblastoma cells. Monil Shah,
Eric Prince, Sujatha Venkataraman, Ilango Balakrishnan, Irina
Alimova, Peter Harris, Marc Remeke, Michael D. Taylor, Michael H.
Handler, Nicholas K. Foreman, Rajeev Vibhakar.
497 Understanding oncogenic fusions: Lessons learned from
inflammatory myofibroblastic tumor. Merrida A. Childress, Abha
Gupta, Doron Lipson, Geoff Otto, Tina Brennan, Catherine T. Chung,
Scott C. Borinstein, Jeffrey S. Ross, Phillip J. Stephens, Vincent A.
Miller, Cheryl M. Coffin, Jason L. Hornick, Christine M. Lovly.
498 A bivalent promoter regulates stress dependent induction
of CXCR4 in Ewing sarcoma. Melanie A. Krook, Elizabeth R. Lawlor.
499 Characterization of the cell death mechanism after
silencing of PAX3-FOXO1 in alveolar rhabdomyosarcoma using a
CRISPR-Cas mediated knockout approach. Marco Wachtel, Felix
Niggli, Beat Schäfer.
500 Bortezomib, a proteasome inhibitor, synergizes with
DFMO to inhibit neuroblastoma cell proliferation via the reversal of
the LIN28/Let-7 axis. Maria Rich, Ping Zhao, Abhinav Nagulapally,
Jeffrey Bond, Giselle Sholler.
501 Inhibition of exportin 1 (XPO1) by selinexor (KPT-330)
synergistically suppresses growth of neuroblastoma in
combination with doxorubicin or bromodomain inhibition. Pietro J.
Ranieri, Rebecca Trillo, Yosef Landesman, William Senapedis, Dilara
McCauley, Sharon Shacham, Michael Kauffman, John M. Maris,
Edward F. Attiyeh.
502 Copy number alterations identify targeted therapies in
preclinical models of osteosarcoma. Leanne C. Sayles, Marcus
Breese, Alejandro Sweet-Cordero.
503 The PPM1D encoded phosphatase Wip1 is a novel
oncogene and potential therapeutic target in neuroblastoma and
medulloblastoma. Jelena Milosevic, Diana Treis, Malin Wickstrom,
Susanne Fransson, Nina Eissler, Baldur Sveinbjörnsson, Ninib
Baryawno, Keiji Tanino, Galina Selivanova, Kazuyasu Sakaguchi,
Tommy Martinsson, John Inge Johnsen, Per Kogner.
504 Glutamine metabolic inhibitors suppress growth and
tumorigenicity in MYC and MYCN-driven pediatric malignancies.
Allison Hanaford, Catherine Guerra, Charles Eberhart, Eric Raabe,
Antoinette Price.
20
20
245
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
21
21
Signaling Axes Regulating Motility and Invasion
Poster
Board
1.
505 Role of TMEPAI-PTEN-PI3K/Akt axis in TGF-␤
mediated growth and metastasis of breast cancer cells.
Prajjal K. Singha, Srilakshmi Pandeswara, Manjeri A.
Venkatachalam, Pothana Saikumar.
2.
506 TROY-EGFR signaling complex mediates
glioblastoma cells invasion and survival. Alison Roos,
Zachary Mayo, Jean Kloss, Serdar Tuncali, Harshil Dhruv,
Michael E. Berens, Joseph C. Loftus, Nhan L. Tran.
3.
507 Ionizing radiation regulates mutant p53-mediated
cancer cell invasiveness through targeting cyclin D1. ShinHee Lee, Phillip Craigmile, Shiyong Wu.
4.
508 Identification of FRA-1 as a potential driver of
pro-invasive properties in pancreatic cancer in conjunction
with MUC1. Ryan L. Hanson, Michael A. Hollingsworth.
5.
509 MicroRNA-140 suppresses the migration and
invasion of colorectal cancer cell possibly through
targeting Smad3. Bo Song, Wenyue Zhao, Lianhong Li.
6.
510 A novel role for Olig2 in the regulation of glioma
invasion. Shiv K. Singh, Nicole Giannonatti, Robert Kupp,
Costanza L. Cascio, Shwetal Mehta.
7.
511 Rictor/mTORC2 drives formation, progression and
therapeutic resistance of HER2-amplified breast cancers.
Meghan M. Morrison, Bayley Jones, Violeta Sanchez, Monica
V. Estrada, Donna Hicks, Michelle Williams, Dana BrantleySieders, Rebecca Cook.
8.
512 Pim kinases and Pim inhibitors in the regulation of
prostate cancer cell migration and invasion. Sini Eerola,
Niina Santio, Johanna Tuomela, Eeva-Marja Rainio, Pascale
Moreau, Fabrice Anizon, Garry Corthals, Pirkko Härkonen,
Päivi Koskinen.
10.
514 ARHGEF15 is associated with a poor prognosis in
patients with pancreatic ductal adenocarcinoma through a
mechanism involving the enhancement of cellular motility
and proliferation. Hiroto Fukushima, Makiko Yasumoto,
Sachiko Ogasawara, Jun Akiba, Yuhei Kitasato, Yoshiki Naito,
Masamichi Nakayama, Yoshinobu Okabe, Masafumi
Yasunaga, Hiroyuki Horiuchi, Etsuko Sakamoto, Hiraku
Itadani, Shinji Mizuarai, Shinji Oie, Hirohisa Yano.
11.
12.
13.
246
Abstract
Number
Poster
Board
Abstract
Number
14.
518 O-GlcNAcylation regulates breast cancer cell
invasion via the NAD+-dependent deacetylase SIRT1.
Christina M. Ferrer.
15.
519 V-set and immunoglobulin domain containing 1
(VSIG1) demonstrates a tumor suppressive function in
gastric cancer and non-small cell lung cancer. Yusuke
Inoue, Nobuya Kurabe, Shun Matsuura, Matsuyoshi Maeda,
Tomoaki Kahyo, Hisaki Igarashi, Kazuhito Funai, Hiroshi Niwa,
Hiroshi Ogawa, Kazuya Shinmura, Hiroyuki Konno, Takafumi
Suda, Haruhiko Sugimura.
16.
520 MIEN1 drives breast cancer invasion by regulating
cytoskeletal dynamics. Marilyne Kpetemey, Jamboor
Vishwanatha.
17.
521 Connexin 43 and E-cadherin modulate prostate
cancer cell migration. Abdulaziz Aloliqi, Ao Zhang, Adina
Brett-Morris, Justin Lathia, Gail C. Fraizer.
18.
522 Involvement of Zyxin in aggressiveness of human
prostate cancer. Kei Yamamoto, Yasuki Hori, Jieun Seo, Saho
Hashimoto, Yoshihiro Endo, Tadashi Nittami, Yusuke Ito,
Hitoshi Ishiguro, Hiroji Uemura, Masatoshi Watanabe.
19.
523 Decrease of ARNT promotes cancer metastasis by
activating the fibronectin/integrin ␤1/FAK axis. Chi-Ruei
Huang, Chung-Ta Lee, Kwang-Yu Chang, Wen-Chang Chang,
Ben-Kuen Chen.
20.
524 Assessing the interaction between acetylenic
tricyclic bis-(cyano enone) and cysteine residues of actin
to inhibit non-small cell lung cancer cell migration. Eddie
Chan, Akira Saito, Tadashi Honda, John Di Guglielmo.
21.
525 PHD3-mediated prolyl hydroxylation of nonmuscle actin impairs polymerization and cell motility.
Weibo Luo, Gregg L. Semenza.
23.
527 Ectopic expression of truncated IFIT2 at C-terminal
tetratricopeptide repeats enhances the migration activity
of oral squamous cell carcinoma cells. Prabha Regmi,
Te-Chang Lee.
24.
515 Cell fate determination factor DACH1 inhibits lung
adenocarcinoma invasion and tumor growth through
repression of CXCL5 signaling. Na Han, Xun Yuan, Hua Wu,
Hanxiao Xu, Qian Chu, Mingzhou Guo, Shiying Yu, Yuan Chen,
Kongming Wu.
528 PP4C plays a braking role in Akt-driven cancer
migration/invasion. Ming-Yi Ho, Shu-Mei Liang, Chi-Ming
Liang.
25.
516 S100P: Cause or effect of vulvar carcinoma
prognostic status. Mayara C. Botelho, Andre M. LavoratoRocha, Iara S. Rodrigues, Beatriz M. Maia, Katia C. Carvalho,
Renato Puga, Fernando A. Soares, Rafael M. Rocha.
529 Phosphorylation of Thr165 within the activation
loop of Nek3 kinase is necessary for its pro-migratory
function in breast cancer cells. Katherine M. Harrington,
Charles V. Clevenger.
26.
530 PDK1 regulates cell migration and 3D invasion of
breast tumor cells by a kinase independent mechanism.
Paolo Armando Gagliardi, Laura di Blasio, Desiana Somale,
Alberto Puliafito, Giulia Chiaverina, Federico Bussolino, Luca
Primo.
517 The role of MYST4 in ovarian carcinoma. Tsui Lien
Mao, Hsuan-Ping Lin, Jim Sheu.
POSTER SESSION
Clinical Research
Diagnostic Biomarkers
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Abstract
Number
531 lncRNA profiling and its potential usage as thyroid
cancer biomarker. Song Tian, Samuel Rulli, Thomas J. Fahey,
Eric Lader.
532 Circulating myeloid precursor profile as potential
marker to differentiate radiation changes from tumor
recurrence after brain stereotactic radiosurgery. Wen
Jiang, Yvo Rodriguez, Nicolas S. Boehling, Sujit S. Prabhu,
Betty Y. Kim, Patrick Hwu, Erik P. Sulman, Paul D. Brown,
Jing Li.
533 S100A10 as a novel biomarker in hepatocellular
carcinoma. David Kung-Chun Chiu, Carmen Chak-Lui Wong,
Irene Oi-Lin Ng, Aki Pui-Wah Tse.
534 Development and validation of sandwich ELISA to
quantify circulating GRP78 as a cancer biomarker.
Eunjeong Yoo, Yvonne Lin, Nicos Petasis, Augustin Garcia,
Stan Louie, Isaac Asante, Eugene Zhou, Song Ah Chae.
535 Selected reaction monitoring (SRM)-based assay
for the quantification of biomarkers in human breast
cancer tissue. Alimatou M. Tchafa, Andrew S. Lemoff, Hamid
Mirzaei.
536 Human endogenous retrovirus K expression as a
possible adjunct to PSA in the diagnosis of prostate
cancer. Ronan Downey, Laura Murillo, Teresa McHale, Tiffany
Wallace, Caleb Seufert, Aaron Schetter, Tiffany Dorsey, Carol
Johnson, Radoslav Goldman, Christopher Loffredo, Peisha
Yan, Francis Sullivan, Francis Giles, Feng Wang-Johanning,
Stefan Ambs, Sharon Glynn.
537 Information-driven approaches to predicting
familial risk for prostate cancer. Emmanuelle Nicolas, Yan
Zhou, Ilya G. Serebriiskii, Mark D. Andrake, Elizabeth A.
Handorf, Roland L. Dunbrack, Veda N. Giri, Eric A. Ross, Erica
A. Golemis, Michael J. Hall, Mary B. Daly.
538 Identification and validation of novel prostate
cancer biomarkers using the Berg Interrogative Biology™
platform. Niven R. Narain, Anne Diers, Rakibou Ouro-Djobo,
Joyce Chan, Leonardo O. Rodrigues, Vivek K. Vishnudas,
Eleftherios P. Diamandis, Viatcheslav R. Akmaev,
Rangaprasad Sarangarajan.
539 Usefulness of genetic markers in pancreatic juice
for the diagnosis of pancreatic cancer distinguishing from
chronic inflammation: A meta-analysis. Tatsuo Hata,
Masaharu Ishida, Fuyuhiko Motoi, Takeshi Naitoh, Yu
Katayose, Shinichi Egawa, Michiaki Unno.
540 A MALDI imaging mass spectrometry approach
using tissue microarrays to identify an N-glycan biomarker
panel for pancreatic cancers. Richard R. Drake, Thomas W.
Powers, Benjamin A. Neely.
541 Application of novel RNA aptamer-based RNase I
activity assay for pancreatic cancer biomarker
development. Shiro Urayama, Aiming M. Yu.
542 CEACAM6 is upregulated by the H Pylori CAG-A
oncoprotein, and is a candidate biomarker for the
diagnosis of early gastric cancer. Anand D. Jeyasekharan,
Rony K. Roy, Michal M. Hoppe, Kar Tong Tan, Henry Yang,
Patrick Tan, Phillip H. Koeffler, Khay Guan Yeoh, Singapore
Gastric Cancer Consortium.
543 A short isoform of DCLK1, transcribed from an
alternate promoter in human colon cancers, represents a
novel biomarker and target for diagnostic and treatment
purposes. Malaney R. O’Connell, Shubhashish Sarkar,
Gurinder Luthra, Yoshinaga Okugawa, Yuji Toiyama, Ajay
Goel, Aakash Gajjar, Suimin Qiu, Lawrence Sowers, Pomila
Singh.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Abstract
Number
544 Lung cancer classification using new
immunohistochemical assay with anti-p40 (BC28) mouse
monoclonal antibody: Comparison with the p40 Echelon
assay and anti-p63 (4A4) antibody. Katerina Dvorak,
Christian Roessler, John Palting, Akira Moh.
545 Plasma-based diagnostics for detection of EML4ALK fusion transcripts in NSCLC patients. Kay Brinkmann,
Daniel Enderle, Tina Koestler, Stefan Bentink, Jennifer
Emenegger, Alexandra Spiel, Romy Mueller, Vincent O’Neill,
Johan Skog, Mikkel Noerholm.
546 Soluble EphA2 is a potential serum biomarker for
lung cancer. Tadanori Kondo, Hiroki Yumoto, Kento Usui,
Kazunori Kato.
547 Diagnosis of lung tumor types based on
metabolomic profiles in lymph node aspirates. Daniel R.
Sappington, Scott A. Helms, Eric Siegel, Susanne K. Jeffus,
Teka Bartter, Thaddeus Bartter, Gunnar Boysen.
548 Exosome as biomarkers and diagnostics in bladder
cancer. Yu-Ru Liu, Christopher Silver, Yi-Fen Lee.
549 A urine based assay to select patients for initial
cystoscopy. Kim E. van Kessel, Willemien Beukers, Irene
Lurkin, Kirstin A. van der Keur, Lars Dyrskjot, Ulrika
Segersten, Torben F. Ørntoft, Nuria Malats, Per-Uno
Malmström, Francisco X. Real, Chris H. Bangma, Ellen C.
Zwarthoff.
550 Evaluation of NQO1 as a potential diagnostic
marker for bladder cancer. Simone Cuff, Ruth Lewis,
Mohammed Jaffar, Richard Knox, Ian Weeks.
551 Identification of gene-expression biomarkers in
urine pathology specimens for the detection of bladder
cancer. Karen B. Chapman, Liqun Qiu, Jennifer Kidd, Aparna
Baxi, Markus D. Lachter, Joseph Wagner, Dorothy L.
Rosenthal, Matthew T. Olson.
552 Aberrant expression of CYR61 in bladder cancer
and its preoperative diagnostic potential in muscle
invasive bladder cancer. Huang Chen, Zhong J. Shou, Yu Liu,
Wei Zheng, Hao Xi, Hui J. Ma, Yan N. Gao.
553 Quantification of the cobalamin (vitamin B12)
TCN2 transport protein, cobalamin CD320 cell surface
receptor and Ki-67 in naturally occurring canine and feline
tumors and comparison to expression in adjacent normal
tissues. Annette M. Sysel, Victor E. Valli, Joseph A. Bauer.
554 Detection and separation of live circulating tumor
cells using lipid dye. Ranjana Mitra, Oscar Goodman Jr, Thuc
T. Le.
555 A workflow for enrichment and whole genome
amplification (WGA) of circulating tumor cells (CTCs) for
next generation sequencing. Merisa Nisic, Sijie Hao,
Ramdane Harouaka, Si-Yang Zheng.
556 The detection of viable human circulating tumor
cells (v-hCTCs) in resectable pancreatic cancer induced by
neoadjuvant chemoradiotherapy (NACRT) using
gemcitabine, S-1 and intensity-modulated radiotherapy
(IMRT). Masahiro Tanemura, Toshimitsu Irei, Masashi Inoue,
Shinya Yamashita, Kenta Furukawa, Masaki Wakasugi,
Kentaro Kishi, Hiroaki Nagano, Hiroki Akamatsu, Yasuo Urata,
Nobuyoshi Hatanaka, Masaki Mori, Yuichiro Doki.
557 A novel integrated i-FISH technology to detect and
characterize non-hematopoietic heteroploid CTC subtypes
with or without expressing vimentin or other tumor
biomarkers. Peter Lin.
23
23
247
POSTER SESSION
Clinical Research
Poster
:LJ[PVU
24
24
Predictive Biomarkers: Lung and Gastrointestinal Cancers
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
11.
12.
13.
14.
15.
248
Abstract
Number
558 Correlations of FGFR1 with ligand signaling in small-cell
lung cancer. Hui Yu, Andrzej Badzio, Theresa Boyle, Xian Lu,
Christopher J. Rivard, Ashley Kowalewski, Brad Rikke, Kim Ellison,
Leslie Rozeboom, Biftu Hassan, Fred R. Hirsch.
559 Inhibition of pro-survival pathways in lung cancer cells
with functional defects in the Fanconi Anemia pathway. Li Gao,
Wenrui Duan, Kathleen Dotts, Arjun Kalvala, Brittany Aguila, Gregory
A. Otterson, Miguel A. Villalona-Calero.
560 Retrospective evaluation, of the randomized Phase 3
MARQUEE trial of tivantinib (T) + erlotinib (E) versus placebo (P) +
erlotinib (E) using VeriStrat in patients with previously treated
nonsquamous NSCLC. Giorgio Scagliotti, Wallace Akerley, Joachim
von Pawel, Joanna Roder, Dale Shuster, Brian Schwartz, Dominic
Spinella.
561 Development of a highly specific Met antibody for
screening Met overexpression in NSCLC. Caiwei Chen, Hsiangmin E.
Lu, Haitao Wei, Kehu Yuan, Donghui Ma,
Wei-Wu He.
562 Alterations in chromatin remodeling pathways as a
predictive biomarker of cisplatin therapy in non-small cell lung
cancer. Erica Hlavin Bell, Arup R. Chakraborty, Xiaokui Molly Mo,
David Carbone, Arnab Chakravarti.
563 Evaluation of EGFR mutation analysis performed by
Sanger sequencing versus real-time PCR (EGFR RGQ PCR Kit).
Wolfgang Dietmaier, Irene Schardt, Petra Rümmele, Eva Geissinger,
Arndt Hartmann, Robert Stöhr.
564 The expression of fetal oncogene 5T4 in CTCs obtained
from NSCLC patients is discordant with the expression measured
in the primary tumor. Steven R.
Pirie-Shepherd, Shibing Deng, Jonathon Golas, Pamela Vizcarra, Eric
Tucker, Dena Marrinuci, Hans-Peter Gerber, Eric L. Powell.
565 Circulating tumor cell (CTC) detection and 5T4
characterization in breast, ovarian, and lung cancer patients on
active therapy. Steven R. Pirie-Shepherd, Iman Jilani, Eric Tucker,
David Valenta, Ryon Graf, Amanda Anderson, Dena Marrinucci, Puja
Sapra, Eric L. Powell.
566 ChemoPlex SRM assay predicts response to specific
chemotherapeutic agents in NSCLC. Eunkyung An, Tae-Jung Kim,
Manish Monga, Kathleen Bengali, Alexi Drilea, Joseph Reilly, Marlene
Darfler, Jon Burrows, Todd Hembrough.
568 Fibroblast growth factor receptors 2 is a novel therapeutic
target in esophagogastric junction adenocarcinoma. Ryuma
Tokunaga, Yu Imamura, Kenichi Nakamura, Takatsugu Ishimoto, Shiro
Iwagami, Junji Kurashige, Daisuke Izumi, Keisuke Kosumi,, Takaaki
Higashi, Katsunobu Taki, Yukiharu Hiyoshi, Yoshifumi Baba, Yasuo
Sakamoto, Yuji Miyamoto, Naoya Yoshida, Saeki Hiroshi, Eiji Oki,
Yoshihiko Maehara, Hideo Baba.
569 Comprehensive analyses of serum biomarkers associating
with the increase of pro-angiogenic Tie2-expressing monocytes in
patients with hepatocellular carcinoma. Hirotaka Shoji, Tatsuya
Kanto, Yohei Mano, Yoshihiko Aoki, Sachiyo Yoshio, Masaya
Sugiyama, Akinobu Taketomi, Masashi Mizokami.
570 PD-L1 expression in paired non-small cell lung cancer
tumor samples. Jhingook Kim, Steffen Filskov Sorensen, Yoon-La
Choi, Zhen (Adelle) Wang, Jong-Mu Sun, Hyejoo Choi, Jeanette Baehr
Georgsen, Marisa Dolled-Filhart, Kenneth Emancipator, Dianna Y. Wu,
Peter Meldgaard, Wei Zhou, Henrik Hager.
571 Circulating proteins in response to combined-modality
therapy in locally advanced rectal cancer identified by antibody
array screening. Erta Kalanxhi, Helga H. Hektoen, Sebastian Meltzer,
Svein Dueland, Kathrine R. Redalen, Kjersti Flatmark, Anne H. Ree.
572 Proteomics analysis of the effect of fluorouracil (5FU) and
5FU/leucovorin (LV) on colorectal cancer (CRC) in patients. Kees
Smid, Erik Meijer, Thang V. Pham, Inge de Reus, Sander R. Piersma,
Godefridus J. Peters, Connie R. Jimenez.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
573 Glypican-3 is a predictive marker for recurrence of
hepatocellular carcinoma after surgical resection, especially in
early stage. Kazuya Ofuji, Keigo Saito, Yasunari Nakamoto, Tetsuya
Nakatsura.
574 CD133 and LGR5 characterize stem-cell like subtype of
colorectal cancer. Luka Stanisavljevic, Mette P. Myklebust, Olav Dahl.
575 Identification of response predictors to capecitabine/
temozolomide in metastatic pancreatic neuroendocrine tumors.
Jonathan Strosberg, Mauro Cives, Marjorie Brelsford, Michael Black,
Alan Meeker, Masoumeh Ghayouri.
576 Development and analytical validation of a novel assay
for tissue detection of hyaluronan in the tumor microenvironment
to select patients for molecularly targeted pancreatic cancer
therapies. Arnold B. Gelb, Ping Jiang, Laurence Jadin, Daniel C.
Maneval, H. M. Shepard.
577 The albumin to globulin ratio predicts chemotherapeutic
outcomes in patients with unresectable metastatic CRC. Masatsune
Shibutani, Kiyoshi Maeda, Hisashi Nagahara, Hiroshi Ohtani, Yasuhito
Iseki, Tetsuro Ikeya, Kenji Sugano, Katsunobu Sakurai, Sadaaki
Yamazoe, Kenjiro Kimura, Takahiro Toyokawa, Ryosuke Amano,
Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Masaichi Ohira,
Kosei Hirakawa.
578 Molecular subgroup analysis of clinical outcomes in a
phase 3 study of gemcitabine and oxaliplatin with or without
erlotinib in advanced biliary tract cancer. Seung T. Kim, Joon Park.
579 TAK1-regulated expression of BIRC3 is responsible for
chemoradiotherapy (CRT) resistance in esophagogastric junction
(EGJ) adenocarcinoma. Geny Piro, Simone Giacopuzzi, Maria
Bencivenga, Carmine Carbone, Giuseppe Verlato, Melissa Frizziero,
Maria Mihaela Mina, Marco Zanotto, Valeria Merz, Giovanni De
Manzoni, Giampaolo Tortora, Davide Melisi.
580 hENT1 testing in pancreatic ductal adenocarcinoma: Are
we ready yet? A comparative analysis of the murine and the rabbit
antibodies. Jerome Cros, Raphael Marechal, Jean Baptiste Bachet,
Pierre Laurent-Puig, Jean Francois Flejou, Pieter Demetter, Magali
Svrcek.
581 Mutational landscape of PIK3CA gene and its association
with oral squamous cell carcinoma in Indian population. Sejalbahen
S. Shah, Siddharth Shah, Harish Padh, Kiran Kalia.
582 Prognostic and predictive value of plasma protein
signatures in a phase I/II trial of abituzumab combined with
cetuximab/irinotecan in second-line KRAS wild-type metastatic
colorectal cancer (mCRC). Josef Straub, Eike Staub, Miriam Lohr,
Giorgio Massimini, Elena Élez, Josep Tabernero.
583 Colorectal cancer cell lines recapitulate molecular and
pharmacological features of clinical samples. Gabriele Picco,
Mariangela Russo, Carlotta Cancelliere, Michela Buscarino, Claudio
Isella, Simona Lamba, Barbara Martinoglio, Federica Di Nicolantonio,
Alberto Bardelli, Enzo Medico.
584 The DEK oncogene may serve as a predictive plasma
biomarker in head and neck cancer patients. Trisha Wise-Draper,
Lisa Privette Vinnedge, Arun Sendilnathan.
585 Elevated levels of CD24 in head and neck squamous
carcinoma cells: A potential marker for unfavorable cisplatin
response. Vishnu Modur.
586 Nuclear translocation of EGFR in ameloblastomas. Núbia
B. Pereira, Carolina C. Gomes, Ana Carolina de M. do Carmo, Marina G.
Diniz, Dawidson A. Gomes, Ricardo S. Gomez.
587 MicroRNA expression in saliva in locally advanced oral
and oropharyngeal squamous cell carcinoma. Fabyane O. Garcia,
Vivian M. Constantino, Milena P. Mak, Gilberto de Castro-Jr, Fatima S.
Pasini.
POSTER SESSION
Clinical Research
Prognostic and Toxicity Biomarkers
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
588 Search for potential penile cancer biomarkers
using frozen tissue proteome profiling by mass
spectrometry. Adriana Bulgarelli, Elisângela D. Silva, Nilson
A. Assunção, Isabela W. Cunha, Stenio D. Zequi, Gustavo C.
Guimarães, Fernando A. Soares, José Vassallo.
2.
589 Expression levels of ABCA6 or ABCA7 predict
primary Ewing sarcoma progression at diagnosis. Michela
Pasello, Marilù Fanelli, Valentina Mularoni, Sonia Ciotti, Piero
Picci, Massimo Serra, Katia Scotlandi.
3.
590 Identification and validation of novel candidate
circulating biomarkers in high-grade soft tissue sarcoma.
Amalia Conti, Claudia Fredolini, Davide Tamburro, Giovanna
Magagnoli, Weidong Zhou, Lance A. Liotta, Piero Picci,
Alessandra Luchini, Maria Serena Benassi.
4.
591 Prognostic implications of PI3K mutation and
amplification in curatively resected liposarcoma. Joo Hoon
Kim, Hyo Song Kim, Jae Seok Lee, Ki Hyang Kim, Yong Jin
Cho, Kyu Hyun Park, Soo Hee Kim, Joong Bae Ahn, Woo Ik
Yang, Young Han Lee, Jin-Suck Suh, Kyoo-Ho Shin, Sun
Young Rha.
5.
592 Prognostic index system based on 20 genes for
predicting recurrence of non-muscle invasive bladder
cancer. Jong Hwan Kim, Seon-Kyu Kim, Seok-Joong Yun,
Wun-Jae Kim, Seon-Young Kim.
6.
593 Kinetic risk assessment with biomarkers of
systemic inflammation in patients with metastatic renal
cell carcinoma. Wayne B. Harris, Omer Kucuk, Bradley
Carthon, Yuan Liu, John Pattaras, Kenneth Ogan, Viraj
Master.
7.
594 AGT mutations as a prognosis factor in patients
with astrocytoma. Talia Wegman-Ostrosky, Ernesto SotoReyes, Silvia Vidal-Millan, Sonia Mejia, José Sánchez-Corona,
Luis A. Herrera.
Poster
Board
Abstract
Number
8.
595 Digital PCR validates 8q dosage as prognostic tool
in uveal melanoma. Mark J. de Lange, Mieke Versluis, Sake
van Pelt, Claudia A. Ruivenkamp, Wilma G. Kroes, Jinfeng
Cao, Martine J. Jager, Gre P. Luyten, Pieter A. van der Velden.
9.
596 Differential cellular localization of Ephrin receptor
tyrosine kinase B4 (EphB4) in melanoma progression. Nitin
Chakravarti, Jonathan L. Curry, Roland L. Bassett, Victor G.
Prieto.
10.
597 Coding and noncoding gene targets in pediatric
soft tissue sarcomas. Sheetal A. Mitra, Anirban P. Mitra,
Jonathan D. Buckley, Timothy J. Triche.
11.
598 Circulating peptides for predicting subsequent
cardiotoxicity in cancer patients with chemotherapies. Jia
Fan, Qing H. Meng, Christopher Bone, Stephen Igo, Ye Hu.
12.
599 A panel of mass spectrometry based serum protein
tests for predicting graft-versus-host disease (GvHD) and
its severity. Heinrich Roder, Andreas-Claudius Hoffmann,
Joanna Roder, Michael Koldehoff.
13.
600 Lower T-lymphocyte mitochondrial DNA copy
number is associated with graft versus host disease in
patients undergoing hematopoietic cell transplantation.
Bharat Thyagarajan, Ryan Shanley, Pallavi Prakash, Helene
Barcelo, Julie A. Ross, Michael R. Verneris, Mukta Arora.
14.
601 Glycodelin expression in lung cancer and
melanoma. Laura Hautala, Hannu Koistinen.
15.
602 Deleterious alterations in DNA damage response
genes are associated with improved outcome in muscleinvasive bladder cancer patients treated with radiationbased bladder preservation. Neil B. Desai, Gopa Iyer,
Eugene K. Cha, Sasinya N. Scott, Joseph Hreiki, John P.
Sfakianos, Philip Kim, Aditya Bagroida, Bernard H. Bochner,
Jonathan E. Rosenberg, Dean F. Bajorin, Michael F. Berger,
Marisa A. Kollmeier, Hikmat Al-Ahmadie, David B. Solit.
25
25
249
POSTER SESSION
Clinical Research
Poster
:LJ[PVU
26
26
Tumor- and Blood-based Genotyping
Poster
Board
1.
2.
3.
4.
5.
6.
7.
603 Consensus molecular subtyping through a community of experts
advances unsupervised gene expression-based disease classification and
facilitates clinical translation. Justin Guinney, Rodrigo Dienstmann, Xin Wang,
Aurelien de Reynies, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul
Roepman, Gift Nyamundanda, Paolo Angelino, Brian Bot, Jeffrey S. Morris, Iris
Simon, Sarah Gerster, Evelyn Fessler, Felipe de Sousa e Melo, Edoardo
Missiaglia, Hena Ramay, David Barras, Krisztian Homicsko, Dipen Maru, Ganiraju
Manyam, Bradley Broom, Valerie Boige, Ted Laderas, Ramon Salazar, Joe W.
Gray, Josep Tabernero, Rene Bernards, Stephen Friend, Pierre Laurent-Puig, Jan
P. Medema, Anguraj Sadanandam, Lodewyk Wessels, Mauro Delorenzi, Scott
Kopetz, Louis Vermeulen, Sabine Tejpar.
604 Impaired cell cycle arrest with concurrent epigenetic deregulation
identified through next generation sequencing in patients with advanced
carcinoma of unknown primary: Implications for personalized medicine.
Ishwaria M. Subbiah, Gauri Varadhachary, Apostolia M. Tsimberidou, Jennifer J.
Wheler, Vivek Subbiah, Filip Janku, Sinchita Roy Chowdhuri, Ralph Zinner, David
S. Hong.
605 The clinical outcome of patients with FOXL2
402C->G mutation positive adult-type Granulosa Cell Tumor of the ovary - a
population based study with analysis of tissue and plasma ctDNA. Anniina
Färkkilä, Melissa K. McConechy, Winnie Yang,, Nirit Rozenberg, Noora
Andersson, Leila Unkila-Kallio, Ralf Bützow, Blake Gilks, David G. Huntsman,
Mikko Anttonen.
606 Novel somatic mutations in the DNA-binding and coiled-coil
domain of the STAT3 gene in LGL-leukemia. Emma I. Andersson, Hanna Rajala,
Heikki Kuusanmäki, Arjan van Adrichem, Samuli Eldfors, Sonja Lagström,
Thomas Olson, Michael Clemente, Pekka Ellonen, Caroline Heckman, Thomas P.
Loughran, Jaroslaw P. Maciejewski, Satu Mustjoki.
607 Genomic analyses and novel models validate CDK4 as a
therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans.
Adrian Marino-Enriquez, Grant Eilers, Jeffrey Czaplinski, Mark Mayeda, Derrick
Tao, Meijun Zhu, Jason L. Hornick, Ewa Sicinska, Andrew J. Wagner, Jonathan A.
Fletcher.
608 Identification of genomic alteration which affects resistance to
induction chemotherapy in patients with locally-advanced head and neck
squamous cell carcinoma. Chan-Young Ock, Bongjun Son, Seungyoun Lee,
Jaewoo Moon, Sehui Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, SeHoon Lee, Dong-Wan Kim, Dae Seog Heo.
609 Molecular subtyping of pancreatic adenocarcinoma identifies SV2
positive subpopulation in classical PDAC. Daniela Dias-Santos, Matteo Ligorio,
Kshitij Arora, Vishal Thapar, Olivia C. MacKenzie, Srinjoy Sil, Niyati Desai, Vikram
Deshpande, Miguel N. Rivera, Cristina R. Ferrone, David T. Ting.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
8.
610 Prospective genomic characterization of small cell lung cancer by
targeted next generation sequencing. Helen H. Won, M. Catherine Pietanza,
Lee M. Krug, Anna M. Varghese, Natasha Rekhtman, Lu Wang, William Travis,
Paul K. Paik, Gregory J. Riely, Maureen F. Zakowski, Marc Ladanyi, Mark G. Kris,
Charles M. Rudin, Michael F. Berger.
23.
9.
611 Exploratory analyses suggest ovarian tumors with somatic or
germline loss of function mutations in BRCA1 or BRCA2 are biologically
similar and sensitive to PARP inhibition. Brian Dougherty, Zhongwu Lai,
Jonathan A. Ledermann, Jane D. Robertson, Tony W. Ho, Wenting Wu, Darren R.
Hodgson, Maria C. Orr, Mark J. O’Connor, Matthew J. Hawryluk, Timothy A.
Brennan, Roman Yelensky, James X. Sun, J. Carl Barrett.
24.
10.
612 The NCI exceptional responders initiatives: Initial feasibility result.
Barbara A. Conley, S. P. Ivy, James V. Tricoli, Jean-Claude Zenklusen, Roy
Tarnuzzer, Irina Lubensky, Naoko Takebe, Paul M. Williams, JoAnne Zujewski,
Richard Little, Jeffrey White, Elise Kohn, Shakun Malik, Ben Kim, Erin Souhan,
Lou Staudt.
11.
12.
13.
250
Abstract
Number
25.
26.
613 Copy number variations distinguish lung adenocarcinomas from
squamous cell carcinomas. Kai Song, Guangqiang Zheng, Luc Girard, Ignacio I.
Wistuba, Jack A. Roth, Carmen Behrens, Milind B. Suraokar, John D. Minna, Adi
F. Gazdar.
27.
614 Clinical implications of NRG1 fusion in invasive mucinous
adenocarcinoma of the lung. Ji-Youn Han, Yeon-Su Lee, Dong Hoon Lee, Dong
Wan Hong, Seung Hyun Hong, Jung-Ah Hwang, Byung Il Lee, Hye Jin You, Dong
Hoon Shin, Geon Kook Lee.
28.
615 Noninvasive diagnosis of actionable mutations by deep
sequencing of circulating tumor DNA in multiple myeloma. Rayan Kaedbey,
Olena Kis, Arnavaz Danesh, Mark Dowar, Tiantian Li, Zhihua Li, Jessica Liu, Mark
Mansour, Mahadeo Sukhai, Tong Zhang, Suzanne Kamel-Reid, Trevor J. Pugh,
Suzanne Trudel.
29.
Abstract
Number
616 Blood-based molecular landscapes of resistance to EGFR blockade
in colorectal cancer patients. Giulia Siravegna, Benedetta Mussolin, Michela
Buscarino, Giorgio Corti, Andrea Cassingena, Giovanni Crisafulli, Ryan B.
Corcoran, Agostino Ponzetti, Alfredo Budillon, Patrizia Racca, Silvia Marsoni,
Federica Di Nicolantonio, Fotios Loupakis, Salvatore Siena, Andrea Sartore
Bianchi, Alberto Bardelli.
617 Ultrasensitive detection of the pretreatment EGFR T790M mutation
in non-small cell lung cancer patients with an EGFR-activating mutation
using picodroplet digital PCR. Yasuhiro Koh, Tomoya Kawaguchi, Masaru
Watanabe, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Hideo
Saka, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Seiichi Kakegawa,
Motohiro Yamashita, Kazuhiko Kataoka, Yukito Ichinose, Yukiyasu Takeuchi,
Kazuhiro Sakamoto, Akihide Matsumura.
618 Comparison of mutational spectra in metastatic tumors and cellfree DNA in breast cancer patients. Kara N. Maxwell, Danielle J. Soucier-Ernst,
Erica L. Carpenter, Andrea B. Troxel, Christopher Colameco, Candace Clark,
Michael D. Feldman, Bijal Kakrecha, Melissa Langer, Joy Lee, David A. Lewis,
David Lieberman, Jennifer Morrissette, Tien-chi Pan, Stephanie S. Yee, Natalie
Shih, Lewis A. Chodosh, Angela M. DeMichele.
619 Identification of clinically actionable genomic alterations in the
tumor and circulation of pancreatic cancer patients. Mark Sausen, Jillian
Phallen, Vilmos Adleff, Siân Jones, Rebecca J. Leary, Karli Lytle, Sonya ParpartLi, Derek Murphy, Michael T. Barrett, David C. Linehan, Anirban Maitra, Ralph
Hruban, Daniel D. Von Hoff, Julia S. Johansen, Luis A. Diaz, Jeffrey A. Drebin,
Victor E. Velculescu.
620 Monitoring leptomeningeal metastasis treatment response using
tumor cell free DNA from cerebral spinal fluid. Melanie Hayden Gephart.
621 Serum circulating DNA and nucleosomes increase in response to
neoadjuvant chemoradiation and surgical resection for pancreatic cancer.
Ibtehaj A. Naqvi, Ruwan Gunaratne, David Pisetsky, Rebekah White.
622 Development and validation of a scalable precision medicine
system for assessing clinically relevant somatic variants in solid tumors.
Daniel H. Hovelson, Andrew S. McDaniel, Andi K. Cani, Bryan Johnson, Kate
Rhodes, Paul D. Williams, Santhoshi Bandla, Catherine S. Grasso, Michael J.
Quist, Venkata Yadati, Anmol Amin, Bryan L. Betz, Karen E. Knudsen, Kathleen
A. Cooney, Felix Y. Feng, Michael H. Roh, Peter S. Nelson, Chia-Jen Liu, David G.
Beer, Seth A. Sadis, Daniel R. Rhodes, Scott A. Tomlins.
623 Evaluation of a multiplex biomarker assay for the detection of
prostate cancer cells in urine. Kristen Nickens, Amina Ali, Tatiana Scoggin,
Shyh-han Tan, Lakshmi Ravindranath, David McLeod, David Tacha, Isabell
Sesterhenn, Albert Dobi, Shiv Srivastava, Gyorgy Petrovics.
624 Evaluation and comparison of two commercially available targeted
NGS platforms to assist oncology decision making. Glen J. Weiss, Brandi R.
Hoff, Robert P. Whitehead, Ashish Sangal, Susan A. Gingrich, Vivek Khemka.
625 The frequency of gene amplifications in cancer revealed by a
droplet digital PCR (ddPCR) based pan-cancer gene panel test. Austin P. So,
Amy Wong, Jennifer Pecson, Girish Putcha, Gregory Jensen, Michael Lucero,
Gary Stone, Jason Gillman, Pravin Mishra, David Loughmiller, Derrick S. Haslem,
Lincoln Nadauld.
626 Cross-site reproducibility and orthogonal validation of copy
number and somatic mutation calls of OncoScan® FFPE Assay Kit in solid
tumors. Joseph M. Foster, Assa Oumie, Fiona S. Togneri, Morag Taylor, Sofia
Alyas, Paula Wojtowicz, Henry Wood, Emma Tinkler-Hundal, Katie Southward,
Dominic McMullan, Phil Quirke, Katherine E. Keating, Mike Griffiths, Karen G.
Spink, Fiona Brew, Eric Fung, Jeanette Schmidt.
627 Detection of chromosomal rearrangements in clinical tissue
samples by chromosome conformation capture. Xiaobin Gao, Jianhui Wang,
Jinglan Wang, Lynnette Tumwine, Jeffrey Sklar.
628 Determinants of quality of next-generation sequencing output
from the strand-specific TruSight Tumor Sequencing Panel in a clinical
diagnostic setting. Swati Garg, Mahadeo A. Sukhai, Mariam Thomas, Michelle
Mah, Tong Zhang, Trevor Pugh, Suzanne Kamel-Reid, Tracey L. Stockley.
629 Label-free isolation of circulating tumor cells for
cytomorphological analysis. Corinne Renier, Edward Pao, Derek E. Go, James
Che, Jianyu Rao, Nagesh Rao, Edward Garon, Jonathan Goldman, Rajan P.
Kulkarni, Stefanie S. Jeffrey, Elodie Sollier, Dino Di Carlo.
630 Detection of copy number variations in breast cancer using
targeted sequencing without normal tissue controls. Jan Budczies, Volker
Endris, Nikola Bangemann, Thomas Wolf, Jens-Uwe Blohmer, Abrecht
Stenzinger, Manfred Dietel, Wilko Weichert, Carsten Denkert.
631 Utilizing Vortex Chip for enumeration and determination of singlecell heterogeneity of circulating tumor cells in prostate cancer. Edward Pao,
James Che, Elodie Sollier, Andrew King, Guoping Fan, Jiaoti Huang, Dino Di
Carlo, Matthew B. Rettig, Rajan P. Kulkarni.
POSTER SESSION
Experimental and Molecular Therapeutics
Antibody Technologies
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
632 Tumor-targeted fusion constructs containing
engineered granzyme B variants with optimized stability
and potency. Khalid A. Mohamedali, Lawrence H. Cheung,
Michael G. Rosenblum.
2.
633 Amanitin-based ADCs with an improved
therapeutic index. Torsten Hechler, Christoph Müller,
Andreas Pahl, Jan Anderl.
3.
634 Novel antibody-drug conjugates targeting Axl
show anti-tumor activity in solid cancer xenograft models.
Esther C. Breij, Sandra Verploegen, Andreas Lingnau, Edward
N. van den Brink, Maarten Janmaat, Mischa Houtkamp, Wim
K. Bleeker, David Satijn, Paul W. Parren.
4.
635 Development of anti-cancer ADCs with Concortis’
C-and K-lock technology. Gang Chen, Tong Zhu, Dylan
Deng, Hong Zhang, David Miao.
6.
636 Next-generation site-specific antibody-drug
conjugates using the SMARTagTM technology platform.
Romas Kudirka.
7.
637 Preclinical activity of hLL2-PBD, a novel anti-CD22
antibody-pyrrolobenzodiazepine (PBD) conjugate in
models of non-Hodgkin lymphoma. Francesca Zammarchi,
David Williams, Karin Havenith, Francois D’Hooge, Philip W.
Howard, John A. Hartley, Patrick van Berkel.
Poster
Board
Abstract
Number
16.
645 Stability and efficacy comparison of site-specific
and lysine-linked maytansinoid antibody-drug conjugates.
Nicholas C. Yoder, Chen Bai, Daniel Tavares, Wayne C.
Widdison, Olga Ab, Kathleen R. Whiteman, Alan Wilhelm,
Erin K. Maloney, Hans K. Erickson, Thomas A. Keating.
17.
646 Structurally guided development of meditopebased antibody-drug conjugates. Michael M. Matho,
Elisabeth M. Gardiner, Calin D. Dumitru.
19.
647 SeriMabs: N-terminal serine modification enables
modular, site-specific payload incorporation into
antibody-drug conjugates (ADCs). Luke Harris, Daniel
Tavares, Lingyun Rui, Erin Maloney, Alan Wilhelm, Juliet
Costoplus, Katie Archer, Megan Bogalhas, Lauren Harvey, Rui
Wu, Xuan Chen, Xiangyang Xu, Sonia Connaughton, Lintao
Wang, Kathleen Whiteman, Olga Ab, Erica Hong, Wayne
Widdison, Manami Shizuka, Michael Miller, Jan Pinkas,
Thomas Keating, Ravi Chari, Nathan Fishkin.
20.
648 Optimization of a PEGylated glucuronideauristatin linker for antibody-drug conjugates. Patrick
J. Burke, Joseph Z. Hamilton, Scott C. Jeffrey, Joshua H.
Hunter, Svetlana O. Doronina, Nicole M. Okeley, Martha E.
Anderson, Peter D. Senter, Robert P. Lyon.
21.
649 Supramolecular assembly of antibody-drug
conjugates using CORDLink platform for targeted drug
delivery. Nimish Gupta, Johny Kancharla, Shelly Kaushik,
Samad Hossain, Arindam Sarkar, Aniruddha Sengupta,
Monideepa Roy, Shiladitya Sengupta.
8.
638 Modulation of antibody-dependent cytokine
release using Fc engineering. Michelle Kinder, Allison
Greenplate, William Strohl, Robert Jordan, Randall Brezski.
9.
639 Site specific conjugation of ARX-788, an antibody
drug conjugate (ADC) targeting HER2, generates a potent
and stable targeted therapeutic for multiple cancers. Robin
C. Humphreys, Jessica Kirtely, Amha Hewit, Sandra Biroc,
Nick Knudsen, Lillian Skidmore, Alan Wahl.
23.
650 A high-throughput conjugation strategy for the
selection of THIOMAB™ antibodies with desired properties
for antibody-drug conjugation. Rachana V. Ohri, Sunil
Bhakta, Helga Raab, Richard Vandlen, Jagath Junutula, Hans
Erickson.
10.
640 Probing the tumorigenic properties of two pore
potassium channels using inhibitory anti-KCNK9 mAbs.
Han Sun, Liqun Luo, Bachchu Lal, John Laterra, Min Li.
24.
11.
641 Trastuzumab-dolaflexin, a highly potent Fleximerbased antibody-drug conjugate, demonstrates a favorable
therapeutic index in exploratory toxicology studies in
multiple species. Natalya Bodyak, Alex Yurkovetskiy, Peter
U. Park, Dmitry R. Gumerov, Michael DeVit, Mao Yin, Joshua
D. Thomas, LiuLiang Qin, Timothy B. Lowinger, Donald A.
Bergstrom.
651 Superior anti-tumor activity compared to T-DM1 in
preclinical studies of targeted therapies for her2-positive
cancers by a novel her2-ADC ZV0201. Hong Zhang, Zhaohui
Li, Tong Zhu, Sheldon Cao, Gang Chen, David Miao.
25.
652 Antibody-drug conjugates (ADCs) of indolinobenzodiazepine DNA-alkylating agents. Michael L. Miller,
Manami Shizuka, Nathan Fishkin, Emily Reid, Katie Archer,
Erin Maloney, Chen Bai, Olga Ab, Nick C. Yoder, Rui Wu, Erica
Hong, Megan Bogalhas, Alan Wilhelm, Kathleen Whiteman,
Ravi Chari.
26.
653 Antibody-drug conjugates: engineered N-terminal
serine residues as a novel approach for site-specific
conjugation. Daniel Tavares, Lingyun Rui, Olga Ab, Luke
Harris, Erin Maloney, Thomas Keating, Thomas Chittenden,
Nathan Fishkin.
27.
654 PG-101 in combination with docetaxel or Herceptin
improves breast cancer survival. Madhuri Wadehra, Meagan
Kiyohara, Christen Dillard, Negin Ashki, Christie Qin.
28.
655 The next generation of targeted toxins: A novel
deimmunized sarcin ribotoxin fused with an EphA2
Abdurin binder. Kurt R. Gehlsen, Anna Demartis, Tim Jones.
29.
656 Discovery of MAbs against difficult GPCRs, ion
channels, and transporters using the MPS Discovery
Engine®. Sharon H. Willis, Kimberly Mattia, Riley Payne,
Moniquetta Hall, Manu Mabila, Christine Rettew, Joseph
Couto, Rohan Keshwara, Cheryl Paes, Benjamin J. Doranz,
Joseph Rucker.
12.
642 Cell-penetrating bispecific antibodies for targeting
androgen receptor signaling in advanced prostate cancer.
Nancy L. Goicochea, Maria Garnovskaya, Mary Blanton, Grace
Chan, Richard Weisbart, Michael Lilly.
13.
643 Identification of novel pancreatic cancer-specific
antibodies and their target antigens through a next
generation immune sequencing platform. David A. Fabrizio,
Sonia Timberlake, Brian Belmont, Stephen J. Goldfless,
Adrian W. Briggs, Teresa J. Broering, Francois Vigneault.
14.
644 Impact of conjugation site on pharmacokinetics
and off-target toxicity of site-specific antibody drug
conjugates. Dangshe Ma, Fang Jin, Frank Barletta, George
Hu, Nathan Tumey, Haige Zhang, Tao He, Eric Sousa, Manoj
Charti, Kiran Khadke, Judy Lucas, Darren Ferguson,
Christoper Brown, Weijun Ma, Scott Gatto, William Brady,
Edmund Graziani, Hans-Peter Gerber, Puja Sapra, Lioudmila
Tchistikova.
27
27
251
POSTER SESSION
Poster
:LJ[PVU
28
28
Signal Transduction Inhibitors
Poster
Board
1.
657 Microtubule stabilizers inhibit the cellular transport and
signaling of EGFR in breast cancer cells. Cristina C. Rohena, Nicholas
F. Dybdal-Hargreaves, Susan L. Mooberry.
2.
658 Phosphorylated HER3 levels associated with trastuzumab
resistance in HER2 gene amplified uterine serous carcinoma
xenograft tumors. Silvia F. Hernandez, Celeste DiGloria, Jolijn
Groeneweg, Darrell Borger, Rosemary Foster, Bo Rueda, Whitfield
Growdon.
3.
659 Sustained inhibition of HER3 and EGFR is necessary to
induce regression of HER2-amplified gastrointestinal carcinomas.
Simonetta Maria Leto, Francesco Sassi, Irene Catalano, Giorgia
Migliardi, Eugenia Rosalinda Zanella, Andrea Bertotti, Livio Trusolino.
4.
660 Polyisoprenylated cysteinyl amide inhibitors exhibit antitumor effects in human breast cancer cell lines. Olufisayo O. Salako,
Rosemary A. Poku, Augustine T. Nkembo, Typhon Mazu, Hernan
Flores-Rozas, Nazarius S. Lamango.
5.
661
Increasing sensitivity of SAIT301, a specific monoclonal
antibody of c-Met, with paclitaxel combination in c-Met positive
gastric cancer. Sun Kyoung Kang, Jeong Min Kim, Won Suk Lee, Woo
Sun Kwon, Tae Soo Kim, Seon-hui Shim, Kyung-Ah Kim, Ho-Yeong
Lim, Hyun Cheol Chung, Sun Young Rha.
6.
662 USP8 modulates ubiquitination of LRIG1 for Met
degradation. Ji Min Lee, Bogyou Kim, Kyung-Ah Kim.
7.
663 Targeting autophagy potentiates the anti-tumoral action
of crizotinib in ALK-positive anaplastic large cell lymphoma.
Géraldine MITOU, Julie FRENTZEL, Laurence LAMANT, Fabienne
MEGGETTO, Estelle ESPINOS, Patrice CODOGNO, Pierre BROUSSET,
Sylvie GIURIATO.
8.
9.
664 Understanding the drug response heterogeneity of BRAFmutated melanomas treated with targeted drugs. Buddhi B.
Paudel, Leonard Harris, Darren Tyson, Vito Quaranta.
665 Inhibition of mitochondrial complex I enhances the
therapeutic benefit of BRAF inhibition in mutant melanoma cell
lines. Laura Schoeckel, Katharina Bitschar, Mélanie Héroult, Charlotte
Kopitz, Andrea Hägebarth.
Poster
Board
Abstract
Number
16.
672 ABTL0812, a new antitumor drug that inhibits the axis
Akt/mTOR through a novel mechanism of action. Tatiana Erazo,
Mariana Gomez-Ferreria, Jose Alfon, Mar Lorente, Maria Salazar, Anna
Lopez, Marc Cortal, Pau
Munoz-Guardiola, Pedro Gascon, Guillermo Velasco, Carles
Domenech, Jose M. Lizcano.
17.
673 Vulnerability of LKB1 deficient NSCLC to C8-modified
adenosine analogs is associated with diminished autophagy
induction. Christine M. Stellrecht, Lisa S. Chen, Mary L. Ayres, John V.
Heymach, Varsha Gandhi.
18.
674 Early integrated stress response induction of ATF4 is
required for the anticancer effects of the dual Akt/ERK inhibitor
and TRAIL pathway inducer ONC201/TIC10. Christina Leah Kline,
Pieter van den Heuvel, Joshua E. Allen, David T. Dicker, Wafik S. ElDeiry.
19.
675 Off-target based drug repurposing opportunities for
tivantinib in acute myeloid leukemia. Brent M. Kuenzi, Lily L.
Remsing Rix, Sateesh S. Kunigal, Fumi Kinose, Claire E. Knezevic,
Gabriela Wright, Jodi L. Kroeger, Jeffrey E. Lancet, Eric Padron, Uwe
Rix.
20.
676 Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)driven leukemia in a distinct and selective fashion. Tea Pemovska,
Eric Johnson, Mika Kontro, Gretchen A. Repasky, Jeffrey Chen, Peter
Wells, Ciarán N. Cronin, Michele McTigue, Olli Kallioniemi, Kimmo
Porkka, Brion W. Murray, Krister Wennerberg.
21.
677 Possible role of nimbolide in prevention and therapy of
prostate cancer. Jingwen Zhang, Muthu K. Shanmugam, Amudha
Deivasigamani, Alan P. Kumar, Kam M. Hui, Gautam Sethi.
22.
678 SOCS-1 inhibits proliferation of ovarian cancer cell lines
by regulating JAK/STAT3 pathway and p53. Satoshi Nakagawa,
Satoshi Serada, Yusuke Takahashi, Yutaka Ueda, Minoru Fujimoto,
Kiyoshi Yoshino, Takayuki Enomoto, Tadashi Kimura, Tetsuji Naka.
23.
679 CF102 induces apoptosis of hepatocellular carcinoma.
Shira Cohen, Faina Barer, Salomon M. Stemmer, Pnina Fishman.
10.
666 Activity of the MEK inhibitor Binimetinib (MEK162) in
combination with paclitaxel in patient-derived xenograft models
of high-grade serous ovarian carcinoma. Shannon L. Winski, Karyn
Bouhana, Susan Rhodes, LouAnn Cable, Deborah Anderson, Lance
Williams, Brian Tunquest, Tiffany Logan, Guy Vigers, Patrice Lee.
24.
680 Identification of GLI1 antagonists for breast cancer
therapy. Helen Oladapo, Jodie M. Fleming, Kezia Addo, Mike Tarpley,
Ben Ehe, Shalonda Ingram, Scott Sauer, Gayathri Devi, Kevin P.
Williams.
11.
667 Regorafenib inhibits colorectal tumor growth through
PUMA-mediated apoptosis. Dongshi Chen, Liang Wei, Jian Yu, Lin
Zhang.
25.
12.
668 Phosphoproteomic characterization of selumetinib action
in KRAS mutant lung cancer. Jae-Young Kim, Eric A. Welsh, Bin
Fang, Fumi Kinose, John M. Koomen, Eric B. Haura.
681 Translational pharmacology approaches to explore the
novel mechanism of a pan-PIM kinase inhibitor, JP-11646, in acute
myeloid leukemia. Krista E. Pundt, Carmen Baldino, Justin Caserta,
Laura B. Pitzonka, Kelvin Lee, Alex Adjei, Gerald J. Fetterly.
26.
669 BGB-283 effectively enhances MEK inhibitor induced
tumor suppression in RAS mutant cancers. Xi Yuan, Zhiyu Tang,
Rong Du, Shing-Hu Cheung, Jing Wei, Yuan Zhao, Yunguang Du, Rui
Hao, Xiaoxia Hu, Wenfeng Gong, Yong Liu, Yajuan Gao, Min Wei,
Changyou Zhou, Lai Wang, Lusong Luo.
682 Targeting heat shock protein 90 with ganetespib for
molecularly targeted therapy of gastric cancer. Hanqing Liu, Jian
Lu, Ye Hua, Peishan Zhang, Zhiquan Liang, Lingling Ruan, Caixia Lian,
Haifeng Shi, Keping Chen, Zhigang Tu.
27.
683 DEBIO0932, an Hsp90 inhibitor downregulates key
signaling pathways and sensitizes glioma cells to temozolomide.
Alessandro Canella, Jihong Xu, W. Hans Meisen, Balveen Kaur, Lara
Rizzotto, Divya Kesanakurti, Prabakaran Nagarajan, Vinay K.
Puduvalli.
29.
685 Mechanisms of intrinsic and acquired resistance to third
generation inhibitors in EGFR mutant NSCLC. Matt J. Niederst.
13.
14.
15.
252
Abstract
Number
670 Targeting PI3K/mTOR leads to MEK/ERK over-activation
in pancreatic cancer through suppression of mTORC2. Heloisa P.
Soares, Ming Ming, Michelle Mellon, Steven H. Young, Liang Han,
James Sinnet-Smith, Enrique Rozengurt.
671 BKM120-mediated G2 arrest: Structural and functional
segregation of off-target action and PI3K inhibition. Thomas
Bohnacker, Florent Beaufils, Andrea E. Prota, John E. Burke, Anna
Melone, Alison J. Inglis, Ludovico Fusco, Vladimir Cmiljanovic, Natasa
Cmiljanovic, Denise Rageot, Katja Bargsten, Gonzalo Saez-Calvo,
Olivier Pertz, Amol B. Aher, Anna Akhmanova, Fernando J. Diaz,
Doriano Fabbro, Marketa Zvelebil, Roger L. Williams, Michel O.
Steinmetz, Matthias P. Wymann.
POSTER SESSION
Targeting Signal Transduction
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
686 Targeting glioblastoma and its stem cells using
novel small molecule inhibitors of the mTOR pathway.
John L. Gillick, Zachary E. Thwing, Sudeepta Sridhara, Raj
Murali, Meena Jhanwar-Uniyal.
2.
687 Compound screen identifies PIM kinases as
therapeutic targets for melanoma. Adina M. Vultur, Batool
Shannan, Quan Chen, Andrea Watters, Stefan Mollin, Eric
Meggers, Clemens Krepler, Michela Perego, Ling Li, Phyllis A.
Gimotty, Xiaowei Xu, Meenhard Herlyn.
3.
688 Activating JAK1-S703I mutation may predict the
sensitivity of JAK-STAT inhibition in hepatocellular
carcinoma patient-derived xenograft tumor models.
Shuqun Yang, Chonglin Luo, Qingyang Gu, Qiang Xu, Hongye
Sun, Ziliang Qian, Yexiong Tan, Hao Wu, Yuxin Qin, Yuhong
Shen, Xiaowei Xu, Shu-Hui Chen, Chi-Chung Chan, Hongyang
Wang, Mao Mao, Douglas D. Fang.
4.
689 Characterization of two novel oncogenic FGFR2
fusions sensitive to the FGFR-selective inhibitor Debio
1347 in cholangiocarcinoma. Anne Vaslin, Stefania Rigotti,
Nathalie Lembrez, Grégoire Vuagniaux, Corinne Moulon,
Hiroaki Tanaka.
5.
690 Characterization of serine/threonine phosphatase
LAPP1 as a diagnostic and therapeutic target for lung
cancer. Yataro Daigo, Atsushi Takano, Yusuke Nakamura.
6.
691 Activity of the BET inhibitor INCB054329 in models
of multiple myeloma. Matthew Stubbs, Xiaoming Wen,
Valerie Dostalik, Sybil O’Connor, Eian Caulder, Alla Vogina,
Thomas Maduskuie, Richard Sparks, Taisheng Huang, Nikoo
Falahatpisheh, Padmaja Polam, Chu-Biao Xue, Xuesong M.
Liu, Timothy Burn , Kris Vaddi, Andrew P. Combs, Reid Huber,
Gregory Hollis, Peggy Scherle, Phillip C. Liu.
7.
8.
9.
10.
11.
692 The BET inhibitor INCB054329 is synergistic with
JAK1 inhibition in models of multiple myeloma. Matthew C.
Stubbs, Xuesong M. Liu, Xiaoming Wen, Jun Li, Valerie
Dostalik, Sybil O’Connor, Eian Caulder, Margaret Favata, Mark
Rupar, Yu Li, Beth Rumberger, Thomas Maduskuie, Richard
Sparks, Nikoo Falahatpisheh, Padmaja Polam, Kris Vaddi,
Timothy Burn, Andrew P. Combs, Wenqing Yao, Reid Huber,
Gregory Hollis, Peggy Scherle, Phillip C. Liu.
693 A yeast synthetic lethal screen identifies a
conserved interaction between PLK1 and CKS1b affecting
cancer cell viability. Robert J. Reid, Xing Du, Ivana
Sunjevaric, Vinayak Rayannavar, John Dittmar, Matthew
Maurer, Rodney Rothstein.
694 Structure-function analysis of RPL18A, a putative
binding target of rigosertib. Irina A. Oussenko, Yogesh K.
Gupta, Rodrigo Vasquez-Del Carpio, M. V. Ramana-Reddy,
Aneel K. Aggarwal, E. Premkumar Reddy, James F. Holland,
Takao Ohnuma.
695 Synergistic antitumor effects of polo like kinase
inhibitor volasertib in combination with ionizing radiation
in glioblastoma. Jianwen Dong, Nghi Nguyen, Ravesanker
Ezhilarasan, Shaofang Wu, Yuji Piao, Soon Young Park,
Ningyi Tiao, Clifford Stephan, Erik P. Sulman, John F.
de Groot.
696 Comprehensive genomic analysis identifies
frequent MET juxtamembrane domain deletions as an
actionable genomic alteration in pulmonary sacromatoid
carcinoma. Xuewen Liu, Yuxia Jia, Yufeng Shen, Haiying
Cheng, Sanjay Koul, Alain C. Borczuk, Balazs Halmos.
Poster
Board
Abstract
Number
12.
697 c-MET as a potential target in ovarian clear-cell
carcinoma. Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae,
Yoo Young Lee.
13.
698 CPI-based Crizotinib systemic study on discovery
of phenotypic off-target. Jiazhi Sun, Lun Yang, Minghua Li,
Shimin Zhang, Ian E. Heller, Johnathan Samuelson, Steven
Cindric, Kunal Mishra, Eslam Mohamed, Feng Cheng, Kevin B.
Sneed, Lin He, Shu-Feng Zhou.
14.
699 PIK3CA/BRAF mutations negatively affect
outcome of patients with KRAS wild-type metastatic
colorectal cancer treated with front line anti-EGFR
monoclonal antibodies: Meta-analysis results. Amr
Mohamed, Kelly Schrapp, Taraq Attumi, Nabil F. Saba, Bassel
F. El-Rayes.
15.
700 Investigating KRAS synthetic lethal/codependency interactions using siRNA and CRISPR. Simon F.
Scrace, Elpida Tsonou, Paul Russell, Julie A. Wickenden,
Steffen Lawo, Tim M. Scales, Ceri M. Wiggins, Jonathan D.
Moore.
16.
701 A novel class of Ras selective inhibitors. Joshua C.
Canzoneri, Xi Chen, Adam B. Keeton, Kevin Lee, Bernard
Gary, Ethan B. Butler, William E. Grizzle, Landon Wilson,
Stephen Barnes, Michael R. Boyd, Gary A. Piazza.
17.
702 BRAF V600E mutation in benign and malignant
epithelial odontogenic tumors. Marina G. Diniz, Carolina C.
Gomes, Bruna V. Guimaraes, Alessandra P. Duarte, Ricardo S.
Gomez.
18.
703 A novel ATP-competitive MEK/Aurora kinase
inhibitor BI-847325 reverses acquired BRAF inhibitor
resistance through suppression of Mcl-1 and inhibition of
MEK expression. Manali S. Phadke, Patrizia Sini, Keiran
Smalley.
19.
704 Scaffold protein KSR1 is negatively regulated by
merlin and promotes tumor development in merlin
deficient tumors. Clemens O. Hanemann, Lu Zhou, Sylwia
Ammoun, Edwin Lasonder, Vikram Sharma, Juergen Muller,
Emanuela Ercolano.
20.
705 Combinatorial therapeutic targeting of BMP2 and
MEK in NF1-null malignant peripheral nerve sheath
tumors. Sidra Ahsan, Daochun Sun, Michael A. Tainsky.
21.
706 Inflammatory and stem-like colorectal cell lines
show differential response to MEK-162 and neratinib in
combination. Rekha Pal, Nan Song, Ashok Srinivasan,
Samuel A. Jacobs, Soonmyung Paik, Katherine L. PogueGeile.
22.
707 Distinct roles of Na,K-ATPase function and
expression in medulloblastoma. Zhiqin Li, Alisa Litan, Seung
Joon Lee, Bruce Graves, Sonali P. Barwe, Sigrid A. Langhans.
23.
708 Androgen receptor activation inhibits papillary
thyroid carcinoma cell cycle progression. Melanie E. Jones,
Timmy O’Connell, Anvita Gupta, Hong Zhao, Codrin Iacob,
Augustine Moscatello, Edward Shin, Zbigniew Darzynkiewicz,
Raj K. Tiwari, Jan Geliebter.
24.
708A Suppression of glycolysis by retinoic acid
sensitizes hepatocellular carcinoma cells to apoptosis
induced by sorafenib via AMPK activation. Goshi Shiota,
Hiroki Shimizu, Keita Kanki.
29
29
253
POSTER SESSION
Poster
:LJ[PVU
30
30
Therapeutic Resistance in Hormone-Sensitive Cancers
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
12.
13.
14.
15.
16.
17.
254
Abstract
Number
709 Resistance to paclitaxel in triple negative breast cancer
cells is associated with ABCB1 gene rearrangement. Elaheh
Ahmadzadeh, Ewa Przybytkowski, Regina Kiu, Adriana AguilarMahecha, Mark Basik.
710 CRP induction in tamoxifen-resistant breast cancer cells.
Min Chang Choi, Aree Moon, Keon Wook Kang.
711 Elimination of multi-drug-resistant breast cancer cells
using combination of high-intensity focused ultrasound and lowdose generic chemotherapeutic. Howard Q. Vo, Yoo-Shin Kim, Brian
E. O’Neill.
712 TNF␣-induced MUC4 elicits trastuzumab resistance in
ErbB-2-positive breast cancer. María F. Mercogliano, Mara De
Martino, Leandro Venturutti, Martín A. Rivas, Gloria Inurrigarro, Isabel
Frahm, Cecilia J. Proietti, Franco Izzo, Patricia V. Elizalde, Roxana
Schillaci.
713 Targeting glycolytic pathway with 2-Deoxy-glucose
enhances lapatinib sensitivity in HER2-amplified breast cancer.
Xiaosong Chen, Junjun Liu, Toby Ward, Xiaofei Liu, Yan Mao, Jessica
Bockhorn, Kunwei Shen, Mark Pegram.
714 Cbl-b Inhibits p-gp transporter function by preventing its
translocation into caveolae in multiple drug-resistant gastric and
breast cancers. Ye Zhang, Xiujuan Qu, Yuee Teng, Ling Xu, Jing Liu,
Zhi Li, Xuejun Hu, Yunpeng Liu.
715 Regulation of the ABCG2 drug efflux transporter in breast
cancer cells. Vivian Y. Chua, Jennet Harvey, Jacqueline Bentel.
716 Targeting Mek-Erk pathway abrogates hypoxia-mediated
lapatinib resistance in ErbB2-positive breast cancer cells. Sergey
Karakashev, Mauricio Reginato.
717 Overexpression of interferon-stimulated genes is critical
for the survival of aromatase inhibitor-resistant breast cancer
cells. Asona Lui, Hye-Joung Choi, Joan
Lewis-Wambi.
718 The effects of trastuzumab, paclitaxel, and carboplatin on
HER2-positive cancer stem cells that are isolated from primary
breast cancer cultures: a preliminary report. Mehmet Artac, Gozde
Kayadibi, Ayca Ceylan, Meltem D. Kars, Hasibe Artac, Murat Cakır,
Cem Boruban, Ahmet Tekin, Lema Tavlı, Adil Kartal. Nabholtz,
Frederique Penault-Llorca.
720 Downregulation of ATP6V1B1 in HER2-overexpressing
human breast cancer cell line leads resistance against
trastuzumab-mediated antibody-dependent cellular cytotoxicity.
Mariko Nishie, Eiji Suzuki, Kosuke Kawaguchi, Keiko Sakamoto, Yuji
Fukushima, Masakazu Hattori, Tomoharu Sugie, Masakazu Toi.
721 Mevalonate pathway mediates acquired anti-HER2
treatment resistance in HER2+ breast cancer. Huizhong Hu, Lukas
Simon, Lanfang Qin, Agostina Nardone, Chad Shaw, Gary Chamness,
Laura Heiser, Nicholas Wang, Joe W. Gray,
C. Kent Osborne, Rachel Schiff.
722 Caveolin-1-dependent endocytosis enhanced
chemosensitivity of TDM-1 in HER-2-positive breast cancer cells.
Yuan-Chiang Chung, Wan-Chen Wei, King-Jen Chang, Wei-Ting
Chao.
723 GRB7 promotes doxorubicin resistance in triple-negative
breast cancer cells via multiple signaling pathways. Kristopher A.
Lofgren, Verónica Calvo, Orsi Giricz, Paraic A. Kenny.
724 Anti-tumor effect of Dasatinib in HER2 positive breast
cancer with Trastuzumab resistance. Tatsuaki Takeda, Hirotaka
Kanzaki, Shinichi Toyooka, Mototsugu Watanabe, Tomoaki Ohtsuka,
Ken Suzawa, Shinsuke Hashida, Yuho Maki, Hiromasa Yamamoto,
Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi,
Yoshihisa Kitamura, Toshiaki Sendo.
725 Restoration of miR-100 sensitizes luminal A breast cancer
to paclitaxel treatment by targeting mTOR. Baotong Zhang, Ranran
Zhao, Yuan He, Xing Fu, Jin-Tang Dong.
Poster
Board
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
726 Constitutive NF-kB-activation loop enhances resistance
to trastuzumab in HER2 positive luminal B breast cancer. Hirotaka
Kanzaki, Nishit Makhopadhya, Xiaojiang Cui, Krishnan V. Ramanujan,
Tatsuaki Takeda, Yoshihisa Kitamura, Toshiaki Sendo, Ramachandran
Murali.
727 Signaling redundancy between EGFR and c-Met:
molecular analysis of concurrent inhibition of c-Src and
therapeutic potential against prostate cancer. Suman Rao, AnneLaure Larroque-Lombard, Ben Allal, Bertrand J. Jean-Claude.
728 New derivative of galiellalactone inhibits the STAT3
activity and suppresses ENZ-resistant Prostate Cancer in vitro.
Daksh Thaper, Sepideh Vahid, Jennifer L. Bishop, Martin Johansson,
Amina Zoubeidi.
729 The role of skp2 in paclitaxel-resistant prostate cancer
cells. Yeguo Yang, Qiong Song, Yi Lu, Jian Zhang, Jiejun Fu.
730 The role of ZEB1/ZEB2 and ␤III-tubulin in mediating
docetaxel-resistant prostate cancer. Karen Hanrahan, Maria
Prencipe, Jane Bugler, Lisa Murphy, Amanda O’Neill, R. William
Watson.
731 Integrative genomic analysis to identify emergent
enzalutamide resistance mechanisms in castration-resistant
prostate cancer. Josha Woodward, Carly King, Daniel Coleman,
Robert Lisac, Jacob Schwartzman, Nicholas Wang, Martin Gleave, Joe
Gray, George Thomas, Tomasz M. Beer, Katy Van Hook, Robert
Baertsch, Ted Goldstein, Josh Stuart, Lina Gao, Joshua Urrutia, Laura
Heiser, Joshi J. Alumkal.
732 Using functional and chemical genomics to identify
mechanisms of Enzalutamide resistance in prostate cancer.
Sujeeve Jeganathan, Amina Zoubeidi, Martin Gleave, Brad G.
Wouters, Anthony M. Joshua.
733 A targetable GATA2-IGF2 axis confers aggressiveness in
lethal prostate cancer. Samuel J. Vidal, Veronica Rodriguez-Bravo,
Aidan Quinn, Estrelania Williams, Janis de la Iglesia-Vicente, Xiaochen
Sun, Xintong Chen, Yujin Hoshida, Carlos Cordon-Cardo, Josep
Domingo-Domenech.
734 Synergistic antitumor effect of vemurafenib and
metformin in thyroid cancer. Elyse K. Hanly, Neha Y. Tuli, Robert B.
Bednarczyk, Augustine L. Moscatello, Zbigniew Darzynkiewicz, Jan
Geliebter, Raj K. Tiwari.
735 Honokiol enhances the anticancer effects of doxorubicin
by regulating Mucin 1 and Multidrug resistance-associated protein
1 (MRP1) in mammary carcinoma MDA-MB-231 cells. Padmamalini
Thulasiraman, Saad Alshareedah.
736 Combining PD1- and CTLA4-inhibiting antibodies with
cisplatin or PARP inhibition in an attempt to eradicate BRCA1deficient mouse mammary tumors. Sohvi Blatter, Charlotte
Guyader, Aslı Küçükosmanoğlu, Stephan Freriks, Karin de Visser, Piet
Borst, Sven Rottenberg.
737 Clonal evolution of the HER2 L755S mutation as a
mechanism of acquired HER-targeted therapy resistance. Xiaowei
Xu, Agostina Nardone, Huizhong Hu, Lanfang Qin, Sarmistha Nanda,
Laura Heiser, Nicholas Wang, Kyle Covington, Edward Chen,
Alexander Renwick, Tamika Mitchell, Marty Shea, Tao Wang, Carmine
De Angelis, Alejandro Contreras, Carolina Gutierrez, Suzanne Fuqua,
Gary Chamness, Chad Shaw, Marilyn Li, David Wheeler, Susan
Hilsenbeck, Mothaffar F. Rimawi, Joe Gray, C. Kent Osborne, Rachel
Schiff.
738 Combined inhibition of non-canonical HER2 signaling as a
strategy to overcome resistance to HER2-targeted therapies.
Ronald J. Bernardi, Rocio Dominguez-Vidana, Christopher S. Bland,
Kathleen A. Scorsone, Siddhartha Tyagi, Earlene M. Schmitt, Martin J.
Shea, Tamika Mitchell, Mitchell Rao, Sarmistha Nanda, Susan G.
Hilsenbeck, Chad Shaw, C. Kent Osborne, Rachel Schiff, Thomas F.
Westbrook.
POSTER SESSION
Therapeutic Resistance in Lung Cancer
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
739 Tumor cell plasticity with transition to a mesenchymal
phenotype is a mechanism of chemoresistance that is reversed by
Notch pathway inhibition in lung adenocarcinoma. Khaled A. Hassan.
740 IL-6 signaling modulates cisplatin resistance in non-small
cell lung cancer via up-regulations of anti-apoptotic and DNA repair
associated molecules. Shan-zhou Duan, Ying Tsai, Peter Keng,
Yongbing Chen, Soo Ok Lee, Yuhchyau Chen.
741 Anti-tumor activity and acquired resistance mechanism of
dovitinib in RET-rearranged lung adenocarcinoma. Chan Woo Kang,
Kang Won Jang, Byoung Chul Cho.
742 Effect of Hsp90 inhibitor NVP-AUY922 with radiation on
lung adenocarcinoma cell lines with acquired resistance to EGFRtyrosine kinase inhibitors. Yuho Maki, Shinsuke Hashida, Hiromasa
Yamamoto, Kazuhiko Shien, Tomoaki Ohtsuka, Ken Suzawa, Masashi
Furukawa, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro
Miyoshi, Susumu Kanazawa, Shinichi Toyooka.
743 Expression profiles of EGFR, c-Met, and mTOR/Wnt
alternative signaling pathway proteins in non-small cell lung cancer.
Caleb Shearrow, Zachary Crees, Jennifer Girard, Kymberly Harrington,
Kavin Arasi, Ceyda Bertram, Andrew Nowak, Leo Lin, Bonnie Sheu, Sunil
Palani, Neelu Puri.
744 Transactivation of HER3 via heterodimerization with
epidermal growth factor receptor (EGFR) or insulin-like growth
factor 1 receptor (IGF-1R) contributes to adaptive resistance to NVPBKM120 in non-small cell lung cancer (NSCLC) and squamous cell
carcinoma of head and neck (SCCHN). Miran Yun, Jinyoung Sohn,
Byoung Chul Cho.
745 Oncostatin M receptor activation leads to molecular
targeted therapy resistance in non-small cell lung cancer. Kazuhiko
Shien, Vassiliki A. Papadimitrakopoulou, Dennis Ruder, Nana E. Hanson,
Neda Kalhor, J. Jack Lee, Waun Ki Hong, Ximing Tang, Roy S. Herbst, Luc
Girard, John D. Minna, Jonathan M. Kurie, Ignacio I. Wistuba, Julie G.
Izzo.
746 Activation of EGFR bypass signaling through TGF␣
overexpression induces acquired resistance to alectinib in ALKtranslocated lung cancer cells. Tetsuo Tani, Hiroyuki Yasuda, Junko
Hamamoto, Aoi Kuroda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Ichiro
Kawada, Katsuhiko Naoki, Hayashi Yuichiro, Tomoko Betsuyaku, Kenzo
Soejima.
747 Glutamine, glutaminase and ␥-glutamyl-transferase
activities are essential for lung tumorigenesis. Daniel R. Sappington,
Eric R. Siegel, Rosalind B. Penney, Gunnar Boysen.
748 The glucose metabolism targeting therapies and withaferin
A eliminate epidermal growth factor tyrosine kinase inhibitorinduced drug-tolerant persisters in non-small lung cancer cells. Kei
Kunimasa, Tatsuya Nagano, Yohei Shimono, Shuntaro Tokunaga,
Daisuke Tamura, Motoko Tachihara, Kazuyuki Kobayashi, Yoshihiro
Nishimura.
749 Both amplification and protein expression are required to
predict FGFR tyrosine kinase inhibitor sensitivity in lung cancer.
Hiromichi Ebi, Hiroshi Kotani, Seiji Yano.
750 Overcoming resistance to anti-EGFR therapy in non-small
cell lung cancer with a T-type Ca2+ channels inhibitor. Barbara
Dziegielewska, Lloyd S. Gray, Jaroslaw Dziegielewski.
751 In vitro activity of dianhydrogalactitol alone or with
platinum drugs in the treatment of non-small cell lung cancer. Anne
Steino, Guangan He, Jeffrey A. Bacha, Sarath Kanekal, Dennis M. Brown,
Zahid H. Siddik.
752 Elucidating the mechanisms of acquired resistance in lung
adenocarcinomas. Sandra Ortiz-Cuarán, Lynnette Fernandez-Cuesta,
Christine M. Lovly, Marc Bos, Matthias Scheffler, Sebastian Michels,
Kerstin Albus, Lydia Meyer, Katharina König, Ilona Dahmen, Christian
Mueller, Luca Ozretić, Lars Tharun, Philipp Schaub, Alexandra Florin,
Berit Pinther, Nike Bahlmann, Sascha Ansén, Martin Peifer, Lukas C.
Heukamp, Reinhard Buettner, Martin L. Sos, Jürgen Wolf, William Pao,
Roman K. Thomas.
753 Genomic alterations of autophagy genes disrupts
autophagic flux in human lung adenocarcinomas. Ines Pulido, Juan L.
Pascual, Margaret Soucheray, Maria L. Rodriguez, Daniel T. Crespo,
Salvador Aparisi, Joan A. Sirerol, Salvador Mena, Javier Pereda, Fatima
Al-shahrour, Angel L. Ortega, Takeshi Shimamura, Julian Carretero.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
5551 Anti-tumorigenic function of polyphenolic
compounds on gefitinib resistant lung cancer. Ai N. Phan,
Yangsik Jeong.
755 Neuropilin-2 promotes acquired resistance to EGFR-tyrosine
31
31
kinase inhibitors in association with the epithelial-mesenchymal
transition in lung cancer. Patrick Nasarre, Joyce Nair-Menon,
Anastasios Dimou, Krystyna Kuchinski, Takeshi Yoshida, Hidetaka
Uromoto, Eric B. Haura, Robert M. Gemmill, Harry A. Drabkin.
756 Inhibition of ABCB1 overcomes cancer stem cell-like
properties and acquired resistance to MET inhibitor in non-small cell
lung cancer. Teppei Sugano, Masahiro Seike, Rintaro Noro, Chie Soeno,
Shinji Nakamichi, Nobuhiko Nishijima, Masaru Matsumoto, Susumu
Takeuchi, Akihiko Miyanaga, Kaoru Kubota, Akihiko Gemma.
757 Activation of receptor-interacting serine/threonine protein
kinase-2 (RIP2K) via EGFR-mediated CRAF transactivation induces
the acquired resistance to Dabrafenib in BRAF V600E mutant nonsmall cell lung cancer. Kangwon Jang, Jinyoung Sohn, Sung-Moo Kim,
Kyoung Jin Kim, Byoung Chul Cho.
758 Loss of USP1 translational control as a targetable cisplatin
resistance mechanism in non-small cell lung cancer (NSCLC). Carole
Helissey, Tony Sourisseau, Hélène Mahieu, Céline Lefebvre, Stephan
Vagner, Jean-Charles Soria, Ken Olaussen.
759 Metformin enhances the benefit of ALK inhibitors in ALK
translocation-positive non-small cell lung cancer cells. Mi Young Kim,
Geum Ock Kim, Dong Hoon Shin, Tae Min Kim, Jin-Soo Kim.
760 On the evolution of erlotinib-resistant NSCLC
subpopulations. Michael E. Ramirez, Robert J. Steininger, Lani F. Wu,
Steven J. Altschuler.
761 Changing the paradigm for treating drug resistance in
NSCLC: Novel combinations of AZD6094, a selective MET inhibitor,
and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291.
Celina D’Cruz, Evan Barry, Ryan Henry, Lillian Castriotta, Alwin Schuller,
Garry Beran, Susan Ashton, Cath Eberlein, Corinne Reimer, Melanie
Frigault, Michael Zinda, Darren Cross, Stephen Fawell.
762 Ganetespib resistance in KRAS mutant NSCLC is mediated
through bypassing the G2/M checkpoint and reactivating the PI3K/
MTOR pathway. Suman Chatterjee, Timothy F. Burns.
763 Implications of resistance patterns with NSCLC targeted
agents. David J. Stewart, Paul Wheatley-Price, Rob MacRae, Jason
Pantarotto.
764 Rational combination of PF-06463922 (next-generation ALK
inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in
EML4-ALK+ NSCLC models. Ping Wei, Ming Qiu, Nathan Lee, Joan Cao,
Hui Wang, Konstantinos Tsaparikos, Conglin Fan, Timothy Sargis, Justine
Lam, Maruja E. Lira, Goldie Lui, James Hardwick, Valeria Fantin, Paul
Rejto, Tod Smeal.
765 Overcoming acquired EGFRi resistance in NSCLC with
targeted beam irradiation in combination with targeted agents.
Andrew McKenzie, Nektaria Papadopoulou, Lucy Page, Simon Jiang,
Jane Wrigley, Yinfei Yin, Qian Shi, Martin Page, Ian Wilson, Rajendra
Kumari.
766 Suppression of gefitinib-induced EMT in EGFR mutant NSCLC
preferentially selects for acquired T790M. Margaret Soucheray, Marzia
Capelletti, Ines Pulido, Yunan Kuang, Cloud P. Paweletz, Jeffrey H.
Becker, Eiki Kikuchi, Chunxiao Xu, Tarun B. Patel, Fatima Al-shahrour,
Julian Carretero, Kwok-Kin Wong, Pasi A. Janne, Geoffrey I. Shapiro,
Takeshi Shimamura.
767 Oncogenic mutant KRAS modulates EZH2 expression
through MEK-ERK and PI3K/AKT signaling in NSCLC: differential
effects of different KRAS mutations and increased efficacy of
inhibition combined with EZH2 targeted therapy. Erick M. Riquelme, Li
Shen, Jing Wang, Carmen Behrens, George Simon, Vassiliki
Papadimitrakopoulou, John D. Minna, Ignacio I. Wistuba.
768 A kinome-wide siRNA screen identifies modifiers of
sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor
(TKI), AZD9291, in EGFR mutant lung adenocarcinoma. Eiki Ichihara,
Joshua A. Bauer, Pengcheng Lu, Fei Ye, Darren Cross, William Pao,
Christine M. Lovly.
255
POSTER SESSION
Poster
:LJ[PVU
32
32
Tyrosine Kinase and Phosphatase Inhibitors
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
256
Abstract
Number
769 In vivo response and molecular characterization of a
Caucasian NSCLC squamous cell carcinoma PDX sensitive to FGFR
inhibitors. Andrew McKenzie, Nektaria Papadopoulou, Yinfei Yin, Simon
Jiang, Jane Wrigley, Jie Cai, Martin Page, Henry Li, Rajendra Kumari.
770 E7090: A potent and selective FGFR inhibitor with activity in
multiple FGFR-driven cancer models with distinct mechanisms of
activation. Saori W. Miyano, Yuji Yamamoto, Kotaro Kodama, Setsuo
Funasaka, Satoshi Nagao, Naoko H. Sugi, Hiroko Kuramochi, Katsuyuki
Ishikawa, Kiyoshi Okamoto, Yukinori Minoshima, Takayuki Nakagawa,
Yusuke Nakatani, Yuki Karoji, Isao Ohashi, Yoshinobu Yamane, Keigo
Tanaka, Toshimi Okada, Tomohiro Matsushima, Junji Matsui, Masao
Iwata, Akihiko Tsuruoka, Toshimitsu Uenaka.
771 Preclinical characterization of the selective FGFR inhibitor
INCB054828. Phillip C. Liu, Liangxing Wu, Holly Koblish, Kevin Bowman,
Yue Zhang, Ronald Klabe, Lynn Leffet, Darlise DiMatteo, Mark Rupar,
Karen Gallagher, Michael Hansbury, Colin Zhang, Chunhong He, Paul
Collier, Maryanne Covington, Richard Wynn, Swamy Yeleswaram, Kris
Vaddi, Timothy Burn, Wenqing Yao, Reid Huber, Peggy Scherle, Gregory
Hollis.
772 Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY
1163877 in preclinical squamous cell carcinoma models of different
origin. Mélanie Héroult, Matthias Ocker, Charlotte Kopitz, Dieter Zopf,
Andrea Hägebarth, Karl Ziegelbauer, Stuart Ince, Peter Ellinghaus.
773 Alectinib shows potent antitumor activity against both ALKand RET-rearranged non-small cell lung cancers. Tatsushi Kodama,
Toshiyuki Tsukaguchi, Yasuko Satoh, Miyuki Yoshida, Yoshiaki
Watanabe, Osamu Kondoh, Hiroshi Sakamoto.
774 Cabozantinib, a multi-target receptor tyrosine kinase
inhibitor, decreases tumor growth and angiogenesis in a patientderived dedifferentiated liposarcoma xenograft. Haifu Li, Agnieszka
Wozniak, Karel Van Den Bossche, Thomas Van Looy, Jasmien Wellens,
Daphne Hompes, Dana Aftab, Maria Debiec-Rychter, Raf Sciot, Patrick
Schöffski.
775 Anti-tumor effects of dovitinib, a multi-target kinase
inhibitor, in patient-derived gastrointestinal stromal tumor (GIST)
xenograft models. Yemarshet K. Gebreyohannes, Thomas Van Looy,
Agnieszka Wozniak, Jasmien Wellens, Haifu Li, Jasmien Cornillie, Ulla
Vanleeuw, Lise Vreys, Matthew Squires, Ana-Maria Rodringuez, Maria
Debiec-Rychter, Raf Sciot, Patrick Schöffski.
776 Pre-clinical evaluation of ceritinib in anaplastic large cell
lymphoma. Siddhartha Ganguly, Sudhakiranmayi Kuravi,
Satyanarayana Alleboina, Brandon Weckbaugh, Deepti Satelli, Jensen
Roy, Scott Weir, Joseph McGuirk, Ramesh Balusu.
777 Effects of Src inhibitors and soy isoflavones on human
prostate cancer cells. Lori P. Rice, Christine Pampo, Sharon Lepler,
Dietmar W. Siemann.
778 The identification and structure-guided optimisation of
potent and selective inhibitors of oncogenes in medullary thyroid
carcinoma and lung adenocarcinoma. Roger J. Butlin, Rebecca
Newton, Mandy Watson, Gemma Hopkins, Ben Acton, Kate Bowler,
Samantha Fritzl, Kristin Goldberg, Niall Hamilton, Sarah Holt, Stuart
Jones, Allan Jordan, Nikki March, Daniel Mould, Helen Small, Alexandra
Stowell, Ian Waddell, Bohdan Waszkowycz, Donald Ogilvie.
779 Blockade of the IL-6/JAK/STAT3 signaling pathway inhibits
pancreatic tumor cell growth in 3D spheroid cultures and in xenograft
models. Jun Li, Eian Caulder, Margaret Favata, Melody Diamond, Beth
Rumberger, Holly Koblish, Taisheng Huang, Chu-Biao Xue, Wenqing
Yao, Jordan Fridman, Peggy Scherle, Mike Liu, Reid Huber, Kris Vaddi.
780 Multi-targeted tyrosine kinase inhibitor Cabozantinib as a
therapeutic agent in MET-overexpressing gastric cancer. Audrey H.
Choi, Jianming Lu, Sangjun Lee, Peiguo Chu, Vincent Chung, Ren-Jang
Lin, Joseph Kim, Joseph Chao.
781 The potent ALK inhibitor AP26113 can overcome
mechanisms of resistance to first- and second-generation ALK TKIs in
preclinical models. Sen Zhang, Sara Nadworny, Scott D. Wardwell,
Lindsey Eichinger, Biplab Das, Emily Y. Ye, J. G. Hodgson, Victor M.
Rivera.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
782 Modulation of receptor tyrosine kinase signaling by cMET
inhibitor, INC280, in cMETmut/amp gastric carcinoma cell line Hs746.T.
Maria C. Pinzon-Ortiz, Xianhui Rong, Jinsheng Liang, Hui Qin Wang, Alan
Huang, Robert Schlegel, Z. Alexander Cao.
783 Ponatinib demonstrates antitumor activity in RET- and
FGFR-driven patient-derived xenografts. Joseph M. Gozgit, Youngchul
Song, Victor M. Rivera.
784 Nonclinical activity of the FGFR, VEGFR and PDGFR inhibitor
lucitanib in FGFR3 translocated tumor models. Minh Nguyen, Kevin K.
Lin, Mike F. Burbridge, Andrew D. Simmons, Thomas C. Harding.
785 IRAK4 inhibitors display synergistic activity when combined
with BTK or PI3K inhibitors in B cell lymphomas. Eric G. Vajda, Robert
Niecestro, Lin Zhi, Keith B. Marschke.
786 Effects of combination treatment with cabozantinib and
bortezomib in the 5TGM1 murine multiple myeloma model. Mari I.
Suominen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen, Jussi
M. Halleen, Dana T. Aftab.
787 FLX925 (AMG 925) is a rationally designed FLT3, CDK4/6
inhibitor that retains potency against clinically relevant secondary
resistance mutations in FLT3. Cong Li, Lingming Liang, Liqin Liu, Zhen
Xia, Zhihong Li, Xianghong Wang, Lawrence McGee, Angus Sinclair,
Sasha Kamb, Dineli Wickramasinghe, Sachie Marubayashi, Juan C. Jaen,
Jordan S. Fridman, Kang Dai.
788 A novel, potent and selective pan-Trk inhibitor ONO5390556, demonstrates therapeutic efficacy in cancer cells harboring
the TrkA rearrangement. Kohki Tsukamoto, Toshio Yoshizawa, Ryohei
Kozaki, Kazuhito Kawabata.
789 CT413 is a novel dual Axl/Mer inhibitor that potently
inhibited the growth of Axl overexpressed tumors. Ning Xi, Tingjin
Wang, Yanjun Wu, Min Liao, Yanming Feng, Ning Kang, Zhaohe Wang,
Yingjun Zhang.
790 Altiratinib is a potent inhibitor of TRK kinases and is
efficacious in TRK-fusion driven cancer models. Bryan D. Smith,
Cynthia B. Leary, Benjamin A. Turner, Michael D. Kaufman, Scott C. Wise,
Maria E. Garcia-Rendueles, James A. Fagin, Daniel L. Flynn.
791 BLU-285, the first selective inhibitor of PDGFR␣ D842V and
KIT Exon 17 mutants. Erica K. Evans, Brian L. Hodous, Alexandra K.
Gardino, Alison Davis, Julia Zhu, Adam Shutes, Joseph L. Kim, Kevin J.
Wilson, Doug Wilson, Yulian Zhang, Tat Chu, Nancy E. Kohl, Vivek
Kadambi, Timothy Guzi, Christoph Lengauer.
792 ASN002: A novel dual SYK/JAK inhibitor with strong
antitumor activity. Sanjeeva Reddy, Nitin K. Damle, Aranapakam M.
Venkatesan, Scott K. Thompson, Niranajan Rao, Roger A. Smith,
Sandeep Gupta.
793 Insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR)
inhibitory activity of rociletinib (CO-1686) and its metabolites in
nonclinical models. Andrew D. Simmons, Sarah Jaw-Tsai, Henry J.
Haringsma, Andrew Allen, Thomas C. Harding.
794 Prognostic value of high c-Met expression in patients with
poor prognosis pancreatic adenocarcinoma following surgical
resection: comparison of three c-Met scoring methods and
exploration of underlying mechanisms of c-Met overexpression.
Cindy Neuzillet, Annemilaï Tijeras-Raballand, Jérôme Raffenne, Armand
de Gramont, Pierre Bedossa, Valérie Paradis, Alain Sauvanet, JeanBaptiste Bachet, Eric Raymond, Pascal Hammel, Anne Couvelard,
Jérôme Cros.
795 Dovitinib exerts potent antitumor effects in gastrointestinal
stromal tumors. Huynh T. Hung, Richard Ong, Pierce Chow.
796 Alofanib, a novel allosteric FGFR2 inhibitor, shows potent
antitumor activity in ovarian cancer with FGFR2 expression. Sergei
Tjulandin, Mikhail Byakhov, Evgenia Stepanova, Dmitry Khochenkov,
Daniel Harrison, Ilya Tsimafeyeu.
797 Discovery of a highly selective and potent small molecule
inhibitor against c-MET for cancer therapy. Rudi Bao, Zhongzong Pan,
Zhiming Zhao, Hongping Yu, Yaochang Xu.
798 NMS-P088, a dual FLT3-KIT inhibitor active also on
gatekeeper mutations and devoid of QTc prolongation. Marina
Ciomei, Nadia Amboldi, Sabrina Cribioli, Daniele Casero, Angela Greco,
Antonella Isacchi, Enrico A. Pesenti, Daniele Donati, Arturo Galvani,
Andrea Lombardi Borgia.
POSTER SESSION
Carcinogenesis
Carcinogenic Mechanisms 1
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
799 Protein kinase C ␧ cooperates with Pten deficiency
to regulate NF-␬B pathway in prostate cancer
progression. Rachana Garg, Jorge Blando, Carlos J. Perez,
Fernando J. Benavides, Marcelo G. Kazanietz.
800 Dysregulation of DLL4 gene expression in LiFraumeni syndrome and tumorigenesis. Zhixing Yao, Zaki
A. Sherif.
801 IKK␣ at the crossroad between inflammation,
oxidative stress and lung carcinogenesis. Na-Young Song,
Jami Willette-Brown, Mahesh Dalta, Yinling Hu.
802 The inactivation of PP2A caused by the
replacement of its regulatory subunit plays a crucial role in
the hemangiomagenesis. Qin Xu, Furong Xie.
803 Overexpression of NRF1 leads to the generation of
cancer stem-like cells and resistance to anoikis _
pathways to anchorage-independent growth during
estrogen-induced malignant transformation. Jayanta Das,
Deodutta Roy.
804 Energetic metabolism and DNA damage response
in fibroblasts from Li-Fraumeni syndrome patients: new
insights into the molecular mechanisms of the disease.
Gabriel Macedo, Sylvie Sauvaigo, Michele Silva Alves, Sylvain
Caillat, Igor Araujo Vieira, Fernanda Timm, Cristina
Brinckmann Oliveira Netto, Mauro Antonio Alves Castro, Ivi
Bristot, Angela Fachel, Fabio Klamt, Patricia Ashton-Prolla.
805 Subcellular distribution of RAGE affects its
functions in melanoma growth and progression. Maike
Reith, Wolf-Henning Gebhardt, Kathrin Tarnanidis, Nikolaus
B. Wagner, Kristian Ikenberg, Coretta Kehrel, Jochen Utikal,
Christoffer Gebhardt.
806 Modeling human UV-induced skin cancer through
genetic manipulation of Src-kinases and Srcasm. Xiaoping
Yang, Sheila Shankar, Hiroshi Maeno, Micheal Gober,
Christine Marshall, Tzvete Dentchev, John Seykora.
807 Parental radiation elicits increased intestinal
tumorigenesis in the F1 generation of APCMin/+ and
APC1638N/+ mice. Shubhankar Suman, Santosh Kumar,
Bo-Hyun Moon, Ziling Fan, Albert J. Fornace, Kamal Datta.
808 Cystine stones as a potential cause of bladder
cancer in Slc3a1 knockout male mice. Kathleen M.
Capaccione, Min Yang, Lourdes Serrano, Jay A. Tishfield,
Amrik Sahota.
809 BrafV637E mutation as an early change in
hepatocarcinogenesis induced by neonatal treatment with
diethylnitrosamine in B6C3F1 mice. Masahiro Yamamoto,
Hiroki Tanaka, Xin Bing, Yuji Nishikawa, Kohsuke Yamazaki,
Keiko Shimizu, Katsuhiro Ogawa.
810 Non-genotoxic hepatocarcinogens induce growth
and anti-apoptotic pathways in hepatocytes via
mesenchymal cytokines. Bettina Grasl-Kraupp, Teresa
Riegler, Marzieh Nejabat, Jakob Paur, Johannes Eichner,
Michael Roemer, Andreas Zell, Rolf Schulte-Hermann,
Wolfgang Huber.
811 Induction of stem-like cells with malignant
properties by chronic exposure of immortalized normal
human urothelial cell line to arsenic. Akira Oki, Shahnaz
Begum, Mariana Brait, David Sidransky, Mohammad O.
Hoque.
812 Processing of core protein by signal peptide
peptidase participates in propagation and pathogenesis of
hepatitis C virus. Toru Okamoto, Sayaka Aizawa, Takahisa
Kouwaki, Tatsuya Suzuki, Takasuke Fukuhara, Kohji Moriishi,
Kazuhiko Koike, Yoshiharu Matsuura.
813 Human papillomavirus 16 oncoprotein E6
upregulates c-Met partially through p53 in squamous cell
carcinoma of the head and neck. Guoqing Qian, Dongsheng
Wang, Kelly R. Magliocca, Praveen Duggal, Sreenivas
Nannapaneni, Sungjin Kim, Zhengjia Chen, Dong M. Shin,
Nabil F. Saba, Zhuo G. Chen.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
814 Truncated HBx-dependent silencing of growth
arrest-specific 2 promotes hepatocarcinogenesis through
inhibition of p53-mediated apoptosis. Alfred S. Cheng,
Ranxu Zhu, Myth T. Mok, Wai Kang, Ka-Fai To, Joseph J.
Sung, Henry L. Chan.
815 DTX1 is an epigenetically regulated tumor
suppressor gene discovered by integrative analysis of
epigenetic and transcriptional alterations in HNSCC. Daria
A. Gaykalova, Veronika Zizkova, Ilse Tiscareno, Yingying Wei,
Rajita Vatapalli, Patrick T. Hennessey, Julie Ahn, Ludmila V.
Danilova, Zubair Khan, Justin A. Bishop, Wayne M. Koch,
William H. Westra, Michael F. Ochs, Joseph A. Califano.
816 Persistent effects of radiation on intestinal stem
cells: implications for colorectal carcinogenesis. Kamal
Datta, Shubhankar Suman, Santosh Kumar, Albert J. Fornace.
817 Lipid, glucose and global oxidation in relation to
prostate cancer development. Tianying Wu.
818 Chronic oxidative stress induces conversion of
estrogen-dependent non-aggressive breast cancer cells
into estrogen-independent aggressive phenotype. Prathap
Kumar S. Mahalingaiah, Logeswari Ponnusamy, Kamaleshwar
P. Singh.
819 Fatty acid synthase, cycloxygenase-2 (COX-2) and
osteoprotegerin (OPG) expression in invasive breast
cancer: Implications in carcinogenesis. Sudeshna Goswami,
Neelam Sharma-Walia.
820 Analysis of potential mutagenic effects of World
Trade Center dust on in vitro systems. Barbara Soares,
Kayla Cortese, Ann Marie DiLorenzo.
821 Human mammary tumor virus(HMTV) is deeply
involved in breast cancer and metastasis. James F. Holland,
Stella Melana, Shabnam Jaffer, Polly Etkind, Teiko Nartey,
Tina Lee, Beatriz G.T. Pogo.
822 Genetically engineered mouse models of
catastrophic pancreatic ductal adenocarcinoma. Takashi
Yamaguchi, Sanae K. Ikehara, Hayao Nakanishi, Yuzuru
Ikehara.
823 Gene expression profiling for oncogenic Kras
mutation in mice and human colorectal cancer. Hiroaki
Niitsu, Takao Hinoi, Yasuo Kawaguchi, Kazuhiro Sentani,
Naohide Oue, Yusuke Sotomaru, Tomohiro Adachi, Yasufumi
Saito, Masashi Miguchi, Masatoshi Kochi, Manabu Shimomura,
Wataru Yasui, Hideki Ohdan.
824 A novel mechanism of areca nut-induced oral
cancer is through the conversion of cancer stem cells to
acquire malignant phenotypes. Yi-Chen Li, Ann-Joy Cheng.
825 Molecular mechanisms of regulation of cytochrome
P4501A enzymes by 3-methylcholanthrene (MC) in mice in
vivo. Bhagavatula Moorthy, Jiang Weiwu, Lihua Wang, Chun
Chu, Sudha R. Kondraganti, Paramahamsa Maturu.
826 DNA adducts induced by in vitro activation of
diesel and biodiesel exhaust extracts. Jeffrey A. Ross,
Garret B. Nelson, Esrta Mutlu, Sarah H. Warren, Matthews P.
Peggy, M. Ian Gilmour, David M. DeMarini.
827 Analysis of p63 protein expression in rat ventral
prostate submitted to intrauterine undernutrition
associated to hormonal exposure in adult life. Jaqueline C.
Rinaldi, Caroline N. Barquilha, Sergio A. Santos, Ana C.
Camargo, Ketlin T. Colombelli, Sergio L. Felisbin, Luis A.
Justulin.
828 Methylation status of HPV16 E2-binding sites
identifies subtypes of HPV-associated oropharyngeal
squamous cell carcinomas. Ernst-Jan M. Speel, Miriam
Reuschenbach, Christian U. Huebbers, Elena-Sophie Prigge,
Justo L. Bermejo, Simon Kalteis, Simon Preuss, Jutta Kolligs,
Nadine C. Olthof, Bernd Kremer, Steffen Wagner, Jens P.
Klussmann, Svetlana Vinokurova, Magnus von Knebel
Doeberitz.
34
34
257
POSTER SESSION
Epidemiology
Poster
:LJ[PVU
35
35
Cancer Risk/Mortality: Exposures, Biomarkers, and Genetics 1
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
258
Abstract
Number
829 Circulating immune/inflammation markers in Chinese workers
occupationally exposed to formaldehyde. Qing Lan, Wei Jie Seow,
Luoping Zhang, Roel Vermeulen, Xiaojiang Tang, Wei Hu, Bryan A. Bassig,
Zhiying Ji, Meredith S. Shiels, Troy J. Kemp, Min Shen, Chuangyi Qiu, Boris
Reiss, Laura B. Freeman, Aaron Blair, Christopher Kim, Weihong Guo, Cuiju
Wen, Laiyu Li, Ligia A. Pinto, Hanlin Huang, Martyn T. Smith, Allan
Hildesheim, Nathaniel Rothman.
830 Gene-specific promoter methylation is related to micronuclei
frequency in urothelial cells from individuals exposed to organic solvents
and paints. Luz S. Hoyos-Giraldo, Luisa F. Escobar-Hoyos, Diana SaavedraTrujillo, Ingrid Reyes-Carvajal, Adriana Muñoz, Elizabeth Londoño-Velasco,
Angela Tello, Silvio Carvajal, Regina Santella.
831 In utero polycyclic aromatic hydrocarbons exposure and
genome-wide DNA methylation modifications at birth in children who
develop acute lymphoblastic leukemia. Semira Gonseth, Todd P.
Whitehead, Ritu Roy, E. Andres Houseman, Adam J. de Smith, Mi Zhou,
Seung-Tae Lee, Margaret R. Wrensch, Stephen M. Rappaport, Catherine
Metayer, Joseph L. Wiemels.
832 Midlife racial differences In leukocyte telomere length and in
associations between modifiable factors and telomere length. Kari A.
Weber, Christopher M. Heaphy, Edward Giovannucci, Elizabeth A. Platz,
Alan K. Meeker, Health Professionals Follow-up Study Investigators.
833 Persistent alterations of gene expression profiling of human
peripheral blood mononuclear cells from smokers. Daniel Y. Weng,
Jinguo Chen, Cenny Taslim, Ping-Ching Hsu, Catalin Marian, Sean P. David,
Christopher A. Loffredo, Peter G. Shields.
834 Plasma MICA and pancreatic cancer. Anna E. Prizment, Heather
H. Nelson, Bharat Thyagarajan, Amy M. Linabery, Kristin E. Anderson.
835 COPD and risk of lung cancer in post-menopausal women:
findings from the Women’s Health Initiative. Michele L. Cote, Amy
Lehman, Rowen Chlebowski, Brittany Haynes, Gloria Ho, Manali Patel, Lori
Sakoda, Michael Simon, Heather Wakelee, Ann Schwartz.
836 Gene-environment interaction of genome-wide association
study-identified susceptibility loci and meat-cooking mutagens in
renal cell carcinoma etiology. Stephanie C. Melkonian, Carrie R. Daniel,
Yuanqing Ye, Nizar M. Tannir, Jose A. Karam, Surena F. Matin, Christopher
G. Wood, Xifeng Wu.
837 Pathogenesis and progression of esophageal adenocarcinoma
by prior diagnosis of Barrett’s esophagus. Michael B. Cook, Jennifer
Drahos, Shannon Wood, Lindsey Enewold, Ruth Parsons, Neal D.
Freedman, Philip R. Taylor, Winnie Ricker, Christian C. Abnet.
838 Household stove improvement and lung cancer mortality in
Xuanwei, China: A 33-years’ follow-up study. Wei Jie Seow, Wen-Qing
Li, Robert S. Chapman, Wei Hu, Roel Vermeulen, Xingzhou He, Bryan A.
Bassig, Christopher Kim, Nathaniel Rothman, Qing Lan.
839 Effects of occupational exposure to carbon black on
peripheral white blood cell counts. Yufei Dai, Rong Zhang, Yong Niu,
Huawei Duan, Tao Meng, Meng Ye, Meili Shen, Ping Bin, Shanfa Yu, Roel
Vermeulen, Nathaniel Rothman, Qing Lan, Yuxin Zheng.
840 Occupational exposure to trichloroethylene and LINE-1
methylation. Wei Hu, Luoping Zhang, Christopher Kim, Xiaojiang Tang,
Sungkyoon Kim4, Bryan Bassig, Wei-Jie Seow, Min Shen, Chuangyi Qiu,
Yechen Ge, Boris Reiss, Mark Purdue, Lee Moore, Laiyu Li, Fei Yue, Hanlin
Huang, Martyn T. Smith, Roel Vermeulen, Nathaniel Rothman, Qing Lan.
841 SNP-FEMS: a method to identify DNA binding proteins
interacting with enhancer elements. Gustavo A. Mendoza-Fandino,
Nicholas Woods, Rebekah Baskin, Anxhela Gjyshi, Alvaro N. Monteiro.
842 Two new loci and gene sets related to sex determination and
cancer progression are associated with susceptibility to testicular germ cell
tumor. Tom Grotmol, Wenche Kristiansen, Robert Karlsson, Trine B.
Rounge, Thomas Whitington, Bettina K. Andreassen, Patrik K. Magnusson,
Hans-Olov Adami, Clare Turnbull, Trine B. Haugen, Fredrik Wiklund.
843 Imputation and meta-analysis of five genome-wide
association studies identify multiple new loci associated with testicular
germ cell tumor. Zhaoming Wang, Peter A. Kanetsky, Katherine A.
McGlynn, D. Timothy Bishop, Charles C. Chung, Marlene D. Dalgaard, Tom
Grotmol, Mark H. Greene, Ramneek Gupta, Trine B. Haugen, Kevin
Litchfield, Jennifer T. Loud, Nandita Mitra, Kasper Nielsen, Clare Turnbull,
Ewa Rajpert-DeMeyts, Saran Vardhanabhuti, Fredrik Wiklund, Stephen
Schwartz, Stephen J. Chanock, Katherine L. Nathanson, TECAC consortium.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
844 Comparison of HPV prevalence between
HPV-vaccinated and non-vaccinated young adult women (20-26
years). Fangjian Guo, Jacqueline M. Hirth, Abbey B. Berenson.
845 The role of childhood immunizations and infections on the risk
of pediatric rhabdomyosarcoma. Hari Sankaran, Heather Danysh, Michael
E. Scheurer, M. Fatih Okcu, Philip J. Lupo.
846 Soluble levels of CD27 and CD30 are associated with risk of
non-Hodgkin lymphoma in a pooled analysis of three prospective
cohorts of Chinese men and women in Shanghai and Singapore. Bryan
A. Bassig, Xiao-Ou Shu, Woon-Puay Koh, Yu-Tang Gao, Mark P. Purdue,
Lesley M. Butler, Jennifer Adams-Haduch, Yong-Bing Xiang, Troy J. Kemp,
Renwei Wang, Ligia A. Pinto, Tongzhang Zheng, Bu-Tian Ji, H. Dean
Hosgood, Wei Hu, Gong Yang, Heping Zhang, Wong-Ho Chow,
Christopher Kim, Wei Jie Seow, Wei Zheng, Jian-Min Yuan, Qing Lan,
Nathaniel Rothman.
847 Human papillomavirus (HPV) type distribution in multi-ethnic
cohort of women: Implications for vaccination programs. Michael E.
Scheurer, Hung N. Luu, Martial Guillaud, Jane Montealegre, Laura M. Dillon,
Michele Follen, Karen Adler-Storthz.
848 Pathogenic oral bacteria and risk of incident cancer in
postmenopausal women: The Buffalo OsteoPerio Study. Xiaodan Mai,
Robert J. Genco, Michael J. LaMonte, Kathleen M. Hovey, Jo L.
Freudenheim, Christopher A. Andrews, Jean Wactawski-Wende.
849 The changing role of GDF15 (growth/differentiation factor 15)
during prostate carcinogenesis. Benjamin A. Rybicki, Dhananjay Chitale,
Nilesh Gupta, LaToya Jackson, Travis Wheeler, Sheri Trudeau, Michelle
Jankowski, Kevin Bobbittt, Andrew Rundle, Delian Tang.
850 Hepatitis B virus genotype, mutations, human leukocyte
antigen polymorphisms and their interactions in hepatocellular
carcinoma: a multi-centre case-control study. Juan Wen, Ci Song, Deke
Jiang, Tianbo Jin, Xiangjun Zhai, Jianfeng Xu, Hongbing Shen, Zhibin Hu.
851 Characteristics of adult men who are willing to give HPV
vaccine to their daughters in the United States: a national survey.
Jessica Rogers, Kolapo A. Idowu, Rahmatalai Coker, Hamidat Segunmaru,
Mohammad Daremipouran, Clinton Burnside, Carla D. Williams, Adeyinka
O. Laiyemo.
852 Smoking and HPV antibodies, a mediation analysis of HPV
re-infection. Ronald C. Eldridge, Michael Pawlita, Lauren Wilson, Philip E.
Castle, Tim Waterboer, Patti E. Gravitt, Mark Schiffman, Nicolas
Wentzensen.
853 The role of germline microRNA-related polymorphisms on
pediatric medulloblastoma prognosis and survival. Erin C. Peckham,
Philip J. Lupo, Austin L. Brown, Mehmet Fatih Okcu, Ching C. Lau, Surya
Rednam, Michael E. Scheurer.
854 Ovarian cancer risk factors by histologic subtypes: evidence
for etiologic heterogeneity. Nicolas A. Wentzensen, Elizabeth Poole, Alan
A. Arslan, Alpa V. Patel,
V. W. Setiawan, Kala Visvanathan, Elisabete Weiderpass, Emily White,
Hans-Olov Adami, Louise A. Brinton, Leslie Bernstein, Julie Buring, Lesley
M. Butler, Saioa Chamosa, Tess V. Clendenen, Laure Dossus, Renee Fortner,
Susan M. Gapstur, Mia M. Gaudet, Inger Torhild Gram, Patricia Hartge,
Judith Hoffman-Bolton, Annika Idahl, Michael Jones, Rudolf Kaaks, Vivki
Kirsh, Woon-Puay Koh, James V. Lacey, I-Min Lee, Eva Lundin, Melissa
Merritt, Ulrike Peters, Jenny Poynter, Sabina Rinaldi, Kim Robien, Thomas
Rohan, Dale P. Sandler, Leo J. Schouten, Louise Sjöholm, Sabina Sieri,
Anthony Swerdlow, Anne Tjønneland, Britton Trabert, Lynne Wilkens,
Alicja Wolk, Hannah P. Yang, Anne Zeleniuch-Jacquotte, Shelley S.
Tworoger.
855 History of oral contraceptive use in breast cancer patients and
risk for early breast cancer events. Louise Huzell, Mia Persson, Maria
Simonsson, Andrea Markkula, Christian Ingvar, Carsten Rose, Helena C.
Jernström.
856 Correlation of prognosis and histologic patterns by the IASLC/
ATS/ERS classification in invasive pulmonary adenocarcinoma: A metaanalysis. Keon Uk Park, Jin Young Kim, Hun Mo Ryoo, Ilseon Hwang.
857 Mammographic density and breast cancer risk: a mediation
analysis. Megan Rice, Tyler VanderWeele, Bernard Rosner, Rulla Tamimi.
858 Periodontal bone loss and risk of epithelial ovarian cancer in
the Nurses’ Health Study. Ana Babic, Elizabeth M. Poole, Kathryn L. Terry,
Daniel W. Cramer, Ricardo P. Teles, Shelley S. Tworoger.
POSTER SESSION
Epidemiology
Lifestyle Factors and Cancer Risk/Mortality
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
859 Impact of obesity in melanoma outcomes: Analysis
of data from a multinational randomized controlled
sentinel lymph node trial. Daniel D. Kirchoff, Gary B.
Deutsch, Stacey L. Stern, Simon Lavotshkin, Delphine J. Lee,
Leland J. Foshag, Mark B. Faries.
860 Effects of breastfeeding and oral contraception use
on the risk of breast cancer recurrence: A multinational
study. Teresa A. Lehman, Mohammed Shaik, Ramakrishna V.
Modali, Borys Hrinczenko.
861 The association between cancer prevention
guidelines and cancer risk in the Southern Community
Cohort Study. Shaneda N. Warren Andersen, Jennifer
Sonderman, Xiao-Ou Shu, Danxia Yu, Mark Steinwandel,
Joesph K. McLaughlin, Margaret K. Hargreaves, William J.
Blot, Wei Zheng.
862 Association of non-steroidal anti-inflammatory
drugs with colorectal cancer by subgroups in the Vitamins
and Lifestyle (VITAL) Study. Xiaoliang Wang, Ulrike Peters,
John D. Potter, Emily White.
863 Exogenous hormone use was inversely associated
with gastric cancer risk among women: The Singapore
Chinese Health Study. Zhensheng Wang, Anna H. Wu,
Woon-Puay Koh, Aizhen Jin, Renwei Wang, Jian-Min Yuan,
Lesley M. Butler.
864 Body size and composition, physical activity and
breast cancer risk in UK Biobank. Wenji Guo, Gillian K.
Reeves, Timothy J. Key.
865 Physical inactivity increases the risk of
endometrial cancer and premenopausal breast cancer.
Anna Johnsson, Per Broberg, Anders Johnsson, Åsa
Tornberg, Håkan Olsson.
866 The proportion of breast and gynecological
cancers in Australian women that can be attributed to the
use of oral contraceptives and hormone replacement
therapy. Susan J. Jordan, Louise Wilson, David Whiteman,
Penelope Webb, PAF Project Group.
867 Reproductive factors and risk of B-cell nonHodgkin lymphoma among women in Los Angeles. Yani Lu,
Jianning Luo, Sophia Wang, Jane Sullivan-Halley, Wendy
Cozen, Leslie Bernstein.
868 The effects of age at term-births on risk of ovarian
cancer. Alice Lee, Celeste L. Pearce, Anna Wu, Malcolm Pike.
869 Body mass index, weight gain, and physical
activity during adulthood in relation to colorectal cancer
risk. Huakang Tu, Xia Pu, Carrie Daniel-MacDougall,
Stephanie C. Melkonian, Yuanqing Ye, Gottumukkala S. Raju,
Scott Kopetz, Xifeng Wu.
870 Physical activity, diet and ovarian cancer risk.
Teresa A. Lehman, Ramakrishna V. Modali, Luke Ratnasinghe.
871 The association between periodontal disease and
pancreatic cancer. Jeffrey S. Chang, Chia-Rung Tsai, YanShen Shan, Li-Tzong Chen.
872 Long-term and recent recreational physical activity
reduces risk of triple negative and other subtypes of
invasive breast cancer in the California Teachers Study .
Huiyan Ma, Jessica Clague, Xinxin Xu, Yani Lu, Kayo Togawa,
Sophia S. Wang, Christina A. Clarke, Eunjung Lee, Hannah L.
Park, Jane Sullivan-Halley, Susan Neuhausen, Leslie
Bernstein.
873 Parity, breastfeeding and ovarian cancer in the
Million Women Study. Kezia Gaitskell, Jane Green, Kirstin
Pirie, Gillian Reeves, Valerie Beral.
874 Personal history of psoriasis and risk of incident
cancer among women: the Nurses’ Health Study. Wen-Qing
Li, Jiali Han, Eunyoung Cho, Shaowei Wu, Hongji Dai, Martin
Weinstock, Abrar Qureshi.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
875 Risk factors for hepatocellular carcinoma (HCC) by
race/ ethnicity in the United States. Oxana V. MakarovaRusher, Sean F. Altekruse, Timothy S. McNeel, Barry I.
Graubard, Austin G. Duffy, Susanna V. Ulahannan, Tim F.
Greten, Katherine A. McGlynn.
876 Long-term use of aspirin and risk of cancer. Yin
Cao, Reiko Nishihara, Kana Wu, Molin Wang, Shuji Ogino,
Donna Spiegelman, Charles S. Fuchs, Edward L. Giovannucci,
Andrew T. Chan.
877 Aspirin and other nonsteroidal anti-inflammatory
drugs, statins, and risk of non-Hodgkin lymphoma. James
R. Cerhan, Megan M. O’Bryne, Grzegorz S. Nowakowski,
Timothy G. Call, Carrie A. Thompson, Tait D. Shanafelt,
William R. Macon, Neil E. Kay, Thomas M. Habermann, Susan
L. Slager, Mark Liebow.
878 Pre-diagnostic aspirin use, lymph node
involvement and mortality in women with stage I-III breast
cancer: A study in the Prostate Lung Colorectal and
Ovarian cancer screening trial. Marie C. Bradley, Amanda
Black, Andrew N. Freedman, Robert N. Hoover, Kala
Visvanathan Visvanathan, Thomas I. Barron.
879 Menopausal hormone therapy and risk of primary
liver cancer in the UK Clinical Practice Research Datalink.
Katherine A. McGlynn, Katrina Hagberg, Jie Chen, Susan Jick,
Vikrant V. Sahasrabuddhe.
880 Obesity predicts prostate cancer-specific mortality
after radical prostatectomy: Results from the SEARCH
database. Adriana C. Vidal, Lauren E. Howard, Matthew R.
Cooperberg, Christopher J. Kane, William J. Aronson, Martha
K. Terris, Christopher L. Amling, Stephen J. Freedland.
881 Association of adult body mass index and height
with risk of ovarian cancer in 39,000 women: Results of a
Mendelian randomization study. Suzanne C. Dixon, Christina
M. Nagle, Aaron P. Thrift, Paul D. Pharoah, Ailith Pirie, Celeste
Leigh Pearce, Wei Zheng, Penelope M. Webb, for the Ovarian
Cancer Association Consortium.
882 Obesity, comorbidity and endometrial cancer
survival: the multiethnic cohort. Veronica W. Setiawan,
Gertraud Maskarinec, Yvonne G. Lin, Dongyun Yang, Lynne R.
Wilkens, Brian E. Henderson, Loic Le Marchand.
883 Body mass, smoking habit, and hypertension and
renal cell cancer survival. Jung Eun Lee, Nayeon Kim, HansOlov Adami, Per Lindblad.
884 Associations of intakes of magnesium and calcium
and survival among women with breast cancer: Results
from Western New York Exposures and Breast Cancer
(WEB) Study. Menghua Tao, Qi Dai, Amy E. Millen, Jing Nie,
Stephen B. Edge, Maurizio Trevisan, Peter G. Shields, Jo
Freudenheim.
885 Lower mortality among married cancer patients:
How much of the effect is explained by socioeconomic and
health insurance status. Scarlett L. Gomez, Alison Canchola,
Susan Hurley, Christina A. Clarke, Iona Cheng, Theresa H.
Keegan, Sally L. Glaser, Maria E. Martinez.
886 Health behaviors of cancer survivors: higher
alcohol drinking, lower smoking and physical inactivity
pattern in survivors with higher household income.
Boyoung Park, Sun-Young Kong, Jeongseon Kim, Yeol Kim,
In Hae Park, So-Youn Jung, Eun Sook Lee.
887 Hormone therapy use and the risk of breast cancer.
Marta Roman, Solveig Sakshaug, Siri Vangen, Sidsel GraffIversen, Elisabete Weiderpass, Giske Ursin, Solveig Hofvind.
888 Reproductive and hormonal factors and mortality
risk among women with colorectal cancer in the NIH-AARP
Diet and Health Study. Hannah Arem, Yikyung Park, Ashley
Felix, Alice Zervoudakis, Louise A. Brinton, Charles E.
Matthews, Marc J. Gunter.
36
36
259
POSTER SESSION
Prevention Research
Poster
:LJ[PVU
37
37
Modeling Cancer Prevention
Poster
Board
Poster
Board
Abstract
Number
1.
889 Mouse model for chemotherapy-induced alopecia with
transplantation of human hair follicles onto immune deficient mouse.
Ohsang Kwon, Ji-Seon Yoon, Mira Choi, Chang Yup Shin, Kyu Han Kim.
16.
904 Lifetime genistein alters mammary tumors’ response to
anti-estrogen tamoxifen treatment by affecting immune function
in rats. Xiyuan Zhang, Katherine Cook, Leena Hilakivi-Clarke.
2.
890 Effects of Lewis lung carcinoma on trabecular
microstructural changes in wild-type and plasminogen activator
inhibitor-1 deficient mice fed a high-fat diet. Lin Yan.
17.
3.
891 FGF21 prevents high fat diet-induced pancreatic cancer in
mice expressing oncogenic Kras. Weiqin Lu, Yaying Yang, Xiaojie
Wang, Yan Liu, Yongde Luo, Robert A. Wolff, James L. Abbruzzese,
Craig D. Logsdon.
905 Influence of high fat diet and APC status on epigenetic
regulation of FXR in colon cells. Ornella I. Selmin, Adam M. Lyon,
Changming Fang, Tom C. Doetschman, Patricia A. Thompson,
Jesse D. Martinez, Jeffrey Smith, Peter M. Lance, Donato F.
Romagnolo.
18.
906 Decreasing omega-6 to omega-3 polyunsaturated fatty
acid dietary ratios inhibit tumorigenesis in prostate cancer cells in
vitro and in vivo. Irvin V. Ma, Michael Mouradian, Arianne G. Sorreta,
Sunggu Kang, Ronald S. Pardini.
19.
907 Chemopreventive effects of a non-camellia tea against
azoxymethane-induced precancerous colorectal lesions in male
rats. Chunnian He, Wu Bi, L. H. Zhang, Li Cao, Pei-Gen Xiao.
20.
893 Metabolomic profiling of APC
mice maintained on a
methyl donor deficient diet reveals alterations to methionine and
fatty acid metabolism associated with cancer protection. Matthew
P. Hanley, Daniel W. Rosenberg.
908 Impact of microbial metabolites and resveratrol in
prostate cancer progression and clearance. James Stokes, Manoj K.
Mishra.
21.
894 Sulforaphane as a chemopreventive agent against oral
carcinogenesis. Julie E. Bauman, Yan Zang, Malabika Sen, Daniel P.
Normolle, Thomas W. Kensler, Sumita Trivedi, Patricia A. Egner,
Siddharth H. Sheth, Jennifer R. Grandis, Daniel E. Johnson.
909 Mechanistic study of synergistic interaction between
genistein and equol in MCF-7 human breast cancer cells in vitro.
MISAKI ONO, KAORU EJIMA, MIKAKO TAKESHIMA, TAKAKO HIGUCHI,
REI WAKIMOTO, SHUJI NAKANO.
22.
910 Genistein does not alter the effectiveness of taxane
chemotherapeutics on human prostate cancer cells. Jillian N. Eskra,
Alaina Dodge, Maarten C. Bosland.
23.
911 Dietary oleuropein (OL) improves high-fat diet-induced
metabolic stress and suppresses solid tumor growth and lymph
node (LN) metastasis in the B16F10 melanoma allograft model.
Hyerim Song, Jae In Jung, Gyoo Taik Kwon, So Young Park, Han Jin
Cho, Jung Han Yoon Park.
24.
912 Sulforaphane suppresses the growth of triple-negative
breast cancer stem-like cells in vitro and in vivo. Nadia P.
Castro, Cristina M. Rangel, David Salomon, Karen Saylor, Young S.
Kim.
25.
913 Determination of individual isothiocyanates/indoles
occurring as a result of glucosinolate degradation and their
relation to biological potential of different Brassica plants.
Agnieszka Bartoszek, Barbara Kusznierewicz, Anna Piekarska,
Dominik Kołodziejski, Tadeusz Pilipczuk, Izabela Koss-Mikołajczyk,
Jacek Namieśnik.
26.
914 Pioglitazone and metformin as potential
chemopreventative treatments in Fanconi anemia related oral
squamous carcinoma. Kim Miller, Beverly Wuertz, Frank G. Ondrey.
27.
915 Effects of black raspberry extract (BRB) and related
compounds on mutagenesis induced by metabolites of the
tobacco carcinogen, dibenzo(a,l)pyrene in cultured rat oral
fibroblasts; and on oxidative stress in human oral cancer cells.
Joseph B. Guttenplan, Seungjin Kim, Ying Zhou, Wieslawa Kosinska,
Ana-Vera Golgotiu, Shantu Amin, Gary D. Stoner, Yuan-Wan Sun,
Kun-Ming Chen, Karam El-Bayoumy.
28.
916 The molecular landscape of colorectal cancer cell lines
unveils clinically actionable targets. Mariangela Russo, Gabriele
Picco, Carlotta Cancelliere, Giorgio Corti, Emanuele Valtorta, Silvio
Veronese, Marco Beccuti, Francesca Cordero, Federica Di
Nicolantonio, Enzo Medico, Alberto Bardelli.
29.
917 The modulatory effects of cancer preventive herbal saponins
on gut microbiota and mucosal environment in ApcMin/+ mice. Lei
Chen, Manreet Singh, Frederick C. C. Leung, W. L. Wendy Hsiao.
30.
918 Physician receptivity to molecular diagnostic testing in
planning treatment for early-stage colon cancer patients. Ronald
E. Myers, Thomas A. Wolf, Scott Waldman.
4.
5.
6.
260
Abstract
Number
892 Vitamin D deficiency regulates TLR7 to promote
hepatocellular cancer in TGF-␤/Smad3 heterozygous mice. Jihyun Shin, Lior H. Katz, Nina M. Munoz, Andrea Cortes, Vivek Shukla,
Sang-Bae Kim, Franklin Herlong, Keigo Machida, Hidekazu
Tsukamoto, Kirti Shetty, Aiwu R. He, Lynt B. Johnson, Asif Rashid,
Jian Chen, Ju-Seog Lee, Lopa Mishra.
⌬14/+
7.
895 Genetic deletion of cyclooxygenase-2 suppresses K-ras
induced lung tumorigenesis. Yong Pan, Yan Jiang, Lin Tan, Murali K.
Ravoori, Mihai Gagea-Iurascu, Mihai Gagea-Iurascu, Vikus Kundra,
Susan M. Fischer, Peiying Yang.
8.
896 Correlation between modulation of RNA expression and
the preventive and therapeutic efficacy of Tamoxifen in an ER+
model of breast cancer. Howard H. Yang, Huaitian Liu, Ronald Lubet,
Clinton J. Grubbs, Holly Nicastro, Maxwell P. Lee.
9.
897 CHOP-deficiency promotes chronic inflammation-induced
pancreatic fibrosis. Katsunobu Taki, Masaki Ohmuraya, Daisuke
Hashimoto, Kota Arima, Hideaki Takeyama, Takayoshi Kaida, Takaaki
Higashi, Hidetoshi Nitta, Hiromitsu Hayashi, Akira Chikamoto, Toru
Beppu, Kimi Araki, Hideo Baba.
10.
898 Exercise inhibits the growth of breast cancer and reduces
fat mass in postmenopausal obese mice associated with a
circulating angiostatic phenotype and the inhibition of
angiogenesis in those tissues. Shelby A. Cole, Jian-Wei Gu.
11.
899 High fat diet induced DNA methylation at transcription
factor binding region and repressed gene expression of a
metastasis suppressor E-cadherin in primary site of murine
metastatic breast cancer (MBC), and promoted invasion of MBC
cells to lung and liver of BALB/c mice. Yukun Zhang, Wendan
Wang, Xujuan Yang, William G. Helferich.
13.
901 Grape seed extract decreases visceral adiposity and
impairs the pro-tumorigenic adipose tissue secretions affecting
colorectal cancer growth and progression. Komal Raina, Sushil
Kumar, Dileep Kumar, Ranganatha R. Somasagara, Reenu Punia,
Rama Kant, Rajesh Agarwal, Chapla Agarwal.
14.
902 RNA-Seq profiling of silibinin effects on bladder cancer
cells. Soichiro Yamamura, Yozo Mitsui, Nathan Bucay, Sharanjot
Saini, Shahana Majid, Guoren Deng, Varahram Shahryary, Rajvir
Dahiya, Yuichiro Tanaka.
15.
903
Comparison of the citrus flavonoid naringenin and
metformin for effects on breast cancer in obese ovariectomized
mice. Jia-Yu Ke, Yung-Hsuan Hsiao, Shana R. Straka, Lisa D. Yee,
Martha A. Belury.
LATE-BREAKING AND CLINICAL TRIALS POSTER SESSIONS
Sunday, 1:00 p.m.-5:00 p.m.
Halls B-E, Pennsylvania Convention Center
Abstracts will be available online and in the Proceedings Part 2.
Section 22
Section 39
Section 41
Phase II, III, and Special Population Clinical Trials
Late-Breaking Research: Experimental and Molecular Therapeutics 1
Late-Breaking Research: Molecular and Cellular Biology 1
261
Sunday, 1:30 p.m.-3:00 p.m.
AACRcentral, MICR Networking and Resource Center, Halls B-E, Booth #725
MICR Council Meet and Greet
Organized by the Minorities in Cancer Research (MICR) Council
Chairperson: Chanita Hughes-Halbert, Medical University of SC Hollings Cancer Center, Charleston, SC
The MICR Meet and Greet is an opportunity for the MICR Council to meet and answer questions from
MICR members, as well as the general Annual Meeting attendance, on issues related to award
opportunities, programs sponsored by the MICR Council, as well as other topics of interest to
attendees. The 2015 recipients of Minority-Serving Institution Faculty Scholar in Cancer Research
Awards and Minority Scholar Awards will also be present. All attendees are encouraged to visit the
MICR Networking and Resource Center in AACRcentral.
Past Chairperson
Christopher I. Li, Fred Hutchinson Cancer Research Center, Seattle, WA
Chairperson-Elect
Edith A. Perez, Mayo Clinic, Jacksonville, FL
Chairperson-Elect Designate
Rick A. Kittles, University of Arizona Cancer Center, Tucson, AZ
Council Members
Claudia R. Baquet, University of Maryland School of Medicine, Baltimore, MD
A. William Blackstock, Jr., Wake Forest University School of Medicine, Winston-Salem, NC
Malcolm V. Brock, Johns Hopkins University School of Medicine, Baltimore, MD
John M. Carethers, University of Michigan, Ann Arbor, MI
Christopher S. Lathan, Dana-Farber Cancer Institute, Boston, MA
Lisa A. Newman, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Sanya A. Springfield, National Cancer Institute-CRCHD, Bethesda, MD
John H. Stewart, IV, Wake Forest University, Winston-Salem, NC
Charles Richard Thomas, Jr., OHSU Knight Cancer Institute, Portland, OR
262
SPECIAL SESSION (not eligible for CME credit)
Sunday, 1:30 p.m.-3:00 p.m.
AACRcentral, AACR Amphitheater, Halls B-E, Booth #725
MEG Working Group: The Future of Molecular Epidemiology
in the Omics Era
This open discussion session provides an opportunity for early-career investigators to interact with
experts in molecular epidemiology and other scientific fields. Plan to attend and join the stimulating
and informative discussion on omics.
Co-Moderators, Introductory Remarks
David C. Christiani, Harvard Medical School, Boston, MA
Jonine D. Figueroa, National Cancer Institute-DCEG, Bethesda, MD
Panelists:
Christopher I. Amos, Dartmouth Geisel School of Medicine, Hanover, NH
Celine M. Vachon, Mayo Clinic, Rochester, MN
David J. Hunter, Harvard School of Public Health, Boston, MA
263
Sunday, 2:00 p.m.-4:00 p.m.
AACRcentral, WICR Networking and Resource Center, Halls B-E, Booth #725
WICR Council Meet and Greet
Organized by the Women in Cancer Research (WICR) Council
Chairperson: Jessie M. English, Dana-Farber Cancer Institute, Boston, MA
The WICR Meet and Greet is an opportunity for the WICR Council to meet and answer questions from
WICR members, as well as the general Annual Meeting attendance, on issues related to award
opportunities, programs sponsored by the WICR Council, as well as other topics of interest to
attendees. The 2015 recipients of WICR Scholar Awards will also be present. All attendees are
encouraged to visit the WICR Networking and Resource Center in AACRcentral.
Past Chairperson
Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX
Chairperson-Elect
Victoria M. Richon, Sanofi Oncology, Cambridge, MA
Chairperson-Elect Designate
Patricia M. LoRusso, Yale Cancer Center, New Haven, CT
Council Members
Lucile L. Adams-Campbell, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Caroline Dive, CRUK Manchester Institute, Manchester, United Kingdom
Lori S. Friedman, Genentech, Inc., South San Francisco, CA
Pearl S. Huang, Roche, Basel, Switzerland
S. Percy Ivy, National Cancer Institute-DCTD, Rockville, MD
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
Judith S. Sebolt-Leopold, University of Michigan, Ann Arbor, MI
Lillian L. Siu, University Health Network Princess Margaret Hospital, Toronto, ON, Canada
Thea D. Tlsty, UCSF School of Medicine, San Francisco, CA
264
MEET THE RESEARCH ICON (not eligible for CME credit)
Sunday, 2:30 p.m.-3:30 p.m.
AACRcentral, Associate Member Resource and Career Center, Halls B-E, Booth #725
Meet the Research Icon
Joan S. Brugge, PhD, FAACR
Harvard Medical School, Boston, MA
Formerly known as Meet the Research Pioneer, these informal sessions, organized by the Associate
Member Council, provide early-career scientists with the special opportunity to meet and hear from a
renowned senior researcher in a small-group setting. Throughout the course of each discussion,
attendees will gain career advice relevant to each speaker’s specific field and learn about the
speaker’s professional and personal experiences, vision for the future of their field, as well as key
decisions that shaped their career path. Meet Dr. Joan S. Brugge, Director of the Ludwig Center and
Louise Foote Pfeiffer Professor for the Department of Cell Biology at Harvard Medical School. Sessions
are open to all graduate students, medical students, residents, and clinical and postdoctoral fellows
and will take place in the Associate Member Resource and Career Center located in AACRcentral.
Limited seating will be available on a first-come,
first-served basis. #AACRcentral
265
Sunday, 2:30 p.m.-4:00 p.m.
The Clinical Sequencing Exploratory Research (CSER) Program:
Investigating the Actionability of Tumor Sequencing Variants
Moderators: Sheri Schully, National Cancer Institute, Rockville, MD; Carolyn M. Hutter, National Human
Genome Research Institute, Rockville, MD
Recognizing the potential of clinical next-generation sequencing (NGS) for the realization of precision
cancer care, the National Cancer Institute (NCI) has expanded its efforts to investigate how the
discovery and analysis of genomic alterations can be translated into more effective diagnosis,
treatment, and prevention of cancer. To this end, NCI participates in the Clinical Sequencing
Exploratory Research (CSER) program, co-funded with the National Human Genome Research
Institute (NHGRI), which aims to leverage these institutes’ experience in genomic sequencing and
analysis to conduct a robust investigation of the use these methods in clinical practice. The goal of
CSER is to guide the development and dissemination of best practices for the integration of clinical
sequencing into clinical care, including how clinical sequencing results will be communicated to
physicians and patients. The collaborative and cooperative nature of the CSER, including the
formation of a tumor sequencing working group, facilitates the development and standardization of
best practices and common approaches to clinical translation of cancer sequencing. One critical issue
that CSER seeks to address is how to determine whether a particular genetic variant is “actionable.”
This NCI-sponsored panel session will focus on how tumor exome sequencing projects within CSER
assess and report the actionability of variants identified through clinical somatic sequencing.
The session will begin with an overview of CSER, which currently comprises nine cooperative U01
grants, nine R01/R21 grants examining return of results, and NHGRI’s intramural ClinSeq program. Four
U01 grants focus on cancer phenotypes:
• Baylor College of Medicine (BASIC3 study) – Tumor and germline sequencing of newly diagnosed
children with high-risk central nervous system (CNS) and non-CNS solid tumors.
• University of Michigan (MI-ONCOSEQ study) – Tumor and germline sequencing of patients with
metastatic and refractory cancers, including sarcomas and rare tumors.
• Dana-Farber Cancer Institute (CanSeq study) – Tumor and germline sequencing of patients with
metastatic or refractory lung and colorectal cancer.
• University of Washington (NEXT Medicine study) – Germline sequencing of patients with colorectal
cancer or polyposis.
In the body of the session, the three CSER projects conducting tumor exome sequencing (BASIC3,
MI-ONCOSEQ, CanSeq) will each briefly describe their clinical context, project goals, study design, and
early study experience with clinical sequencing. Each group will then describe the pipeline utilized at
their institution for the annotation and evaluation of tumor variants, including 1) their working
definition of “actionable” (e.g., informative for choice of drug or potential entry into clinical trial),
2) the evidence considered to make that assessment (e.g., institutional databases, published
literature), and 3) the process by which a final determination of actionability is made (e.g., consensus
meetings or tumor board/panel).
The session will close with a panel discussion, in which representatives from each project will answer
audience questions. The panelists will also highlight key lessons learned in their development of
clinical NGS programs; discuss connections to other NIH initiatives including the Clinical Genome
Resource (ClinGen); and outline current opportunities and challenges to translating genomic medicine
into routine clinical cancer care.
Panelists:
Michael O. Dorschner, University of Washington, Seattle, WA
Gail Jarvik, University of Washington, Seattle, WA
Donald W. Parsons, Baylor College of Medicine Cancer Center, Houston, TX
Dan Robinson, University of Michigan, Ann Arbor, MI
Nikhil Wagle, Dana-Farber Cancer Institute, Boston, MA
266
REGULATORY SCIENCE AND POLICY SESSION (not eligible for CME credit)
Sunday, 3:00 p.m.-5:00 p.m.
Evolution of Personalized Drug Development in
Oncology-Kinase Inhibitors
Chairperson: Gideon M. Blumenthal, U.S. Food and Drug Administration, Silver Spring, MD
Advances in biomarker identification have revolutionized oncology drug development and patient care
by enabling precision targeting of tumor mutations usually accompanied by increased efficacy and
lower adverse effects. In conjunction, the regulatory requirements for approval of targeted cancer
drugs have also changed, most notably by requiring the development and approval of a companion
diagnostic to identify the appropriate patient subpopulation who will benefit from the therapy. Several
kinase inhibitors targeting specific mutations in genes such as BRAF and EGFR have been approved,
demonstrating the success of such approaches. However, new scientific and regulatory challenges
have arisen, specifically with regards to differential tumor response to targeted therapies based on the
specific genomic alteration or tissue of origin, alternative pathway selection within the tumor resulting
in resistance to targeted therapies, and the development of new technologies enabling multiple
biomarker identification, confounding the one-drug/one-test paradigm.
This session will highlight the evolution of the scientific and regulatory underpinnings of approved
kinase inhibitors, using EGFR and BRAF inhibitor development as case studies, as well as future
considerations for targeted drug development. The session will address issues such as:
• Understanding mechanisms of acquired resistance to kinase inhibitors
• Combining multiple targeted therapeutic agents to combat resistance
• Use of novel technologies such as circulating tumor DNA to identify and predict development
of resistance
• Development of companion diagnostics in the era of multiplex testing and massively
parallel sequencing
A panel discussion moderated by Gideon M. Blumenthal, U.S. Food and Drug Administration, and
audience Q and A will follow the presentations.
Speakers:
Gideon M. Blumental, U.S. Food and Drug Administration, Silver Spring, MD
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
Mehdi Shahidi, Boehringer Ingelheim, Berkshire, United Kingdom
Gideon Bollag, Plexxikon Inc., Berkeley, CA
Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX
Reena Philip, U.S. Food and Drug Administration, Silver Spring, MD
267
MEET THE RESEARCH ICON (not eligible for CME credit)
Sunday, 3:15 p.m.-4:15 p.m.
Franklin Room 8 (Level 4), Philadelphia Marriott Downtown
Meet the Pancreatic Cancer Research Icon
Anirban Maitra, MBBS
The University of Texas MD Anderson Cancer Center, Houston, TX
This interactive and informal session is an opportunity to chat with a senior pancreatic cancer
physician-scientist and learn how he charted a successful career in this field. Meet Dr. Anirban Maitra,
Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson
Cancer Center, Scientific Director of the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic
Cancer Research, and member of the Pancreatic Cancer Action Network Scientific and Medical
Advisory Board. Learn about the opportunities that exist in the pancreatic cancer research
field and broaden your professional network. Suggestions and tips will be provided. Topics to be
addressed relate to postdoctoral development, starting your own laboratory, choosing a mentor,
grantsmanship, networking, publications, collaborations, biospecimen access, little known
professional opportunities, etc.
268
AWARDS AND LECTURES
Sunday, 3:15 p.m.-4:30 p.m.
Terrace Ballroom II-III (400 Level), Pennsylvania Convention Center
Tenth Annual AACR-Minorities in Cancer Research
Jane Cooke Wright Memorial Lectureship
A Prospective Approach to Breast Cancer Risk in Black Women:
A View from Two Cohorts - WHI and BWHS
Lucile L. Adams-Campbell, PhD
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
The AACR- Minorities in Cancer Research Jane Cooke Wright Memorial Lectureship was established in
2006 to give recognition to an outstanding scientist who has made meritorious contributions to the
field of cancer research and who has, through, leadership or by example, furthered the advancement
of minority investigators in cancer research.
This year’s recipient of the AACR- Minorities in Cancer Research Jane Cooke Wright Memorial
Lectureship is Dr. Lucile Adams-Campbell, who is a Professor of Oncology and Associate Director of
Minority Health and Health Disparities Research at the Georgetown University Medical Center,
Lombardi Comprehensive Cancer Center. She is also Associate Dean of Community Health & Outreach
at the Georgetown University Medical Center.
Dr. Adams-Campbell is recognized for her scientific contributions in the area of epidemiology and
health disparities. Dr. Adams-Campbell’s work reflects a commitment to research areas that have the
potential to influence cancer care nationally and internationally. In addition, her dedication to fostering
the development of minorities in cancer research is recognized and greatly appreciated.
Dr. Adams-Campbell exemplifies many firsts as an African American scientist in epidemiology and
health disparities research, a woman, and an academic and community leader in cancer research. She
was the first African American woman to receive a doctorate in epidemiology in the U. S. Her interests
and collaborations in breast cancer susceptibility genes helped lead to the creation of the Black
Women’s Health Study which involves 59,000 black women across the country and is the largest,
long-term study of black American women’s health ever conducted in the U.S. This study, which is
now approaching two decades of research, importantly demonstrates the feasibility of long-term
follow-up among minority women.
Among numerous awards, honors, and appointments are the 225th Anniversary Medallion Award from
the University of Pittsburgh for alumni whose achievements have brought honor to the University. In
2008, she joined the esteemed group of scientists as an elected Member of the Institute of Medicine
and to its National Cancer Policy Forum in 2014.
Dr. Adams-Campbell’s scientific achievements and commitment to the advancement of minority
scientists clearly embody the AACR-Minorities in Cancer Research Jane Cooke Wright
MemorialLectureship’s mission.
269
LATE-BREAKING MINISYPOSIUM
Sunday, 3:15 p.m.-4:15 p.m.
Minisymposium: Late-Breaking Research
Co-Chairpersons: Judy Lieberman and William C. Hahn
3:15 p.m.
Introduction
3:20 p.m.
LB-050 Patient-derived tumor xenografts in humanized NSG mice: A model to study
immune responses in cancer therapy
Minan Wang, James G. Keck, Mingshan Cheng, Danying Cai, Leonard Shultz, Karolina
Palucka, Jacques Banchereau, Carol Bult, Rick Huntress.
3:35 p.m.
LB-051 Tumor heterogeneity and dissemination in breast cancer: Deep sequencing of
single disseminated cells from bone marrow compared to primary tumor and lymph
node metastases
Elen Møller, Parveen Kumar, Silje Nord, David Wedge, Peter van Loo, April Peterson,
Randi R. Mathiesen, Renathe Fjelldal, Masoud Z. Esteki, Jason A. Grundstad, Elin Borgen,
Lars O. Baumbusch, Anne-Lise Børresen-Dale, Kevin P. White, Thierry Voet, Bjørn
Naume, Vessela N. Kristensen.
3:50 p.m.
LB-052 Kinase identification of proximal substrates (KIPS): A novel chemical
genetics approach for kinase substrate identification
Jon Roffey, Andrew Turnbull, Christian Dillon, Susan Boyd, Philippe Riou, Mark Linch,
Peter Parker, Sven Kjaer, Neil McDonald.
4:05 p.m.
LB-053 Monitoring rearrangement of EML4-ALK in blood platelets predicts outcome
to crizotinib treatment in non-small-cell lung cancer patients
Jonas A. Nilsson, Niki Karachaliou, Pepijn Schellen, Ana Gimenez-Capitan, Jordi
Berenguer, Cristina Teixido, Justine L. Kuiper, Esther Drees, Magda Grabowska,
Marte van Keulen, Jihane M. Tannous, Danielle A.M. Heideman, Erik Thunnissen,
Anne-Marie C. Dingemans, Santiago Viteri, Bakhos A. Tannous, Ana Drozdowskyj,
Rafael Rosell, Egbert F. Smit, Thomas Wurdinger.
4:20 p.m.
LB-054 Normal stem cell divisions, cancer incidence, and driver gene mutations
Cristian Tomasetti, Bert Vogelstein. Johns Hopkins University School of Medicine,
Baltimore, MD.
4:35
LB-055 Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant
colorectal cancer through MAPK pathway alterations
Leanne G. Ahronian, Erin M. Sennott, Eliezer M. Van Allen, Nikhil Wagle, Eunice L. Kwak,
Jason E. Faris, Jason T. Godfrey, Koki Nishimura, Kerry D. Lynch, Craig H. Mermel,
Elizabeth L. Lockerman, Anuj Kalsy, Joseph M. Gurski, Samira Bahl, Kristin Anderka,
Lisa M. Green, Niall J. Lennon, Tiffany G. Huynh, Mari Mino-Kenudson, Gad Getz,
Dora Dias-Santagata, A. John Iafrate, Jeffrey A. Engelman, Levi A. Garraway,
Ryan B. Corcoran.
4:50 p.m.
LB-056 TP53 and RB1 alterations promote reprogramming and antiandrogen
resistance in advanced prostate cancer
Ping Mu, Zhen Cao, Elizabeth Hoover, John Wongvipat, Chun-Hao Huang, Wouter
Karthaus, Wassim Abida, Elisa De Stanchina, Charles Sawyers.
5:05 p.m.
Discussion
270
CLINICAL TRIALS MINISYMPOSIUM
Sunday, 3:15 p.m.-5:15 p.m.
Clinical Trials Minisymposium
Co-Chairpersons: David B. Solit, Memorial Sloan Kettering Cancer Center, New York, NY, and
Alessandro D. Santin, Yale University, New Haven, CT
3:15 p.m.
Introduction
3:25 p.m.
CT131: HPV-specific immunotherapy for cervical intraepithelial neoplasia using
VGX-3100 induces regression of cervical lesions and potent T-cell responses:
Results from a randomized, double-blind, placebo-controlled phase II study
Matthew Morrow, Cornelia Trimble, Xuefei Shen, Michael Dallas, David Weiner,
Jean Boyer, Jian Yan, Kimberly Kraynyak, Albert Sylvester, Mary Giffear, Kathleen
Marcozzi-Pierce, Divya Shah, Kate Broderick, Amir Khan, Jessica Lee, Laurent Humeau,
Niranjan Sardesai, Mark Bagarazzi.
3:45 p.m.
CT132: Long-term treatment with single-agent ibrutinib 420 mg leads to durable
responses including complete responses in CLL
Steven Coutre, Richard Furman, Ian Flinn, Jan Burger, Kristie Blum, Jeff Sharman,
Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla Heerema, Amy Johnson, Anh Tran,
Cathy Zhou, Elizabeth Bilotti, Danelle James, John Byrd, Susan O'Brien
4:05 p.m.
CT133: The impact of gene panel sequencing on clinical care in patients with cancer
David Neil Hayes, Juneko E. Grilley-Olson, David A. Eberhard, Nirali M. Patel,
Joel S. Parker, Karen E. Weck, William Y. Kim, Michele C. Hayward, H. Shelton Earp, III,
Norman E. Sharpless.
4:25 p.m.
CT134: Androgen receptor mutations in patients with castration-resistant prostate
cancer with and without prior abiraterone acetate treatment
Dana E. Rathkopf, Matthew R. Smith, Emmanuel S. Antonarakis, Charles J. Ryan,
William R. Berry, Neal D. Shore, Glenn Liu, Celestia Higano, Joshi J. Alumkal,
Ralph Hauke, Ronald Tutrone, Mansoor Saleh, Edna Chow Maneval, Shibu Thomas,
Deborah Ricci, Margaret K. Yu, Carla J. de Boer, Angela Trinh, Thian Kheoh,
Rajesh Bandekar, Howard I. Scher.
4:45 p.m.
CT135: Uncovering the genomic heterogeneity of multifocal breast cancer
Christine Desmedt, Debora Fumagalli, Elisabetta Pietri, Gabriele Zoppoli, Serena
Nik-Zainal, Gunes Gundem, David Brown, Francois Rothe, Samira Majjaj, Anna Garuti,
Enrico Carminati, Sherene Loi, Thomas Van Brussel, Marion Maetens, Laura Mudie,
Delphine Vincent, Naima Kheddoumi, Luigi Serra, Ilaria Massa, Alberto Ballestrero, Dino
Amadori, Roberto Salgado, Alexandre de Wind, Diether Lambrechts, Martine Piccart,
Denis Larsimont, Peter J. Campbell, Christos Sotiriou.
5:05 p.m.
Discussion
271
CLINICAL TRIALS PLENARY SESSION
Sunday, 3:15 p.m.-5:15 p.m.
Grand Ballroom (300 Level), Pennsylvania Convention Center
Clinical Trials of Combinations of Molecularly Targeted and
Nontargeted Therapeutic Agents
Co-Chairpersons: Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Timothy A.
Yap. The Royal Marsden Hospital, Sutton, United Kingdom
3:15 p.m.
CT136: Final biomarker analysis of the phase I study of the selective BRAF V600
inhibitor encorafenib (LGX818) combined with cetuximab with or without the
α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant
colorectal cancer
Jan H. M. Schellens, The Netherlands Cancer Institute, Amsterdam, The Netherlands
3:35 p.m.
Discussant
Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN
3:45 p.m.
CT138: Translating preclinical observations to the clinic: Combination of the dual
m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer
Udai Banerji, Institute of Cancer Research and The Royal Marsden, London,
United Kingdom
4:05 p.m.
Discussant
Lillian L. Siu, University Health Network Princess Margaret Hospital, Toronto, ON, Canada
4:15 p.m.
CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with
gemcitabine in patients with refractory solid tumors
Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN
4:35 p.m.
Discussant
Gary K. Schwartz, Columbia University Irving Comprehensive Cancer Center,
New York, NY
4:45 p.m.
CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and
anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
David L. Bajor, University of Pennsylvania, Philadelphia, PA
5:05 p.m.
Discussant
Paul B. Chapman, Memorial Sloan Kettering Cancer Center, New York, NY
Please refer to the online Itinerary Planner or Annual Meeting App for program updates.
272
DRUG DEVELOPMENT TRACK: SPECIAL SESSION
Sunday, 3:15 p.m.-5:15 p.m.
New Drugs on the Horizon 2
Co-Chairpersons: Alfonso De Dios, Eli Lilly and Company, Indianapolis, IN; Katerina Leftheris, Celgene
Corp., San Diego, CA
Advances in the understanding of the molecular basis of cancer have led to the identification of key
pathways involved in tumor initiation and progression, and translating this innovative science into the
next generation of therapeutic agents remains one of the major hurdles to meaningful improvements
in cancer treatment. While clinical successes remain extremely challenging to achieve, increasing
numbers of targeted agents are emerging through clinical trials and making differences in the lives of
patients. This symposium will provide the first disclosure of several new clinical agents that continue
the drive for successful targeted therapies.
3:15 p.m.
Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel
approach to treat cancer [DDT02-01]*
Daniel J. Anderson, Cleave Biosciences, Inc., Burlingame, CA
3:40 p.m.
Discussion
3:45 p.m.
BAY 1143572: A first-in-class, highly selective, potent, and orally available inhibitor of
PTEFb/CDK9 currently in phase I, inhibits MYC and shows convincing antitumor
activity in multiple xenograft models by the induction of apoptosis [DDT02-02]*
Arne Scholz, Bayer Pharma AG, Berlin, Germany
4:10 p.m.
Discussion
4:15 p.m.
Discovery of CPI-0610: A novel BET protein bromodomain inhibitor for
hematologic malignancies
Robert Sims, Constellation Pharmaceuticals, Cambridge, MA
4:40 p.m.
Discussion
4:45 p.m.
SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed
PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia
(AML) [DDT02-04]*
Dana A. Kennedy, Seattle Genetics, Inc., Bothell, WA
5:10 p.m.
Discussion
273
MINISYMPOSIUM
Carcinogenesis
Sunday, 3:15 PM-5:15 PM
Terrace Ballroom I (400 Level), Pennsylvania Convention
Center
New Carcinogenic Mechanisms Revealed
by Gastrointestinal Tract Cancers
Clinical Research
Chairpersons: S. Perwez Hussain and Yinling Hu
Chairpersons: Caroline Dive and Jorge S Reis-Filho
Liquid Biopsies
3:15 Introduction
3:15 Introduction
3:20 919 Adeno-associated virus 2 (AAV2) induces recurrent
insertional mutagenesis in human hepatocellular carcinomas.
Shalini Datta, Jean-Charles Nault, Andrea Franconi, Sandrine
Imbeaud, Maxime Mallet, Gabrielle Couchy, Eric Letouze, Camilla
Pilati, Benjamin Verret, Jean-Frédéric Blanc, Charles Balabaud,
Julien Calderaro, Alexis Laurent, Mélanie Letexier, Paulette BioulacSage, Fabien Calvo, Jessica Zucman-Rossi.
3:20 926
ESR1 mutations evolve during the treatment of
metastatic breast cancer, and detection in ctDNA predicts
sensitivity to subsequent hormone therapy. Gaia Schiavon, Sarah
Hrebien, Isaac Garcia-Murillas, Alex Pearson, Noelia Tarazona, Elena
Lopez-Knowles, Ricardo Ribas, Ashutosh Nerurkar, Peter Osin,
Lesley-Ann Martin, Mitch Dowsett, Ian E. Smith, Nicholas C. Turner.
3:35 920 Mechanism of the transferrin receptor 1 dysregulation in
hepatocarcinogenesis. Iryna Kindrat, Volodymyr Tryndyak, Aline
de Conti, Svitlana Shpyleva, Anna Erstenyuk, Frederick A. Beland,
Igor Pogribny.
3:50 921 Opposing effects of the Hippo-Yap pathway and c-Myc in
phenotypic determination of mouse hepatocytic tumors induced
by myrAkt. Masahiro Yamamoto, Bing Xin, Xi Chen, Kiyonaga Fujii,
Takako Ooshio, Yuji Nishikawa.
4:05 922 Macrophage migration inhibitory factor (MIF) and miR301b interactively enhance disease aggressiveness by targeting
NR3C2 (nuclear receptor subfamily group c member 2) in human
pancreatic cancer. Shouhui Yang, Peijun He, Jian Wang, Aaron
Schetter, Wei Tang, Naotake Funamizu, Jochen Gaedcke, Michael
Ghadimi, Matthias Gaida, Thomas Ried, Nader Hannah, H. Richard
Alexander, S. Perwez Hussain.
4:20 923 Nitric oxide signaling pathway as a pathogenic driver in
pancreatic cancer. Jian Wang, Peijun He, Matthias M. Gaida,
Shouhui Yang, Aaron Schetter, Jochen Gaedcke, Michael Ghadimi,
Thomas Ried, Harris G. Yfantis, Dong H. Lee, Jonathan M. Weiss,
Nadar Hanna, H. Richard Alexander, S. Perwez Hussain.
4:35 924 GM-CSF induces CREB signaling pathways and modulates
tobacco carcinogen-induced pancreatic tumorigenesis. Jason
Castellanos, Kumaraswamy Honnenahally, Chanjuan Shi, Nipun
Merchant, Nagaraj Nagathihalli.
4:50 925 Helicobacter pylori induces phosphorylation of STAT3 at
Ser727 to promote mitophagy in gastric cancer cells. Juan-Yu
Piao, Hee Geum Lee, Su-Jung Kim, Do-Hee Kim, Hye-Kyung Na,
Young-Joon Surh.
5:05 Discussion.
3:35 927 Pretreatment and serial plasma assessments of EGFR
mutations in NSCLC patients treated with rociletinib (CO-1686).
Jonathan W. Goldman, Chris Karlovich, Elaina Mann, Lindsey Rolfe,
Shannon Matheny, Darrin Despain, Philipp Angenendt, Claudia
Stamm, Heather A. Wakelee, Jean-Charles Soria, Benjamin
Solomon, D. R. Camidge, Rafal Dziadziuszko, Leora Horn, Shirish
Gadgeel, Mitch Raponi, Andrew R. Allen, Lecia V. Sequist.
3:50 928 Bias-corrected next generation sequencing of cell free
DNA for detection of actionable mutations and rearrangements
in advanced non-small cell lung cancer. Cloud P. Paweletz, Chris
K. Raymond, Adrian G. Sacher, Yanan Kuang, Allison O’Connell, Lee
Lim, Mark Li, Chris Armour, Jessie M. English, Paul T. Kirschmeier,
Pasi A. Jänne, Geoffrey Oxnard.
4:05 929 Tumor genotyping in the phase III GRID study of
regorafenib vs placebo in tyrosine kinase inhibitor (TKI)refractory GIST: Detection of KIT mutations in circulating tumor
DNA comparing digital PCR and massive parallel sequencing.
Michael Jeffers, Henrik Seidel, Susanne Schwenke, Joachim Reischl,
Mark Rutstein, Christian Kappeler, Iris Kuss, Michael Teufel.
4:20 930 Analysis of cell-free tumor DNA in cerebrospinal fluid to
characterize and monitor the genetic alterations of brain tumors.
Leticia De Mattos-Arruda, Regina Mayor, Charlotte K. Ng, Britta
Weigelt, Francisco Martínez-Ricarte, Davis Torrejon, Mafalda
Oliveira, Carolina Raventos, Alexandra Arias, Elena Guerini-Rocco,
Elena Martínez-Sáez, Sergio Lois, Oscar Marín, Xavier de la Cruz,
Salvatore Piscuoglio, Russell Towers, Ana Vivancos, Vicente Peg,
Santiago Ramon y Cajal, Jordi Rodon, Enriqueta Felip, Joan
Sahuquillo, Josep Tabernero, Javier Cortes, Jorge S. Reis-Filho, Joan
Seoane.
4:35 931 Enrichment and characterization of propagating
circulating tumor cells from late stage prostate and pancreatic
cancer patients. James I. Lim, Charles J. Ryan, Thomas Krahn,
Nikolas H. Stoecklein, Johannes Fischer, Bruce Adams.
4:50 932 A plasma microRNAs test predicts prognosis and disease
status at follow-up in screening-detected lung cancer patients.
Gabriella Sozzi, Stefano Sestini, Mattia Boeri, Carla Verri, Alfonso
Marchiano’, Carlotta Galeone, Nicola Sverzellati, Carlo La Vecchia,
Ugo Pastorino.
5:05 Discussion.
274
MINISYMPOSIUM
Terrace Ballroom IV (400 Level), Pennsylvania Convention
Center
Epidemiology
Biomarkers and Cancer: New Insights
Cell Cycle Mechanisms of Anticancer Drug
Action
Chairperson: Sonja I. Berndt
Chairperson: Geoffrey I. Shapiro
3:15 Introduction
3:15 Introduction
3:20 933 Circulating biomarkers of B vitamins in relation to lung
cancer risk in the Lung Cancer Cohort Consortium. Anouar Fanidi,
David.C Muller, Ross Prentice, Albanes Demetrius, Jian-Min Yuan,
Victoria Stevens, Stephanie J Weinstein, Mattias Johansson, Paul
Brennan, Lung Cancer Cohort Consortium (LC3).
3:20 940 Identification of Palbociclib response signature across
indications. Xianxian Zheng, Mark Ozeck, Zhou Zhu, Keith Ching,
David Shields, James Hardwick, Paul Rejto, Todd VanArsdale.
3:35 934 A pooled investigation of circulating adiponectin levels
and risk of multiple myeloma. Jonathan N. Hofmann, Brenda M.
Birmann, Lauren R. Teras, Ye Wang, Demetrius Albanes, Dalsu Baris,
Graham A. Colditz, Anneclaire J. De Roos, Graham G. Giles, Lindsay
M. Morton, H. Dean Hosgood, Qing Lan, Ola Landgren, Linda M. Liao,
Ruth M. Pfeiffer, Nathaniel Rothman, Stephanie J. Weinstein,
Michael N. Pollak, Marian L. Neuhouser, Mark P. Purdue.
3:50 935 Lung cancer metabolomics identifies metabolites as
robust risk biomarkers. Majda Haznadar, Qiuyin Cai, Kristopher W.
Krausz, Elise D. Bowman, William J. Blot, Frank J. Gonzalez, Curtis C.
Harris.
4:05 936 Serum lipid metabolites and alpha-ketoglutarate are
inversely associated with aggressive prostate cancer. Alison
Mondul, Steven Moore, Joshua Sampson, Stephanie Weinstein,
Demetrius Albanes.
4:20 937 Soluble receptor for advanced glycation end-products is
a player in obesity-related colorectal cancer. Liang Chen, Zhigang
Duan, Lesley Tinker, Haleh Sangi-Haghpeykar, Howard Strickler,
Gloria Ho, Thomas Rohan, Marc Gunter, Craig Logsdon, Donna
White, Kathryn Royse, Hashem El-Serag, Li Jiao.
4:35 938 Circulating biomarkers of gut barrier function: Correlates
and responses to calcium supplementation among sporadic
colorectal adenoma patients in a dose-response randomized
controlled trial. Baiyu Yang, Roberd M. Bostick, Andrew T. Gewirtz,
Hao Quang Tran, Veronika Fedirko.
4:50 939 A prospective investigation of PTEN loss and ERG
expression in lethal prostate cancer. Thomas U. Ahearn, Andreas
Pettersson, Ericka M. Ebot, Travis Gerke, Carlos De Morais, Jessica
Hicks, Kathryn M. Wilson, Jennifer R. Rider, Michelangelo Fiorentino,
Stephen Finn, Edward L. Giovannucci, Massimo Loda, Meir J.
Stampfer, Angelo M. De Marzo, Lorelei A. Mucci, Tamara L. Lotan.
3:35 941 G1T28-1, a novel CDK4/6 inhibitor, protects murine
hematopoietic stem and progenitor cells from cytotoxic
chemotherapy. Jessica A. Sorrentino, Shenghui He, John E. Bisi,
Partick J. Roberts, Jay C. Strum, Norman E. Sharpless.
3:50 942 Novel CDK2/9 inhibitor has antineoplastic activity in lung
cancer by inducing anaphase catastrophe. Masanori Kawakami,
Lisa M. Mustachio, Xi Liu, Shanhu Hu, Yun Lu, David Sekula, Sarah
Freemantle, Ethan Dmitrovsky.
4:05 943 The critical role of CDK2 activation in determining the
differential sensitivity of cell lines to Chk1 and Wee1 inhibitors.
Nandini Sakurikar, Ruth Thompson, Ryan Montano, Alan Eastman.
4:20 944 Development of predictive and pharmacodynamic
biomarker strategies for GDC-0425, a checkpoint kinase 1
inhibitor, in combination with gemcitabine. Sami Mahrus, Kelly
DuPree, Kaska Kowanetz, Jenille Tan, Jarrod Tremayne, Diana
Jakubiak, Peter Haverty, Yuda Zhu, Franklin Peale, Elizabeth
Blackwood, Richard Bourgon, Robert Yauch, Mark Lackner, Marie
Evangelista.
4:35 945 Synthetic lethal screen identifies Aurora A as a selective
target in HPV driven cervical cancer. Brian G. Gabrielli, Fawzi
Bokhari, Max Ranall, Zay Yar Oo, Alex Stevenson, Weili Wang, Sara
McKee, Graham Leggatt, Paul Leo, Thomas J. Gonda, Nigel A.
McMillan.
4:50 946 SGN-CD70A, a pyrrolobenzodiazepine (PBD) dimer
linked ADC, mediates DNA damage pathway activation and G2
cell cycle arrest leading to cell death. Sharsti L. Sandall, Renee
McCormick, Jamie Miyamoto, Travis Biechele, Che-Leung Law,
Timothy S. Lewis.
5:05 Discussion.
5:05 Discussion.
275
MINISYMPOSIUM
Drug Discovery: New Targets and Antibody
Drug Conjugates
Cancer Genomics: Characterization,
Evolution, and Function
Chairperson: Elizabeth A. Harrington
Chairperson: Christoph Lengauer
3:15 Introduction
3:15 Introduction
3:20 947 An antibody drug conjugate (ADC) directed to
lymphocyte antigen 6 complex, locus E (LY6E) delivers targeted
chemotherapy to a wide range of solid tumor malignancies. Jyoti
Asundi, Lisa Crocker, Jarrod Tremayne, Paul Polakis, Ron Firestein.
3:20 954 The landscape of kinase fusions in cancer. Nicolas
Stransky, Ethan Cerami, Stefanie Schalm, Joseph L. Kim, Klaus
Hoeflich, Christoph Lengauer.
3:35 948 A novel antibody-drug conjugate that induces long-term
tumor regression and anticancer stem cell activity. Jay W. Harper,
Chris Lloyd, Shenlan Mao, Xin Lin, Nazzareno Dimasi, Phil Howard,
Ellen O’Connor, David Farkas, Christopher Barton, Jeff Smith, Helen
Zhong, Tracy Chen, Mary Jane Hinrichs, Marlon Rebelatto, XiangQing Yu, Susan Spitz, Andrew Pierce, Dominic Lai, Hurt Elaine, Lilian
van Vlerken-Ysla, Jalla Sanjoo, Katy Miller, Karen McCullough, Priya
Kannan, Simon Thompson, Parthiv Mahadevia, Chris Martin, Robert
Hollingsworth, Adeela Kamal.
3:50 949 An ER-␣36 monoclonal antibody exhibits anticancer
activity in triple-negative breast cancer cells. Qingcong Lin,
Junma Zhou, Jing Wang, Zonghui Wang, Jun Wang, Feng Chen,
Xueming Qian, Xiao Shang, Jun Bao, Zhaoyi Wang, Kun Meng.
4:05 950 Antitumor activity of a novel phosphodiesterase 10
inhibitor in an orthotopic mouse model of lung cancer. Veronica
Ramirez-Alcantara, Michele Schuler, Bing Zhu, Nan Li, Evrim
Gurpinar, Dennis Otali, Joshua Canzoneri, Adam Keeton, Bernard
Gary, Suzanne Russo, Lori Coward, Gregory Gorman, William
Grizzle, Xi Chen, Michael Boyd, Gary Piazza.
4:20 951 LY500307 as a novel therapeutic agent for treatment of
glioblastoma. Gangadhara R. Sareddy, Aleksandra Gruslova, David
A. Cavazos, Rajeshwar R. Tekmal, Andrew J. Brenner, Ratna K.
Vadlamudi.
4:35 952 Induction of avidity-driven hyperclustering of DR5 by a
new FAP-DR5 bispecific antibody (RG7386) leads to strong antitumor efficacy. Thomas Friess, Stefanie Lechner, Esther Abraham,
Ann-Marie Broeske, Sabine Bader, Andreas Roller, Meher Majety,
Katharina Wartha, Suzana Vega-Harring, Hadassah Sade, Oliver
Krieter, Peter Bruenker.
4:50 953 An anti-CD38 antibody drug conjugate for the treatment
of diverse hematologic malignancies. James R. Prudent, David J.
Marshall, John Murphy, Fabio Malavasi.
3:35 955 High-throughput functional screening for metastasis
drivers of lung cancer. Caitlin L. Grzeskowiak, Rosalba Minelli, Ping
Wu, Samrat Kundu, Don L. Gibbons, Kenneth L. Scott.
3:50 956 The evolutionary history of lethal metastatic prostate
cancer. Gunes Gundem, Peter Van Loo, Barbara Kremeyer, Ludmil
B. Alexandrov, Jose M. Tubio, Elli Papaemmanuil, Daniel S. Brewer,
Heini Kallio, Gunilla Högnäs, Matti Annala, Kati Kivinummi, Victoria
Goody, Calli Latimer, Sarah O’Meara, Kevin J. Dawson, William
Isaacs, Michael R. Emmert-Buck, Matti Nykter, Christopher Foster,
Zsofia Kote-Jarai, Douglas Easton, Hayley C. Whitaker, David E.
Neal, Colin S. Cooper, Rosalind A. Eeles, Tapio Visakorpi, Peter J.
Campbell, Ultan McDermott, David C. Wedge, G. S. Bova.
4:05 957 Towards precision functional genomics via nextgeneration functional mapping of cancer variants. Alice Berger,
Eejung Kim, Angela Brooks, Yashaswi Shrestha, Yuen-Yi Tseng,
Xiaoyun Wu, Nina Ilic, Lihua Zou, Atanas Kamburov, Xiaoping Yang,
Cong Zhu, Paula Keskula, Sara Seepo, Andrew Hong, John Doench,
Aravind Subramanian, Keith Ligon, Philip Kantoff, Katherine
Janeway, Levi Garraway, David Root, Todd Golub, Matthew
Meyerson, William Hahn, Gad Getz, Jesse Boehm.
4:20 958 Early hepatocellular carcinoma as another entity from
classical hepatocellular carcinoma by integrated genomic
analysis. Yutaka Midorikawa, Shogo Yamamoto, Kenji Tatsuno,
Hiroki Ueda, Shingo Tsuji, Genta Nagae, Kotaro Sonoda, Tatsuhiro
Shibata, Kyle R. Covington, Chad J. Creighton, Masahiko Sugitani,
David A. Wheeler, Tadatoshi Takayama, Hiroyuki Aburatani.
4:35 959 Aromatase inhibition shapes the clonal architecture of
estrogen receptor-positive breast cancers. Christopher A. Miller,
Yevgeniy Gindin, Charles Lu, Obi Griffith, Malachi Griffith, Dong
Shen, Jeremy Hoog, Mark Watson, Sherri R. Davies, Kelly Hunt,
Jacqueline E. Snider, Katherine DeSchryver, Richard K. Wilson,
Mathew J. Ellis, Elaine Mardis.
4:50 Discussion.
5:05 Discussion.
276
MINISYMPOSIUM
MYC Family Deregulation and Targeting
Oncogenic Signaling and Cell Death
Chairperson: David Dominguez-Sola
Chairperson: Alex Toker
3:15 Introduction
3:15 Introduction
3:20 960 Deregulation of the Hippo pathway in soft tissue sarcoma
promotes FOXM1 expression and tumorigenesis. T.S. Karin
Eisinger, Vera Mucaj, Kevin Biju, Michael Nakazawa, Mercy Gohil,
Timothy Cash, Sam Yoon, Nicolas Skuli, Kyung Min park, Sharon
Gerecht, Celeste Simon.
3:20 968 Co-occurring genomic alterations define major subsets of
KRAS-mutant lung adenocarcinoma (LUAC) with distinct biology
and therapeutic vulnerabilities. Ferdinandos Skoulidis, Lauren
Byers, Lixia Diao, Vassiliki Papadimitrakopoulou, Pan Tong, Julie
Izzo, Carmen Behrens, Humam Kadara, Edwin R. Parra, Jaime
Rodriguez-Canales, Jianjun Zhang, Uma Giri, Jayanthi Gudikote,
Maria A. Cortez, Chao Yang, You Hong Fan, Michael Peyton, Luc
Girard, Kevin R. Coombes, Carlo Toniatti, Timothy P. Heffernan,
Murim Choi, Garrett M. Frampton, Vincent Miller, John N. Weinstein,
Roy S. Herbst, Kwok-Kin Wong, Jianhua Zhang, Padmanee Sharma,
Gordon M. Mills, Waun K. Hong, John D. Minna, John P. Allison,
Andrew Futreal, Jing Wang, Ignacio Wistuba, John V. Heymach.
3:35 961 Genome– and proteome–wide analyses of HOXB13 and
the G84E variant associated with prostate cancer. Dorhyun Johng,
Michael C. Haffner, David M. Esopi, William B. Isaacs.
3:50 962 PA2G4 predicts poor prognosis in neuroblastoma
patients and promotes neuroblastoma progression by enhancing
MYCN protein stability. Jessica Koach, Bing Liu, Jessica L. Bell,
Stefan Hüttelmaier, Tao Liu, Daniel R. Carter, Michelle Haber, Murray
D. Norris, Jamie Fletcher, Belamy B. Cheung, Glenn M. Marshall.
4:05 963 Regulation of protein synthesis in primary malignant B
cells: engagement of the B-cell receptor of chronic lymphocytic
leukemia increases global RNA translation and translation of
MYC RNA. Alison Yeomans, Steven Thirdborough, Sergey Krysov,
Marina Sanchez Hidalgo, Elodie Leonard, Anne E. Willis, Andrew J.
Steele, Freda K. Stevenson, Francesco Forconi, Mark Coldwell,
Graham Packham.
4:20 964 GATA3 modulates chromatin structure to establish active
enhancers in breast cancer cells. Motoki Takaku, Sara A. Grimm,
Takashi Shimbo, Lalith Perera, Shinichi Machida, Hitoshi
Kurumizaka, Paul A. Wade.
4:35 965 Identification of KJ-Pyr-9 as a potent MYC inhibitor.
Jonathan R. Hart, Klaus Bister, Kim D. Janda, Peter K. Vogt.
4:50 966 LSD1 functions as a global androgen receptor coactivator
and is a therapeutic target in prostate cancer. Shuai Gao, Yanfei
Gao, Hansen He, Myles Brown, Steve Balk, Changmeng Cai.
5:05 Discussion.
3:35 969 B-Raf activation loop phosphorylation is crucial for
efficient MAPK signalling in vivo. Martin Koehler, Michael Roering,
Sandra Braun, Tilman Brummer.
3:50 970 Broad therapy resistance is induced by suppression of
apoptotic priming by lineage programs and oncogenic
activation. Kristopher A. Sarosiek, Alison Karst, Peter Winter,
Antonio Sorrentino, Sourav Bandyopadhyay, Andrei Goga, Kris C.
Wood, Ronny Drapkin, Anthony Letai.
4:05 971 Pro-apoptotic Bid preserves hematopoietic stem cell
function through restraint of necrosis: implications for
myelodysplastic syndrome. Sandra S. Zinkel.
4:20 972 Targeting glucose and glutamine regulated BCL2 family
members for multiple myeloma therapy. Richa Bajpai, Shannon M.
Matulis, Changyong Wei, Ajay K. Nooka, Lawrence H. Boise, Mala
Shanmugam.
4:35 973 Coordinated regulation of cap-dependent translation
and microRNA function by convergent signaling through the
PI3K/Akt/mTOR and Jak/Stat/Pim signaling pathways. Scott H.
Olejniczak, Gaspare La Rocca, Megan Radler, Craig B. Thompson.
4:50 Discussion.
277
MINISYMPOSIUM
Tumor Biology
Tumor Biology
Cancer Stem Cells 1
Signaling of the Microenvironment
Regulates Tumor Progression
Chairperson: Andreas Trumpp
Chairperson:
3:15 Introduction
3:20 974 FAK inhibitors VS-6063 and VS-4718 target cancer stem
cells: Implications for TNBC sequential and combination
therapies. Vihren N. Kolev, Kam Sprott, Qunli Xu, Jonathan A.
Pachter, David T. Weaver.
3:35 975 Monoclonal antibody targeting of ADAM17 is an effective
treatment for metastatic colorectal cancer resulting in tumor
growth control and reductions of cancer stem cells. Joseph
Dosch, Elizabeth Ziemke, Theodore Welling, Karin Hardiman, Juidth
Sebolt-Leopold, Emil Michelotti, Robert Hollingsworth, Elaine Hurt.
3:50 976 Metabolic eradication of treatment resistant cancer stem
cells in pancreatic tumors: A clonal tracking-based platform for
identifying the best personalized treatment. Denise Corti,
Alessandro Carugo, Seth Sahil, Matteo Marchesini, Piergiorgio
Pettazzoni, Luigi Nezi, Tessa Green, Joseph R Marszalek, Maria
Emilia Di Francesco, Timothy P Heffernan, Giulio F Draetta, Andrea
Viale.
4:05 977 3D-models of patient-derived colon tumors for the
identification of genetic factors important in the regulation of
cancer stem cells. Joseph L. Regan, Dirk Schumacher, Stephanie
Staudte, Karsten Boehnke, Ulrich Keilholz, Johannes Haybaeck,
Hans Lehrach, David Henderson, Reinhold Schaefer, Christian R.
Regenbrecht, Dominik Mumberg, Martin Lange.
4:20 978 QKI deletion enhances self-renewal of glioma stem cells
and promotes gliomagenesis. Takashi Shingu, Allen Ho, Liang
Yuan, Jian Hu.
4:35 979 Dynamic epigenetic regulation of glioblastoma
tumorigenicity through LSD1 modulation of MYC expression. Jie
Li, David Kozono, Masayuki Nitta, Oltea Sampetrean, David Gonda,
Deepa S. Kushwaha, Dmitry Merzon, Valya Ramakrishnan, Shan
Zhu, Kaya Zhu, Hiroko Matsui, Olivier Harismendy, Wei Hua, Ying
Mao, Chang-Hyuk Kwon, Hideyuki Saya, Bob S. Carter, Donald P.
Pizzo, Scott R. VandenBerg, Clark C. Chen.
3:15 Introduction
3:20 981 Activation of EGF receptor in macrophages inhibits M2
polarization and suppresses proliferation and epithelial-tomesenchymal transition in gastric epithelial cells. Gang Zhao,
Liping Liu, D. Brent Polk, Richard M. Peek, Xishan Hao, Hui Li, Fang
Yan.
3:35 982 Hyaluronan (HA) depletion increases tumor accessibility
of T cell and therapeutic PD-L1 monoclonal antibody in HAhigh
tumors. Netai C. Singha, Chunmei Zhao, Jesse Bahn, Adrian Radi, H.
Michael Shepard, Zhongdong Huang.
3:50 983 Gas6/Axl mediation of prostate cancer cell dormancy
requires cooperation with additional bone marrow niche
components. Haley Axelrod, Kenneth J. Pienta.
4:05 984 FGF2 from the bone marrow promotes resistance to FLT3
inhibitors in AML. Jacqueline Martinez, Elie Traer, Nathalie JavidiSharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Tibor
Kovacsovics, Jeffrey Tyner, Melissa Wong, Brian Druker.
4:20 985 Stromal PDGFR-␣ activation stalls mammary ductal
development and increases tumorigenic potential of mammary
epithelia. Anisha Mathur, Gina M. Sizemore, Subhasree
Balakrishnan, Vasudha C. Shukla, Maria Cuitino, Anthony J. Trimboli,
Samir Ghadiali, Gustavo W. Leone, Michael C. Ostrowski.
4:35 986 Role of Gpr43 in intestinal inflammation and
carcinogenesis. Sathish Sivaprakasam, Ashish Gurav, Ganapathy
Vadivel, Nagendra Singh.
4:50 987 NGF promotes gastrointestinal cancer development
through tumor-associated neurogenesis. Yoku Hayakawa, Samuel
Asfaha, Bernhard W. Renz, Christoph B. Westphalen, Yagnesh
Tailor, Karan Nagar, Daniel L. Worthley, Duan Chen, Timothy C.
Wang.
5:05 Discussion.
4:50 980 Encoding immortality: Transcriptional control of
telomerase in stem cells in vivo. Matthew Pech, Alina Garbuzov,
Meena Sukhwani, Berenice Benayoun, Shengda Lin, Anne Brunet,
Kyle Orwig, Steven E. Artandi.
5:05 Discussion.
278
Sunday, 3:30 p.m.-4:30 p.m.
AACRcentral, AACR Amphitheater, Halls B-E, Booth #725
Meet the Mentor
Undergraduate Focus
Roy S. Herbst, MD, PhD
Yale Cancer Center, New Haven CT
Roy S. Herbst, MD, PhD, will engage undergraduate students in an informal discussion about cancer
research. Key answers will also be provided to important questions to help guide students in their
professional development throughout their cancer research career. All undergraduate student
attendees at the Annual Meeting are invited to participate in this session.
Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and
research. He is best known for his work in developmental therapeutics and the personalized therapy of
non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to
novel therapies.
He is a member of the American Association for Cancer Research (AACR), where he chairs the
Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of
Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians.
Dr. Herbst is also a vice chair of the Southwest Oncology Group’s lung committee, a member of the
medical advisory committee for the Lung Cancer Research Foundation and chair of the
communications committee for the International Association for the Study of Lung Cancer. He has
authored more than 200 peer-reviewed papers and has current grant funding for his work from
numerous sources including the National Cancer Institute, AACR, and multiple charitable foundations.
Dr. Herbst received his medical degree from Cornell University Medical College and earned a PhD in
molecular cell biology from the Rockefeller University. He completed his medical oncology fellowship
at Dana-Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s
Hospital in Boston, where he additionally received a master’s degree from Harvard University in their
clinical investigator training program.
279
Sunday, 4:00 p.m.-5:00 p.m.
Booth #1827 (Publications Booth), Halls B-E
Meet the Editor-in-Chief of Cancer Research
George C. Prendergast, PhD
President, CEO, and Professor
Lankenau Institute for Medical Research
Join us at Booth #1827 at AACR Annual Meeting 2015 to meet the editors of the AACR Publications.
The Editors-in-Chief will explain the mission and scope of their journal, recent submission trends, and
other topics of interest for researchers looking to publish their work in the highly esteemed AACR
journals. Learn what Editors look for in manuscripts and participate in a unique Q&A session.
Cancer Research is the most frequently cited cancer journal in the world. The journal publishes original
studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience
spanning basic, preclinical, clinical, prevention, and epidemiologic research. Cancer Research seeks
manuscripts that offer pathobiological and translational impact to inform the personal, clinical, and
societal problems posed by cancer. The main scope of the journal is captured in its primary
subsections, which focus on molecular and cellular pathobiology, tumor and stem cell biology,
therapeutics and targets, microenvironment and immunology, prevention and epidemiology, and
integrated systems and technology.
280
EUROPEAN RESEARCH COUNCIL-SPONSORED SESSION (not eligible for CME credit)
Sunday, 4:00 p.m.-5:30 p.m.
Funding Opportunities in Europe for Creative Minds From
Anywhere in the World
Launched 2007, the European Research Council is already shaping Europe’s research scene and
is highly regarded by the international research community, establishing itself as a world-class
research funding agency. This investigator-driven, pioneering frontier research funded is now starting
to bear fruit.
Horizon 2020 (H2020), the new European Union framework program for research and innovation runs
from 2014-2020. With a budget of €77 billion, Horizon 2020 is a key component of Europe’s strategy
to create economic growth and to reinforce its global competitiveness. The European Research
Council (ERC) is part of H2020’s first pillar of “Excellent Science” and has a budget of over €13 billion,
an approximate 75% increase compared to the previous framework program. This substantial budget
increase will allow the ERC to continue its mission – finding and funding the very best researchers with
the most creative ideas.
Through highly competitive selections for attractive grants, the ERC promotes junior and established
researchers to pursue their work in Europe in any field of research and regardless of their nationality.
Encouraging international scientific cooperation, the ERC supports top researchers from anywhere in
the world, including the USA. Since 2007, more than 4,000 projects have been selected for funding
from more than 43,000 applications, including several Nobel Prize winners.
The workshop will explain the ERC’s funding schemes as well as provide answers to practical
questions such as:
• How does the ERC support research careers?
• What are their main features?
• What are the main changes for the ERC with respect to the new Horizon 2020 framework?
• What are the selection criteria and how long is the selection process?
• How does the application process work?
• How many researchers are funded each year?
• What are the chances of success?
Speakers:
Nadia El Mjiyad, European Research Council, Brussels, Belgium
Laura Soucek, Vall d’Hebron Institute of Oncolgy, Barcelona, Spain
Jason Carroll, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
Cedric Blanpain, Université Libre de Bruxelles, Bruxelles, Belgium
Viktória Bodnárová, Euraxess, Washington, DC
281
PEZCOLLER-AACR AWARD LECTURE
Sunday, 4:30 p.m.-5:30 p.m.
Eighteenth Annual Pezcoller Foundation-AACR
International Award for Cancer Research
Immune Checkpoint Blockade in Cancer Therapy:
New Insights, Opportunities, and Prospects for a Cure
James P. Allison, PhD, FAACR
The University of Texas MD Anderson Cancer Center, Houston, TX
The Pezcoller Foundation-AACR International Award was
established in 1997 to recognize a scientist who has made a
major scientific discovery in basic cancer research, or who
has made significant contributions to translational cancer
research; who continues to be active in cancer research,
and has a record of recent and noteworthy publications;
and whose ongoing work holds promise for continued
substantive contributions to progress in the field of cancer.
This award honors James P. Allison, PhD, for his seminal
discoveries that established new paradigms in basic cancer
immunology and led to the development of novel cancer
therapeutics. Specifically, he is recognized for his
identification of CTLA-4 as an inhibitory receptor on T cells
that serves as a checkpoint to ensure proper control of
immune responses. He subsequently developed and tested
the hypothesis that blockade of CTLA-4 would enhance
antitumor T cell responses by releasing CTLA-4
suppression. The success of these studies opened the field
of immune checkpoint blockade in human cancer therapy.
Dr. Allison’s findings have had a profound impact on
patients and revolutionized the way we think about
cancer treatment.
Throughout his career, Dr. Allison has contributed
significantly to the field of immunology. Early in his career,
his laboratory provided several important insights into the
basic mechanisms involved in T cell activation, T cell
receptor structure, and antigen recognition. He also
investigated other receptors that participated in regulation
of T cell activation or inhibition; for example, the CD28 and
CTLA-4 pair of T cell receptors was found to regulate
dichotomous T cell responses when linked to their
common binding protein, B7-1,2, on antigen presenting
cells. Dr. Allison demonstrated that CD28 engagement
stimulated T cell function, whereas CTLA-4 suppressed T
cell activation. These studies and subsequent mechanistic
investigations led Dr. Allison to propose that CTLA-4
inhibition of T cells limited immune destruction of tumor
282
cells and that blockage of this receptor might unleash T
cell antitumor activity.
He then established models to test this hypothesis,
generating blocking monoclonal antibodies to CTLA-4 and
showing that these antibodies induced tumor regression in
mice. The success of these preclinical studies motivated Dr.
Allison to work with Bristol-Myers Squibb to develop and
test a therapeutic monoclonal anti-CTLA-4 antibody
(iplilimumab) in cancer patients. Treatment with
ipilimumab was shown to induce remission in a subset of
patients, providing further evidence of efficacy in phase II
and III trials, and therefore led to FDA approval of the drug
in 2011. These studies of CTLA-4 laid the foundation for
development of a new class of “immune checkpoint
therapies,” drugs that target T cell inhibitory pathways
(e.g., pembrolizumab for PD-1/PD-L1 blockade), and
changed the landscape of cancer treatment.
Dr. Allison’s outstanding accomplishments have been
recognized by his appointment as a Howard Hughes
Medical Institute Investigator, his election to the National
Academy of Sciences, the Institute of Medicine, the
American Association of Arts and Sciences, the American
Society of Microbiology, and as a Fellow of the AACR
Academy. Likewise, he is the recipient of several
prestigious awards such as the Canada Gairdner
International Award, the 2013 Innovation Award for
Bioscience, and two AACR awards, the AACR-Lloyd J. Old
Award in Cancer Immunology and the AACR G.H.A. Clowes
Memorial Award.
PRESIDENTIAL ADDRESS
Sunday, 5:30 p.m.-6:30 p.m.
Resistance to Endocrine Therapy: Insights from Presurgical
Trials in Breast Cancer
Carlos L. Arteaga, MD, FAACR
Vanderbilt-Ingram Cancer Center, Nashville, TN
AACR President Carlos L. Arteaga, MD, is professor of
medicine and cancer biology at Vanderbilt University
School of Medicine, where he holds the Donna S. Hall chair
in breast cancer research. He serves as associate director
for translational/clinical research; director of the Breast
Cancer Program; director of the Vanderbilt-Ingram Cancer
Center Research Network (VICCRN); and director of Center
for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer
Center in Nashville, TN.
Dr. Arteaga’s research interests include oncogene signaling
and molecular therapeutics in breast cancer with an
emphasis on targeted therapies, mechanisms of drug
resistance, translational research, and investigator-initiated
clinical trials. Early in his career, he was the first to report
the roles of IGF-I receptors and TGF beta in breast cancer
progression and their use as therapeutic targets. More
recent work has focused on the role of presurgical and
neoadjuvant trials to discover molecular biomarkers that
inform patient selection in clinical trials and/or for the
discovery of mechanisms of drug resistance in breast
cancer. In studies focused on hormone receptor-positive
breast cancer, he showed the role of aberrant activation of
the PI3K pathway in promoting escape from antiestrogens
and the ability of inhibitors of HER2 and PI3K to reverse
resistance to antiestrogen therapy in human breast cancer.
Since 2001, he has led the National Cancer Institute-funded
Vanderbilt Specialized Program of Research Excellence
(SPORE) in breast cancer. His work has significant
implications for novel clinical trials in patients with breast
cancer.
Dr. Arteaga received his medical degree in 1980 from the
Facultad de Ciencias Médicas at the Universidad de
Guayaquil in Ecuador. Following internal medicine
residency at Emory University in Atlanta, he completed a
fellowship in medical oncology at The University of Texas
Health Science Center at San Antonio. Dr. Arteaga joined
the faculty at Vanderbilt University in 1989.
He has received many honors and awards, including the
AACR-Richard and Hinda Rosenthal Award; the American
Cancer Society Clinical Research Professor Award; the
Gianni Bonadonna Award from the American Society of
Clinical Oncology; the Brinker Award for Scientific
Distinction from Susan G. Komen; and, early in his career,
the Clinical Investigator Award from the U.S. Department of
Veteran Affairs. In 2013, he was elected as a fellow of the
American Association for the Advancement of Sciences.
Additionally, he is an elected member of the American
Society for Clinical Investigation and the Association of
American Physicians and member of Susan G. Komen
Scientific Advisory Board.
Dr. Arteaga’s involvement in the AACR spans more than a
decade. He was a member of the Board of Directors
(2004-2007); chair of the AACR Special Conferences
Committee (2002-2008); chair of the AACR/NCI/EORTC
Molecular Targets meeting in 2001; member of the Annual
Meeting Program Committee in 2012 and 2013; co-chair of
the Molecularly Targeted Therapies: Mechanisms of
Resistance special conference in 2012; member of the
Clinical and Translational Cancer Research Grants Scientific
Review Committee in 2012; member of the AACR
Outstanding Investigator Award for Breast Cancer
Research Selection Committee in 2011; co-chair of the
AACR-Japanese Cancer Association joint conference; cochair of the AACR special conference, Advances in Breast
Cancer Research, in 2003, 2005, 2007, 2009, and 2013;
and an editorial board member of an AACR journal,
Molecular Cancer Therapeutics, from 2002 to 2012.
Dr. Arteaga was also an editorial board member for the
AACR’s Clinical Cancer Research from 2001 to 2004 and
deputy editor from 2004 to 2013. He has served as AACR
co-chair of the annual San Antonio Breast Cancer
Symposium since 2009, is a principal investigator on the
Stand Up To Cancer Dream Team, Targeting the PI3K
Pathways in Women’s Cancers, and has recently been
elected to the 2015 class of Fellows of the AACR Academy.
283
CIMM TOWN MEETING (not eligible for CME credit)
Sunday, 6:00 p.m.-8:30 p.m.
Commonwealth Hall A-C (Second Floor), Loews Philadelphia Hotel
Cancer Immunology (CIMM) Working Group Town Hall Meeting
Co-Sponsored by the Cancer Research Institute (CRI)
This co-sponsored session is an opportunity for all interested to hear from our colleagues in the
AACR-Cancer Immunology (CIMM) Working Group and the Cancer Research Institute (CRI) speak on
“Regulating T Cell Responses: Lessons for Cancer Immunotherapy.” Dr. E. John Wherry, University of
Pennsylvania, will speak on “Molecular mechanisms of T cell exhaustion: Implications for
immunotherapy”; Dr. Ana C. Anderson, Harvard Medical School, will speak on “Navigating the growing
landscape of immune checkpoint receptors”; and Dr. Holbrook E. Kohrt, Stanford University, will speak
on “Intratumoral immunotherapy to unlock systemic T cell and antitumor responses.” Additionally, Dr.
Jill O’Donnell-Tormey, Chief Executive Officer and Director of Scientific Affairs of CRI, will introduce
the program, and Dr. Glenn Dranoff, Editor-in-Chief of Cancer Immunology Research will provide an
update about this journal. After this exciting program, a networking reception will follow. Come learn
about these and other important CIMM initiatives, meet members of the working group and steering
committee, in addition to taking advantage of the opportunity to join the CIMM Working Group.
6:00 p.m.
Chairperson: Opening Remarks
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY
6:15 p.m.
Chairperson-Elect: Remarks
Pamela S. Ohashi, Ontario Cancer Institute/University of Toronto, Toronto, ON, Canada
6:30 p.m.
Editor-in-Chief, Cancer Immunology Research: Cancer Immunology Research Update
Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA
6:40 p.m.
Program Opening Remarks
6:45 p.m.
Program Introduction
Jill O’Donnell-Tormey, Cancer Research Institute (CRI), New York, NY
6:50 p.m.
Molecular mechanisms of T cell exhaustion: Implications for immunotherapy
E. John Wherry, University of Pennsylvania, Philadelphia, PA
7:05 p.m.
Navigating the growing landscape of immune checkpoint receptors
Ana C. Anderson, Harvard Medical School/Brigham and Women’s Hospital, Boston, MA
7:20 p.m.
Intratumoral immunotherapy to unlock systemic T cell and antitumor responses
Holbrook E. Kohrt, Stanford University, Stanford, CA
7:35 p.m.
Closing Remarks
284
AACR NETWORKING HUBS (not eligible for CME credit)
Sunday, 6:30 p.m.-8:00 p.m.
Broad Street Atrium, Pennsylvania Convention Center
AACR Networking Hubs
The AACR Annual Meeting brings together senior and junior investigators from all over the world to
learn about the latest in cancer research. In an effort to facilitate more intimate networking
opportunities for attendees in focused scientific areas, the AACR debuted a series of Networking
Hubs in 2014.
Join us on Sunday, April 19, from 6:30 p.m.-8:00 p.m. for one of the six new topics that will be
featured in this year’s Hubs. The Networking Hubs do not feature a formal program, but instead will be
your chance to speak face-to-face with potential colleagues and collaborators. Junior investigators are
especially encouraged to take advantage of this unique opportunity to mingle with respected senior
investigators and meet fellow junior investigators with similar research interests. It is our hope that
discussions started during the Networking Hubs will be continued throughout the Annual Meeting
and beyond.
2015 Networking Hubs:
• Biomarker-Driven Clinical Trials
• Cell Death
• Diabetes and Cancer Prevention
• DNA Repair
• Epigenetics
• Metabolism
Each Hub will be limited to 60 registrants. Registration is free for Annual Meeting attendees, but will
be accepted on a first-come, first-served basis. Light fare will be provided and each registrant will
receive one drink ticket upon entry.
Don’t miss this opportunity.
Reserve a spot in the Networking Hub of your choice:
https://www.surveymonkey.com/s/AACR2015_hubs
285
PCWG TOWN MEETING (not eligible for CME credit)
Sunday, 6:30 p.m.-9:00 p.m.
Regency Ballroom C (Second Floor), Loews Philadelphia Hotel
AACR Pediatric Cancer Working Group
Town Hall Meeting and Networking Reception
All attendees of the AACR Annual Meeting are invited to attend this special evening session and
networking reception hosted by the AACR Pediatric Cancer Working Group. In addition to open
discussion and a networking reception, this meeting will consist of an interactive summary of AACR’s
past, present, and future pediatric oncology-related initiatives, as well as recognition of the Pediatric
Cancer Working Group’s leadership and sponsors.
Speakers:
Lee J. Helman, National Cancer Institute, Bethesda, MD
Garrett M. Brodeur, Children’s Hospital of Philadelphia, Philadelphia, PA
Crystal L. Mackall, National Cancer Institute, Bethesda, MD
286
SPECIAL SESSION
Sunday, 7:00 p.m.-8:15 p.m.
Philadelphia Marriott Downtown, Franklin 12
Clinical Oncology/Hematology Fellows
Networking and Mentoring Reception
All meeting attendees who are clinical research fellows, postdoctoral fellows, assistant professors, or
equivalent early-career investigators actively engaged in any aspect of clinical oncology/hematology
cancer research are cordially invited to attend this inaugural networking and mentoring reception.
This special informal event will feature remarks by current AACR President, Dr. Carlos L. Arteaga.
Complimentary hors d’oeuvres and beverages will be available for all attendees.
Speaker:
Carlos C. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
287
ANNUAL RECEPTION (not eligible for CME credit)
Sunday, 8:30 p.m.-11:30 p.m.
Grand Ballroom, Philadelphia Marriott Downtown
Annual Reception
All Annual Meeting registrants are invited to attend the Annual Reception on Sunday evening, April 19,
from 8:30 p.m. to 11:30 p.m. in the Grand Ballroom of the Philadelphia Marriott Downtown.
Complimentary light refreshments will be served, and a live band will provide music for dancing. On
Sunday evening, shuttle buses will run between all AACR hotels where busing is provided during the
day and the Philadelphia Marriott Downtown. Shuttle schedules will be posted in each hotel. Each
registrant will receive a voucher for a complimentary beverage at the Annual Reception with his/her
registration materials.
288

Sunday, April 19 - American Association for Cancer Research

Transcription

Similar documents

Exsanguination - Northern Health

AMPULLA OF VATER STAGING FORM

Leaving Cert Craft Exam-Poster Question By Ruth Graydon

Tumor Antigens and Cancer Vaccines

tumor marker`s

Evolutionary optimization in (deformable) registration of medical

poster packs - Oxford SA Blog

Full text in pdf format

An Introduction to Next-Generation Sequencing for

Assessing Response to Chemotherapy in Bone and Soft Tissue

call for abstracts - American Association for Cancer Research